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ABSTRACT 
 
The aim of this research project was to determine whether temperate 
bacteriophages could be used as markers for bacterial evolution in chronic 
microbial infections and in the progression of respiratory diseases [Cystic 
Fibrosis (CF) and Bronchiectasis (BR)]. CF and BR have diverse clinical origins 
but similar pathophysiological burdens including inflammation and the production 
of a nutrient rich mucus. This thick, dehydrated mucus is an ideal colonisation 
site for opportunistic bacteria such as Pseudomonas aeruginosa (P. aeruginosa). 
Some strains of P. aeruginosa have been found to harbour multiple inducible 
temperate bacteriophages that are believed to have an effect on P. aeruginosa 
functionality.  
In order to try and answer the research question proposed, the research was split 
into three subgroups: (1) a cross-infection study utilising 94 clinical P. aeruginosa 
isolates and their associated mixed phage communities to determine changes in 
phage-host interactions alongside the progression of the clinical disease. We 
here illustrate that phages induced from the older CF patient isolates were the 
most infective, whilst the phages originating from the youngest CF patients or the 
patients with <10 years of BR diagnosis were the least infective.  
(2) Metagenome analysis of the total induced viral DNA from each of these 94 P. 
aeruginosa isolates was used to determine whether disease progression offered 
complexity or additional gene function that would offer a selective advantage for 
the bacterium or virus in these clinical backgrounds. This research importantly 
shows differences in phage metagenome complexity and an increase in gene 
function that correlates with the advancement of disease progression. Therefore, 
phage metagenomes originating from the older CF patients were the most 
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enriched in functions relating to survival within the chronic lung. It also shows a 
snapshot of phage evolution and their impact on the bacteria colonising the lower 
lung. If higher numbers of phage genes with defined function is a marker of the 
levels of adaptation and evolution that has occurred, then this research 
determines that phages isolated from CF metagenomes had undergone more 
rounds of evolution compared to the BR metagenomes.   
(3) Changes in metabolite profiles in the bacterium when infected with a single 
phage may further show the involvement and subversion of host cell functionality 
by these phages. A panel of plaque-purified phages were used to create 
lysogens of lab strain PAO1. Changes in the metabolite profiles between naïve 
and infected PAO1 were investigated throughout pellicle growth where distinct 
differences were seen and further show the impact of prophage formation on the 
core gene function of respiring bacteria. Both the E. coli metabolome database 
and the human metabolome database were utilised in order to identify potential 
metabolites that were both statistically significant and had a low CV score. We 
illustrate different metabolite profiles when comparing naïve bacterial strain to 
lysogen and thus, we establish the intricacy of how the virus subverts host cell 
functionality. One metabolite was observed that was present in a lysogenic strain 
and not in the naïve host cell, so potentially leading to the assumption that this 
metabolite is phage derived. Further LCMS work is required in order to confirm 
this preliminary finding. 
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1. INTRODUCTION  
 
1.1. CHRONIC RESPIRATORY DISEASE 
Chronic respiratory diseases affect the airways and structures of the lungs and 
account for circa 4 million deaths annually according to the World Health 
Organisation (WHO). Approximately 50 % of patients diagnosed with acquired 
chronic respiratory diseases live in low-to-middle-income countries and it is 
believed that this acquisition may in part be due to high levels of indoor air 
pollution and tobacco smoke (WHO, 2004). In higher income countries, both 
acquired and inherited diseases contribute at equivalent levels to the onset of 
chronic respiratory diseases. This thesis is focused on an acquired respiratory 
disease, Bronchiectasis (BR) and an inherited disease, Cystic Fibrosis (CF). 
 
1.2. CYSTIC FIBROSIS 
CF is the most common autosomal recessive genetic disorder in Caucasian 
populations and in 2003, around one in every twenty five children born in the 
United Kingdom was a carrier of the mutation (Gibson et al., 2003). In Europe 
(2011), nearly thirty five thousand children and young adults were diagnosed with 
CF (~ 0.004 %). The prevalence is different in the USA and Canada with the 
numbers being thirty thousand (~ 0.009 %) and three thousand (~ 0.009 %) 
respectively (Hoiby, 2011). Population size needs to be considered when 
drawing conclusions regarding CF prevalence. CF arises due to genetic 
mutations in the Cystic Fibrosis transmembrane conductance regulator (CFTR) 
gene, a 189 kb gene located on the long arm of chromosome 7. The CFTR gene 
encodes for a 1480 amino acid protein that is located on the epithelial cell 
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surface, see figure 1.1. The correct functionality of this protein involves the 
transportation of negatively charged chloride ions (Cl-) across the lung epithelia. 
The CFTR is composed of two domains that span the plasma membrane thus, 
creating a channel for ion transport. The CFTR is also involved in the 
maintenance of other epithelial ion transport channels including the positively 
charged sodium (Na+) channel. These channels are essential for transport in 
both the lungs and the pancreas (Frizzell, 1995, Cant et al., 2014). This ion 
transport controls not only the osmotic potential of the cell but also the essential 
production of normal free flowing mucus (Riordan et al., 1989, Cant et al., 2014, 
Frizzell, 1995).  
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Figure 1.1: Structure of the CFTR protein and details relating to its functionality, 
from (Goodman and Percy, 2005). Opening and closing the CFTR channel is an energy 
dependent process. The correct functionality of this channel is required for the 
transportation of Cl- ions across the epithelial membrane, in order to ensure that the 
correct mucus levels are retained within the airways and around the body. In order to 
generate the energy for this transportation, the regulatory domain (R domain), requires 
phosphorylation which in turn allows for adenine triphosphate (ATP) hydrolysis to occur 
(Riordan et al., 1989). ATP hydrolysis occurs at the nucleotide binding domains (NBD1 
and NBD2) and the production of free phosphate ions and adenosine diphosphate (ADP) 
releases the energy required to ensure that the channel opens and closes effectively 
(Hwang and Sheppard, 2009). The activity of this channel is also dependent on the 
presence of intracellular ATP (Sheppard and Welsh, 1999, Berger et al., 1991). When the 
R domain is not phosphorylated, the channel is closed which causes the movement of Cl- 
to cease. Phosphorylation of R and the subsequent binding of the ATP onto the 
nucleotide binding domains occurs in a sequential manner, which increases the likelihood 
of the channel remaining open (Goodman and Percy, 2005). 
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1.3. BRONCHIECTASIS 
BR is the irreversible dilation of the lower bronchi caused by chronic airway 
inflammation. Subsequent scarring of the lung tissue through reactive oxygen 
species generation or lung obstruction transcends into consistent and recurrent 
bacterial chest infections (Boyton, 2012, Cole, 1985, Barker, 2002, Laennec, 
1962). BR doesn’t have a clear cause as it can be triggered by a chronic infection 
or it can be the downstream problem of a localised lung trauma event. Around 
half of the known causes of BR are idiopathic, table 1.1 details the proposed 
causes for the non-idiopathic BR patients.  
Upon reduction, reactive oxygen species are formed and these can have 
detrimental effects on lung health and functionality (Anderson, 1996). Reactive 
oxygen species aside from having a potentially damaging role in the human body 
are also involved in numerous other important cellular events such as protein 
phosphorylation, transcription factor activation, gene expression, DNA synthesis 
and cell proliferation (Hoidal, 2001, Schreck et al., 1991, Sen and Packer, 1996). 
Reactive oxygen species are known to also have a role in phagocytosis so these 
species can protect the host from the effects of pathogenic organisms. Reactive 
oxygen species induce polymorphonuclear leukocytes which in turn triggers 
phagocytosis. Reactive oxygen species can be effectively cleared from a healthy 
human body. For example, Superoxide Dismutase (SOD) can convert 
superoxides into hydrogen peroxide in the mitochondria and this hydrogen 
peroxide is removed from the body by catalases (Anderson, 1996, Chance et al., 
1979). Another important antioxidant that is present within mammalian cells is 
Glutathione (GSH), this has been shown to have a critical role in preventing lung 
epithelial cell apoptosis (Hoidal, 2001). It has been shown that the GSH level is 
around 100 fold greater in the alveolar epithelial lining fluid compared to the 
plasma (van der Vliet et al., 1999). However, in numerous inflammatory 
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conditions including CF/BR, GSH levels are reduced and this reduction is 
potentially a contributing factor to the elevation observed in epithelial cell 
apoptosis (Roum et al., 1993, Hoidal, 2001).    
Apoptosis therefore, may play a role in the scarring observed in BR lungs. Due to 
a lack of mucociliary clearance, a vicious cycle develops where persistent 
bacterial colonisation of the mucus leads to chronic bronchial mucosal 
inflammation and progressive tissue destruction (Rogers et al., 2013). This 
inflammation can then drive further bacterial infections, which in turn drives 
further tissue damage and inflammation. This cycle leads to the typical symptoms 
observed in BR patients such as chronic and frequently purulent expectoration, 
multiple exacerbations and progressive dyspnoea (Rogers et al., 2013). 
Exacerbations are when the disease symptoms become more serve, normally 
these last for a couple of days and they are normally triggered by either an 
environmental stimulus or a microbial/viral infection. 
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Table 1.1: Diseases that can contribute to the onset of BR, adapted from (Boyton, 
2012). Recognised causes of bronchiectasis; around 50 % of the diagnosed cases of BR 
are idiopathic but the remaining 50 % of cases are often associated with other clinical 
conditions with BR being a disease endpoint. 
Cause Example Reference 
Post infection Can be caused by bacterial and 
viral infections e.g. Measles’s 
(Boyton, 2012) 
Mucociliary clearance 
defects 
Primary ciliary dyskinesia  (Morillas et al., 
2007) 
Inhalation of toxins Toxic gases 
Smoke inhalation 
(Boyton, 2012) 
 
Lung obstruction Foreign Body (Boyton, 2012) 
Immunodeficiency Hypogammaglobulinemia - 
characterised by reduction of 
all types of gamma globulins 
(Kainulainen et 
al., 1999) 
Malignancy Cancer and Leukaemia 
Chemotherapy (related to 
treatment) 
(Boyton, 2012) 
 
Autoimmune conditions Rheumatoid Arthritis – related 
to auto antibodies and 
abnormal serum 
immunoglobulin levels 
& 
Systemic lupus erythematous – 
causes systemic inflammation 
in the heart, joints, skin, lungs, 
blood vessels, liver, kidneys 
(McMahon et al., 
1993, Cohen and 
Sahn, 1999) 
 
 
(Higenbottam et 
al., 1980) 
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and the nervous system 
& 
Relapsing polychondritis – 
damage to cartilage containing 
tissues, it can become life 
threatening when starts to 
affect the respiratory tract 
& 
Ulcerative colitis – an 
inflammatory bowel disease 
that mainly affects the colon  
 
 
(Cohen and Sahn, 
1999) 
Congenital conditions Tracheobronchomegaly –
abnormal widening of the upper 
airways leading to lower airway 
infections, also known as 
Mounier-Kuhn syndrome 
(Schwartz and 
Rossoff, 1994) 
 
Other Yellow nail syndrome 
Mercury poisoning 
Fibrosis of the lung for 
example, Sarcoidosis 
(Cohen and Sahn, 
1999) 
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1.4. THE INCDENCE OF BACTERIAL SPECIES COLONISING THE 
CHRONIC LUNG 
The thick, nutrient mucus lining the lungs of chronic lung disease patients 
provides an environment that is ideal for opportunistic bacteria to colonise and 
proliferate within. Opportunistic bacteria are classed as species that can take 
advantage of environmental changes and rapidly adapt to successfully colonise 
new niches (Peloux, 1985).  
In 2010, the commonly isolated bacterial species of the CF lung were reviewed 
and it was seen that they included Staphylococcus aureus (S. aureus), 
Haemophilus influenzae (H. influenzae), Stenotrophomonas maltophilia, 
Achromobacter xylosoxidans, Burkholderia cepacia complex C and 
Pseudomonas aeruginosa (P. aeruginosa) (LiPuma, 2010).  
It has been proposed that the pattern of bacterial colonisation in paediatric CF 
patients usually involves early colonisation with S. aureus and non – capsulated 
H. influenzae (Hart and Winstanley, 2002). These pathogens are the main ‘early’ 
opportunistic bacterial species to colonise the lungs of paediatric CF patients. 
They remain the main colonisers until their succession by P. aeruginosa and 
Burkholderia cepacia complex C. This succession is believed to occur around 
school age or during early adolescence (Tümmler and Kiewitz, 1999). 
Burkholderia cepacia complex C is only found in a small percentage of CF 
patients. It is a metabolically versatile bacterium that is found in a wide variety of 
environmental niches and its association with the CF lung can have serious 
health implications, somewhat more so than P. aeruginosa (Davis et al., 1996, 
Govan and Deretic, 1996). 
Recent studies involving metagenomics and 16S rRNA (ribosomal RNA) gene 
sequencing have highlighted that the complexity of the microbial communities in 
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the CF and BR lung is greater than previously perceived. However, care must be 
taken when using the data generated via 16S rRNA sequencing as the data can 
sometimes make it hard to resolve taxonomies at the species level and may also 
introduce bias via the PCR amplification step in the sequencing programme (Lim 
et al., 2014, Filkins et al., 2012, Cai et al., 2013). P. aeruginosa growth in the 
mucus lining the chronic lung generates steep oxygen gradients which allows for 
the colonisation of the lung with anaerobes thus, making chronic lung infections 
polymicrobial in nature (Tunney et al., 2008). It has been seen that anaerobes 
are present in comparable numbers to P. aeruginosa and S. aureus (Worlitzsch 
et al., 2009). Staphylococcus saccharolyticus and Peptostreptococcus prevotii 
are the most prevalent anaerobes detected in the CF lung (Worlitzsch et al., 
2009). The presence of P. aeruginosa doesn’t have any impact on the likelihood 
of the onset of colonisation by anaerobes (Worlitzsch et al., 2009).  
Filamentous fungi have also been isolated from the respiratory tract of CF 
patients, in particularly Aspergillus fumigatus which is associated with reduced 
lung function (Saunders et al., 2016). Fungi comprise under < 0.1 % of the total 
microbiota of the lung but they have been shown to have major roles in 
maintaining structure, metabolic function and immune priming functions (Zelante 
et al., 2016). These studies have emphasised the complexity of the microbiota of 
the lower lung in chronic respiratory disease patients, the viral diversity is 
described in detail in section 1.4.1. 
The bacterial species which colonise the BR lung are similar to the bacterial 
species isolated from the CF lung but there are a few exceptions. Bacterial 
isolates that are present in both disorders include P. aeruginosa, H. influenzae 
and S. aureus. Bacterial species that are more descriptive of the BR lung include 
Streptococcus pneumoniae and Moraxella catarrhalis (Rogers et al., 2013, 
Pasteur et al., 2000, Nicotra et al., 1995, Pang et al., 1989, Angrill et al., 2002, 
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Barker, 2002). Emerging evidence has led to the observation that P. aeruginosa 
and H. influenzae colonisation of the BR lung stimulates numerous neutrophilic 
and inflammatory responses, which may be a driving force for the numerous 
cycles of bacterial infections which are characteristic of BR (Barker, 2002, Angrill 
et al., 2001). Numerous research groups have shown that P. aeruginosa 
colonisation within the BR lung correlates to increased sputum production, more 
hospitalisations and reduced quality of life (Wilson et al., 1997, Ho et al., 1998, 
Barker, 2002). 
 
1.4.1. Viral diversity within the chronic lung 
Bacterial communities in the CF lungs are spatially heterogeneous, so it has 
been proposed that the viral communities in the lower lung may also vary 
spatially leading to localised viral infections (Willner et al., 2012). Spatial 
heterogeneity is the uneven distribution of various concentrations of the different 
species within a microenvironment. It has been seen that the apical lobes of the 
lungs harbour very few viral genotypes, this niche in 2012 was proposed to be 
one of the least inhabited niches known (Willner et al., 2012). The basal lobes 
harbour ~ 102 viral genotypes and so these distribution differences show the 
spatial nature of viral species within the lungs (Willner et al., 2012). Generally, 
bacteriophages (section 1.6) outnumber eukaryotic viruses both in abundance 
and diversity in the human virome which includes the lungs (James et al., 2015, 
Lim et al., 2014). Metagenomic analysis of the CF lung virome couldn’t identify all 
the viral species present but out of the proportion identified it was seen that the 
majority were mostly infective against CF pathogens and these included many 
bacteriophages which targeted Pseudomonas species (Lim et al., 2014, James 
et al., 2015). 
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Before the invention of polymerase chain reaction (PCR), the incidence of viral 
infections in the CF lung was believed to be low (around 10 - 28 % of patients) 
(Wang et al., 1984, Ong et al., 1989, Smyth et al., 1995, Ramsey et al., 1989, 
Singanayagam et al., 2012). However, since the advent of this technology the 
detection of viruses in CF patients has risen to around 50 – 60 % (Armstrong et 
al., 1998, Wat et al., 2008, ALMEIDA et al., 2010, Singanayagam et al., 2012).  
There is now an increasing amount of evidence which states that viral infections 
particularly the influenza virus and the respiratory syncytial virus increase the 
incidence and severity of secondary bacterial infections such as sepsis and 
pneumonia (Bustamante-Calvillo et al., 2001, Kim et al., 1996, KORPPI et al., 
1989, Schwarzmann et al., 1971, Avadhanula et al., 2006). It is proposed that 
viral infections may predispose the sufferer to develop secondary bacterial 
infections due to impaired mucocillary function, host inflammation alterations and 
also by damaging the respiratory epithelium (Murphy and Sethi, 1992, Wilson 
and Cole, 1988, Avadhanula et al., 2006). The most frequently isolated bacterial 
species from the chronic lung environment which have associated viral infections 
are non-typeable H. influenzae and Streptococcus pneumonia (Smith et al., 
1976, White et al., 2003, Avadhanula et al., 2006). In 1996, it was observed that 
85 % of new pseudomonal colonisations of the chronic lung were preceded by an 
upper respiratory viral infection (Collinson et al., 1996, van Ewijk et al., 2005).  
Viral infections in CF have been associated with an increase in patient morbidity 
as infections result in prolonged hospital stays, a persistent but noticeable 
decrease in pulmonary function, increased antibiotic use and a higher occurrence 
exacerbation events (van Ewijk et al., 2005). The respiratory syncytical virus is 
found in the highest numbers in CF patients, it is found in some cohorts in 9 – 58 
% of virus infected CF patients (Abman et al., 1988, Armstrong et al., 1998, van 
Ewijk et al., 2005). This is followed by Influenza virus (type A and B) which has 
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been reported in 12 – 27 % of CF patients infected with a respiratory virus 
(Hordvik et al., 1989, van Ewijk et al., 2005). Other viral entities have been 
detected but their detection rate is low; Parainfluenza, Enteroviruses, Epstein 
Barr virus and cytomegalovirus (Pribble et al., 1990, van Ewijk et al., 2005).  
 
1.5. PSEUDOMONAS AERUGINOSA 
P. aeruginosa is a member of the Ȗ-subdivision of the Proteobacteria and is a 
species of the Pseudomonas genus. P. aeruginosa is normally between 1 to 5 
µM long and 0.5 to 1.0 µM in diameter. P. aeruginosa harbours a GC rich (65 %), 
double-stranded DNA chromosome (dsDNA) with the chromosome ranging in 
size from between 5.2 to 7 Megabase pairs (Mb) (Tümmler and Kiewitz, 1999, 
Qiu et al., 2006). P. aeruginosa is a Gram negative bacterium with a highly 
conserved genetic core region and a mosaic accessory element. This accessory 
element is generated due to the presence of multiple genomic islands 
(Winstanley et al., 2009).  P. aeruginosa was originally isolated from the soil as a 
plant pathogen where it was found to be capable of breaking down polycyclic 
aromatic hydrocarbons, in order to generate rhamnolipids and quinolones (Maier 
and Soberon-Chavez, 2000, Rendell et al., 1990). In accordance with the 
previously described opportunism of P. aeruginosa; P. aeruginosa has now been 
isolated from a range of human clinical disorders such as urinary tract infections 
(Salmen et al., 1983, Ferroni et al., 1998), burn victims (Japoni et al., 2009, 
Church et al., 2006, Altoparlak et al., 2004, Estahbanati et al., 2002), and in CF, 
BR and Keratitis patients (Dart and Seal, 1988, Stewart et al., 2011). Nosocomial 
pneumonia in patients who require mechanical ventilation is one of the most 
common hospital infections and P. aeruginosa often plays a key role in the onset 
of disease in this patient subgroup (Bodey et al., 1983, Vallet et al., 2001). The 
isolation of P. aeruginosa from the hospital environment compounds the notion 
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that P. aeruginosa infections have serious implications in human health and this 
supports work undertaken by researchers who want to determine how to control 
the spread of P. aeruginosa infection within an environment. 
In order for P. aeruginosa to thrive in so many environmental niches, it is not 
surprising that the bacterium utilises multiple respiratory pathways which relate to 
the environment in which the bacterium is residing. P. aeruginosa is traditionally 
thought of as an aerobic bacterium with a coccobacillus phenotype but it can also 
be referred to as a facultative anaerobe. Quinn et al (2014) studied the sputum of 
CF patients using Kyoto Encyclopaedia of Genes and Genomes (KEGG) profiles 
and it was seen that nitrate reductase was an abundant electron acceptor. This 
indicates the role that P. aeruginosa has in nitrogen denitrification in the CF lung 
and therefore, in anaerobic metabolism (Quinn et al., 2014). This was also 
emphasised as the concentration of ammonia in the sputum was elevated in 
relation to the saliva of healthy individuals, so again showing the ability of P. 
aeruginosa to persist in anaerobic conditions (Quinn et al., 2014). It is also 
possible that this nitrogen by-product will have an effect on the pH of the mucus 
lining the airways, which in turn may influence which other bacteria can co-
colonise this particular niche. Another elevated compound observed is 
Cytochrome C oxidase. This finding further supports the hypothesis that P. 
aeruginosa can respire and survive in anaerobic conditions, such as the biofilms 
lining the airways of patients (Quinn et al., 2014).  
 
1.5.1. Phenotypic differences between P. aeruginosa strains isolated 
from chronic respiratory disease patients 
It has been reported that CF patients are initially colonised with a clonal 
population of P. aeruginosa (Martin et al., 1995, Oliver et al., 2000). Therefore, 
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studies that show variation in the behaviour or phenotype of P. aeruginosa during 
the course of an infection are of particular interest. This again becomes 
increasingly interesting if the core genetic backbone shows no alteration 
throughout the infection timeline. In a bacterial population, clones are defined as 
bacteria that are not distinguishable by genetic methods and have descended 
from a common ancestor (Spratt, 2004, Maatallah et al., 2011). Several studies 
have recently proposed that P. aeruginosa doesn’t have a clonal population like 
originally thought, rather P. aeruginosa has a non-clonal population which is 
dotted with highly successful epidemic clones (Maatallah et al., 2011, Denamur 
et al., 1993, Picard et al., 1994, Cornelis, 2008, Curran et al., 2004, Kiewitz and 
Tümmler, 2000, Scott and Pitt, 2004).  
Transmissible strains have been isolated which can infect a large number of 
patients and these strains have been seen to move around human host 
populations. These strains also exhibit phenotypic differences when compared to 
lab strains of P. aeruginosa and so these differences may allude to the success 
rates of these transmissible strains. Examples of some of these transmissible 
strains are described in table 1.2 along with the pre-mentioned phenotypic 
differences.  
Interestingly, clinical studies have often showed that clonal populations of P. 
aeruginosa in fact can exhibit diverse colony morphologies (Drenkard and 
Ausubel, 2002b, von Gotz et al., 2004, Haussler et al., 2003, Workentine et al., 
2013). When investigating colony morphologies between clonal isolates, 
differences are proposed when there are alterations relating to motility (Lee et al., 
2005a, Leone et al., 2008, Workentine et al., 2013), quorum sensing (Workentine 
et al., 2013, Wilder et al., 2009, Lee et al., 2005a), production of virulence factors 
(Lee et al., 2005a, Leone et al., 2008, Fothergill et al., 2010, Workentine et al., 
2013), antibiotic susceptibility (Workentine et al., 2013, Foweraker et al., 2005, 
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Foweraker et al., 2009, Fothergill et al., 2010) and biofilm formation (Lee et al., 
2005a, Workentine et al., 2013). Some key virulence factors of P. aeruginosa are 
listed in table 1.3, the overexpression or down-regulation of some of these 
factors may trigger the phenotypic differences that are observed within P. 
aeruginosa populations.  
During the course of P. aeruginosa infection within the lower airways of the 
CF/BR lung, P. aeruginosa can alter its phenotype but these colony phenotypic 
alterations are not always due to genetic changes occurring within the core P. 
aeruginosa genome (Zierdt and Schmidt, 1964, Häußler et al., 1999). These 
phenotypic alterations include the production of a mucoid phenotype (Deretic et 
al., 1994), formation of dwarf/small colony variants (Martin et al., 1995), 
generation of lipopolysaccharide deficient variants (Dasgupta et al., 1994), 
formation of a rough phenotype (Martin et al., 1995), and some P. aeruginosa 
isolates have also been observed to have a hyperpilated phenotype upon 
isolation from the chronic lung (Deziel et al., 2001). All these phenotypic 
alterations enforce the heterogenic nature of the bacterial communities which 
colonise the CF/BR lung.  
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Table 1.2: Examples of some of the transmissible strains of P. aeruginosa isolated 
from CF patients around the globe. Some phenotypic differences between the various 
strains has been alluded to which may explain the success rates of these transmissible 
strains globally.  
P. aeruginosa 
transmissible strain 
Phenotypic differences References 
Liverpool (LES) Greater virulence 
observed, 
Can replace previously 
established P. aeruginosa 
strains, 
Infect non-CF 
parents/carers, 
Possess genomic islands, 
Upregulation of 
antimicrobial sensitivity 
genes, 
Non-motile due to the 
lack of a visible 
flagella/pili, 
Premature expression of 
Quorum sensing genes 
(Scott and Pitt, 2004, 
McCallum et al., 2001, 
McCallum et al., 2002, 
Parsons et al., 2002, 
Winstanley et al., 2009, 
Salunkhe et al., 2005) 
Manchester (MES) Identified in 2001 in a 
Manchester (UK) CF 
clinic, 
Highly resistant to anti-
pseudomonal antibiotics, 
(Scott and Pitt, 2004, 
Jones et al., 2001, 
Fothergill et al., 2012) 
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Contains only one 
pathogenicity island – MA 
island 
Australian (AES-1/AES-
2) 
AES-1 first identified in 
Melbourne, now also 
isolated in Brisbane 
AES-1 causes increased 
hospital visits, 
AES-2 is more common 
in Brisbane, 
AES-2 exhibits elevated 
antibiotic resistance, 
Both strains cause an 
increase in virulence 
factors such as protease 
IV, elastase and alkaline 
protease, 
Both strains also exhibit 
up-regulation of type III 
secretion systems and 
enhanced biofilm growth 
(Scott and Pitt, 2004, 
Armstrong et al., 2002, 
Syrmis et al., 2004, 
O'Carroll et al., 2004, 
Smith et al., 2006, 
Tingpej et al., 2007, 
Manos et al., 2008, 
Manos et al., 2009, 
Fothergill et al., 2012) 
Clone C Widespread distribution in 
both clinical and 
environmental settings, 
Not detected to cause an 
elevation in biofilm 
formation or antibiotic 
(Scott and Pitt, 2004, 
Römling et al., 2005, 
Fothergill et al., 2012) 
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resistance 
Midlands-1 Little is known about this 
strain even though it has 
a high prevalence within 
the CF community, 
Not highly antibiotic 
resistant, 
No link to increased 
morbidity, 
Possible link between age 
and the time of 
acquisition of the strain 
(Scott and Pitt, 2004, 
Chambers et al., 2005, 
Fothergill et al., 2012) 
Stoke/Trent Little is known about this 
strain 
(Fothergill et al., 2012, 
Scott and Pitt, 2004) 
Sheffield Little is known about this 
strain 
(Fothergill et al., 2012, 
Edenborough et al., 
2004) 
Leeds Little is known about this 
strain 
(Fothergill et al., 2012, 
Denton et al., 2002) 
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Table 1.3: Some key virulence factors of P. aeruginosa. Through the overexpression 
or down-regulation of some of these factors it is proposed that some of they will generate 
some of the phenotypic differences observed within P. aeruginosa populations. 
Virulence factor Role of this factor in P. 
aeruginosa 
Reference 
Quorum Sensing (QS) High bacterial cell density 
triggers the QS system, 
the activation of this 
system leads to the 
production of two P. 
aeruginosa toxins: 
Elastase 
Pyocyanin 
(Hauser, 2011) 
Type II Secretion system System utilised by 
bacteria in order to inject 
a set of toxins into the 
cytosol of the host, 
In P. aeruginosa the 
toxins injected are: 
ExoU 
ExoS 
both of the toxins have 
links to bacterial 
virulence 
(Hauser, 2011, Hauser, 
2009) 
Lipopolysaccharide O-
antigen 
Variable polysaccharide 
that decorates the outer 
surface of P. aeruginosa 
(Hauser, 2011, Pier, 
2007) 
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and protects the bacterial 
cell from complement 
mediated lysis, 
Differences in the O-
antigen of P. aeruginosa 
also allows for bacterial 
serotyping 
Flagella and pili These bacterial 
appendages are required 
for adhesion, motility and 
mediating an 
inflammatory response in 
the host’s immune 
system 
(Gellatly and Hancock, 
2013) 
Proteases Bacterial proteases can 
degrade immunoglobins 
and fibrin in order to 
disrupt the functioning of 
the tight epithelial 
junctions of the host’s 
immune system, 
In the lung proteases can 
degrade the lung 
surfactant which allows 
for enhanced bacterial 
colonisation, 
Some examples of P. 
(Gellatly and Hancock, 
2013, Kipnis et al., 
2006, Fleiszig and 
Evans, 2002, Laarman 
et al., 2012, Toder et 
al., 1994, De Kievit and 
Iglewski, 2000) 
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aeruginosa proteases 
include: 
Alkaline protease 
LasA 
LasB 
Protease IV 
Exotoxin A Inhibits the host’s 
elongation factor 2 which 
affects protein synthesis, 
which in turn causes 
death of the host cell 
(Gellatly and Hancock, 
2013) 
Lipases and 
phospholipases 
These products break 
down surfactant lipids 
and phospholipids of host 
cell membrane’s in order 
to allow the bacterial 
strains to pass unaided 
into their host cell 
(Gellatly and Hancock, 
2013, Kipnis et al., 
2006) 
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1.5.1.1. Small colony variants  
Small colony variants (SCVs) are often resistant to aminoglycosides and have 
been seen to develop in P. aeruginosa populations both in vivo and in vitro. 
Drenkard and Ausubel (2002) indicated that P. aeruginosa was capable of 
undergoing transient phenotypic changes and that these changes allowed for the 
appearance of antibiotic resistant SCVs both in vitro and in vivo. This conversion 
is a result of phase variation; a common phenomenon in Gram negative bacteria 
that is governed by alterations in environmental signals resulting in an change to 
the observable phenotype of the bacterial cell (Drenkard and Ausubel, 2002b, 
Henderson et al., 1999). A unique feature of P. aeruginosa SCVs is their ability to 
revert back to their wild-type, fast growing phenotypes after the pressure of 
antibiotic treatment has been reduced and the surrounding environment has 
become more stable and less stressed due to the antibiotic treatment (Häußler et 
al., 1999). This phenotype is often selected for when P. aeruginosa has been 
subjected to prolonged antibiotic therapy and is growing as part of a biofilm 
(Deziel et al., 2001, Häußler, 2004). P. aeruginosa biofilms can also harbour 
multiple P. aeruginosa isolates which all have different phenotypes thus, 
indicating the diversity and synergy of P. aeruginosa (Drenkard and Ausubel, 
2002b, Woo et al., 2012).  
The detection of SCVs in the chronic CF lung has been not only been associated 
with lesser lung function but SCV-positive patients are also normally lower in 
weight when compared to their CF counterparts who are the same height but 
SCV-negative (Häußler et al., 1999). SCV-positive patients are given anti-
psuedomonal drugs via aerosols because it increases the concentration of the 
drug that can reach the infected lower lung. Even though these aerosolised drugs 
have been seen to decrease the density of P. aeruginosa in the chronic CF lung, 
they do not eradicate SCVs completely (Häußler et al., 1999, Ramsey et al., 
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1993). SCV formation is a key adaptation technique for P. aeruginosa and it may 
explain why this bacterium can become so predominant in chronic lower lung 
infections (Malone et al., 2012).  
 
1.5.1.2. Mucoid phenotype 
The mucoid phenotype of P. aeruginosa, figure 1.2, is commonly isolated in 
chronic respiratory disease patients and it is caused by the overexpression of 
alginate, normally through a mutation in the mucA transcriptional regulator gene 
(Lee et al., 2005a, Speert et al., 1990, Mathee et al., 1999, Govan and Deretic, 
1996). The appearance of a mucoid P. aeruginosa phenotype is associated with 
a poorer prognosis and a deterioration in lung function, due to the increased 
tissue damage which is caused by the overproduction of alginate (Høiby et al., 
2001). Alginate overproduction causes this deterioration in lung function through 
accelerating biofilm production which allows for cells to become antibiotic 
resistant. Alginate also causes cells to become resistant to opsonisation and so 
this affects the host’s immune system. Another alteration that occurs in the host’s 
immune system is a decrease in polymorphonuclear leukocyte chemotaxis. All 
these factors trigger the reduction in lung function observed in CF/BR patients 
however, alginate overproduction can also be advantageous for P. aeruginosa 
cells colonising the lungs. 
Alginate as mentioned allows for the formation of an extracellular matrix (ECM) 
which encases the bacterial cells and so provides them with protection from 
external challenges like antibiotics and antimicrobials for example (Damron et al., 
2011). It is believed that the optimum time to treat chronic CF lung infections is 
before conversion to the mucoid phenotype, as the bacterial infection 
subsequently becomes increasingly difficult to treat with antimicrobials and 
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antibiotics due to the ECM (Damron and Goldberg, 2012). Alginate can therefore, 
be referred to as a virulence factor that P. aeruginosa can utilise in order to 
successfully colonise the chronic lung. However, non-mucoid phenotypes of P. 
aeruginosa can be isolated after long-term colonisation in the CF lung alongside 
mucoid P. aeruginosa isolates (Mahenthiralingam et al., 1994). This observation 
implies that the mucoid phenotype is not essential for long-term adaptation and 
colonisation of the chronic lung. Alginate is a polymer composed of D-
mannuronic and L-guluronic acid (Hogardt and Heesemann, 2010) and its 
production is tightly controlled by the algD-algA operon. This operon is controlled 
by AgtT (AlgU) which controls the expression levels of algD. algT belongs to the 
operon which also includes mucA, which as described previously has a role in 
mucoid phenotype conversion. 
It is of particular interest as to how one mutation can have such dramatic effects 
on the phenotype of the bacterium and how the bacterial cell evolves, in order to 
overcome the host’s defence system and aid its own survival within the chronic 
lung (Hogardt and Heesemann, 2010, Govan and Deretic, 1996).  
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Figure 1.2: Phenotypic differences that can be observed between Pa isolates 
originating from the chronic lung (Hauser et al., 2011). The two different phenotypes 
are shown on this image, mucoid (A) and non-mucoid (B). Both phenotypes are often 
isolated side-by-side from chronic respiratory disease patients.  
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1.5.2. P. aeruginosa colonisation of the chronic lung 
When CFTR is functioning correctly, long term colonisation of P. aeruginosa 
within the mucus layer doesn’t occur as the P. aeruginosa is detected and 
internalised. When a patient harbours a faulty CFTR, not only can P. aeruginosa 
remain associated with the airway due to impaired binding to the mucus layer but 
the concentration of sialylated glycolipids present on the surface of mucins is 
also higher than normal and these glycolipids provide additional binding 
receptors for P. aeruginosa (Callaghan and McClean, 2012). Another alteration 
that occurs in CF lungs is an increase in the number of fucosyl residues present 
on membrane glycopeptides to which P. aeruginosa can bind via fucose specific 
lectins. So this alteration further increases the amount of binding sites available 
for P. aeruginosa within the chronic lung environment (Callaghan and McClean, 
2012). Cell death is elevated in CF airways due to raised ceramide levels and the 
associated cell debris generates more adherence sites for P. aeruginosa.  
P. aeruginosa is also able to interact with the host’s immune system, for 
example, through the overproduction of alginate (section 1.5.1.2) which allows for 
the bacterium to become more successful when colonising the chronic lung. A 
common problem detected in CF patients is reduced macrophage clearance. The 
amount of white blood cells that are able to engulf and phagocytise bacterial 
pathogens is reduced which gives P. aeruginosa a greater chance of avoiding 
host cell detection and enabling its survival in the chronic CF lung (Callaghan 
and McClean, 2012).  
Comparative genomic studies have revealed that bacteriophages also play key 
roles in the evolution and adaptation of P. aeruginosa in the chronic lung as well 
as influencing the genomic diversification of the bacterial population (Davies et 
al., 2016b, Brüssow et al., 2004). Bacteriophages are described in more detail in 
section 1.6, as well as in further chapters where the interactions between the 
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bacterial and phage communities within the CF/BR lungs have been studied in 
greater depth (Chapters 3 and 4 predominantly). Bacteriophages in brief, may 
allow P. aeruginosa to adapt to the chronic lung as they can help the bacteria to 
develop a biofilm community which enhances the antimicrobial resistance profiles 
of the bacterium whilst also enhancing the ability of the bacterium to avoid host 
cell defence systems (Silby et al., 2011, Costerton et al., 1995, Drenkard and 
Ausubel, 2002b). It has previously been mentioned how virulence factors of P. 
aeruginosa (section 1.5.1) can also lead to the development of a biofilm 
community so showing that P. aeruginosa colonisation to the CF/BR lung is 
multifactorial.  
Biofilms/pellicles are described in more depth later in this thesis (chapter 5). 
However, biofilms occur when cell-density reaches a threshold level and this 
triggers the activation of the quorum sensing system. Upon activation of this 
system, an extracellular matrix is generated which encases the bacteria cells and 
provides them with protection from antimicrobials, antibiotics and detergents. A 
pellicle forms by the same principles as a biofilm however, their production 
requires an air-liquid interface. Pellicles are studied in this thesis as it is believed 
that they are more representative of the chronic lung environment.  
The CF airways are a complex network of different niches and these areas allow 
for the development of bacterial populations which are well adapted to colonise 
the particular niches due to the individual selection pressures imposed upon 
them by the different areas of the lung (Marvig et al., 2015). The heterogeneity of 
the lung has been previously mentioned when the various viral species 
colonising the lung where discussed (section 1.4.1).  
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1.5.3. Identification and characterisation of P. aeruginosa strains in 
CF/BR 
P. aeruginosa isolates collected at routinely attended CF clinics are typed via 
variable number tandem report (VNTR) in order to aid strain identification (Turton 
et al., 2010). VNTR typing involves determining the number of repeats at nine 
variable-number tandem repeat sites throughout the genome. These repeats are 
targeted using Polymerase Chain Reaction (PCR) which allows for the rapid 
identification of bacteria and this has large implications in clinical settings (Turton 
et al., 2010). The most prevalent P. aeruginosa strain isolated in a study of adult 
CF patients being treated at CF clinics throughout England and Wales was the 
Liverpool Epidemic Strain (LES), followed by the Manchester Epidemic Strain, 
Midlands 1, Melbourne Strain and Clone C (Fothergill et al., 2012, Scott and Pitt, 
2004). Various other strains of P. aeruginosa were isolated but these were 
classed as unique until they had been identified in a larger patient cohort 
(Fothergill et al., 2012, Scott and Pitt, 2004). These transmissible strains have 
been previously described in table 1.2.  
LES was initially isolated in 1996 due to its high incidence rate and also due to its 
resistance to ȕ lactamase antibiotics (Cheng et al., 1996). LES has been 
characterised as super infective as it out-competes other strains of P. aeruginosa 
in the CF lung. Interestingly, this bacterium has been reported to colonise non-
CF patients/CF carers and it has been shown to cross the species barrier as it 
has also been isolated in a CF patients cat (Mohan et al., 2008). Ashish (2012) 
showed the increase in resistance of LES to standard anti-pseudomonal 
antibiotics from 2004 to 2008; figure 1.3.  
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Figure 1.3: Increase in resistance of LES to standard anti-pseudomonal antibiotics. 
The period from 2004 to 2008 is shown and it shows the increase in resistant isolates 
and the decrease in sensitive isolates to current antibiotics (Ashish et al., 2012).  
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1.5.4. Bacterial cross infection in the chronic lung environment 
The first case of bacterial cross infection observed between chronic respiratory 
disease patients was in 1984 when 11 patients in a CF clinic based in Leeds, UK 
were infected with the same strain of Pseudomonas cepacia (P. cepacia) 
(Simmonds et al., 1990). However, it was not generally accepted that the 
isolation of this bacterium in all 11 patients was due to cross infection until 1993. 
It was more envisaged that each patient had become colonised with P. cepacia 
individually (Govan et al., 1993, Smith et al., 1993). In the early 1λ70’s, CF 
patients were treated at CF summer camps and it was observed that the 
frequency of P. cepacia being isolated from patients steadily increased as time 
progressed; 10 % of patients in 1971 compared to 18 % of patients in 1981 
(Thomassen et al., 1986, Isles et al., 1984). In 1984, it was shown that this 
increase in patients becoming colonised with P. cepacia was leading to higher 
morbidity rates (Isles et al., 1984). Even though the premise of bacterial cross 
infection between CF patients pre-1993 was not proven, some hospitals from 
1983 onwards did treat CF patients colonised with P. cepacia separately to 
culture negative individuals. These interventions and precautions are still 
followed in all UK hospitals. In 1992, P. cepacia was reclassified as Burkholderia 
cepacia (B. cepacia). In 1997, it was found through serotyping that B. cepacia 
was in fact split into at least 17 genetically distinct species groups, which is why 
this bacteria is often referred to as B. cepacia complex C (Coenye et al., 2001, 
Vermis et al., 2002, Eram et al., 2004, Rushton et al., 2013, LiPuma, 2010).  
Cross infections occurring in the BR lung are not as well-known but it is premised 
that P. aeruginosa will behave in a similar manner. BR patients are not always 
treated in hospitals according to their bacterial colonisation as they are often 
being treated in various wards relating to other health problems, which normally 
are a result of increased patient age (personal communication).  
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1.6. BACTERIOPHAGE/PHAGE 
Francis Twort and Felix d’Herelle are given the honour of independently 
discovering bacteriophages in the 1900’s (d’Herelle, 1λ17, Twort, 1915). They 
both observed altered growth in the bacterial strains they were investigating and 
named these entities ‘bacteria eaters’ or ‘bacteriophages’. These ‘bacteria eaters’ 
were described as entities that could be filtered away from bacteria yet still 
eradicate subsequent bacterial populations (d’Herelle, 1λ17, Twort, 1915). 
Sulakvelidze et al (2001) detailed that there were in fact two earlier discoveries of 
bacteriophages but neither labs followed up their discoveries. A British 
bacteriologist Hankin in 1896 reported the presence of marked antibacterial 
activity against Vibrio cholera by an unidentified substance (Hankin, 1896). Two 
years later a Russian bacteriologist Gamaleya, also observed a similar 
phenomenon but in this instance the bacterial background was Bacillus subtilis 
(Samsygina and Boni, 1984, Sulakvelidze et al., 2001, Van Helvoort, 1992). As 
neither labs followed up this research, it allowed the honour of discovering 
bacteriophages to be accredited to both Twort and d’Herelle (Sulakvelidze et al., 
2001).  
Bacteriophages are thought to be the most abundant biologically related entity in 
nature, outnumbering bacterial cells in a ten to one ratio (Fineran et al., 2009, 
Chibani-Chennoufi et al., 2004, Wommack and Colwell, 2000, Ashelford et al., 
2003). Recent estimates using epifluorescence microscopy has indicated that the 
amount of viruses in the ocean spans from ~ 106 mL-1 in the deep sea to ~ 108 
mL-1 in coastal waters (Suttle, 2005, Guixa-Boixereu et al., 2002, Ortmann and 
Suttle, 2005).  
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In the last century, phage research has shown that these viral entities are 
extremely diverse and ubiquitous in the biosphere. In 1987, it was described that 
there were around 4,500 different double stranded DNA phages which were 
capable of infecting a wide range of Gram negative and Gram positive bacterial 
hosts (Coetzee, 1987, Hendrix et al., 1999). Studies have also shown that any 
environment harbouring bacterial cells also allows for the isolation of 
bacteriophages (Hendrix et al., 1999, Ackermann, 1996, Bergh et al., 1989).  
Phages can also be isolated from a range of environments spanning from marine 
ecosystems to the human gut, showing the wide spanning nature of 
bacteriophages in environmental and clinical settings (Paul et al., 2002, Breitbart 
et al., 2008). Free phage has been isolated in sputum of CF patients at densities 
which were directly proportional to the levels of LES within the sputum (James et 
al., 2015). LES contains multiple prophages (Winstanley et al., 2009) however, 
James et al (2015) identified that phage 2 and 4 were most abundant in the 
sputum of the 10 LES infected patients studied. This is not the first finding of free 
phage in the sputum of CF patients (Ojeniyi et al., 1991, Fothergill et al., 2011) 
so the study presented by James et al (2015) adds strength to the hypothesis 
that free phage are widely identifiable in clinical settings.  
1.6.1. Bacteriophages and their life cycle 
 
1.6.1.1. Lytic bacteriophages 
Lytic bacteriophages cannot integrate into the bacterial chromosome and thus, 
are truly vegetative in nature. They infect their sensitive bacterial host, replicate 
and then lyse this host cell. This lysis allows their transmission into the 
surrounding cellular environment where the progeny viruses can infect other 
sensitive host cells and the circle can be repeated. Table 1.4 details some of the 
lytic bacteriophages of P. aeruginosa however, this is not an exhaustive list. 
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1.6.1.2. Temperate or lysogenic phages 
Bacteriophages have evolved 2 different life cycles in order to alter how they 
infect and proliferate within their bacterial host cells. These life cycles are termed 
lytic and lysogenic and are detailed in figure 1.4. Temperate/lysogenic 
bacteriophages upon infection of a sensitive host cell have the ability to integrate 
their viral genome into the chromosome of the recipient bacteria. This integrated 
phage, now termed a prophage, is replicated alongside any other bacterial 
chromosomal loci. These prophage regions remain site specifically integrated in 
the bacterial chromosome until an environmental stimulus induces the cellular 
SOS system and Rec mediated response (typical method in lysogenic 
bacteriophage). However, certain phages have been shown to integrate into 
multiple sites within the bacterial chromosome (Fogg et al., 2010) whereas, other 
phages can only integrate into their bacterial chromosome at specific sites. Table 
1.5 details some of the temperate bacteriophages of P. aeruginosa.  
Bacteria have been shown to have genomes studded with multiple prophages. 
The Gram negative bacteria P. aeruginosa and E. coli have been shown to 
harbour multiple inducible prophage regions (Winstanley et al., 2009, George et 
al., 1975, Bertani, 1951, Perna et al., 2001). The Gram positive bacteria S. 
aureus also has been seen to contain prophage regions (Goerke et al., 2009, Gill 
et al., 2005). Ramirez and colleagues found that around 75 % of the strains of 
Streptococcus pneumoniae harboured prophage regions (Ramirez et al., 1999, 
Obregón et al., 2003). 
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Table 1.4: Examples of some lytic bacteriophages which can target P. aeruginosa. 
This is not an exhaustive list of all the bacteriophages present in the environment with P. 
aeruginosa as a host.  
Lytic bacteriophage Reference 
LKD16 (Ceyssens et al., 2006) 
LKA1 (Ceyssens et al., 2006) 
PA1Ø (Kim et al., 2012) 
MPK1 (Heo et al., 2009) 
MPK6 (Heo et al., 2009) 
JG004 (Garbe et al., 2011) 
BVPaP-3 (Ahiwale et al., 2012) 
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Table 1.5: Examples of some temperate bacteriophages which can target P. 
aeruginosa. This is not an exhaustive list of all the bacteriophages present in the 
environment with P. aeruginosa as a host.  
Temperate bacteriophage Reference 
Pan70 (Holguín et al., 2015) 
PaMx73 (Cazares et al., 2014) 
H70 (Cazares et al., 2014) 
D3112 (Roncero et al., 1990) 
B3 (Roncero et al., 1990) 
F116 (Holloway et al., 1960) 
ɸCTX (Byrne and Kropinski, 2005) 
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Figure 1.4: Lytic and lysogenic pathway of phage infection (Sturino and 
Klaenhammer, 2006). This image shows the two pathways that phages can follow upon 
infection of a sensitive host. The lysogenic pathway shows the incorporation of the phage 
genome into the bacterial chromosome forming prophage regions. These prophages 
remain integrated into bacterial chromosome until the bacterium is stressed 
(UV/antibiotics), these regions are then induced from the bacterial chromosome. The 
phage particles upon induction from the bacterial chromosome enter into the lytic 
lifecycle causing host cell lysis and the release of infective phage particles which can 
spread and infect all the susceptible hosts within a particular niche (Sturino and 
Klaenhammer, 2006). 
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1.6.2. Lambdoid-like phages 
The typical phage lambda (Ȝ ) model of E. coli is described in detail here and this 
genetic model was initially proposed in the 1λ50’s (Fry, 1959, Lieb, 1953). The 
relationship between lysogenic conversion and the induction of the lytic cycle is 
very complex and involves multiple phage encoded proteins. Recently, new 
phages have been discovered which challenge the conventional mechanism.  
For example, some phages have the ability to re-infect their originating host cell 
so indicating that prophage carriage doesn’t prevent further phage infect ion in 
some bacterial species (Smith et al., 2012, Tariq et al., 2015). This phenomenon 
is further described in chapter 3.  
 
1.6.2.1. Phage adsorption and infection 
Ever since the initial observation of phage particles by electron microscopy in the 
1λ40’s, it has been possible to study the mode of adsorption that phages utilise 
in order to infect their susceptible host (Ruska, 1941, Luria and Anderson, 1942, 
Luria et al., 1943, Bayer, 1968). In the typical E.coli Ȝ model, the phage DNA is 
injected into the host’s chromosome via the phages tail protein, J. J interacts with 
LamB, which permits the entry of phage DNA into the bacterial host cell 
(Ptashne, 2004, Turner et al., 2007, Ptashne and Switch, 1992, Rakhuba et al., 
2010, Randall-Hazelbauer and Schwartz, 1973). Pilus dependant filamentous 
and RNA phages have been found for P. aeruginosa (Feary et al., 1964, Bradley, 
1966, Takeya and Amako, 1966, Olsen and Shipley, 1973, Bradley and Pitt, 
1974). Phage DNA is normally injected into the bacterial host cell as a linear 
segment which can re-circularise upon entry through the use of cos sites and 
host DNA ligase. 
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1.6.2.2. Phage life cycle decision – genetic regulation of lambdoid 
phage infection 
Host DNA gyrase causes the supercoiled DNA to unwind which allows for 
transcription to commence. Immediate early transcripts utilise phage encoded 
promoters; PL, PR and PR’. These transcripts lead to the expression of N and Cro. 
Cro functions by binding to the OR3 site on PRM which stops any PRM expression 
of CI. N functions via two N utilisation (Nut) sites; one binds to the PL reading 
frame and the other one binds to the cro gene region in PR. N is an anti-
terminator protein that allows for the expression of the reading frame to which it 
is bound. It does this by recruiting the host’s RNA polymerase which causes the 
expression of ‘late early’ gene transcripts; N, cro, CII, CIII, xis, int, O, P and Q 
(McLennan et al., 2012, Ptashne, 2004). CII and CIII are substrates for FtsH, a 
bacterial protease. CIII can prevent CII from being degraded since it acts as an 
alternative substrate (Shotland et al., 1997, Shotland et al., 2000). CII stability 
determines whether the phage enters into either a lytic or lysogenic lifecycle. 
When CII is available there is a propensity for lysogeny and lysis occurs if CIII 
and CII levels are depleted (Michalowski and Little, 2005). Figure 1.5 describes 
and details some of the genes involved in the phage life cycle decision process 
(Smith et al., 2007). The integration site of the prophage region can provide the 
bacterial host with selective advantages due to lysogenic conversion. Lysogenic 
conversion is described in more detail in chapter 3, but the principle is that the 
diversity of the bacterial host is elevated upon prophage formation and this may 
provide the host with a selective advantage compared to non-lysogenic/naïve 
bacterial cells. The expression of moron/accessory genes from the phage 
chromosome may also offer a selective advantage to both the bacterium and the 
phage. 
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Figure 1.5: Linear genome organisation of the well-studied stx phage, 933w (Smith 
et al., 2007). Upon entry of the phage genome into the E. coli host cell, the phage protein 
J interacts with LamB which allows for internalisation of the phage genome. The phage 
genome upon internalisation is in a linear format with att sites located at either end of the 
genome (not shown here). The annotations shown on this figure are: Int – integrase 
gene, Xis – excisionase gene, CIII – involved in the stabilisation of CII, N –early gene 
regulation role (its two operator sites are shown as oL1 and oL2), CI - λ repressor which 
inhibits iniation of the lytic lifecycle, cro – repressor involved in the regulation of the lytic 
lifecycle, CII – regulator of λ integrase synthesis and the λ repressor, O and P – phage 
DNA replication machinery, Q – late gene regulation, stxA2 and stxB2 – toxin genes. All 
the genes that fall under the bracket of structural genes are involved in the formation of 
the capsid, head, tail spike and the tail fibre.  
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1.6.2.3. Lysogenic lifecycle 
When CII reaches saturation levels it becomes stable, which in turn leads to the 
activation of its own promoters and this activation generates lysogeny and stops 
‘late early’ expression (Herskowitz and Hagen, 1980). CII promotes transcription 
from PRE, PI and Pantiq; PRE causes the OR3 site on PRM to be released by Cro 
which can therefore, also promote the transcription of CI. PI encodes for 
integrase (int) which contributes towards the incorporation of a lysogenic phage 
into the bacterial chromosomal backbone to form a prophage region. Pantiq 
switches off Q (anti-terminator) and stops late gene transcription thus, preventing 
expression and assembly of lytic and structural proteins. CI produced by PRE 
expression stabilises both the PR and PL promoters so therefore, ensuring that 
Cro is continually turned off. The operator regions of these promoters bind to 
both the OR1 and OR2 sites on Cro, which allows for constant CI expression. 
Once CI expression is established the promoters, PR and PL are switched off. 
This leads to a decrease in the production of CII/CIII and an overall reduction in 
transcription from the ‘late early’ gene promoters. The only promoters that remain 
active during lysogeny are involved in the maintenance of CI; PRM and PR’ 
(McLennan et al., 2012, Ptashne, 2004). 
 
1.6.2.4. Maintenance of the lysogenic state  
When CI binds to the OR1 site on Cro it prevents any further transcription from PL 
thus, causing any transcription to be terminated. CI can easily dimerise so upon 
binding to the OR1 site it can also bind to the OR2 site. This dimerisation leads to 
transcription commencing from PRM in the opposite direction. This expression can 
activate PR’ which ensures that only CI is transcribed when the phage is residing 
in the bacterial chromosome as a prophage (McLennan et al., 2012, Ptashne, 
2004).  
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1.6.2.5. Induction of the prophage  
When the host bacterium is stressed by external stimuli such as 
antimicrobials/antibiotics/UV radiation, the SOS response is activated and in 
most instances this leads to the activation of RecA. RecA* in lysogenic cells 
cleaves the CI dimer, CI upon cleavage loses its affinity for DNA. This means 
that the PR and PL promoters are no longer repressed and the phage can enter 
into the lytic lifecycle. Upon induction from the prophage region, temperate 
phages switch to lytic infection and cause host cell lysis in a manner similar to 
purely lytic bacteriophages. In order for the phage to be excised from the 
bacterial host chromosome a phage encoded integration protein, Xis, is required 
(Fogg et al., 2014).  
 
1.6.2.6. Lytic lifecycle 
Purely lytic bacteriophages and temperate phages that have been induced from 
their bacterial host cell chromosome follow the same pathway as soon as they 
enter into lysis. O binds to the origin of replication (ori) which determines the 
direction of phage expression. Then another product of late early gene 
expression, P, binds to DnaB (part of the E. coli replication machinery) and 
establishes lytic phage infection. Q (late early gene expression product) is also 
involved in lytic replication, as this protein binds to Q utilisation (Qut) sites on 
RNA polymerase which promotes lytic phage replication. PR’ expression 
continues throughout lytic phage infection, which generates mRNA for the 
production of the lysis, head and tail proteins. These structural proteins can then 
assemble to form new infective phage particles which can be excised from the E. 
coli genome via the production of holin. Holin aids the release of the phage 
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particles whilst also promoting host cell lysis (McLennan et al., 2012, Ptashne, 
2004).  
 
1.6.2.7. Mosaic layout of lambdoid-like phages 
Genetic mosaicism was identified for the first time in the later 1λ60’s/early 1λ70’s 
within the lambdoid phages isolated from enteric environments (Simon et al., 
1971, Westmoreland et al., 1969, Pedulla et al., 2003b). It was clear from these 
genetic studies that there were mosaic joints within the phage genomes and the 
occurrence of these joints was not due to random integration events. It was 
proposed that these joints occurred between genes or conserved clusters of 
genes on the phages backbone (Pedulla et al., 2003b).  
Mosaic genomes have also been seen in mycobacteriophages; L5, D29, Bxb1 
and TM4 (Pedulla et al., 2003b, Ford et al., 1998a, Ford et al., 1998b, Hatfult and 
Sarkis, 1993, Mediavilla et al., 2000). Even though these phages were isolated at 
different geographic locations and at different times, the phages have many 
features in common including morphology, genome size, structure and assembly 
gene organisation and related gene products (Pedulla et al., 2003b). L5 and D29 
have been shown to share over 75 % of their genes based on amino acid 
similarity, so showing the mosaic and modular nature of bacteriophages (Ford et 
al., 1998a, Pedulla et al., 2003b).
 
 
1.6.3. Bacteriophage of Pseudomonas 
The International Committee on the Taxonomy of Viruses (ICTV) defines that the 
temperate phage of Pseudomonas can be subdivided into tailed and non-tailed 
morphologies and can also be categorised according to their core genetic 
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backbone. The vast majority of Pseudomonas phage (over 97 % in 2010) had a 
morphology that represented the order Caudovirales. These phages have a 
dsDNA genome and are tailed. Around 3 % of the described Pseudomonas 
phage have a polyhedral, filamentous or pleomorphic morphology (PFP) 
(Ceyssens and Lavigne, 2010). The Caudovirales can be subdivided into three 
families (Myoviridae, Podoviridae and Siphoviridae). Some of the most common 
morphologies of tailed Pseudomonas phage are shown in figure 1.6. 
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Figure 1.6: Phenotypic differences observed in the tailed phages of Pseudomonas 
(Ceyssens and Lavigne, 2010). This is a representation of some of the most common 
tailed phages of Pseudomonas which had been isolated and characterised by 2010. A 
scale bar is included in order to scale the phage particles. 1) LUZ24 like phage LUZ14, 2) 
PB1-like phage LBL3, 3) D3112–like phage LAD2, 4) ɸ KZ, 5) YuA, 6) F116–like phage 
LL02 and 7) ɸKMV–like phage LUZ2. 
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1.6.3.1. Caudovirales phages of P. aeruginosa 
1.6.3.1.1. Myoviridae phages of P. aeruginosa 
The Myoviridae family all have long, helical tails that contract upon infection of 
their bacterial host. Within the Myoviridae, three distinct types of phage groups 
have been isolated which all have highly discrete genome architectures; these 
are phage KZ, phage CTZ and phage PB1 (Ceyssens and Lavigne, 2010). 
Phage KZ, a jumbo phage, was originally isolated in 1975 in Kazakhstan (Krylov 
et al., 1977). It was one of first of the large genome phages that can infect P. 
aeruginosa to be characterised. Jumbo phages have more than 200 bp of DNA 
and the majority of the predicted proteins from these phages have no similarity to 
known phage proteins (Hendrix, 2009). Phage KZ has a circular genome of 280 
kb, which means that it fits into the range of jumbo phage genomes that are seen 
in other bacterial species (210 – 316 kb) and it also encodes for between 201 – 
461 genes (Ceyssens and Lavigne, 2010). Phage CTZ is a temperate, cytotoxin 
converting myovirus that infects the P. aeruginosa strain, PAS10, via the γ’ end 
of the bacterial serine transfer RNA (tRNA) (Hayashi et al., 1990). It has a 35 kb 
genome and produces CTX, a pore-forming cytotoxin that increases host 
virulence (Baltch et al., 1994). Phage PB1 represents another distinct group of 
the Myoviridae phages of P. aeruginosa and it is composed of at least 22 
different proteins. 
 
1.6.3.1.2. Siphoviridae phages of P. aeruginosa 
Members of the Siphoviridae family are characterised by long and non-contractile 
tails. All the family members identified to date (2010) are temperate phages of P. 
aeruginosa (Ceyssens and Lavigne, 2010). With the most characterised 
examples being D3112; this is a type IV pili specific phage that can replicate its 
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40 kb genome by transposition. Interestingly, on excision from their bacterial 
host’s genome they accrue part of the bacterial host chromosome as it is 
incorporated inside the newly formed viral particles (Morgan et al., 2002). This 
misexcision aids the horizontal dissemination of genetic material throughout the 
phages host range. Phage D3, even though it is morphologically identical to 
D3112 its genome is larger (56 kb). D3 is also not transposable and it contains 
two distinct integration sites for prophage formation (Ceyssens and Lavigne, 
2010). YuA–like phage are also Siphoviruses but they are not as well studied, 
they do however, have elongated head sections which are similar to the ones 
identified when studying phage D3112 (Ceyssens and Lavigne, 2010).  
 
1.6.3.1.3. Podoviridae phages of P. aeruginosa 
Pseudomonas-specific podoviruses have short tails and only display minor 
differences in terms of capsid size and tail structure. Phage KMV is a podovirus 
which has a 42 kb genome. Recently, other phages have been isolated with 
similar sequence homology and these phages only carry minor insertions and 
deletions upon comparison to the original phage KMV genome. Examples of 
these phages are LKD16, LUZ19, PT2, PT5 and KF77; these phages share 
between 83 and 97 % homology with the KMV phage (Kulakov et al., 2009, 
Lammens et al., 2009, Ceyssens et al., 2006, Ceyssens and Lavigne, 2010). 
F116 and LUZ24-like phages are also associated with the Podovirus family; F116 
is unusual as it replicates as a pseudo-lysogen within its host cell, as it forms a 
plasmid rather than integrating into the host chromosome to form a prophage 
(Byrne and Kropinski, 2005). 
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1.6.3.2. Polyhedral, filamentous or pleomorphic morphology phages 
of P. aeruginosa 
The Inoviridae family are rod shaped, single stranded DNA (ssDNA) filamentous 
phages that adhere to their bacterial hosts via the pilus (Ceyssens and Lavigne, 
2010). The longest filamentous phages that have been found to infect P. 
aeruginosa are Pf1 and Pf3. Pf prophage sequences are common in P. 
aeruginosa strains and can account for some of the variation present between 
the multiple Pseudomonas strains (Ceyssens and Lavigne, 2010). Pf4 for 
example, has been shown to be involved with the appearance of SCV ’s in PAO1 
mature biofilms (Webb et al., 2004). The Cystoviridae are a family of the 
filamentous phages which have a double stranded RNA (dsRNA) genome 
encased within a lipid-containing membrane (Mindich et al., 1999). The 
Leviviridae family is the final family within these filamentous phages; these have 
positive sense single stranded RNA (ssRNA) genomes. These genomes are 
encased within an icosahedral capsid and they also have relatively small 
genomes of approximately 3.5 x 102 nucleotides (Persson et al., 2008, Ceyssens 
and Lavigne, 2010). 
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1.6.4. Prophage integration into susceptible bacterial hosts  
The incorporation of a prophage region increases the genetic size of the bacterial 
host and can offer positive or negative pressures which may aid selection for the 
bacterium. Desiere et al (2001) proposed that phage infection must offer a 
selective advantage for the bacterium otherwise Darwinian considerations would 
lead to the assumption that prophage inclusion would decrease bacterial fitness 
levels. It is proposed that prophage inclusion can increases the metabolic burden 
of the bacterial host due to the addition of extra DNA into the host bacterium. 
This therefore, makes replication more costly which reinforces the hypothesis 
that prophage regions must be advantageous for the host in order to compensate 
for this increased cost (Desiere et al., 2001, Ferretti et al., 2001). This increase in 
genome size may play a role in the evolutionary pathway of the bacteria. These 
potential evolutionary changes may be due to gene alterations which are 
generated as a result of transduction between the phage and the bacterium 
(Weinbauer and Rassoulzadegan, 2004).  
This genome size alteration is seen in both P. aeruginosa and E. coli upon phage 
incorporation. Winstanley et al (2009) showed that the LES genome (6.6. Mb) 
contained 5 inducible prophage regions and 1 defective prophage region. This is 
in contrast to the lab strain, PAO1, which has a smaller genome size of 6.3 Mb 
and is believed to harbour only two prophage regions which may explain the 
reduced genome size (Stover et al., 2000). The pathogenic strain of E. coli 
O157:H7, which originates from an E. coli outbreak within school children in 
Sakai, Japan has been shown to contain 18 prophages and prophage-like 
elements however, not all these phages are inducible (Ohnishi et al., 2001). This 
shigatoxigenic E. coli isolate has a genome size of 5.5 Mb (Hayashi et al., 2001) 
which is considerably larger than the lab strain of E. coli K12 which has a 
genome size of 4.6 Mb (Blattner et al., 1997, Lawrence and Ochman, 1998).  
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1.6.5. Bacterial and phage resistance mechanisms 
As a key focus of the research in this thesis is on the evolving interactions 
between the phage and its bacterial host thus, the ways in which bacteria prevent 
phage infections are important to understand. There are multiple anti–phage 
mechanisms described to date that limit bacterial sensitivity to viruses and will be 
described in detail in the next few sections. Detailed descriptions of the various 
mechanisms bacteria have evolved in order to reduce phage infection are shown 
in sections 1.6.5.1 to 1.6.5.5. 
 
1.6.5.1. Preventing phage adsorption 
In order to prevent phage adsorption, bacteria can alter their surface structures to 
prevent phage internalisation as phages wouldn’t recognise these new 
adsorption domains. In 1983, is was shown that phage resistant strains of 
Streptococcus lactis were resistant to phage infection by M18 (Streptococcus 
cremoris phage) due to alterations in the cell surface receptor sites, these sites 
therefore, altered phage adsorption (Sanders and Klaenhammer, 1983, King et 
al., 1983). Bacteria have also evolved mechanisms that prevent phage DNA 
injection into the bacterial chromosome thus preventing, lysis or prophage 
formation.  
 
1.6.5.2. Restriction modification (RM) systems 
RM systems were proposed by Arber and described by Smith and Welcox 
(Kühnlein and Arber, 1972, Smith and Welcox, 1970, Blumenthal and Cheng, 
2002). RM systems are one of the best studied host defence systems (Tock and 
Dryden, 2005, Stern and Sorek, 2011). They are composed of 2 components 
which restrict and modify the DNA entering into a bacterial host cell. Their main 
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function is to provide the bacterial host cell with protection cell against incoming 
foreign DNA, such as bacteriophage DNA (Arber, 1979, Pingoud and Jeltsch, 
2001). The restriction aspect of the system involves an endonuclease breaking 
the DNA backbone of the invading DNA sequence and generating a dsDNA 
break (Blumenthal and Cheng, 2002). The modification aspect involves a 
methyltransferase which ensures that non-foreign DNA is methylated and so is 
protected against restriction activity (Blumenthal and Cheng, 2002). Figure 1.7 
details the functionality of a typical type II RM system (Stern and Sorek, 2011). 
There are three types of RM system currently known which are characterised 
and identified according to their cofactor requirements, mode of action and 
subunit composition (Smith and Nathans, 1973, Pingoud and Jeltsch, 2001). 
Over 3,000 RM systems had been discovered by 2002 and they had been found 
in the full spectrum of known bacterial systems (Blumenthal and Cheng, 2002). 
Over 90 % of sequenced bacterial and archaea genomes contain RM systems 
(Roberts et al., 2010, Stern and Sorek, 2011). Haemophilus influenzae, 
Methanococcus jannaschii, Helicobacter pylori, Neisseria gonorrhoeae and 
Neisseria meningitids contain multiple RM systems whilst Treponema pallidum, 
Chlamydia and Buchnera almost always lack RM genes (Stein et al., 1995, Tomb 
et al., 1997, Alm et al., 1999, Kobayashi, 2001).  
Phage can counteract the effects of these systems through various alterations 
such as mimicking the DNA of the host and thus, not being detected by the host’s 
RM system. The Ocr protein of phage T7 blocks the active site of some of the 
restriction enzymes in E. coli RM systems through mimicking a 24 bp fragment of 
DNA and this prevents the degradation of the invading phage DNA 
(Bandyopadhyay et al., 1985, Stern and Sorek, 2011). Phage 1 of Bacillus 
subtilis would be recognised by its host RM system due to the non-methylated 
sequence CGCG. However, the phage can alter some of the bases within this 
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detection site, thus preventing its detection (Krüger and Bickle, 1983, Stern and 
Sorek, 2011, Blumenthal and Cheng, 2002). Figure 1.7 describes the 
functionality of RM systems whilst figure 1.7B details some mechanisms that can 
be utilised by phages in order to avoid host RM systems (Stern and Sorek, 
2011).  
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Figure 1.7: Type II RM systems: panel A shows the functionality of a typical type II 
system whilst panel B shows the variety of ways that phage can evolve in order to 
avoid the RM systems (Stern and Sorek, 2011). The type II RM system is shown in 
panel A (R – restriction enzyme and M – methytransferase). It shows that non-methylated 
DNA sequences are recognised as foreign, whilst methylated DNA is incorporated into 
the bacterial host chromosome as it is not detected by the RM system. Panel B shows 
the various ways in which phages have evolved in order to prevent their detection by host 
RM systems. 1) Incorporation of an unusual base which prevents the detection of the 
foreign DNA (Krüger and Bickle, 1983). 2) Masking the restriction enzyme site on the 
phage DNA by a phage protein (Iida et al., 1987). 3) Stimulation of methyltransferase 
activity by the incoming phage. 4) Neutralisation of the restriction enzyme by a phage 
protein mimicking the DNA to which the enzyme normally binds (Dryden and Tock, 2006, 
Stern and Sorek, 2011).  
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1.6.5.3. CRISPR/Cas systems 
CRISPR/Cas systems are small, RNA based defence systems that can provide 
either a bacterial/archaeal system with adaptive and heritable immunity against 
invading foreign DNA/RNA (Terns and Terns, 2011). CRISPR/Cas systems were 
initially described in 1987, when a Japanese group led by Ishino discovered a set 
of short tandem repeats in E. coli (Ishino et al., 1987, Deveau et al., 2010). 
CRISPR are composed of repeat sequences that can range from between 21 to 
48 bp. These repeats are separated from one another by spacers that can span 
from 26 to 72 bp (Barrangou et al., 2007, Bhaya et al., 2011, Cady et al., 2012). 
The sequences of these spacer regions are variable but are often 100 % identical 
to the genetic sequence of frequently encountered bacteriophages, plasmids or 
other foreign nucleic material (Van Der Oost et al., 2009, Cady et al., 2012).  
Cady et al (2012) investigated the genomes of 122 clinical isolates of P. 
aeruginosa and determined that 36 % of these isolates harboured CRISPR/Cas 
systems. It was also found that many of these CRISPR/Cas systems were 100 % 
identical to P. aeruginosa chromosomal integrating mobile genetic elements. This 
similarity supports the idea that CRISPR/Cas systems function to detect and 
cleave foreign nucleic acid thus, protecting the bacteria or archaea from 
deleterious effects due to the incorporation of a phage or plasmid.  
Three stages have been proposed in the CRISPR/Cas pathway; adaptation of 
the CRISPR system to the invading nucleic acid, biogenesis of mature transcripts 
and finally, silencing of the invader sequence (Terns and Terns, 2011). Copies of 
the foreign nucleic material (protospacer sequence) are initially acquired from an 
invading entity such as a bacteriophage/plasmid and this protospacer sequence 
becomes integrated into the host CRISPR locus. This integration is controlled by 
the protospacer adjacent motifs (PAM) located on the invading DNA sequence 
(Terns and Terns, 2011). The CRISPR regions are then transcribed as one long 
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transcript prior to processing into shorter and mature CRISPR RNAs (crRNAs). 
This processing either is undertaken by CRISPR associated (Cas) proteins or by 
Cas proteins combined with host RNase III (Brouns et al., 2008, Deltcheva et al., 
2011, Haurwitz et al., 2010, Cady et al., 2012). The mature crRNAs transcripts 
are then complexed with subtype specific Cas proteins. These complexes can 
then interact with the foreign nucleotide sequences, these sequences are 
complementary to the CRISPR spacer sequences and so generate innate 
immunity towards the invading DNA sequence (Brouns et al., 2008, Hale et al., 
2009, Jinek et al., 2012, Wiedenheft et al., 2011, Cady et al., 2012). A schematic 
of the functionality of a type II CRISPR/Cas system is shown in figure 1.8 
(Samson et al., 2013).  
Phages, to counteract the effects imposed upon them by CRISPR/Cas sytems, 
can mutate the region of their genome which the bacterial CRISPR/Cas system 
detects or even in extreme cases delete this section (Deveau et al., 2008). 
Alternatively, the phage can develop anti-CRISPR genes (Bondy-Denomy et al., 
2013), so ensuring that detection by the bacteria cannot occur. 
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Figure 1.8: CRISPR/Cas functionality (Samson et al., 2013). A type II CRISPR/Cas 
system is shown in this figure and it shows the three general steps that are involved in all 
CRISPR/Cas defence systems; (1) adaptation involving the acquisition of spacer 
sequences, (2) biogenesis of crRNA and CRISPR-Cas complexes and finally, (3) 
interference which involves the cleavage of the invading phage DNA. All these process 
prevent the formation of either a prophage due to lysogenic phage activity or host cell 
lysis due to lytic phage activity (Samson et al., 2013). Type I CRISPR/Cas systems 
involve Cas3 in the expression and biogenesis step (Makarova et al., 2011, Sinkunas et 
al., 2011). Type II CRISPR/Cas systems involve RNAse II and tracrRNA (trans encoded 
small RNA) whilst type III systems utilise Csm or Cmr proteins (Makarova et al., 2011). 
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1.6.5.4. Toxin Antitoxin (TA) systems 
TA defence systems are either based upon programmed cell death or the 
induction of dormancy within the prokaryote in response to infection by foreign 
nucleic material (Makarova et al., 2013). TA systems are widespread in bacteria 
and archaea. These systems have evolved in order to enhance bacterial and 
archaeal survival through promoting persistence, maintaining specific genetic loci 
whilst also providing resistance to phage infection (Blower et al., 2012).  
TA systems typically consist of two genes encoded within a single operon, these 
genes encode for both a stable toxin (disrupts an essential cell process) and an 
unstable antitoxin (controls toxicity levels within a prokaryotic host) (Wang and 
Wood, 2011). TA systems are characterised according to the nature of the 
antitoxin component because the toxin is always a protein. In type I TA systems, 
the antitoxin is a RNA fragment which shows complementarity to the mRNA 
sequence of the toxin. These TA systems have not been implicated in virus 
resistance (Makarova et al., 2013, Van Melderen and Saavedra De Bast, 2009). 
In type II systems, the antitoxin is a small and unstable protein which complexes 
with the toxin, so negatively auto-regulating the operon. This in turn leads to the 
development of an effective immune defence system against the invading foreign 
nucleic acid (Van Melderen and Saavedra De Bast, 2009, Wang and Wood, 
2011). Type II systems are the most prevalent TA systems currently known in 
prokaryotic species. The toxin in these systems is normally degraded by an 
essential housekeeping protease, which in bacterial species is often Lon or ClpP. 
This degradation of the toxin is counterbalanced by the continuous production of 
the antitoxin. Maintenance of a stable level of the antitoxin is essential in order to 
reduce the detrimental effects of the toxin on the bacterial host (Van Melderen et 
al., 1996, Roberts et al., 1994, Lehnherr and Yarmolinsky, 1995, Christensen et 
al., 2001, Christensen et al., 2003, Christensen et al., 2004, Cherny and Gazit, 
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2004, Aizenman et al., 1996, Van Melderen and Saavedra De Bast, 2009, Sberro 
et al., 2013). Type III TA systems contain RNA antitoxins but in this instance they 
inhibit toxin activity and functionality (Wang and Wood, 2011, Leplae et al., 
2011). Type IV and V TA systems have been proposed in the last 5 years; 
classification of these systems is based upon the mechanistic action of their 
respective antitoxins (Wang et al., 2012, Masuda et al., 2012, Makarova et al., 
2013). 
 
1.6.5.5. Abortive phage infection (Abi) 
Abi systems are often the last resort for bacterial cells to protect themselves 
against phage infection. These systems function after a phage particle has 
managed to successfully enter into a host cell and avoid the RM, CRISPR/Cas 
and TA systems (Stern and Sorek, 2011). The Abi system functions to block 
phage replication, which in turn leads to the premature death of the infected 
bacterial cell. This cell death decreases the amount of phage particles that can 
be released into the surrounding cellular environment which controls the levels of 
phage predation within an environment (Chopin et al., 2005). This ‘altruistic 
suicide’ is thought to occur due to phage having corrupted an essential host 
cellular process (Stern and Sorek, 2011).  
The ubiquitous nature of this defence system is apparent in a range of Gram 
negative and Gram positive bacteria including Vibrio cholerae (Chowdhury et al., 
1989), Bacillus subtilis (Hemphill and Whiteley, 1975), Lactococcus lactis (Forde 
and Fitzgerald, 1999, Chopin et al., 2005), Bacillus licheniformis (Tran et al., 
1999), Shigella dysenteriae (Smith et al., 1969) and Streptococcus pyogenes 
(Behnke and Malke, 1978). A large amount of work on Abi systems has been 
undertaken in Lactococcus lactis; a Gram positive bacterium that is extensively 
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used for lactic acid production during the manufacture of fermented dairy 
products (Bouchard et al., 2002). Some large dairy plants can process up to 106 
litres of milk per day, which leads to the generation of 1018 lactococcal cells. Not 
surprisingly, this process is highly susceptible to infection by both lytic and 
temperate bacteriophages which can have dramatic effects on the fermentation 
process both biologically and economically (Whitehead and Cox, 1935, Chopin et 
al., 2005). Chopin et al (2005) reviewed the Abi systems in Lactococcus lactis 
and it was identified that there were currently 20 known Abi systems, however, 
there may be more systems but the proteins have little or no homology to 
currently known proteins (Bouchard et al., 2002). 
 
1.7. AIMS AND OBJECTIVES 
The aim of this study was to characterise the influence temperate bacteriophages 
of P. aeruginosa have on the progression of chronic lung infections. The 
temperate bacteriophages involved in this study were induced from P. 
aeruginosa isolates collected from a cohort of adult BR patients, paediatric CF 
patients and adult CF patients. This study is split into chapters which try to use 
different scientific methodologies in order to elucidate the effect that 
bacteriophages have on disease progression.  
Initially, the work focused on looking at the ability of mixed phage communities to 
be induced from individual isolates of clinical P. aeruginosa and how they can 
infect different P. aeruginosa isolates. This was undertaken in order to determine 
whether the different clinical aetiologies had an effect on the dynamic interplay of 
phage-host infection profiles. Plaque purified phages were utilised in order to 
generate lysogenic bacteria and the lab strain, PAO1, was selected as the host 
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bacterium for these lysogenic conversions. The lysogens were further 
characterised for differences in growth rates and antibiotic resistance.  
Liquid Chromatography Mass Spectroscopy (LCMS) was also utilised in order to 
determine the impact that phages have on host cell metabolism during pellicle 
formation. Metabolic profiles were compared between P. aeruginosa isolates 
which were lysogenic or non-lysogenic for prophage formation.  
Due to the continuous nature of phage and bacterial interactions in the lower 
lung, it was decided to undertake a metagenomics study of the phages in order 
to determine whether there were any functionality differences that could be seen 
between the different aetiological subgroups. Metagenomic analysis utilising 
Metagenomics Rapid Annotations based on Subsystem Technology (MG–RAST) 
was conducted.  
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2. GENERAL MATERIALS AND METHODS 
 
2.1. BACTERIAL STRAINS 
This study used 94 clinical Pseudomonas aeruginosa (P. aeruginosa) bacterial 
isolates (10 paediatric Cystic Fibrosis (CF) isolates, 37 adult CF isolates, 16 < 10 
years since clinical diagnosis bronchiectasis (BR) isolates and 30 > 10 years 
since clinical diagnosis BR isolates); sample ID numbers are detailed in table 2.1 
These isolates were all stored post collection from the Freeman Hospital or Royal 
Victoria Infirmary, part of the Newcastle upon Tyne Hospital Trust, UK in 50 % 
volume per volume (v/v) Glycerol (ReAgent, Runcorn, UK) at -80 ⁰C.  
The samples were collected from the Freeman Hospital, Newcastle upon Tyne 
Hospital Trust on muller-hinton agar slopes. Prior to collecting the samples, the 
sputum samples were grown on blood agar, chocolate bacitracin agar and 
chocolate agar prior to incubation at 37 ⁰C for 48 hours. In order to confirm that 
P. aeruginosa had in fact been isolated mass spectroscopy was carried out on 
the samples (personal communication). 
In the CF cohort, there were 4 P. aeruginosa strains that were typed as the 
Liverpool Epidemic Strain, 4 typed as the Manchester Epidemic Strain, 2 typed 
as the Leeds Epidemic Strain, 1 strain typed as the Midlands-1 Epidemic Strain 
and 2 strains which were typed as Clone C Epidemic Strains. There were 13 
mucoid P. aeruginosa samples in the cohort and 34 non-mucoid P. aeruginosa.  
In the BR cohort, the only epidemic strains belonged to Clone C and there were 
only three strains typed in this sample set. There were also 22 mucoid P. 
aeruginosa samples and 25 non-mucoid P. aeruginosa samples.  
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Table 2.1: Sample ID for the 94 P. aeruginosa isolates and their clinical origin. More 
detailed clinical data for each sample is included in appendix data 1 and 2. 
Sample ID Clinical Origin 
3, 5, 6, 16, 23, 24, 28, 30, 34, 42, 44, 
52, 54, 55, 57, 60, 63, 65, 67, 72, 74, 
77, 78, 79, 81, 121, 125, 126, 127, 
136, 140, 142, 145, 177, 183, 211  
 
Adult CF 
47, 53, 69, 70, 124, 165, 187, 208, 
213, 214 
Paediatric CF 
52, 53, 58, 136, 141, 143, 1, 146, 153, 
161, 177, 178, 181, 195, 197, 199, 
200, 201, 204, 205, 208, 213, 222, 
228, 243, 244, 285, 313, 322, 326 
 
Over 10 BR 
59, 123, 133, 150, 152, 193, 206, 227, 
233, 293, 298, 299, 319, 320, 327, 
331, 332 
 
Under 10 BR 
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2.2. CHEMICALS AND GROWTH MEDIA 
 
2.2.1. Growth Conditions 
Unless stated, liquid bacterial cultures of P. aeruginosa were grown in Lysogeny 
Broth [LB] (Scientific Laboratory Supplies, Hessle, UK) and 0.01 M CaCl2 (Sigma 
Aldrich, Gillingham, UK). LB contains tryptone, sodium chloride, yeast extract 
and water.  
Constituents for each of the agars and broths used in this thesis are shown in 
table 2.2. Bacterial cultures were propagated at 37 °C under aerobic conditions, 
shaking at 200 revolutions per minute (rpm) for 18 hours. In order to propagate 
the cultures, LB stock plates were grown at 37 °C for 18 hours in a static 
incubator prior to being stored at 4 °C for < 1 month.  
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Table 2.2: Constituents of all the media and broths utilised during this 
investigation.  
Media/Agar Constituents 
1 M CaCl2.2H20 147.02 g CaCl2.2H20 
1000 mL H20 
LB Broth + 0.01 M CaCl2.2H20 12.5 g LB 
500 mL H20 
5 mL 1 M CaCl2.2H20 
LB Stock plates 12.5 g LB 
7.5 g High Clarity Agar (Lab M, 
Lancashire, UK) 
5 mL 1 M CaCl2.2H20/500 mL H20 
500 mL H20 
Soft Agar 5g LB 
0.8 g High Clarity Agar 
2 mL 1 M CaCl2.2H20 
200 mL H20 
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2.2.2. Bacteria and phage storage 
Unless stated, all the bacterial isolates were stored at  -80 °C for long-term 
storage in 50 % glycerol. Laboratory or working stocks of bacteria were stored on 
LB stock plates at 4 °C. Liquid phage stocks were also stored at 4 °C and 
checked every month for viability.  
 
2.2.3. Sterilisation of media and glassware 
To maintain pure enrichment of bacterial cultures and phage preparations, all the 
glassware and reagents used were autoclaved at 120 °C for 15 minutes at a 
pressure of 1.0 bar.  
 
2.2.4. Equipment  
The media used in this thesis is stated in the text whilst the equipment including 
the manufacturers and the associated addresses are detailed in appendix data 3. 
 
2.3. MICROBIOLOGY AND PHAGE BIOLOGY 
 
2.3.1. Raising microbial cultures and enumeration of bacteria 
As P. aeruginosa carries other transposable genetic elements alongside 
bacteriophages, it was essential not to store working stocks of isolates together. 
Therefore, small batches of P. aeruginosa were raised 2 days prior to 
experimentation from  -80 °C, streaked onto individual LB plates and then 
cultures in 10 mL of LB media were raised from the single colonies (37 °C, 200 
rpm). To enumerate bacteria in culture, 10-fold series dilutions and serial plating 
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onto LB allowed a viable cell count to be calculated for each microbial culture 
following an 18 hour incubation period at 37 °C. 
 
2.3.2. Growth curves 
To identify the growth profiles of the P. aeruginosa isolates used, the bacteria 
were grown for an 18 hour period and the increase in the optical density of the 
culture over this time period was detected on the Synergy HT plate reader. 75 ȝL 
of culture (OD 600 0.03) was added to an assigned well in a 96 well cell culture 
plate and absorbance readings were taken serially every 30 minutes for 3.5 
hours, followed by readings every hour for a period of 7 hours before the final 
reading was taken at 18 hours. Between readings, the plates were incubated at 
37 °C. The optical density was detected using a 600 nanometer (nm) wavelength 
and data was recorded using Gen5 1.06.  
 
2.3.3. Bacteriophage induction from P. aeruginosa 
Bacteriophages were chemically induced from P. aeruginosa using the 
floroquinolone antibiotic, Norfloxacin (NFLX) (1 µg.mL -1). NFLX (10 mg) was 
dissolved in H2O with limited additions of Sodium Hydroxide (NaOH) and made 
up to a final volume of 10 mL; aliquots were stored at -20 °C. 
From a single colony, 18 hour cultures were raised as previously described in 
section 2.3.1. A 2 % (v/v) inoculum from this culture into fresh 10 mL LB offered 
an actively growing culture from which to induce bacteriophages. The bacterial 
cultures were then grown to mid exponential growth phase (0.4 - 0.6 OD 600). 
NFLX was added for 1 hour (37 °C, 200 rpm) to stimulate cellular stress and 
therefore, bacteriophage induction. The culture containing NFLX was diluted 
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(1:10) to limit the cytotoxic effect of the drug, whilst also allowing for the cascade 
of phage induction to occur (Matsushiro et al., 1999, Smith et al., 2007, James et 
al., 2001). Phage lysates were filtered through 0.22 µM syringe filters (Scientific 
Laboratory Supplies) and stored at 4 °C for < 1 week. 
 
2.3.4. Bacteriophage enumeration 
 
2.3.4.1. Spot infection assays 
To determine the ability of a phage to infect a bacterial host, spot infection 
assays were utilised. 100 µL of mid exponential growth phase P. aeruginosa (0.4 
- 0.6 OD 600) was added to 5 mL 0.4 % weight per volume (w/v) soft agar aliquots 
and overlaid onto solid LB plates. Once surface dry, 10 µL of phage lysate was 
spotted onto the soft agar containing the bacteria and incubated for 18 hours at 
37 °C. In order to determine whether the P. aeruginosa host was susceptible to 
phage infection, one would expect to see zones of clearance on the plate 
whereas, results like this would not be expected on non-susceptible hosts.  
 
2.3.4.2. Purification and phage enumeration using plaque assays 
Plaque assays can be used to enumerate and isolate individual phages from 
mixed communities and to confirm the presence or absence of pyocin production. 
A ten-fold serial dilution of each phage lysate was mixed with 100 ȝL of phage-
sensitive mid-exponential P. aeruginosa. These dilutions were incubated for 25 
minutes at 37 °C. Each dilution was added to 5 mL of 0.4 % (w/v) soft agar and 
overlaid onto bottom agar plates then incubated at 37 °C for 18 hours (Sambrook 
et al., 1989, Green and Sambrook, 2012). Individual plaques were picked and the 
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phage was allowed to disperse into 450 ȝL of LB broth for 18 hours at 4 °C 
(Sambrook et al., 1989, Green and Sambrook, 2012). Plaque assays from these 
picked plaques allowed for the observation of the LB agar plate with the most 
discrete plaque morphologies. The agar from this plate was scraped and stored 
for 18 hours at 4 °C. The agar and bacterial debris was pelleted by centrifugation 
at 4,000 rpm for 10 minutes, 4 °C. The supernatant was then filtered through a 
0.22 µM syringe filter. These phage preparations were then used for subsequent 
rounds of ten-fold serial dilutions and plaque assays to validate a pure 
enrichment of a single bacteriophage (if required). The Plaque forming units per 
mL (Pfu.mL-1) were calculated in order to determine the amount of phage 
particles present in the lysate. 
 
2.3.5. Lysogen formation 
 
Using a ratio of phage to bacterium (MOI 0.1), it is possible to stimulate lysogenic 
over lytic phage infection. With an increase in multiplicity of infection (MOI), there 
is a drive towards lysogenic infection (Boyd, 1951, Fry, 1959, Kourilsky, 1973, 
Lieb, 1953). This culture was then incubated for 30 minutes at 37 °C and spread 
plated onto LB plates. These plates were incubated at 37 °C for 18 hours. 
Individual colonies were picked and patched onto LB plates, enriched and 
stocked in 50 % glycerol at -80 °C. To confirm lysogeny, without a phage related 
genetic marker of infection, each putative lysogen was subjected to genomic 
DNA extraction (section 2.5.1.1.) and a DNA restriction endonucleases digestion 
(section 2.5.6.). Any change in the profiles may relate to the integration of phage 
genomic DNA into the bacterial backbone. The lysogens generated in this study 
were all derivatives of PAO1 (standard laboratory P. aeruginosa strain) with the 
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addition of a paediatric CF phage, an adult CF phage, a < 10 BR phage or a > 10 
BR phage. 
 
2.4. MICROBIOLOGICAL TECHNIQUES 
 
2.4.1. Minimum Inhibitory Concentration (MIC) test 
The assays were set up using an adapted protocol from (Andrews, 2001). MIC 
assays were set up in order to test whether there was any alteration in antibiotic 
tolerance between the lysogens generated previously (section 2.3.5.) and naïve 
PAO1. In brief, a 150 ȝL total volume comprising of a 1μ1 ratio of P. aeruginosa 
culture at an OD 600 of 0.03 and lysogeny broth containing the antibiotic 
concentration was utilised. In order to determine the MIC, a five-fold dilution for 
each antibiotic, listed in table 2.3 was prepared. All the antibiotics were obtained 
from the Freeman Hospital CF clinic, as these are antibiotics that are routinely 
given to the CF patients in the Newcastle upon Tyne Hospital Trust.  
Colistin was used at a stock concentration of 96.29 mM, Ceftazidime was used at 
a stock concentration of 45.55 mM. Piperacillin was used at a stock centrationoin 
of 101.69 mM and Meropenem was used at a stock concentration of 137.25 mM. 
Colistin, Ceftazidime and Meropenem were all reconstituted in water whilst 
Piperacillin was reconstituted in methanol. The five-fold dilution series were 
prepared using LB broth.  
The MIC assays were prepared in triplicate with readings taken at 3 time points 
(0 hours, 9 hours and 18 hours). Plates were prepared in triplicate so that there 
was no contamination risk upon the removal of the breathable seal before the 
absorbance readings were taken. Breathable seals (AeraSeal Sterile, Alpha 
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Labs, Eastleigh, UK) were used to allow for aerobic growth throughout the 
process. The plates were kept at 37 °C and rotated at 50 rpm between 
absorbance readings to maintain aeration in the cultures and to limit biofilm 
formation. The absorbance of the plate was detected using a 600 nm wavelength 
and the data was recorded using Gen5 1.06 plate reader. 
In order to determine the differences in antibiotic tolerance between the naïve P. 
aeruginosa (PAO1) and the lysogens, it was decided to normalise the results 
according to PAO1. This gave strength to the conclusions that were drawn from 
this analysis.   
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Table 2.3: Antibiotics utilised in the MIC work including their mode of action and 
stockist.  
Antibiotic  Target Stockist 
Ceftazidime Peptidoglycan synthesis Sigma Aldrich 
Colistin Cytoplasmic membrane Forest Laboratories, 
London, UK and Sigma 
Aldrich 
Meropenem Peptidoglycan synthesis Fresenius Kabi Limited, 
Runcorn, UK 
Piperacillin Peptidoglycan synthesis Bowmed Ibisqus Limited, 
Wrexham, UK 
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2.4.2. Growth of P. aeruginosa as a pellicle 
It was decided to use a pellicle for this thesis, as a pellicle grows at the air liquid 
interface thus, inferring possible clinical relevance to the results. A pellicle is a 
derivative of a biofilm; the bacterial cells are protected from environmental 
changes and stimuli by the formation of an extracellular matrix. As phages can 
also be isolated from environments in which these pellicles develop, a method 
was derived to study the development and impact of phage on pellicle formation.  
6 well tissue culture plates were used for all pellicle studies; 2 mL of LB was 
added to each well. A 10 % inoculum of a freshly sub-cultured lysogen (OD 600 
0.03) was added to each well and the plates were sealed and left at 37 °C. 
Plates were generated in quadruplicate so that they could be removed at the 
specific time points required. The plates were removed when the cultures were in 
early growth, (3 hours), mid-exponential growth phase (5 hours) and stationary 
phase growth (10 hours). A final reading was taken 36 hours post inoculum. 
The pellicle was separated from the fresh cultures via careful extraction using a 
P1000 pipette, in most instances however, there was no remaining fresh culture 
as it had all formed part of the pellicle structure.  
 
2.4.3. 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carbox-
anilide (XTT) assay 
XTT is a tetrazolium dye that is used in quantification assays to determine viable 
cells in a community via metabolic activity (Peeters et al., 2008, Gabrielson et al., 
2002, McCluskey et al., 2005). The XTT assay indicates the metabolic activity of 
P. aeruginosa during both pellicle formation and growth. 1 mL of pellicle was 
sheared by pipetting and then further sheared by forcing it through a 0.22 µM 
syringe filter, the filter was then washed through using 1 mL of molecular grade 
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water (Fisher Scientific, Loughborough, UK). 80 µL of the pellicle suspension 
was added to the appropriate well of a 96 well plate along with 20 µL of the 
working concentration of XTT (Sigma Aldrich). The stock XTT was reconstituted 
with 5 mL filtered 1 x TAE (to generate a stock of 1 mg.mL-1). To generate a 
working concentration of 0.3 mg.mL-1, 1 mL of the reconstituted stock was added 
to 3 mL 1 x TAE. Readings were taken every 10 minutes over a 2 hour period to 
determine any metabolic changes in the pellicles over time using Gen5 1.06 (490 
nm).  
 
2.4.4. Twitching motility assays 
Bacterial isolates were grown from -80 °C stocks onto solid LB plates. Following 
incubation, a colony was selected and pierced straight into a fresh LB plate 
ensuring that the sterile loop containing the bacterial culture touched the base of 
the plate (Winstanley et al., 2005, Fonseca et al., 2004, Semmler et al., 1999). 
LESB58 was used as a negative control during these assays as it is known that 
this P. aeruginosa isolate is non-motile (Winstanley et al., 2009). PAO1 was used 
as a positive control.  
When looking at the effect of phages on bacterial motility, 100 µL of mixed phage 
lysate was spotted onto the plate in the same location as the bacterial colony. 
The plates were then incubated at 37 °C for 18 hours before the agar was 
carefully removed. The empty plates were flooded with 1 mL of crystal violet 
(TCS Biosciences, Botolph Claydon, UK) and the staining was allowed to 
progress at room temperature (~ 16 °C) for 30 minutes. Crystal violet was used 
as it binds to negatively charged molecules such as DNA thus, indicating where 
the bacterial cells have moved during the twitching assay. After incubation the 
stain was washed off and bacterial motility was recorded in millimetres (mm). 
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2.5. MOLECULAR TECHNIQUES 
 
2.5.1. Phage DNA Isolation method development 
After induction and filtration in section 2.3.3.; bacterial chromosomal DNA will 
remain within the phage lysate. Bacterial chromosomal DNA was removed using 
1 µL of TURBO DNAse and 1 µL of RNAse Cocktail (Life Technologies Limited, 
Paisley, UK) and incubation at 37 °C for 30 minutes. This was followed by heat 
inactivation at 65 °C for 10 minutes along with the addition of γ0 ȝL 0.5 M EDTA, 
shown in table 2.9. The manufacture’s guidelines were followed for this part of 
the thesis.  
 
2.5.1.1. Phage precipitation using polyethylene glycol (PEG8000) 
PEG8000 (Promega, Southampton, UK) purification was utilised in order to aid 
the purification process through the precipitation of phages, the protocol 
described by Sambrook et al (1989) was used. 0.5 M final concentration of NaCl 
(added in order to change the weight of the phage particles) was added to the 
NFLX induced phage lysate at 4 °C. The lysates were then centrifuged at 7,000 
rpm for 15 minutes, 4 °C in order to pellet the bacterial debris. The supernatant 
was carefully removed and used for further downstream processing and the 
pellet containing the bacterial debris was discarded. 10 % final concentration of 
PEG8000 (w/v) was added slowly to the supernatant prior to being left overnight 
(18 hours) at 4 °C. This culture was then centrifuged at 10,000 rpm for 20 
minutes at 4 °C. In this instance, the supernatant was discarded and the pellet 
containing the phage particles was retained. The speed of the centrifugation 
process allowed for the phage to become pelleted as PEG8000 altered the 
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charge and weight of the particles in the lysate thus, causing the phage to pellet. 
To the pellet, 7.5 mL TBT buffer (100 mM Tris-HCl (pH 7.0), 100 mM NaCl, 100 
mM MgCl2, pH 7.0) was added along with an equivalent volume of Chloroform 
(Fisher Scientific). The sample was then centrifuged again at 4,000 rpm for 15 
minutes at 4 °C. 1 mL of the top phase was removed and used for further 
downstream processing analysis. 
 
2.5.1.2. QIAGEN QIAmp MinElute Viral Spin Kits 
QIAGEN QIAmp MinElute Viral Spin Kits (QIAGEN, Manchester, UK) were also 
used in order to purify the phage nucleic acid; this kit can purify DNA greater than 
200 bp. The manufactures’ guidelines were followed for this kit.  
β5 ȝL of QIAGEN protease was added to a 1.5 mL microcentrifuge tube, followed 
by β00 ȝL of the phage lysate. β00 ȝL of Buffer AL/RNA-AVE was also added. 
An incubation period of 15 minutes at 56 °C followed, prior to 250 µL of absolute 
ethanol being added. The lysate was then incubated for 5 minutes at room 
temperature (~ 16 °C). All the lysate was loaded onto the provided QIAmp 
MinElute column. The column was centrifuged at 8,000 rpm for 1 minute and the 
collection tube and filtrate discarded, the column was then reassembled with a 
new collection tube. 500 µL of Buffer AW1 was then loaded onto the column and 
the column was centrifuged at 8,000 rpm for 1 minute and again the collection 
tube containing the filtrate was discarded (Buffer AW1 denatured the proteins in 
the sample and allowed them to pass through the column). This process was 
repeated when 500 µL of Buffer AW2 was loaded onto the column and again 
when 500 µL of absolute ethanol was loaded (Buffer AW2 removes salts from the 
column thus, aiding DNA purification). In order to prevent any problems with 
downstream applications due to ethanol carryover, the column was dried by 
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centrifugation at 14,000 rpm for 3 minutes. 75 µL of Buffer AVE (warmed to 37 
°C to increase elution efficiency) was added to the column, which was placed in 
a new collection tube before centrifugation at 14,000 rpm for 1 minute. The 
filtrate was retained and used for further downstream processing. 
 
2.5.1.3. Chosen method: NORGEN phage DNA isolation kit 
The NORGEN phage DNA isolation kit (Geneflow Limited, Lichfield, UK) was the 
method chosen to purify the viral DNA in this thesis. The kit works via affinity 
binding and has no DNA size prerequisite which makes it an ideal kit for de novo 
work. The manufactures’ guidelines were followed for this kit but in the brief the 
protocol is as follows. 1 mL of phage lysate was transferred to a 15 mL sterile 
falcon tube along with 500 ȝL of lysis solution prior to a vigorous vortex for 10 
seconds. The falcon tube containing the phage and lysis buffer was incubated at 
65 °C for 15 minutes; the tube was inverted every 5 minutes to ensure efficient 
chemical mixing and heat lysis. 320 ȝL of isopropanol (Thermo Fisher Scientific) 
was added to the falcon tube and briefly vortexed. DNA is less soluble in 
isopropanol meaning that DNA precipitates out of solution rapidly and at lower 
concentrations thus, decreasing the amount of time required for sample 
purification. 650 ȝL of lysate was added to a provided spin column prior to 
centrifugation at 8,000 rpm for 1 minute, the filtrate containing the cell debris and 
unwanted protein was discarded. This step was repeated until all the phage 
lysate in the 15 mL falcon tube had been run through the spin column so that the 
entire DNA load was bound to the matrix of the column. 400 ȝL of wash solution 
was added to the column and the column was again centrifuged at 8,000 rpm for 
1 minute and the flow through was discarded. This wash step was undertaken in 
triplicate in order to ensure efficient washing and the removal of any cell debris or 
protein contamination. Ethanol carryover can have a detrimental effect in 
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downstream DNA analysis so the column was centrifuged at 14,000 rpm for 2 
minutes in order to dry the resin and remove any excess ethanol. The column 
was then placed into a fresh collection tube to which 75 ȝL of elution buffer 
(warmed to 37 °C prior to use in order to increase efficiency) was added. The 
column was again centrifuged at 8,000 rpm for 1 minute. The flow through from 
this centrifugation was then collected and run through the column again in order 
to increase the yield of the final phage DNA sample.  
 
2.5.2. Bacterial DNA Isolation 
P. aeruginosa DNA was isolated using the UltraClean Microbial DNA isolation kit 
(Mo Bio, Cambio, Cambridge, UK); this kit yields DNA that is greater in size than 
50 Kb and each filter in the kit has the capacity to bind 20 µg of DNA. 
The manufactures’ guidelines were followed for this kit. In brief, 1.8 mL of mid 
exponential P. aeruginosa culture was added to a 2 mL collection tube and 
centrifuged at 10,000 rpm for 30 seconds to pellet the bacterial cells. The 
supernatant was discarded before the tubes were centrifuged at 10,000 rpm for 
30 seconds. The cell pellet generated from the previous two centrifugation steps 
was re-suspended in 300 µL of microbead solution prior to the sample being 
transferred to a microbead tube. The microbead solution stabilises the sample as 
well as homogenously dispersing the cells in order to allow for efficient lysis. 50 
µL of solution MD1 was added to the microbead tube; this solution contains 
sodium dodecyl sulphate (SDS) which allows for cell lysis and solubilisation of 
membrane lipids. The microbead tubes were vortexed at full speed for 10 
minutes in order to allow for chemical and mechanical lysis. The tubes were 
centrifuged at 10,000 rpm for 30 seconds in order to pellet the cellular debris and 
the supernatant retained. 100 µL of MD2 was added to the collection tube which 
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contained the harvested supernatant prior to incubation at 4 °C for 5 minutes. 
MD2 aids the precipitation of non-DNA organic and inorganic material which can 
potentially have a negative effect in downstream applications. The incubated 
sample was centrifuged at 10,000 rpm for 1 minute prior to the addition of 900 µL 
of MD3. MD3 has a high salt concentration and generates the gradient required 
to bind DNA to the spin filter membrane. 700 µL of the supernatant (containing 
both the lysate and buffer MD3) was added to a tube containing the spin filter 
and centrifuged at 10,000 rpm for 30 seconds. The flow through was discarded 
and the remaining 700 µL of the sample and MD3 was run through the column. 
These wash steps ensure that the DNA remains bound to the column whilst the 
contaminants are washed through the column and discarded. 300 µL of MD4 
was added to the spin filter (MD4 is an ethanol based wash solution which cleans 
the DNA sample). The sample was then centrifuged at 10,000 rpm for 30 
seconds and the flow through discarded. In order to dry the membrane and 
remove final traces of MD4, the column was centrifuged at 10,000 rpm for 1 
minute. 50 µL of warmed MD5 elution buffer was added to the centre of the 
membrane and allowed for the elution of DNA from the column.   
 
2.5.3. NanoDrop 1000 Spectrophotometer V 3.7 
The nanodrop is a UV spectrophotometer that utilises small volumes of a 
DNA/RNA sample in order to determine the purity and quantity of the nucleic 
acid. After the blank reading (1 ȝL of elution buffer appropriate to the sample in 
question) the stage was cleaned with water and 1 µL of the sample was loaded 
in order to determine the concentration and nucleic acid yield.  
The 260/280 nm ratio assess the purity of the DNA/RNA in the sample; a ratio of 
around 1.8 can be used to assess whether the sample contains pure DNA and a 
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ratio of around 2.0 can be used to assess whether the sample contains pure 
RNA. When the ratio is appreciably lower in both instances, then it indicates the 
presence of a contaminant which has absorbance of or near 280 nm. Commonly 
the contaminant is either a protein or phenol which is left over from the nucleic 
acid preparation stage.  
The 260/230 nm ratio assess the purity of nucleic acid in the sample; an 
accepted purity ratio falls between 2.0 and 2.2. If the ratio is lower than expected, 
it is possible that there is contamination with a product that has an absorbance of 
or near 230 nm. Commonly these contaminants can be EDTA, carbohydrates 
and again phenol and these are again often leftovers from DNA prep kits.  
 
2.5.4. QUBIT 2.0 
In order to effectively test the DNA concentration prior to sequencing, the QUBIT 
2.0 (Life Technologies Ltd, Paisley, UK) was used.  The QUBIT 2.0 fluorometer is 
a bench-top fluorometer that is highly sensitive and utilises fluorescence based 
techniques in order to quantify DNA, RNA and protein. The QUBIT dsDNA high 
sensitivity (HS) assay kit was used for this analysis (Life Technologies Ltd). 197 
µL of HS buffer was combined with 1 µL of fluorescence dye and 2 µL of DNA. 
This occurs in minimal light as the reagents are light-sensitive and the reagents 
are also temperate-sensitive so handling is kept to a minimum. The tubes were 
vortexed for 5 seconds prior to incubation in the dark for 2 minutes, in order to let 
any bubbles generated by vortexing settle. The sample can then be read on the 
fluorometer selecting the dsDNA option; care was taken to observe for bubbles 
and scratches on the tube which may influence the output reading.  
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2.5.5. Polymerase Chain Reaction (PCR) 
All the primer sequences used in this investigation are detailed in table 2.4. 
Regardless of the primers and their concentrations all the PCR’s were set up 
according to table 2.5, with 25 µL reactions being used throughout this work. 
The timings for each individual PCR experiment varied according to the primers 
used and their associated annealing temperatures. The various time alterations 
for each primer set are described in table 2.6. 
80 
 
Table 2.4: Details all the primer sequences that were used during this investigation 
at a 1 x working concentration. All the primers are purchased from Integrated DNA 
Technologies, Heverlee, Belgium. 
Name Sequence (5’ – 3’) Region Reference 
V3F CCTACGGGAGGCAGCAG V3 region 
of the 16S 
rRNA  
(Muyzer et 
al., 1993) 
V3R ATTACCGCGGCTGG V3 region 
of the 16S 
rRNA  
(Muyzer et 
al., 1993) 
Q 5’ ATGTTCTTATGGTTCACCG Q gene of  
ɸ 24B 
(Smith et 
al., 2007) 
Q γ’ TTACGATCGTAAACTATTTTT Q gene of 
ɸ 24B 
(Smith et 
al., 2007) 
tRNA thr CGAATGAGCTGCTCTACCGACAGAGCT pilA (Kus et al., 
2004) 
pilA TCCAGCAGCATCTTGTTGACGAA pilA (Kus et al., 
2004) 
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Table 2.5: PCR set up; all the suppliers and volumes of reagents used are listed. 
PCR Component Amount Supplier 
Phusion High Fidelity 
PCR Mastermix with high 
fidelity (HF) Buffer 
12.5 µL New England Biolabs, 
Hitchin, UK 
Forwards Primer  
(10 mM) 
 
1.25 µL  Integrated DNA 
Technologies 
Reverse Primer 
(10 mM) 
1.25 µL  Integrated DNA 
Technologies 
DNA 1 µL Own 
Biotech grade water Make up to 25 µL Fisher Scientific 
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Table 2.6: PCR timings utilised throughout this thesis.  
 Temperature Timings Stage Cycles Reference 
16
 
S 
rR
NA
 
98 °C 10 minutes Initial 
Denaturation 
 
(M
uyze
r
 et
 al
.
,
 1993)
 
98 °C 1 minute Denaturation 30 
cycles 
Drop 0.5 
°C / 
cycle 
55.5 °C 30 
seconds 
Annealing 
72 °C 1 minute Extension 
72 °C 7 minutes Final 
Extension 
 
4 °C Forever Hold  
Q 
 
ge
n
e 
98 °C 10 minutes Initial 
Denaturation 
 
(S
m
ith
 et
 al
.
,
 2007)
 
98 °C 1 minute Denaturation  
30  55.5 °C 30 
seconds 
Annealing 
72 °C 1 minute Extension 
72 °C 7 minutes Final 
Extension 
 
4 °C Forever Hold  
pi
lA
 
ge
n
e 
95 °C 5 minutes Initial 
Denaturation 
 
(K
u
s
 et
 al
.
,
 2004)
 
95 °C 30 
seconds 
Denaturation  
30  
45 °C 60 
seconds 
Annealing 
72 °C 2 minutes Extension 
72 °C 7 minutes Final 
Extension 
 
4 °C Forever Hold  
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2.5.6. Restriction Digestion 
In order to differentiate between the plaque purified phages (section 2.3.4.2.), 
they were subjected to restriction digestion in order to determine any genetic 
differences between the phages. The pure phage DNA (section 2.5.1.3) was 
used at 300 ng and combined with 5 units of each restriction digest enzyme; 
BamHI, ClaI, EcoRI – HF and HindIII (New England Biolabs), cut sites are shown 
in table 2.7. 1.5 µL of Cut Smart buffer (New England Biolabs) was used and the 
volume made up to 15 µL with sterile water (Fisher Scientific). The digests were 
left at 37 °C for one hour in order to allow for effective cleavage but the time was 
restricted in order to prevent star activity. Post digestion, the products were run 
on 1 % agarose gels (section 2.5.7).  The setup of the digestions is shown in 
table 2.8. 
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Table 2.7: Restriction digest cleavage sites shown in both the 5’ to 3’ orientation 
and in the 3’ to 5’ orientation, taken from the New England Bio labs website 
(accessed 20.07.15). HF refers to high fidelity enzymes which were used wherever 
possible.  
Enzyme Cut sites 
BamHI – HF 5’…GˇGATCC…γ’ 
γ’…CCTAGˆG…5’ 
ClaI 5’…ATˇCGAT…γ 
γ’…TAGCˆTA…5’’ 
EcoRI - HF 5’…GˇAATTC…γ’ 
γ’…CTTAAˆG…5’ 
HindIII 5’…AˇAGCTT…γ’ 
γ’…TTCGAˆA…5’ 
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Table 2.8: Volumes of reagents used to set-up the restriction digestion reactions. 
The restriction digestion enzymes are used at a volume of 0.5 µL and the final reaction 
volume is 15 µL. 
 
ΦCF70 ΦCF24 ΦBR123 ΦBR136 
Water (µL) 8.5 10.5 11 10.5 
Smart Cut 
Buffer (µL) 
1.5 1.5 1.5 1.5 
DNA (µL) 3 1 0.5 1 
Restriction 
Digest 
Enzyme 
(total µL) 
2.0 2.0 2.0 2.0 
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2.5.7. Agarose Gel Electrophoresis  
In order to visualise the PCR products, 1 % agarose gels were used, the gel 
setup is detailed in table 2.9. The agarose (Melford Laboratories Limited) and 1 X 
Tris-acetate-EDTA (TAE) was heated to approximately 50 °C in order to melt the 
agarose. 5 µL of SYBR safe DNA stain (Life Technologies Ltd) was added to the 
gel in order to aid visualisation of the DNA and the mixture was poured into gel-
forming casts (two sizes available depending on sample set size) prior to a comb 
being inserted to generate the wells required. The gel was allowed to set for 
around 30 minutes prior to the gel being immersed in 1 x TAE, the sample wells 
and electrodes needed to be covered with TAE. The wells on either side of the 
gel were loaded with 5 µL of HyperLadder 1 Kb (Bioline, London, UK) and 5 µL of 
Quick-Load 100 bp ladder, respectively (New England Biolabs). The DNA 
samples were mixed with 5 µL of loading dye (Bioline) and loaded into the 
appropriate wells. The loading dye contains a pre mixed loading buffer of two 
dyes; Dye 1 (pink/red loading front) and Dye 2 (blue loading front). The gels were 
then run at 120 milliamps (mA) for 25/40 minutes depending on gel size. Results 
were viewed under ultraviolet (UV) transillumination.  
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Table 2.9: Constituents for the generation of Agarose Gels and the associated 
buffers required for gel electrophoresis.   
Media/Gel Constituents 
0.5 M Ethylenediaminetetraacetic acid 
(EDTA) 
93 g EDTA (Melford Laboratories 
Limited, Ipswich, UK) 
500 mL H20 
Slowly dissolve with NaOH to generate 
a pH of 8 
50 x TAE (Tris-acetate-EDTA) 242 g Tris 
57.1 mL Acetic Acid 
100 mL 0.5 M EDTA 
Make up to 1 L with H20 
1 x TAE 20 mL 50 x TAE 
980 mL H20 
1 % Agarose Gels 0.3 g Agarose/30 mL 1 x TAE 
1 g Agarose/100 mL 1 x TAE 
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2.6. ELECTRON MICROSCOPY 
Electron microscopy was undertaken at the Electron Microscopy Unit, Newcastle 
University, Newcastle upon Tyne, UK. In brief, a 5 – 10 µL droplet of the 
biological sample was added to the support film of a mesh grid (Gilder Grids, 
Grantham, UK). After a few seconds, the droplet was touch dried using filter 
paper to leave behind a thin film on the grid which contained both the absorbed 
and freely suspended biological sample. 10 µL of 2 % aqueous uranyl acetate 
(Agar Scientific, Stansted, UK) was added to the grid before being touched dried. 
Uranyl acetate was used as the negative stain and it allowed for quick staining 
and visualisation of the biological sample. The mesh grid was allowed to 
completely air dry prior to imaging. The grids were examined using a Philips CM 
100 Compustage (FEI, Oregon, USA) Transmission Electron Microscope (Philips 
UK, Guildford, UK). The biological sample was visualised using a 100 kV current 
and the digital images generated were collected using an AMT CCD Camera 
(Deben, Bury St Edmunds, UK). 
 
2.7. LIQUID CHROMATOGRAPHY – MASS SPECTROSCOPY (LCMS) 
LCMS was used to study the metabolite profiles of the bacteria both with and 
without phage infection. 1 mL of harvested pellicle (section 2.4.2) was added to a 
sterile 1.5 mL eppendorf and washed with 1 x phosphate-buffered saline (PBS) 
(Sigma Aldrich) prior to centrifugation at 14,000 rpm for 20 minutes. This 
procedure was repeated in triplicate in order to clean the pellicle as effectively 
and efficiently as possible. The eppendorf lid was pierced with a flamed needle 
and the tube was placed in the - 80 °C freezer for a minimum of 30 minutes in 
order to completely freeze the pellicle samples prior to lyophilisation. The 
samples were then placed in the freeze drier for 18 hours at temperatures 
reaching -55 °C (Alpha 1 – 2, Scientific Laboratory Supplies). 
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The lyophilised products were stored at - 80 °C. When required, the samples 
were weighed to 0.001 g (+/- 0.0005 g) prior to the addition of LCMS Grade 
Methanol (Sigma Aldrich) and 0.66 % LCMS Grade Formic Acid (Thermo Fisher 
Scientific Ltd). A stock solution of methanol and formic acid was created and the 
volume added to each sample depended on the lyophilised product weight, this 
method was utilised in order to generate a normalised 0.5 % (w/v) solution. The 
samples were vortexed for 3 minutes prior to sonication (Bandelin Sonorex, 
Sigma Aldrich) for 75 minutes at 25 °C. The samples were cooled on ice every 
15 minutes to prevent pressure build up. The resulting product was filtered 
through 0.22 µM syringe filters (Camlab, Cambridge, UK) and added to LCMS 
vials containing 200 µL inserts (Fisher Scientific Limited). The UltiMate 3000 LC 
System [C18 Thermo Accurate column (Thermo Scientific)] and Q Exactive 
(Thermo Scientific) was used. Acetonitrile (VWR, Lutterworth, UK) and water 
(VWR) were used as the mobile phases. 
 
2.7.1. Run parameters LCMS 
The experimental work was undertaken in triplicate as well as each sample 
having a technical duplicate. All the samples were loaded onto the LCMS in a 
random order (Excel function = rand(), sort smallest to largest). Between every 9 
samples, a blank sample (0.5 % TFA [Trifluroacetic acid, Sigma Aldrich] in 99.5 
% LCMS Grade Water [VWR]) was run alongside a pooled sample, this allowed 
for maintenance of the columns accuracy and performance. The injection time for 
each of the samples was 25 minutes and the gradient was 17 minutes to allow 
for optimal levels of acetonitrile (VWR) and water (VWR) containing 0.1 % formic 
acid (Thermo Fisher Scientific Ltd) to be achieved. 3 µL of each sample was 
injected onto the column along with 195 µL of acetonitrile and water; the injection 
90 
 
and retention time on the column determined the interaction strength between 
the mobile and stationary phases.  
 
2.7.2. Analysis of metabolite profiling Progenesis QI 
The raw data files (MZNLD files) were downloaded from the Q Exactive post run, 
in order to upload the files onto Progenesis QI 64 bit v 4.1 (Nonlinear Dynamics 
Limited, Newcastle Upon Tyne, UK). Thermo (.raw) data files were uploaded in 
an order relating to the experimental design. The files were automatically aligned 
and various adducts were included for both the Electrospray ionisation (ESI) 
positive and ESI negative runs; the adducts included are shown in table 2.10. 
Upon alignment, the groups of data were stratified according to the experimental 
design; this allowed for comparison between both growth stages and pellicles 
with/without phage infection. The parameters used for peak picking were 
stringent in order to generate the best quality data; ions released in the first 0.5 
minutes of the run were excluded from further analysis as were ions released 
after 16.30 minutes. This was done in order to prevent any debris from the 
column being present in further downstream analysis. 
Various search engines were used to analyse the raw data files, these include 
the human metabolome database (HMDB) (Wishart et al., 2013, Wishart et al., 
2009, Wishart et al., 2007) and the E. coli metabolome database (ECMDB) (Guo 
et al., 2013). All the files were used in the .sdf format. The following parameters 
were applied to the comparison searches to aid the accuracy of these MS1 
identifications. These parameters were ‘mass within 0.1 Dalton (Da)’, and 
‘fragment search theoretical and fragmentationμ 1β parts per million (ppm)’. The 
files were then tagged in order to allow for further downstream analysis. The 
samples were tagged according to statistical significance including p values and 
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minimum coefficient of variation (CV) which illustrates the high degree of 
repeatability. Files with p values ≤ 0.05 and CV values ≤ 5 were tagged and 
combined in order to determine metabolites of interest in the raw data set. All the 
compounds that were identified were exported into Excel and searched against 
the raw data from the individual runs. Compounds with retention time differences 
within +/- 0.6 and a mass to charge ratio (m/z) ratio +/- 0.6 of the searched 
compounds were included for further analysis. 
Upon further analysis, the metabolites that were significant according to a 
variance of importance plot (VIP) were again analysed on Progenesis in order to 
potentially generate a functional ID for the compound. Only metabolites with the 
same m/z ratio and a mass error of +/- 2 were selected for further processing but 
MS/MS analysis would be needed to allow for accurate identifications.  
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Table 2.10: Adducts included in Progenesis QI Analysis for both the Positive and 
Negative runs. 
ESI Positive ESI Negative 
M + Na M – H 
M + K M + FA – H 
M + ACN + Na 2M – H 
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2.8. NEXT GENERATION SEQUENCING 
The Illumina Nextera XT (Illumina, Saffron Waldon, UK) library preparation kit 
was used to prepare and multiplex the isolated phage DNA in order to undertake 
next generation sequencing (NGS) on the Illumina MiSeq platform. A 2 x 250 
cycle V2 kit was used. The DNA samples were diluted to 0.2 µg/µL (Qubit 2.0 DS 
HS DNA Kit [Life Technologies Ltd]) (section 2.5.4.) prior to normalisation and 
pooling. The samples were sequenced using the NU-OMICS facility at 
Northumbria University. Paired end sequencing reads were provided as FASTQ 
files (NU-OMICS, Northumbria University at Newcastle, UK) and then subjected 
to downstream analysis (Tariq et al., 2015). The preparation process in brief, 
follows these basic guidelines: 
- DNA is diluted to 0.2 ng/uL and tested on the QUBIT 2.0 
- Amplification tagmentation occurs (two step PCR process) 
- Clean up of the DNA solution via beads (removes primer dimer etc) 
- Bioanalyser run undertaken (gives a general DNA fragment size and 
provides a rough idea on the DNA concentration of the sample) 
- Normalisation step via beads (balances the DNA concentration between 
the samples so can generate the correct final concentration) 
- Pool all the samples and add the hybridisation buffer 
- Heat shock the samples so they become single stranded 
- Spike the DNA prep with phix (phage polymerase) 
- Load onto the cartridge (contains all the reaction mixture pre-loaded) 
 
2.8.1. Sequencing by synthesis 
Illumina sequencing utilises a sequencing-by-synthesis methodology. This 
involves the utilisation of single stranded DNA fragments bound to flow cells via 
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adaptor regions. Isothermal bridge amplification of the template strain 
commences upon addition of DNA polymerase (Bentley et al., 2008). Post 
amplification, the template strand was washed away leaving the double strand 
DNA complex denatured thus, allowing for both strands to undergo further 
rounds of isothermal bridge amplification forming a DNA cluster on the flow cell 
(Bentley et al., 2008). A universal primer bound to the template DNA strand 
(reverse strand was cleaved and removed) and along with fluorescently labelled 
terminator nucleotides allowed for the generation of thousands of reads of data. 
The incorporation of a terminator nucleotide sequence ensures that the process 
occurs in a step-wise manner. The fluorescent signals emitted upon terminator 
incorporation can be clearly determined by two internal detection lasers (Bentley 
et al., 2008).  
 
2.9. DATA ANALYSIS 
 
2.9.1. Metagenomics Rapid Annotations based on Subsystem 
Technology (MG-RAST) analysis 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) atlas maps were 
generated using the tab on Metagenomics Rapid Annotations based on 
Subsystem Technology (MG-RAST); the default settings were used (60 % 
similarity of 15 amino acids).  
 
2.9.2. Statistical analysis 
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2.9.2.1. Simca P analysis 
The generation of data modelling plots [Principle Least Squares Discrimination 
Analysis (PLS-DA)] was undertaken using the SIMCA-P v 13.0 software 
(Umetrics, Umea, Sweden). The data was analysed according to the 
experimental conditions imposed upon it whilst the R2Y value was used to 
assess the strength of the model and its prediction power when the data was 
uploaded to the software in a semi supervised manner (some information about 
the data was known prior to analysis). The confidence in the data was assessed 
using the Hotelling’s T2 tolerance limit (0.95). 
 
2.9.2.2. ANOVA analysis 
This work was undertaken in collaboration with Professor Michael Brockhurst, 
York University, York, UK. ANOVA analysis was utilised in order to determine the 
interactions between the bacteria and phages, bipartite infection networks were 
generated. The bacterial and phage interactions both within and between the 
diseases were assessed (CF phage vs. CF P. aeruginosa, CF phage vs. BR P. 
aeruginosa, BR phage vs. CF P. aeruginosa, & BR phage vs. BR P. aeruginosa). 
Nestedness was measured using the binary matrix nestedness temperature 
calculator (binmatnest) (Rodríguez‐Gironés and Santamaría, 2006) within the 
'nestedness' metric from the R package 'bipartite' - v 2.04 (Dormann et al., 2008, 
Dormann et al., 2009). All the binmatnest values given were statistically 
significant compared to the associated null model analysis. Network 
visualisations were generated using R package 'bipartite' - v 2.04.  
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3. CHARACTERISING THE DYNAMIC INTERPLAY AND 
HOST-RANGE OF TEMPERATE PHAGES INDUCED FROM 
PSEUDOMONAS AERUGINOSA COLONISING THE 
CHRONIC LUNG 
 
3.1. INTRODUCTION 
The dynamic interplay between phages and their bacterial hosts occurs in both 
environmental and laboratory settings. In the oceans, it is thought that there are 
1023 new phage infections every second (Suttle, 2007), so it may be pertinent to 
think that these frequencies could be higher within the constrained environment 
of the lower lung. Davies et al. (2016) showed that in a clinically relevant 
environment such as the lung, the inducible phages from the Liverpool Epidemic 
strain (LES) were likely to have key roles in the spread of LES around a 
particular environment. This potentially indicates that phage infections are 
occurring at an elevated rate within the lung. However, lysogenic conversions of 
the bacterial species by the LES phages occurred at lower levels than in vitro, so 
proposing that lysogenic conversion maybe impeded within the chronic lung 
environment. 
The observation that phages may be aiding the spread of a Pseudomonas 
aeruginosa (P. aeruginosa) isolate in the lung lower lung is also supported by 
previous work undertaken using insect and observational models (Burns et al., 
2015, James et al., 2015, Davies et al., 2016a). James et al (2015) showed that 
the presence of free temperate phage in the sputum of CF patients was 
comparable to the number of P. aeruginosa particles present; it was also shown 
that these phages were active in vivo. All these studies indicate that activity of 
the phage communities present within the lung.  
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This bacteria-phage interplay may in part be responsible for the successful 
colonisation of P. aeruginosa and how a particular clone can become the 
predominant strain and cause severe infections in chronic respiratory disease 
patients.  
As described in chapter 1, P. aeruginosa has evolved to present certain adaptive 
traits and phenotypes which permit its long-term colonisation in the lower lung 
(section 1.4.). An example includes the generation of a mucoid phenotype which 
is associated with long term and chronic colonisation of the lung (section 
1.5.1.2.). Mucoid strains of P. aeruginosa were first cultivated in 1927 from a 
patient suffering with an abscess of the gall bladder (Sonnenschein, 1927, Govan 
and Deretic, 1996) but it was not until the 1λ60’s, that the first association was 
drawn between the mucoid phenotype and chronic colonisation of the lungs 
(Doggett, 1969, Doggett et al., 1966, Doggett et al., 1964, Govan and Deretic, 
1996). The mucoid phenotype is caused by the overexpression of alginate 
through mutation and dis-regulation of the mucA transcriptional regulator (Speert 
et al., 1990, Mathee et al., 1999, Lee et al., 2005b, Govan and Deretic, 1996).  
This thesis focuses on P. aeruginosa isolated from cystic fibrosis (CF) and 
bronchiectasis (BR) patients to try to understand how these bacteria evolve 
within the lower lung. Only a limited number of studies look at the bacteriophages 
that infect and integrate into the chromosome of P. aeruginosa and determine 
how these phages affect P. aeruginosa adaptation, survival and evolution in the 
lung (Davies et al., 2016a, James et al., 2015). Phages are known to co-evolve 
and interact with their bacterial hosts. This war of infection and the subsequent 
exclusion occurs over a period of time and leads to the development of an ‘arms-
race’ between the two entities.  
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Phages are of great interest in both academic and clinical communities due to 
their ability to convert their bacterial hosts, which may aid bacterial survival or 
drive bacterial evolution which may support their persistence in the chronic lung.  
3.1.1 The role of temperate bacteriophage in bacterial adaptation and 
evolution 
 
3.1.1.1. Bacteriophage superinfection 
In 1957, it was determined that an isogenic phage could not infect a bacterial 
host if the host already harboured the same phage and this led to the generation 
of resistance towards the super-infecting phages (Kaiser and Jacob, 1957, 
Ptashne, 1967). The classical system of Ȝ phage lysogeny maintenance involves 
the gene product CI (section 1.6.2.). Kaiser and Jacob (1957) found that this 
gene product was also responsible for preventing infection by other phages 
belonging to the same immunity group through inhibiting early gene expression in 
the invading phage.  
When undertaking phage induction studies in Shigella, it was observed that there 
were 3 immunologically discrete prophages (Bertani, 1951, Bertani, 2004). These 
temperate phages were classified as P1, P2 and P3 (Bertani and Nice, 1954). 
Bacteriophage P2 further demonstrated the superinfection inhibition described by 
Kaiser and Jacob, in this instance the incoming phage DNA was not degraded by 
the host Shigella cell but instead was prevented from replicating alongside the 
primary infecting P2 phage. Copies of the invading phage were passed onto 
daughter cells but were unable to replicate unless the resident prophage was lost 
or a rare double lysogen was established (Bertani, 2004, Bertani, 1953, Bertani, 
1954, Bertani, 1956).  
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3.1.1.2. Phage-encoded exclusion of superinfection  
The prophage ɸ80 prevents superinfection within its Escherichia coli (E. coli) host 
cell by the expression of the Cor protein. This prophage incorporation inactivates 
FhuA, an E. coli cell surface receptor, which in turn prevents further binding at 
the cell surface by ɸ80 (Uc-Mass et al., 2004). When this receptor is blocked, 
bacteriophages T1, T5, HK022, N1 also cannot bind to this receptor nor can the 
toxin, Colicin M (Harkness and Ölschläger, 1991, Hernández-Sánchez et al., 
2008). The Salmonella phage P22 prevents superinfection of its host cell through 
the expression of an inner membrane protein, SieA. SieA encodes an inner 
membrane protein that blocks the movement of invading DNA into the cytoplasm 
of the host cell, potentially through interactions with components in the DNA 
transport system of Salmonella (Susskind et al., 1974, Taneja and Chakravorty, 
1978). This protein prevents further infection by phage ɸL, MG178 and MG40 as 
well as P22 (Susskind et al., 1974, Hofer et al., 1995). Another mechanistic 
action of phage immunity is seen in E. coli isolates due to the expression of an 
83-residue lipophilic polypeptide; the immunity protein (Imm) (Lu and Henning, 
1989, Lu et al., 1993). The imm protein of E.coli upon infection by ɸT4 or any 
other T-even phages, can prevent further phage infections as the DNA of the 
secondary invading phage is excluded from the cytosol of the host cell thus, 
preventing replication of the invading phage (Anderson and Eigner, 1971, 
Dulbecco, 1952, Graham, 1953, Lu et al., 1993). 
HK97, a lambdoid like phage capable of infecting E. coli, encodes for a protein, 
gp15, which is present on the phage’s tail and provides resistance to the E. coli 
host from infection by other HK97 phage particles and its close relative, phage 
HK75. It is believed that this resistance is due to gp15 containing a putative 
helical transmembrane domain that is likely to localise to the inner membrane 
thus, preventing the entry of invading phage DNA into the cytoplasm (Cumby et 
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al., 2012). Due to the presence of this putative membrane spanning protein, 
when E. coli harbours the HK97 prophage, it is possible to classify gp15 as a 
member of the superinfection exclusion family of proteins/Sie (Labrie et al., 
2010a). These proteins are classed as being expressed from phage accessory 
genes as they are not required for essential bacterial growth but they do provide 
a selective advantage for the bacterium under certain extracellular pressure and 
stresses. 
 
3.1.1.3. Alteration of cell function through bacteriophage conversion  
Infection and integration into the bacterial chromosome changes the 
nomenclature of the bacteriophage to prophage. Detailed description regarding 
the formation of prophages and their prevalence has been described in chapter 1 
(section 1.6.4). Phage encoded diversity and the expression of accessory genes 
through phage integration has often been shown to offer a selective advantage to 
both the phage and the bacterium. An example of beneficial lysogeny is 
demonstrated in Shigella when integration interrupts the cadA gene, an anti-
virulence gene that normally encodes for the lysine decarboxylase enzyme. This 
enzyme normally produces cadaverine, which is involved in blocking the action of 
enterotoxins. So prophage incorporation into Shigella can enhance the 
pathogencity of the lysogen (Day et al., 2001).  
Phage incorporation can also have a negative effect on the bacterial host cell 
dependant on the environmental conditions, this is termed negative phage 
conversion [term coined by Brüssow et al. (2004)]. Negative lysogeny indicates 
that phage genes can inactivate the bacteria’s chromosomal genes upon 
incorporation resulting in loss of cellular function which is detrimental to the 
bacterium (Brüssow et al., 2004). Negative conversion has been seen in 
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Staphylococcus aureus (S. aureus) as infection and conversion by ɸ13, a 
serotype F bacteriophage, inactivates the genes encoding for ȕ haemolysin and 
lipase. Both these genes are involved in bacterial virulence and thus, the impact 
of pathogenicity is reduced (Coleman et al., 1989, Lee and Iandolo, 1985).  
However, lysogeny can be perceived to always be beneficial to the bacterial host 
cell as the phage is providing the bacteria with additional diversity compared to a 
naïve strain. Negative lysogeny can be classed as beneficial in some instances, 
such as aiding survival within a particular environment when virulence is no 
longer needed as an essential resource. 
  
3.1.1.4. Moron/accessory genes encoded by bacteriophages can alter 
disease progression 
Phages can aid the spread of bacterial disease and alter its progression. 
‘Lysogenic conversion’ of a bacterial cell by a phage and the expression of 
moron or accessory genes including toxins can raise the pathogenicity of a 
bacterium. Moron genes, as described by Brüssow et al (2004) are classed as 
extra DNA sections that are present in some bacterial hosts upon prophage 
incorporation but are not required for essential bacterial growth.  
Table 3.1 lists moron genes which have a direct impact on the pathogenicity of 
their bacterial hosts. Genetic relationship studies to identify moron genes were 
first undertaken in 1971 by Simon and colleagues; they utilised the technique of 
DNA heteroduplex mapping to show mosaicism between bacterial genomes 
(Simon et al., 1971, Juhala et al., 2000). These studies showed the prevalence of 
genes that appeared to have associations with prophage inclusion into the 
bacterial genome. Moron genes were described in the genomes of two E. coli 
strains in 2000 when the genomes were infected with siphoviridae HK97 and 
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HK022 (Juhala et al., 2000). Juhala et al. (2000) showed that the accessory 
genome was altered between E. coli strains harbouring Ȝ compared to the strains 
with the siphoviridae integrated.  
In E. coli, these moron genes are often seen in the late gene operons of the 
phage genome and are believed to aid fitness of the phage (Hendrix et al., 2000). 
An example of a moron gene in a Gram negative bacterium is SopE (encoded for 
by ɸSopE). SopE is a SPI1-dependant translocated protein which is known to 
support cellular growth and the entry of Salmonella typhimurium into mammalian 
host cells. It is a phage encoded effector which encodes for a type III secretion 
system in Salmonella typhimurium and this system is important for the bacterium 
during the infection process within the gut (Mirold et al., 1999, Hueck, 1998, 
Galán and Curtiss, 1989, Watson et al., 1998). 
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Table 3.1: Bacteriophage encoded moron genes which may have beneficial advantages for their lysogenic bacterial host cells. Prophage encoded 
moron genes are believed to have an influence on the bacterial host’s survival, as well as promoting for future selection of prophage infected bacterial isolates 
and therefore, promoting bacterial and phage survival within a particular environmental niche. 
Bacteria Phage Moron gene of 
interest 
Function Disease Reference 
Vibrio cholerae ɸCTX CTX toxin Alongside toxin production, this 
phage also encodes for a 
pathogenicity island. The island 
encodes a toxin co-regulated pilus 
which is also a receptor for the CTX 
phage  
Cholera 
 
(Karaolis et al., 1999, 
Waldor and Mekalanos, 
1996) 
Corynebacterium 
diphtheriae 
ɸȕ Diphtheria toxin 
(DIP0222) 
Produces an exotoxin protein which 
inhibits protein synthesis by altering 
elongation factor 2 
Diphtheria (Cerdeño‐Tárraga et 
al., 2003, Holmes, 2000, 
Leong and Murphy, 
1985) 
104 
 
S. aureus ɸETA Exfoliative toxin 
A 
Induces skin exfoliation by splitting 
the epidermis near the adrenal 
gland, more common in babies and 
young children 
Scalded skin 
syndrome 
(Ladhani et al., 1999, 
Dajani, 1972, Melish and 
Glasgow, 1970, Parker 
et al., 1955, Lyell, 1956) 
Clostridium 
botulinum 
Ceȕ C1 and D Neurotoxin that affects the nervous 
system and blocks the passage of 
a nerve impulse at nerve endings. 
Leads to paralysis in cranial nerve 
functions 
Botulism (Eklund et al., 1971, 
Eklund et al., 1972, 
Sugiyama, 1980) 
E. coli ɸT4 52 
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Alters host DNA methylation 
mechanisms which affects the 
incorporation of foreign phage DNA 
into the bacterial chromosome 
Prevents 
superinfection of 
the E. coli host 
with other phages 
(Raleigh and Wilson, 
1986, Hattman et al., 
1985, Fujimoto et al., 
1965, Gold et al., 1964, 
Hausmann and Gold, 
1966) 
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S. aureus ɸN315 Staphylokinase 
encoded for by 
Sak  
Enhances immune resistance as 
the bacterium activates the 
Plasminogen/Plasmin system.  
Which allows the bacteria to avoid 
host defence systems 
Increases S. 
aureus infection 
rates 
(Molkanen et al., 2002, 
Bokarewa et al., 2006, 
Wagner and Waldor, 
2002, Novick, 2000, 
Sako and Tsuchida, 
1983) 
Salmonella 
typhimurium 
Gifsy – 2 
Gifsy - 1 
Fels – 1 
Superoxide 
dismutases 
SodC1 
SodC111 
nanH 
Sod enzymes catalyse the 
conversion of superoxide to 
hydrogen peroxide and provide 
defence for the bacterial cells 
against macrophages 
Gastroenteritis (Figueroa-Bossi et al., 
2001, Figueroa-Bossi 
and Bossi, 1999, 
Figueroa-Bossi et al., 
1997, De Groote et al., 
1997, Farrant et al., 
1997, Fang et al., 1999) 
Streptococcus 
mitis 
SM1 pblA and pblB  Helps bind bacteria to platelets, 
pblA and plbB are surface encoded 
Endocarditis (Bensing et al., 2001, 
Sullam, 1994) 
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to encourage platelet binding 
Salmonella 
choleraesuis 
ɸ14 Lysogens Alters the O antigen chain by 
increasing the length compared to 
non-lysogenic strains. Leads to 
increased resistance and virulence 
Food poisoing 
often originating 
from infected 
swine ingestion 
(Nnalue et al., 1990, 
Nnalue and Stocker, 
1986) 
P. aeruginosa D3 Wzyȕ/A Confers O-Antigen switching to its 
bacterial host 
Avoid detection by 
the host’s immune 
system 
(Kropinski, 2000, 
Holloway et al., 1960, 
Kaluzny et al., 2007) 
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3.1.2. Phage-bacterial host interactions 
 
3.1.2.1. Bacteriophage and bacterial evolution 
Co-evolution between bacteriophages and their bacterial hosts has been 
proposed within the scientific community for over 30 years. It was suggested that 
co-evolution allows for the dynamic evolution of two different biological 
populations in order to inhabit the same environmental niche (Lenski and Levin, 
1985, Gómez and Buckling, 2011, Weitz et al., 2005, Rosvall et al., 2006). One 
of the first mentions of coevolution was in 1983, when it was stated that co-
evolution between a bacteria and a parasite depended on the transmission of the 
parasite (May and Anderson, 1983). It has been proposed that antagonistic co-
evolution often occurs between hosts and parasites, this has been observed in 
both nature and in lab settings (Buckling and Rainey, 2002). These evolution 
events are believed to play pivotal roles in population dynamics (Buckling and 
Rainey, 2002, Thompson, 1998) and parasite virulence (Buckling and Rainey, 
2002, Thompson, 1998, Bull, 1994).  
Buckling and Rainey (2002) demonstrated that a phage of Pseudomonas 
fluorescens, SBW25, was able to co-evolve with its bacterial host for > 300 
bacterial generations and proposed that a bacterial-phage arms race may be 
occurring. This study showed that time-lagged coevolution was occurring 
between the phage and the bacterial host, as the later generations of the phage 
communities showed an increase in infectivity profiles and the later generations 
of bacteria showed an elevated resistance to phage infection. These bacteria-
phage arm races have been shown to have an impact on a wide range of 
environmental processes including global nutrient cycling within the ocean 
(Suttle, 2007, Fuhrman, 1999, Brüssow et al., 2004), virulence of human 
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pathogens (Stern and Sorek, 2011, Brüssow et al., 2004), the global climate and 
the evolution of the biosphere (Comeau and Krisch, 2005, Brüssow et al., 2004).  
Antagonistic coevolution can also be referred to as the red queen hypothesis, 
which was proposed by Van Valen and colleagues in 1973 (Stern and Sorek, 
2011, Van Valen, 1973, Lenski and Levin, 1985, Schaffer and Rosenzweig, 
1978, Dawkins and Krebs, 1979). The red queen hypothesis proposes that in 
tight co-evolutionary relationships a change in one community may lead to the 
near extinction of the other community. This then causes the other community in 
the relationship to increase its fitness in order to remain a viable entity (Van 
Valen, 1973, Stern and Sorek, 2011). The specific ways which bacteria and 
phage can evolve to allow for the maintenance of both communities within a 
particular evolutionary niche are detailed in section 1.6.5. These include 
restriction modification, CRISPR/Cas, toxin-antitoxin and abortive phage infection 
systems.  
 
3.1.3. Polylysogeny  
Through the development and implementation of DNA sequencing platforms and 
continuingly improving sequencing chemistries, pathogenic bacteria have been 
shown to harbour multiple, inducible temperate bacteriophages in their genetic 
backbone. These bacterial strains can be classed as polylysogens (Burns et al., 
2015, Schuch and Fischetti, 2009, Winstanley et al., 2009, Wang et al., 2010). 
LES has been shown to harbour multiple novel prophage regions carrying genes 
with unknown function, figure 3.1. LES harbours 5 inducible prophage regions 
and 1 defective prophage region which is in contrast to the lab strain PAO1 which 
harbours only 2 prophage regions (Stover et al., 2000). Winstanley et al (2009) 
showed that disrupting these prophage regions resulted in a reduction of 
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bacterial fitness in a rat model of chronic lung infection, and so proposed that 
these prophage regions must offer a beneficial evolutionary advantage for their 
bacterial host. The pathogenic E. coli sakai O157:H7 isolated in Japan has been 
shown to contain 18 prophages however, not all of these prophages are inducible 
(Ohnishi et al., 2001). Polylysogeny is not restricted to just Gram negative 
bacteria as Streptococcus pneumoniae has been seen to harbour multiple 
prophage regions (Ramirez et al., 1999, Obregón et al., 2003). 
Burns et al (2015) demonstrated that during the initial stages of LES infection in a 
Galleria mellonella insect larvae model, lysogens initially had no beneficial 
advantage compared to naïve bacterial strains and over time there was in fact an 
associated 10 % increase in bacterial fitness in the single lysogen relative to the 
non-lysoge. Importantly, the largest fitness benefit was observed in the double 
lysogen suggesting that polylysogeny may be adaptive for the bacterial host in 
terms of growth and antimicrobial resistance (Burns et al., 2015).  
In summary, the effects of phages on their bacterial hosts are wide spanning and 
can have serious consequences on host cell behaviour and disease progression, 
these are made more apparent in clinical settings. The increased use of 
antibiotics and alterations in the host’s immune response in CF/BR patients also 
adds a layer of complexity when studying bacterial-phage infections within the 
lung. These factors make the lung a very stressful environment for both the 
phage and the bacterial host.  
In order for phages to survive in the chronic lung, they need to stay associated 
with and constantly evolve alongside their P. aeruginosa host cells. Their P. 
aeruginosa hosts are also evolving in order to remain within the chronic lung 
which generates the aforementioned, co-evolution or red queen hypothesis. The 
complex interaction between phages and their hosts can dramatically alter the 
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way in which communities react to an environment. It is believed that these 
bacteria-phage evolution events may influence the patient-patient transmissions 
of P. aeruginosa that are often seen in CF patients.  
Due to the severity of bacterial infections crossing into parents or carers of CF 
patients, the desire to understand the ‘antagonistic coevolution’ between phages 
and their bacterial host cells is becoming more pressing. It also poses the 
question “are temperate bacteriophages a new clinical challenge that need to be 
considered in order to effectively and efficiently treat chronic respiratory disease 
patients colonised with P. aeruginosa?” 
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Figure 3.1: Circular chromosomal map of the LES genome (Winstanley et al., 2009). 
The origin of replication is indicated on the image along with the potential prophage 
regions (identified in orange) and genomic islands (identified in green). The two most 
genetically similar prophage regions are marked by the linking purple loops which show 
the genetic relatedness of the prophage regions. The outer concentric circle represents 
the GC content of the bacterium whilst the inner circle represents the GC skew. Work has 
shown that disrupting these prophage regions within the LES genome leads to a 
reduction in bacterial fitness in a rat model.  
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3.2. AIMS  
The aim of this chapter was to characterise the interaction of possible mixed 
phage communities induced from described clinical P. aeruginosa isolates [CF (n 
= 47) and BR (n = 47)]. P. aeruginosa is referred to as Pa in figures in order to 
make them and the legends clearer for the reader. 
The 47 BR P. aeruginosa isolates have been subdivided according to the length 
of time since diagnosis with BR [under 10 years (< 10, n = 17) and over 10 years 
(> 10, n = 30)]. The 47 CF samples have been subdivided according to patient 
age [paediatric CF patients (under 15 years old, n = 10) and adult CF patients 
(over 15 years old, n = 37)].  
The inducible reservoir of phages from each clinical P. aeruginosa isolate is 
focused upon in this chapter. Once these putative mixed temperate phage 
preparations have been chemically induced away from their bacterial 
chromosome, it is possible to map the effects of these phages in terms of phage 
infectivity and bacterial sensitivity towards phage infection. This investigation also 
identified P. aeruginosa phages that were capable of re-infecting their originating 
P. aeruginosa bacterial isolate.  
It is hypothesised that the adult CF P. aeruginosa isolates and the associated 
phages will be the most adapted for survival within the chronic lung due to the 
fact that CF is a lifelong disease. However, it is pertinent to mention that even 
though CF is a lifelong disorder this doesn’t make P. aeruginosa colonisation 
also a lifelong event. An adult CF patient for example, may have only recently 
been colonised with P. aeruginosa, so care needs to be taken when drawing 
conclusions regarding P. aeruginosa colonisation in CF patients.  
It is also hypothesised that the phages and P. aeruginosa isolates originating 
from paediatric CF patients and < 10 BR patients will be the least evolved to 
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survive in this environment due to both these diseases being ‘new’ diseases. 
Even though BR occurs later in life it is possible to class it as a ‘new’ lung 
disease due to the late onset of clinical symptoms. Again a caveat needs 
mentioning, just because these diseases are ‘new,’ this doesn’t necessarily mean 
that P. aeruginosa colonisation is also a new event.  
 
3.3. RESULTS 
 
3.3.1. Phage induction and cross infection  
Before a cross infection study could be initiated phages were induced from their 
P. aeruginosa host. This was achieved using norfloxacin (NFLX) inductions 
(section 2.3.3). The induced phage lysates were then utilised in spot assays 
(section 2.3.3.1.) in order to elucidate the host range of the lysates and to identify 
any differences in the phage infectivity profiles. It was observed that all the P. 
aeruginosa isolates contained at least one inducible bacteriophage and were 
capable of infecting more than one P. aeruginosa isolate in the cohort. This is 
one of the first studies to utilise such a large panel of clinical P. aeruginosa 
isolates and focus on the mixed phage populations for each isolate.  
When analysing the data presented in this study, it is important to remember the 
aforementioned caveat – even though CF is a lifelong disease this doesn’t 
predispose the patient to lifetime colonisation with P. aeruginosa. This statement 
is also true when considering the BR results, even though a patient may have 
only recently been diagnosed with BR there is no clinical data to support the 
notion that this would be when P. aeruginosa would be first isolated from a 
patient. 
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The cross infection potential of the mixed phage lysates against the 94 clinical P. 
aeruginosa isolates is shown in figure 3.2. This figure describes the raw data 
generated during this investigation and it shows that that the CF phages have the 
broadest host range across the entire P. aeruginosa cohort. The BR phages 
meanwhile have a limited host range. The phages originating from paediatric CF 
and < 10 BR patients were the least infective and this is perceived to be related 
to their naivety in the chronic lung environment.  
 
Principle Least Squares Discrimination Analysis (PLS-DA) to look for 
trends present within the data set whilst using a semi-supervised model 
It is difficult to glean information from the cross infection raw data detailed in 
figure 3.2 and therefore, other approaches are needed to show potential 
differences in the data. Principle least squares discriminant analysis plots were 
used, as this modelling approach maximises the variation in the data. This may 
make it easier to identify differences between infection profiles or disease 
aetiologies. Bacterial sensitivity towards phage infection was also studied.  
Figure 3.3, panel 1 illustrates the differences seen using PLS-DA plots of the 
infectivity profiles for the different CF aetiologies. These plots are semi-
supervised which means that the plots are informed where to look for variation. 
The data is robust because of the high R2Y value of 0.72, values > 0.5 are 
believed to be representative of robust model. Figure 3.3, panel 1 shows that the 
adult CF phages (blue) align in a discrete group away from the paediatric CF 
phages (yellow) and this variation is proposed due to the separation along the x-
axis.  
Figure 3.3, panel 2 describes the infectivity profile differences between the CF 
and BR phages. In this instance the BR phages (blue) and the CF phages (red) 
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show clear variation according to their separation along the x-axis. However, 
there are some CF isolates that align with the BR phages, so indicating that 
these phages must have similar infection profiles. Three of these four phage 
lysates originate from paediatric CF P. aeruginosa isolates, potentially showing 
the naivety of these phages (ɸCF214, ɸCF165 and ɸCF213). Unusually, the 
fourth phage lysate which aligns with the BR lysates originates from a 33 year 
adult CF patient (ɸCF77). The data presented in this model is again robust 
because the R2Y value is 0.77.  
As mentioned previously, it was decided to model the sensitivity of the P. 
aeruginosa isolates towards phage infection and to show the maximum variation 
present within the data via PLS-DA plots. Figure 3.3, panel 3 describes the 
sensitivity of the CF P. aeruginosa isolates to phage infection, the paediatric CF 
P. aeruginosa isolates are represented in red and the adult CF P. aeruginosa 
isolates are represented in blue. There is clear variation between the two groups 
but there is one exception to this variation because one P. aeruginosa isolate 
originating from a paediatric CF patient aligns with the adult CF P. aeruginosa 
isolates. This shows that these isolates must exhibit similar sensitivity profiles. 
This paediatric CF P. aeruginosa isolate is CF208 and it originates from a 15 
year old patient. 15 years is the upper age limit for the paediatric cohort so this 
leads to the assumption that this bacterial isolate may behave more like adult CF 
P. aeruginosa isolates due to colonisation time within the CF lung. The R2Y value 
for this model is 0.66, this indicates that the model is robust as it passes the > 
0.5 threshold but the strength of the model is reduced in comparison to panel 1 
and 2.  
Figure 3.3, panel 4 describes the variation in the sensitivity differences between 
the CF/BR P. aeruginosa isolates; BR isolates are blue and CF isolates are 
green. The R2Y value is 0.83. Clear stratification is observed within the model but 
116 
 
two CF P. aeruginosa isolates are seen to align with the BR P. aeruginosa 
isolates. These CF P. aeruginosa isolates originate from adult CF phages, so this 
may indicate that this variation from the trend is not driven by naivety. The two 
CF P. aeruginosa isolates are CF136 and CF177 and the patients that these 
isolates originate from are 30 and 38 years old, respectively. It is interesting to 
note that these isolates are both epidemic strains of P. aeruginosa; CF136 is a P. 
aeruginosa isolate from the Manchester epidemic strain whilst CF177 is a P. 
aeruginosa isolate from the Midlands-1 epidemic strain. 
In order to further glean information from the cross-infection raw data, PLS-DA 
models were generated to look for variation between the mucoid and non-mucoid 
P. aeruginosa isolates with phage infectivity and bacterial sensitivity again being 
modelled in order to show the maximum variation present, shown in figure 3.4. In 
all the PLS-DA models, the mucoid isolates are shown in red and the non-mucoid 
isolates are shown in blue.  
Figure 3.4, panel 1 describes the phage infectivity differences when the BR 
phages are stratified according to their host’s phenotype. The isolates do not 
form discrete groups on the PLS-DA which may indicate that there is less 
variation present between the BR phages infectivity and the mucoid phenotype is 
not a clear driving factor. The R2Y value is 0.67, which shows that the model is 
robust as it is above the > 0.5 threshold.  
Figure 3.4, panel 2 details the variation in the infectivity profiles of the CF phages 
when they are stratified according to the presence/absence of a mucoid 
phenotype in their host, the R2Y value is 0.72. There are two outliers in this PLS-
DA plot which fall outside of the 95 % confidence eclipse, both these outliers are 
phages induced from mucoid P. aeruginosa isolates. ɸCF54 originates from an 
adult CF patient (17 years) whilst ɸCF187 originates from a paediatric CF patient 
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(2 years). This suggests that age differences are not driving the differences in the 
phage infectivity profiles. 
Figure 3.4, panel 3 describes BR P. aeruginosa isolates sensitivity towards 
phage infection when the BR isolates exhibit either a mucoid or a non-mucoid 
phenotype. In a similar trend to the observation in figure 3.4, panel 1 there 
appears to be less stratification between the two groups. This would indicate that 
the variation in the data is not due to the bacterial isolates phenotype. The R2Y 
value for this PLS-DA plot is 0.67.  
The final panel in figure 3.4 determines the variation in the bacterial sensitivity 
profiles towards phage infection when the CF P. aeruginosa isolates are grouped 
according to the presence/absence of a mucoid phenotype. This plot indicates 
that a mucoid P. aeruginosa isolate aligns with the non-mucoid P. aeruginosa 
isolates. This mucoid P. aeruginosa isolate is CF208 and it originates from a 
paediatric CF isolate which potentially indicates that time is a discriminating 
factor in the variation seen in this plot. The R2Y value is 0.73.  
 
Statistical modelling of the data to support the data previously presented 
via PLS-DA plots 
Figure 3.5 describes the cross infection data using ANOVA analysis. This 
method uses nestedness as a measure of network order where a highly nested 
pattern describes a hierarchy from generalists (broad host range) to specialists 
(narrow host range) for both species. The binmatnest value is the deviation of the 
network pattern from an optimal nested pattern of the same dimensions; values 
are on a scale from 0 (highly nested) to 100 (not nested at all). These plots were 
generated in collaboration with Professor Mike Brockhurst at the University of 
York, York, UK. 
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Panel 1 represents that ability of the BR/CF phages to infect the entire P. 
aeruginosa cohort. It is possible to propose from these data that the adult CF 
phages are the most infective across the P. aeruginosa cohort. This was 
illustrated by the higher gradient of infections in the nested plot for the CF 
phages against both bacterial backgrounds (an infection is indicated via a black 
mark).  
When the data was modelled using the mucoid phenotype (panel 2), then it was 
observed that only the mucoid BR P. aeruginosa isolates (n = 22) generated any 
significant data. The findings from these nested plots showed that the BR phages 
could infect mucoid BR P. aeruginosa isolates at a higher rate compared to non-
mucoid BR P. aeruginosa isolates. This may be indicative of the environment in 
the lower lung of BR patients and so the phages will have evolved in order to 
infect and survive these adverse conditions. 
Panel 3 shows the associated statistical information relating to these plots. The 
use of ANOVA to describe these data was important for this analysis due to its 
ability to confer statistical weight to the results and findings proposed.  
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Figure 3.2: Raw cross infection data obtained showing the > 3000 reactions 
involved in generating this data. Excel derived table showing cross infection data. 
Black cells illustrate phage lysates that were incapable of infection on that particular 
bacterial host. Green cells represent infection and infection assays showing total lysis of 
the bacterial host. Yellow cells represent infection including a central, cleared lysed zone 
and a turbid halo on the bacterial host. Red cells represent turbid zones of clearing.  
CF background refers to P. aeruginosa isolates originating from CF patients whilst BR 
background refers to P. aeruginosa isolates originating from BR patients.  
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Figure 3.3: PLS-DA plots to show the differences in phage infectivity profiles and 
bacterial sensitivity profiles between the CF/BR isolates and upon stratification of 
the CF isolates according to age. Panel 1 shows the differences in the phage infectivity 
profiles between the paediatric CF phages (yellow) and the adult CF phages (blue) - R2Y 
is 0.72. Panel 2 shows the total differences in phage infectivity for the BR phages (blue) 
and the CF phages (red) - R2Y is 0.77. Panel 3 shows the bacterial sensitivity profiles 
comparing the paediatric CF phages (red) and the adult CF phages (blue) - R2Y value is 
0.66. Panel 4 shows the bacterial sensitivity profiles comparing the CF (green) and BR 
phages (blue) - R2Y value is 0.83. 
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Figure 3.4: PLS-DA plots to show differences in phage infectivity and bacterial 
sensitivity when the isolates are stratified according the presence/absence of a 
mucoid phenotype. All the mucoid isolates are shown in red and the non-mucoid are 
shown in blue. Panel 1 describes the variation in the phage infectivity profiles of the BR 
phages, R2Y value is 0.67. Panel 2 describes the differences seen between the phage 
infectivity profiles for the CF phages upon stratification for a mucoid phenotype, R2Y 
value is 0.72. Panel 3 describes the variation in the BR isolates sensitivity to phage 
infection, R2Y value is 0.67. Panel 4 shows the difference observed in the sensitivity 
profiles for the CF isolates, R2Y value is 0.73. 
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Figure 3.5: Nestedness and Connectance plots to map the cross infection data 
from the mixed temperate phage communities induced from the 94 clinical P. 
aeruginosa isolates. Analysis of the data has been undertaken by Rosanna Wright 
and Michael Brockhurst (York University, UK). Each black square represents an 
infection event between a phage lysate (x-axis) and a P. aeruginosa isolate (y-axis). A 
white square indicates when no infection occurred. Panel 1 shows the binary nested 
network for the 94 mixed phage lysates compared against the 94 P. aeruginosa isolates, 
the quadrants are of equal size. Panel 2 shows the binary nested network of the mucoid 
BR P. aeruginosa isolates (n = 22) against the entire cohort of induced mixed temperate 
phage lysates. The mucoid data was derived from the associated clinical data for each of 
the P. aeruginosa isolates involved in this investigation. Panel 3 describes the metric 
values for the results shown in panels 1 and 2. 
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3.3.2. Isogenic phage infection of originating bacterial isolates 
When the cross infection data was modelled, it was determined that certain 
phages were capable of infecting their originating host. It has also been seen that 
the E. coli phage 24B can infect its originating E. coli host cell due to the 
presence of a novel integrase (Fogg et al., 2007)    
Figure 3.6 illustrates that 66 % of CF phage lysates cause an infection on their 
originating host bacteria whilst 49 % of BR phage lysates cause an infection on 
their originating host. Panel 1 shows the stratification of the phage lysates that 
can re-infect their originating P. aeruginosa lysate when looking only at CF and 
BR. Panel 2 further subdivides these data by age/time to look for differences in 
the phages that have the ability to re-infect their originating P. aeruginosa host. 
84 % of the adult CF phage lysates could re-infect their originating P. aeruginosa 
host whilst only 16 % of paediatric CF phage lysates had this ability. When 
looking at the stratification of the BR phage lysates it was seen that 30 % of the < 
10 BR phage lysates could infect their originating host compared to 70 % of the 
lysates > 10 BR could infect their originating P. aeruginosa host. These results 
may show a link between the ability to re-infect their originating bacterium as 
being an adaptive or evolved trait that is linked to disease progression. 
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Figure 3.6: Ability of phages in this investigation to re-infect their originating host 
cell. Graphical representation of the percentage of phages that are capable of re-
infecting their originating host (% inf. ori. host = % infection of originating host); this 
image is taken from (Tariq et al., 2015). Panel 1 shows the percentage of phage lysates 
from BR and CF P. aeruginosa isolates. Panel 2 shows further stratification of the data 
shown in panel A according to the clinical data. 
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3.3.3. Stratification of the cross infection results based on the clinical 
data – phage infectivity 
The ability of each phage lysate sub-group to infect P. aeruginosa hosts from the 
various aetiologies has been illustrated in figure 3.7. The mean rates of infectivity 
and the host range distribution of the phage infections are detailed in table 3.2. 
The phages have been characterised according to the clinical data available, so 
it has been possible to elucidate any potential differences in the infection 
capabilities of the phage lysates according to patient age (CF) and length of time 
since diagnosis (BR). The previously mentioned caveat is also applicable in the 
analysis of this data set. The data is also further subdivided so that it is possible 
to study differences in the infectivity of a particular clinical phage group against 
the various subgroups of the P.aeruginosa isolates.  
These data indicates that the adult CF phages have the greatest mean rate of 
infectivity across the entire clinical P. aeruginosa cohort, possibly due to these 
phages being long term colonisers of the chronic lung environment. The ‘newer’ 
colonisers, paediatric CF phages and < 10 BR phages, showed a lower rate of 
infectivity. It is proposed that time influences the infectivity patterns seen, as the 
longer that the phage has had to colonise an environment correlates to a greater 
infectivity range being observed.  
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Table 3.2: Infectivity rates for each phage lysate against the various bacterial 
aetiologies. Mean rates of phage infectivity and the host range distribution for each 
aetiological subgroup of phages against the different P. aeruginosa hosts involved in this 
thesis.  
For each phage infection against a particular P. aeruginosa background, a % score was 
given in order to elucidate the host range of the particular phage lysate. From these 
values, the mean % of infection could be calculated as could the distribution of infection 
around the mean.   
Bacterial 
host 
Phage lysate Panel  Mean rate of 
infectivity (%) 
Distribution of 
infectivity  
Paediatric CF Paediatric CF  1 11 9 
 Adult CF   68 38 
 < 10 BR   57 37 
 > 10 BR   49 49 
Adult CF Paediatric CF  2 36 36 
 Adult CF   55 44 
 < 10 BR   63 52 
 > 10 BR   41 41 
< 10 BR Paediatric CF  3 49 34 
 Adult CF   78 63 
 < 10 BR   63 51 
 > 10 BR   54 54 
> 10 BR Paediatric CF  4 48 34 
 Adult CF   76 49 
 < 10 BR   56 42 
 > 10 BR   45 38 
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Figure 3.7: Infection capabilities of each phage aetiological group against the 
various bacterial aetiological groups. Non parametric t tests were utilised with two 
tailed p values shown in order to display the most discrete statistical significant data; * ≤ 
0.05, ** ≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001.   
Panel 1 shows the challenge of paediatric CF phage lysates onto the complete P. 
aeruginosa panel. 
 Panel 2 shows the addition of adult CF phage lysates onto the complete P. aeruginosa 
panel.  
Panel 3 shows the addition of < 10 BR phage lysates onto the complete P. aeruginosa 
panel.  
Panel 4 shows the addition of > 10 BR phage lysates onto the complete P. aeruginosa 
panel. 
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3.3.4. Sensitivity to phage infection by the P. aeruginosa panel 
The sensitivity of each of the P. aeruginosa isolates to be infected by the NFLX 
induced phage lysates is important alongside phage infectivity, as it shows the 
permissiveness of the bacteria to phage infection from the varying evolving 
disease states. These data are shown in figure 3.8. The mean rate of sensitivity 
for each P. aeruginosa isolate to phage infection is detailed in table 3.3 and the 
host range distribution of sensitivity is also described. Care needs to be taken 
when analysing this data as these subgroups of clinical data may not relate to 
length of time of P. aeruginosa colonisation of the CF/BR lung. 
When looking at the sensitivity of the P. aeruginosa hosts to phage infection on 
figure 3.8, it is interesting to note that all the sensitivity profiles are similar for the 
specific P. aeruginosa backgrounds, regardless of the clinical origin of the phage 
lysate. The adult CF P. aeruginosa isolates are not only the most resistant to 
phage infection but they have the smallest difference relating to sensitivity. It is 
also important to note that sensitivity to phage infection decreases over time in 
the CF population.  
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Table 3.3: Sensitivity of the P. aeruginosa isolates to phage infection. The mean 
rate of sensitivity and the distribution of the sensitivity of P. aeruginosa isolates towards 
phage infection, subdivided according to the associated clinical data. 
For each sensitivity profile for a particular P. aeruginosa background, a % score was 
given in order to elucidate how sensitive the P. aeruginosa strain was towards phage 
infection, the phages were subdivided into groups according to their origin. From these 
values, the mean % of infection could be calculated as could the distribution of infection 
around the mean.   
P. 
aeruginosa  
Phage lysate Panel  Mean rate of 
sensitivity 
(%) 
Distribution of 
sensitivity  
Paediatric CF Paediatric CF  1 54 24 
 Adult CF   46 36 
 < 10 BR   44 34 
 > 10 BR   48 38 
Adult CF Paediatric CF  2 58 18 
 Adult CF   70 19 
 < 10 BR   75 24 
 > 10 BR   76 24 
< 10 BR Paediatric CF  3 57 3 
 Adult CF   63 26 
 < 10 BR  63 53 
 > 10 BR   56 38 
> 10 BR Paediatric CF  4 49 22 
 Adult CF   52 15 
 < 10 BR   54 30 
 > 10 BR   45 35 
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Figure 3.8: Varying sensitivities of each bacterial isolate to phages originating from 
the various clinical aetiologies. Non parametric t tests were utilised with two tailed p 
values shown in order to display the most discrete statistical significant data; * ≤ 0.05, ** 
≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001. The different origins of the phage lysates are 
indicated on the x axis of the plots and the bacteria host which the sensitivity tests were 
undertaken on is represented by the panel number.  
Panel 1 shows the addition of phage lysates from the varying aetiologies onto the 
paediatric CF P. aeruginosa isolates. 
 Panel 2 shows the addition of phage lysates from the varying aetiologies onto the adult 
CF P. aeruginosa isolates.  
Panel 3 shows the addition of phage lysates from the varying aetiologies onto the < 10 
BR P. aeruginosa isolates. 
Panel 4 shows the addition of mixed phage lysates from the varying aetiologies onto the 
> 10 BR P. aeruginosa isolates. 
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3.3.5. Is phage infectivity linked to polylysogeny? 
We have demonstrated different infectivity profiles between phages from each 
stratum of the chronic respiratory disease cohort (section 3.3.1). Due to previous 
research on LES and its multiple inducible phages (Winstanley et al., 2009), it 
was presumed that polylysogeny is important in bacterial survival and evolution 
in the chronic lung. We cannot determine from the cross-infection raw data 
whether the broad host range of phages isolated from the later stages of disease 
is linked to a specific phage or is simply linked to a higher incidence of 
polylysogeny. Single plaque purified five phages from each of the four clinical 
aetiologies were used to determine whether the results were due to a single 
predominant phage. Figure 3.9 details the total change in the cross infection 
profiles for the mixed and single phage infection across the 94 P. aeruginosa 
isolates.  
Figure 3.9 shows that mixed phage lysates mostly exhibit an elevated propensity 
for infection in comparison to the single, plaque purified phages. Upon 
stratification for the different clinical aetiologies the same trend was seen apart 
from in the paediatric cohort. In this instance, the plaque purified phages had a 
greater infection profile. With the exception of the paediatric cohort, the elevation 
in the infection profiles of the mixed phage lysates would lead to the hypothesis 
that the P. aeruginosa bacterial hosts may harbour multiple inducible phages in 
their chromosomal DNA. In LES it has seen that harbouring multiple prophages 
increases the bacterium’s overall infectivity, so it may be possible to propose that 
this is also within our P. aeruginosa cohort (Winstanley et al., 2009). This 
therefore, may explain how P. aeruginosa becomes the primary and predominant 
coloniser of the chronic lung environment. Polylysogeny is a currently overlooked 
area in the field of chronic lung diseases and it may be the driving factor behind 
the results described previously in this chapter.  
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Figure 3.9: The additive effect of phage infections compared to the effect of 
singular plaque purified phage infections. Twenty bacteriophages were selected (5 
from each of the 4 clinical aetiologies) and were plaque purified. These plaque purified 
phages were then cross-infected against the 94 clinical P. aeruginosa isolates; CF n = 47 
and BR n = 47. Black bars indicate when the mixed phage lysate was used whilst the 
grey bars indicate the use of single, plaque purified phages.  
The results from the single phage cross infections were compared to the previous results 
which utilised mixed phage communities in order to show if the infection  patterns were 
due to additive phage infection or a single and predominant plaque purified phage. Panel 
1 illustrates the infection profiles for the CF isolates when comparing mixed and purified 
phages. Panel 2 illustrates the infection profiles for the BR isolates when comparing 
mixed and purified phages 
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3.4. DISCUSSION 
These data contribute towards one of the largest reported studies looking at the 
relationship and interaction between temperate bacterial viruses and their 
bacterial hosts. This study initially focused on mixed temperate phage 
communities, as this was believed to represent the most realistic scenario for 
studying the interactions of the entire viral community with their bacterial hosts in 
vitro. However, in order to study more detailed interactions, single phages were 
purified and used for further downstream applications. Phages may represent a 
potential novel area of research when trying to elucidate the progression and 
evolution of chronic lung diseases. This is due to the ability of phages to enhance 
the spread of DNA around a community and so enhance the levels of 
recombination.  
This work is original due to its large scale nature and a key finding was that 
multiple phages were isolated from P. aeruginosa isolates originating from the 
later stages of CF and BR and that these phages were associated with an 
increased bacterial host range. This could represent the possible impact that 
polylysogeny has during P. aeruginosa infections. These data also support work 
previously published by Buckling and Rainey (2002), which showed the 
development of antagonistic co-evolution between bacteria and phage. It is 
believed that this work shows antagonistic co-evolution as it is assumed that the 
phage communities evolve and adapt alongside their P. aeruginosa host, this 
adaptation and evolution is perceived to aid the survival and retention of both 
biological entities in the chronic lung setting.  
It was interesting to note that the phages isolated from the later stages of 
disease, were able to readily infect and replicate in P. aeruginosa isolates from 
the “earlier” disease isolates. It was observed that all the P. aeruginosa isolates 
in this cohort harboured inducible temperate bacteriophages which could infect at 
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least one of the P. aeruginosa isolates. It is possible to hypothesise that this 
ability to infect the more naïve isolates of P. aeruginosa provides an advantage 
for the evolved phages, as it increases their host range ensuring their longevity 
within the chronic lung environment. The CF phages were also seen to infect BR 
P. aeruginosa isolates at an elevated level suggesting that the CF phages are 
more evolved to avoid the host defence systems of BR P. aeruginosa isolates. It 
is also possible to speculate that this evolution is due to the fact that CF is a 
lifelong disorder and that the phages have acquired efficient anti-CRISPR genes 
which target a wide range of CRISPR/Cas defence systems. It could also be 
proposed that the BR P. aeruginosa isolates are not as evolved in terms of 
phage defence systems, as the bacterial isolates are new colonisers of the 
chronic lung environment and so may not be used to constant bombardment by 
phages. All this work emphasises the complexity of the lung microbiome and the 
evolving nature of the chronic lung.  
ANOVA models to show nestedness and connectance, generated statistically 
significant results for the cross-infection raw data (section 3.3.1.). These 
analyses lead to the proposition that the adult CF phages were the most infective 
across the two P. aeruginosa cohorts. It also showed that the BR phages could 
infect BR P. aeruginosa mucoid isolates (n = 22) at elevated levels compared to 
non-mucoid isolates and this led to a hypothesis that the BR phages are used to 
encountering mucoid P. aeruginosa isolates within the chronic lung and 
therefore, have evolved infection strategies to overcome this phenotypic 
alteration.  
When studying PLS-DA plots to look at the variation in the data relating to phage 
infectivity, it was seen that the adult CF phages formed a discrete group away 
from the paediatric CF phages. This would indicate that phage infectivity profiles 
alter as the bacteria evolve within the chronic lung. PLS-DA plots were also used 
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to show the total difference in the phage infectivity profiles for the CF and BR 
phages. These two cohorts showed maximum variation upon modelling and this 
may be an example of evolution of the phages which colonise the chronic lung. 
Some CF phages were seen to align with the BR phages in terms of their 
infectivity profiles but 75 % of these phages originated from paediatric CF 
phages. This indicated to us that naivety was driving the variation observed. 
Similar variation patterns were seen when the PLS-DA plots were used to show 
differences in bacterial sensitivity towards phage infection. All the PLS-DA plots 
shown in this chapter have R2Y values greater than 0.5 which shows the 
robustness of the model.     
A large percentage of the phages in this investigation do not conform to the 
typical lambda model of phage infection, as they have the ability to re-infect their 
originating host cell. The lambda model proposes that upon infection with one 
phage the bacterium is immune to further phage infection events including self-
infection (Kaiser and Jacob, 1957, Ptashne, 1967). The E. coli phage 24B also 
exhibits this atypical non-lambda infection pattern as it has been demonstrated 
that this phage is able to infect its host cell multiple times and at high 
frequencies. Potentially increasing the pathogenicity of its host cell through each 
passing round of infection due to gene addition (Smith et al., 2012). Phages 
induced from P. aeruginosa isolates originating from adult CF patients had the 
greatest ability to re-infect their originating host, which supports earlier findings 
that the CF phages isolated from later disease isolates were the most infective. 
The proposal that superinfecting phages have a higher propensity for 
polylysogeny is supported in these data, as the older P. aeruginosa isolates 
harboured on average more than one inducible phage and also had an elevated 
propensity to re-infect their originating host cell.  
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It was proposed that the adult CF phages had the greatest mean infection rates 
due to their long term colonisation of the lower lung. This long term colonisation 
may have allowed the phages to evolve in order to harbour effective anti-
bacterial systems such as alteration of the sequence recognised in the 
restriction-modification systems. The phages may have also evolved in order to 
infect the P. aeruginosa isolates through the utilisation of a different cellular 
target to aid phage adsorption.  
When looking at bacterial sensitivity it was seen that in the CF isolates this was 
reduced as time progressed whereas, the sensitivity increased in BR isolates. 
This would indicate that the BR isolates are evolving in order to overcome phage 
infectivity by the more evolved and complex phages. This would also indicate 
that the evolutionary distance between the P. aeruginosa isolates maybe 
increasing in relation to their clinical aetiology. It may also indicate that the 
isolates have different survival strategies which alter the direction of evolution 
and adaption of the isolates within the chronic lung. Low sensitivity profiles may 
indicate that some of the phages in this study may have alternative infection 
capabilities or targets, which may not be present on all the bacterial hosts which 
could therefore, prevent observation of an infection.  
In order to confirm whether polylysogeny was driving the results seen in this 
thesis it was decided to undertake the cross infection study utilising single plaque 
purified phages. It was observed that the mixed phage lysates had an elevated 
ability to generate an infection. Upon stratification of both the mixed and single 
phage lysates into clinical aetiological groups, it was observed that the same 
trend was still apparent even in the smaller cohorts. The only exception to the 
trend was the paediatric CF single, where the plaque purified had greater 
infectivity capabilities against the entire P. aeruginosa cohort in comparison to 
the mixed paediatric CF phage lysates. It is possible to hypothesise that 
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polylysogeny is providing the bacteria with a selective advantage within the 
chronic lung, this can be proposed because greater infectivity profiles are 
observed when using mixed lysates compared to single, plaque purified phages.  
All these data presented here indicate the effect of phages on P. aeruginosa host 
cells whilst also indicating that prophage incorporation alters the bacterial 
response to the environment in the lower lung. It also leads to the conclusion that 
phages may be a new clinical target of interest for clinicians treating CF and BR 
patients who are chronically colonised with P. aeruginosa. 
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4. PROPHAGE MEDIATED CHANGE IN PHENOTYPE AND 
ANTIMICROBIAL RESISTANCE 
 
4.1. INTRODUCTION 
In section 1.5.4 the presence of multiple inducible prophage regions within the 
chromosome of P. aeruginosa is described. Integration of new prophages can 
offer positive or negative benefits with respect to bacterial fitness or evolutionary 
selection but these benefits are dependent on the health and fitness of the 
bacterial cell, as discussed in section 3.1.2. This chapter focuses on how 
prophages influence the bacterial host and how this may drive selection and 
longevity in the lower lung. A key focus is phage encoded antibiotic resistance 
and phage mediated increases in growth rate. This chapter also focuses on 
bacterial motility through twitching and how phage infection can mediate 
microbial movement in the lower lung.  
 
4.1.1. Antibiotic resistance development in P. aeruginosa 
Antibiotic resistance is becoming a global concern with reported bacterial 
resistance to all major classes of antibiotics (WHO, 2015). Some well-known 
examples of multidrug resistant (MDR) Gram positive bacteria include methicillin 
resistant Staphylococcus aureus (MRSA) and vancomycin resistant 
Enterococcus species (VRE) (Hancock and Knowles, 1998, Hancock and Speert, 
2000, Enright et al., 2002).  
The focus of this thesis is P. aeruginosa and table 4.1 is adapted from Hancock 
et al (2000). It shows the antibiotics that are commonly used to treat 
Pseudomonad infections. It is now common practice in clinics to treat P. 
aeruginosa infections with a combination of drugs from the various classes, most 
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commonly a ȕ lactam and an aminoglycoside (Hancock and Speert, 2000, 
Vardakas et al., 2013, Tamma et al., 2012). P. aeruginosa sometimes requires a 
combination of mutations to gain resistance to various classes of antibiotics so 
multiple drug administration can slow down resistance acquisition (Livermore, 
2002). It is believed that the mutations in P. aeruginosa accrue in an additive 
manner which aids the development of the MDR phenotype (Lee et al., 2000, 
Livermore, 2002). The hypermutator phenotype of P. aeruginosa may explain the 
alterations in resistance profiles that are seen during longitudinal studies. In 
these studies, the bacterium can convert to an antibiotic resistant phenotype 
during antimicrobial treatments but revert back to the less costly antibiotic 
sensitive profile when the external stimuli is removed or reduced (Oliver et al., 
2000). P. aeruginosa as previously described often has a mucoid phenotype 
upon isolation from the chronic lung environment. This mucoid phenotype has 
the potential to reduce the effects of antibiotic treatment as the mucoid 
exopolysaccharide (EPS) layer may interfere with the penetration of certain 
antibiotics (Slack and Nichols, 1981, Oliver et al., 2000, Pressler et al., 2006, 
Hoffmann et al., 2005, Costerton et al., 1999, Ciofu et al., 2001, Worlitzsch et al., 
2002).  
Variation in the antimicrobial resistance profiles of P. aeruginosa within 
populations colonising the CF lung has been observed (Mowat et al., 2011). It 
has also been observed that treating P. aeruginosa infections with sub-inhibitory 
concentrations of antibiotics leads to greater diversity within antimicrobial 
resistance profiles of P. aeruginosa isolates (Wright et al., 2013). 
S. aureus phages have been seen to transfer phage encoded resistance genes 
to non–aureus staphylococcal strains such as Staphylococcus epidermidis and 
Staphylococcus xylosus, they have also been seen to transfer this 
staphylococcal phage encoded resistance to other bacterial genera such as 
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Listeria monocytogenes (Quiles-Puchalt et al., 2014, Chen et al., 2015, Chen and 
Novick, 2009, Kenzaka et al., 2010). Modi et al (2013) demonstrated that when 
mice were treated with antibiotics, their phage metagenomes became enriched 
for genes involved in antibiotic resistance (Modi et al., 2013). When the faeces of 
healthy human participants was studied via metagenomics, a large number of 
genes relating to antibiotic resistant genes were observed in bacteriophage DNA 
including blaTEM, blaCTX-M-1, mecA, qnrA and qnrS (Quirós et al., 2014). These 
studies indicate that phages may play a potentially crucial role in the spread of 
resistance around a population, through acquisition of bacterial chromosomal 
DNA and the transfer of this material to another susceptible bacterial host. 
It is believed that the large genome size, plasticity and the ability to carry large 
numbers of plasmids is the cause of the antimicrobial resistance in P. 
aeruginosa. P. aeruginosa harbours ~5570 genes (strain dependent) with a large 
proportion of these genes being assigned to regulation. This is consistent with 
the observation that most of the antibiotic resistant P. aeruginosa strains 
characterised have regulatory gene mutations (Hancock and Speert, 2000). 
Sherrard et al (2014) generated a visual representation of the various antibiotic 
resistance mechanisms exploited by P. aeruginosa and other Gram negative 
bacterium as shown in figure 4.1. P. aeruginosa antibiotic resistance is often due 
to the presence of multiple efflux pumps and the impermeability of the outer 
membrane (Poole, 2001, Poole et al., 1993, Ma et al., 1994, Germ et al., 1999, Li 
et al., 2000). Bacterial porins are water filled channels that are often the major 
entry point for antibiotics to enter into their intended target (Nikaido, 1992, 
Hancock, 1987, Nikaido, 2001).  
Impermeability of the outer membrane to antibiotics can occur due to mutations 
in OprD; a P. aeruginosa outer membrane porin, which is normally only 
accessible for small molecules and a few antibiotics, such as ȕ lactams 
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(Studemeister and Quinn, 1988). These channels close through mutation 
preventing the entry of antibiotics into the host cell and this leads to the 
observation of a resistance profile (Studemeister and Quinn, 1988).  
P. aeruginosa also harbours a large porin, OprF, which allows for the movement 
of large compounds such as tetra-saccharides along with the potential movement 
of antibiotics. Again this entry point can become inhibited which leads to the 
onset of resistance (Bellido et al., 1992, Hancock and Speert, 2000). Escherichia 
coli (E. coli) K-12 ompF mutants have been found to be resistant to carbenicillin 
antibiotics, this shows how bacterial species can alter their phenotypic structures 
in order to combat the effects imposed upon them by antibiotics (Nikaido, 2003, 
Harder et al., 1981, Ziervogel and Roux, 2013).  
MexAB-OprM is a key efflux pump in P. aeruginosa and is involved in the 
removal of ȕ lactams (Li et al., 1995, Masuda et al., 1999, Nakae et al., 1999), 
chloramphenicol (Li et al., 1995), fluoroquinolones (Li et al., 1995), 
sulphonamides (Köhler et al., 1996, Poole, 2001), and trimethoprim (Poole, 2001, 
Köhler et al., 1996) antibiotics. P. aeruginosa also harbours another efflux pump, 
MexX-MexY, that has the ability to efflux the same molecules as MexAB-OprM 
but this efflux pump is also involved in the intrinsic resistance of P. aeruginosa to 
aminoglycoside antibiotics (Aires et al., 1999, Westbrock-Wadman et al., 1999, 
Hancock and Speert, 2000).  
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Table 4.1: Clinical anti-pseudomonal antibiotics and a description of their 
functionality, adapted from (Hancock and Speert, 2000). The various P. aeruginosa 
resistance mechanisms are also described for each class of antibiotic emphasising the 
importance of understanding the underlying mechanisms of antibiotic resistance build up.  
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Class Agent(s) Clinical advantages Clinical disadvantages P. aeruginosa resistance 
mechanisms 
Penicillin Ticarcillin 
Carbenicillin 
Piperacillin 
Synergistic with 
aminoglycosides used to 
treat P. aeruginosa 
May induce ȕ lactamases 
in P. aeruginosa  
De-repression of 
chromosomal ȕ lactamase 
which allows for the 
inactivation of ȕ lactams 
via hydrolysis and so 
generates increased 
resistance to other ȕ 
lactams  
Overexpression of the 
MexAB-OprM efflux pump 
is also detected  
(Hancock and Speert, 
1996) 
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Cephalosporin Ceftazidime 
Cefoperazone 
Cefepime 
Cefpirome 
Can be used as a single 
antibiotic treatment 
method 
May induce ȕ lactamases 
in P. aeruginosa 
Expression of 
chromosomal ȕ lactamase 
which allows for the 
inactivation of ȕ lactams 
via hydrolysis and so 
generates increased 
resistance to other ȕ 
lactams 
Overexpression of the 
MexAB-OprM efflux pump 
is also detected 
 (Hancock and Speert, 
1996) 
Aminoglycoside Gentamicin 
Tobramycin 
Synergistic with ȕ lactam 
antibiotics administered to 
Narrow therapeutic/toxic 
ratio 
Overexpression of the 
MexX-MexY pump leading 
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Amikacin treat P. aeruginosa 
infections 
Known to penetrate poorly 
into the cerebrospinal fluid 
Most large studies have 
shown that around 10 % of 
P. aeruginosa isolates are 
resistant to 
aminoglycosides 
(Hancock and Speert, 
1996) 
to P. aeruginosa 
impermeability 
Quinolone Ciprofloxacin Can be given orally to a 
patient 
Contraindication in 
children < 16 years 
Target site mutations arise 
in codon 83 of the GyrA/B 
topoisomerase subunit so 
altering DNA synthesis 
levels 
Overexpression of multiple 
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efflux pumps 
(Mouneimné et al., 1999, 
Takenouchi et al., 1999) 
Polymyxin Colistin Very active antibiotics with 
very little resistance 
developed thus far 
Possible toxicity concerns Outer lipopolysaccharide 
changes arise due to 
regulatory mutations in 
PhoP/Q however, there is 
no in vitro evidence to 
document this change  
 (Macfarlane et al., 2000) 
Carbapenem (ȕ lactams) Imipenem 
Meropenem 
Very broad spectrum 
against a range of Gram 
negative bacteria 
Meropenem is not 
administered as a first line 
May induce ȕ lactamases 
in P. aeruginosa 
Rapid resistance has been 
seen to develop 
Reduction in OprD levels 
Overexpression of 
MexAB-OprM efflux pump 
(when Meropenem is 
used) 
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Figure 4.1: Antibiotic resistance mechanisms in Gram negative bacteria (Sherrard 
et al., 2014). The various antibiotic resistance mechanisms that are present in bacteria 
isolated from the chronic lung environment such as Staphylococcus aureus, Burkholderia 
cepacia complex C and P. aeruginosa. 
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4.1.1.1. Antibiotic resistance in chronic respiratory disease patients  
 It has been observed that CF patients clear antibiotics including 
aminoglycosides and penicillins from their systems faster when compared to 
healthy individuals (Yaffe et al., 1977, Jusko et al., 1975, Martini et al., 1984, 
Bosso et al., 1984, Groot et al., 1990, Spino et al., 1984, Touw, 1998, Zobell et 
al., 2013, Alice S and Neu, 1980). Touw (1998) undertook a review of this 
elevated clearance rate before concluding that this elevation in penicillin 
clearance in CF individuals could be potentially be due to CF patients having 
generally lower body weights leading to lower body surface area ratios, whilst 
also having increased metabolism rates and increased renal clearance (Yaffe et 
al., 1977, Jusko et al., 1975, Martini et al., 1984, Bosso et al., 1984, Groot et al., 
1990, Spino et al., 1984, Touw, 1998). This elevation in clearance presents 
clinicians with a challenge delivering the therapeutic dose of antibiotic into the 
lung (Hutabarat et al., 1991a, Hutabarat et al., 1991b, Levy et al., 1984, Marks, 
1981).  
To reduce the development of antibiotic resistance, clinicians have started 
cycling antibiotics. This involves the replacement of a front line antibiotic with a 
structurally different antibiotic for a period of time, this is done in order to try and 
reduce the selective pressures which lead to bacterial resistance developing 
whilst prolonging the efficacy of the front line antibiotic (Bergstrom et al., 2004, 
Masterton, 2005, Kollef, 2001, McGowan, 1986, Pujol and Gudiol, 2001, 
Niederman, 1997, Moss et al., 2002). Cycling however, does not provide a long 
term solution since resistant strains persist in the resident bacterial population 
and when the initial front line antibiotic is used again, these resistant strains can 
start to rapidly proliferate (Bergstrom et al., 2004). In order to try to prevent 
resistance developing towards ȕ lactam antibiotics, antibiotics are often 
administered with potent inhibitors of ȕ lactamase enzymes. Clavulanic acid is 
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one of the early inhibitors of ȕ lactamase and combining this inhibitor with a ȕ 
lactam antibiotic has been successful in clinical settings (Reading and Cole, 
1977, Drawz et al., 2014, Shlaes, 2013).  
 
4.1.2. Growth rate alterations of lysogenic bacteria 
It has been observed that prophages in E. coli strains can contribute towards 
greater proliferation rates when nutrients are scarce within an environment. This 
lead to the proposal of a potential beneficial advantage for the incorporation of 
phages into bacterial chromosomal DNA (Gama et al., 2013, Edlin et al., 1975, 
Edlin et al., 1977, Lin et al., 1977). This work has previously only been 
undertaken in laboratory strains of E. coli with some very well-studied phages 
including Ȝ, P1, Pβ and Mu (Gama et al., 2013) and it is interesting to consider 
whether this increase in growth will also be apparent in clinical isolates of P. 
aeruginosa with non-characterised phages.  
 
4.1.3. Type IV pili and twitching motility 
Type IV pili are around 6 nm in diameter and normally ~2 µM in length and are 
primarily located at the poles of the P. aeruginosa bacterial cell (Hahn, 1997). 
The first observation of these appendages on the surface of P. aeruginosa was in 
1950 by Houwink and van Interson. These appendages are described as either 
pili or fimbriae (Houwink and Van Iterson, 1950, Weiss, 1971). In P. aeruginosa, 
the main structural subunit is PilA and there are 5 distinct and discrete 
phylogenetic versions of pilA. When characterising the different pili groups of P. 
aeruginosa, there are 5 subgroups as detailed in table 4.2 and visualised in 
figure 4.2 (Kus et al., 2004). It is believed that this diversity is encoded for by 
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either random mutations within a strain or through horizontal gene transfer (HGT) 
occurring with other bacterial species which also harbour pili (Kus et al., 2004).  
Each pilin (product of pilA) is distinct and can be used for bacterial typing and 
can be identified by polymerase chain reaction (PCR) (Kus et al., 2004). 
Downstream of the pilA gene is a tRNA site. This region is the target site for 
primers during PCR amplification and can also be a preferred integration site for 
bacteriophages (Kus et al., 2004). In 2000, Ochman reviewed the function of 
tRNA and tRNA-like loci as these loci appear to be common sites for the 
incorporation of foreign DNA and allow for the formation of many pathogenicity 
islands (Ochman et al., 2000). tRNAselC has been seen to serve as the integration 
site for pathogenicity islands in enteric bacteria (Ochman et al., 2000, Ritter et 
al., 1995). The 70 kb PAI-1 island in uropathogenic E. coli integrates at this site 
(Blum et al., 1994, Ochman et al., 2000) as does the 24 kb SHI-2 island in 
Shigella flexneri (Moss et al., 1999, Vokes et al., 1999, Ochman et al., 2000). 
Several phages have also been seen to utilise tRNA sites for integration 
including ɸR73 (Inouye et al., 1991) and P44 of E. coli, P22 of Salmonella and 
HPI of Haemophilus influenzae (Ochman et al., 2000). The Streptococcus 
pyogenes temperate phage T12 also uses a serine tRNA site in order to insert 
into its bacterial host cell chromosome (McShan et al., 1997). These studies 
show the varying uses of the tRNA loci and their importance for pathogenic 
phage conversions. It is proposed that the integration of phages into the tRNA 
site within the pilus will have an effect on the diversity or activity of the pilin 
(Reiter et al., 1989). 
Type IV pili can aid bacterial movement on a semi solid surface via a technique 
called twitching (Semmler et al., 1999, Winstanley et al., 2005, Fonseca et al., 
2004, Henrichsen, 1983, O'Toole and Kolter, 1998, Bradley, 1980, LAUTROP, 
1961, Mattick, 2002). Twitching occurs as a response to a chemical stimulus and 
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the bacteria moves via chemotaxis through the extension and retraction of the 
pilus. Pilus retraction was initially proposed in 1969 to account for the 
disappearance of type F pili post phage infection and the association of mating 
cells during conjugation (Marvin and Hohn, 1969, Skerker and Berg, 2001). 
Subsequent studies have shown that pilus retraction plays a role in the 
translocation of pilus specific phages in various bacterial host backgrounds 
including E. coli, P. aeruginosa and Caulobacter crescentus (Skerker and Berg, 
2001, Jacobson, 1972, Novotny and Fives-Taylor, 1974, Bradley, 1972a, Bradley 
and Pitt, 1974, Sommer and Newton, 1988, Skerker and Shapiro, 2000).  
It is also possible to hypothesise that the incorporation of a bacteriophage 
genome into the pilus locus may have an effect on the twitching motility of the P. 
aeruginosa host. Numerous studies have suggested a relationship between 
phage sensitivity and the presence of functional type IV pili. These studies have 
also demonstrated that phage resistant mutants are incapable of twitching so 
linking phage infection and twitching motility (Bradley, 1972a, Bradley, 1972b, 
Bradley, 1972c, Bradley, 1973c, Bradley, 1973b, Bradley, 1973a, Bradley and 
Pitt, 1974, Bradley, 1974, Pemberton, 1973, Johnson et al., 1986, Roncero et al., 
1990, Whitchurch and Mattick, 1994). It may also be feasible that bacteria lose 
their type IV pili in order to gain immunity from invading phages. It has been seen 
that PAO1 harbouring a mutation in the type IV pili biosynthesis genes provides 
the bacteria with resistance to pilus specific phages (Nunn et al., 1990, O'Toole 
and Kolter, 1998). To support this statement it has been shown by Kim et al 
(2012) that a lytic phage of P. aeruginosa, PA1Ø, utilises the pilus to enter into 
the P. aeruginosa host cell. This shows that it is possible that over time P. 
aeruginosa may lose its pilus in order to provide itself with protection against 
further phage infections.  
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Twitching motility is often reduced in CF patients and it has been proposed that 
this is because there is no evolutionary advantage for the bacterial isolates to 
retain this function in such a nutrient rich environment (Mahenthiralingam et al., 
1994). Earlier isolates have been seen to be motile and express both pili and 
flagella suggesting that a reduction in motility occurs as CF patients age 
(Mahenthiralingam et al., 1994).  
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Table 4.2: The various subgroups of type IV pili of P. aeruginosa. Descriptions of the 
various subgroups are also shown in this table.  
Group Description Reference 
I Highly conserved, high 
GC content 51 % and is 
the most commonly seen 
subgroup  carried by CF 
P. aeruginosa isolates 
(Kus et al., 2004, Castric 
and Deal, 1994) 
II Harbour only the pilA 
gene, no associated 
accessory genes so is 
the shortest type IV pili 
(Johnson et al., 1986, 
Pasloske et al., 1985, 
Sastry et al., 1985, Kus 
et al., 2004, Castric and 
Deal, 1994) 
III Contains an open 
reading frame 
downstream of pilA 
which encodes for a 
protein that is 
homologous to FimB: a 
pilin accessory protein in 
Dichelobacter nodosus 
(Gram negative 
anaerobe) 
(Kennan et al., 2001, Kus 
et al., 2004) 
IV Contains two open 
reading frames 
downstream of pilA and 
has a GC content of 54.8 
(Kus et al., 2004) 
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% 
V Contains an accessory 
gene that encodes for a 
putative protein which 
shows homology to PilB 
in Eikenella corrodens 
(Gram negative 
facultative anaerobic 
bacillus) 
(Villar et al., 1999, Kus et 
al., 2004) 
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Figure 4.2: The five distinct pilin alleles that are present in P. aeruginosa (Kus et 
al., 2004). Each of the various group’s accessory genes are located between the 
conserved pilB and tRNAThr genes. Table 4.2 details the accessory genes associated 
within these 5 pilin alleles. Primer locations are represented by the small arrows above 
the group II image. 
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4.2. AIMS  
The aim of this chapter was to investigate how bacteriophages can pressure 
twitching motility, growth profiles and antimicrobial resistance of the bacterial 
hosts. This study again uses the panel of clinical P. aeruginosa isolates [CF (n = 
47) and BR (n = 47)]. 
Chapter 3 describes the infection profiles of mixed phage communities whilst in 
this chapter work begins to focus on how specific bacteriophages influence their 
bacterial hosts and the bacterium’s phenotypic response. To inform the impact of 
these bacteriophages, singular phage lysogens were created in PAO1. These 
phages were selected from the panel of P. aeruginosa phages due to their ability 
to re-infect their originating host cell.  
These newly created lysogens were then further characterised for P. aeruginosa 
function including antibiotic resistance and growth rates. This chapter focuses 
mainly on the characterisation of bacterial growth and antimicrobial sensitivity 
profiles, as it has been demonstrated that phage integration can have a positive 
effect on bacterial proliferation. It was proposed that the adult CF lysogen would 
have the most elevated antibiotic resistance profile and growth rate. This 
proposition is based upon the fact that CF is a lifelong disease and so the P. 
aeruginosa populations will have had to evolve in order to out-compete the other 
bacterial strains in the lung. However, this isn’t always the case and so care is 
needed when analysing the data presented in this chapter.  
Twitching motility assays were undertaken to determine where the mixed viral 
populations induced from each P. aeruginosa isolate in chapter 3, targeted and 
how this may alter twitching motility. It was hypothesised that the addition of 
exogenous phage to a bacterial isolate would increase the twitching motility of 
the isolate. This hypothesis was drawn as it was proposed that the additional 
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motility which may be generated would be beneficial for both the phage and the 
P. aeruginosa cell in terms of reaching high nutrient areas.  
It was also hypothesised that the adult CF phages would be the least motile as it 
was assumed that this costly function would be lost due to long term colonisation 
within the chronic lung.  
 
4.3. RESULTS 
 
4.3.1. Purification of bacteriophages and comparison by restriction 
analysis 
The lab strain of P. aeruginosa, PAO1, was infected with 4 purified phages using 
the method described in section 2.3.5. In order to see if there were any genetic 
differences between the purified phages, the purified phage DNA obtained from 
each phage was used in restriction digestions (section 2.5.6). The DNA 
concentration and the 260/280 nm ratios for each phage lysate are detailed in 
table 4.3.
 
It was interesting to find that 3 of the 4 isolates had similar genetic fingerprints 
when subjected to restriction digestion which potentially indicates that this 
genetic profile is a requirement for host re–infection, digests are shown in figure 
4.3. In order to confirm this conclusively however, restriction digestion profiles 
would need to be compared for phages which do not have the capability to re-
infect their originating host. Although this doesn’t mean that the diversity is small 
between these phages, the restriction enzymes used may target areas of the 
phages that are conserved between phages and thus, banding patterns on the 
agarose gel may be similar.  
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Table 4.3: DNA concentrations and 260/280 nm ratios for the different phage 
lysates. These values were then utilised to set-up the restriction digests. 
Purified phage 
origin 
ng/µL 260/230 ratio 260/280 ratio 
CF70 176.7 1.90 1.89 
CF24 319.4 2.05 1.91 
BR123 3000 1.75 1.83 
BR136 668.8 1.85 1.91 
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Figure 4.3: Restriction digestion profiles of the four plaque purified phages. A 1 % 
agarose gel is shown here. Lane 1 – Hyperladder 1 kb, 2 – Quick Load 100 bp ladder, 3 
– Uncut 1 µL of ɸ CF24 DNA, 4 – Cut 1 µL ɸ CF24 DNA, 5 – Uncut 3 µL of ɸ CF70 DNA, 
6 – Cut 3 µL ɸ CF70 DNA, 7 – Uncut 0.5 µL of ɸ BR123 DNA, 8 – Cut 0.5 µL ɸ BR123 
DNA, 9 – Uncut 1 µL of ɸ BR136 DNA, 10 – Cut 1 µL ɸ BR123 DNA 
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4.3.2. Electron Microscopy images of the plaque purified phages  
In order to visualise the plaque-purified phages, electron microscopy images 
were generated with thanks to the Electron Microscopy unit at Newcastle 
University, Newcastle upon Tyne, UK (section 2.6). The images provided by the 
Electron Microscopy unit all had different scale bars so the images which showed 
the phage morphology the best were chosen to include in this thesis.  
These images (figure 4.4) have shown that there is similarity between three of 
the P. aeruginosa phages whilst the fourth has alternative tail morphology. This 
phage also generates a different banding pattern upon restriction digestion. All 
the phages shown have a Caudovirales morphology due to long flexible tails 
being apparent.  
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Figure 4.4: Electron microscopy images of the plaque purified phages utilised in 
this investigation. Panel 1 shows the plaque purified paediatric CF phage, panel 2 
shows the plaque purified adult CF phage, panel 3 shows the < 10 BR plaque purified 
phage whilst panel 4 shows the phage which was plaque purified from a > 10 BR isolate. 
With thanks to the Electron Microscopy unit at Newcastle University, Newcastle upon 
Tyne, UK for the generation of these images.  
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4.3.3. Growth changes of P. aeruginosa lysogens compared to naïve 
PAO1  
Upon colonisation of any environment, it is an advantage for a bacterial isolate to 
localise and out-compete other bacterial species residing within that environment 
in order for the new bacteria to survive. It has been previously determined that 
non-clinical E. coli strains harbouring a prophage exhibit an elevated growth rate 
compared to non-lysogenic strains (Edlin et al., 1977, Edlin et al., 1975, Lin et al., 
1977).   
Comparative growth curves were used to compare each of the purified phage 
lysogens versus the uninfected PAO1. Figure 4.5 shows the growth rates for 
each lysogenic bacterium compared to the non-lysogenic PAO1. In order to 
determine that the increase in absorbance detected was due to an elevation in 
cell count rather than an accumulation of cell debris, the cfu/mL for each lysogen 
was determined at 9 hours and 18 hours, as shown in figure 4.6. All the 
associated raw data is shown in appendix 4. 
The lysogens demonstrated an elevated growth rate compared to the naïve 
PAO1 in terms of growth over an 18 hour growth period with the exception of 
BR123 however, this growth rate was not always statistically significant. These 
lysogens showing an elevation in growth supports previous findings in E. coli 
(Edlin et al., 1977, Edlin et al., 1975, Lin et al., 1977). These previous studies 
were undertaken in non-clinical isolates and also under nutrient starvation whilst 
here clinical isolates were utilised and the lysogens grown in nutrient rich 
conditions.  
It was seen that the most significant differences between non-lysogenic and 
lysogenic growth was determined for the adult CF lysogen; CF24. This potentially 
is due to the adult CF phages being a long term coloniser of the lung and thus, 
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has adapted numerous methods in order to provide its bacterial host with a 
selective advantage and allow for the maintenance of both entities within this 
community. It is also a possibility that this phage is just more adapted to its 
bacterial host and the disease state of the patient is irrelevant to the phages 
functionality within this experiment. The > 10 BR lysogen (BR136) showed 
similar growth patterns as the non-lysogenic PAO1 until around 4.30 hours of 
growth after this the lysogen showed an elevation in growth compared to the 
control.  
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Figure 4.5: Comparing growth rates for lysogenic bacteria compared to naïve non-
lysogenic bacteria. Growth rate comparisons of the lysogens compared to the naïve 
PAO1 host, absorbance is determined at 600 nm and growth was recorded over an 18 
hour period (n = 15). Non parametric t tests were utilised with two tailed p values shown 
in order to display the most discrete statistical significant data; * ≤ 0.05, ** ≤ 0.01, *** ≤ 
0.001 and **** ≤ 0.0001.  
Panel 1 shows the growth rate changes of the adult CF lysogen (CF24) compared to 
naïve PAO1 over an 18 hour period.  
Panel 2 shows the growth rate changes of the paediatric CF lysogen (CF70) compared to 
naïve PAO1 over an 18 hour period.  
Panel 3 shows the growth rate changes of the < 10 BR lysogen (BR123) compared to 
naïve PAO1 over an 18 hour period.  
Panel 4 shows the growth rate changes of the > 10 BR lysogen (BR136) compared to 
naïve PAO1 over an 18 hour period. 
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Figure 4.6: Validation that the growth curve absorption results are due to cell 
growth and not a build-up of cell debris. Non parametric t tests were utilised with two 
tailed p values shown in order to display the most discrete statistical significant data; * ≤ 
0.05, ** ≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001 (n = 15). 
Cell counts were done for the 4 lysogens and naïve PAO1 after growth for 9 and 18 
hours in order to validate the observations that the increase in absorbance was due to 
elevated bacterial growth rather than a build-up of cellular debris which would affect the 
absorbance readings. 
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4.3.4. Changes to antibiotic sensitivity to clinically relevant anti-
pseudomonal antimicrobials  
 
4.3.4.1. Minimum Inhibitory concentration (MIC) calculation 
Differences in the antibiotic sensitivity profiles between the purified phage 
lysogens and the naïve PAO1 were investigated. The lysogens were subjected to 
MIC assays using clinically relevant anti-pseudomonal antibiotics, as described in 
methods section 2.4.1. Untreated PAO1 was used as a growth control and 
determined basal resistance. The raw data values are shown in appendix 5.  
The MIC assay results are shown in figure 4.7, section 1. The MIC assays were 
based upon absorbance changes (OD 600) with an elevated absorbance 
indicating an increase in the number of bacteria surviving. The results post 9 
hours of antibiotic treatment are shown.  
 
4.3.4.2. Normalisation for bacterial growth rate 
Growth differences were also taken into account by normalising the results 
against the growth rates of the bacteria over the same time period but without 
antibiotic treatment. This was completed in order to calculate the fold change in 
growth in the presence of an inhibitory concentration of the drug, this allowed 
conclusions to be drawn to determine whether the increase in antibiotic tolerance 
was in fact due to elevated bacterial growth or whether it was related to the 
prophage or a prophage encoded process; figure 4.7, section 2. In order to 
confirm that the increase in absorbance was not due to an increase in cell debris 
which could be generated by lytic phage induction, cell counts and plaque assays 
were undertaken (table 4.4). 
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The lysogens had elevated resistance after 9 hours of growth compared to PAO1 
treated with the same amount of antibiotic. Naïve PAO1 with and without 
antibiotic treatment was included as a control. These results indicate that the 
prophage is providing the lysogen with a beneficial advantage for survival in an 
environment that is often treated with large numbers of antibiotics.  
In accordance with the hypothesis initially proposed, it would appear that the 
lysogen containing the phage originating from the adult CF P. aeruginosa isolate 
had an elevated tolerance to antibiotic treatment. It was observed upon 
normalisation for growth, that the lysogens derived from CF P. aeruginosa 
isolates had the lowest change in growth. The change in bacterial growth and 
antibiotic resistance was higher for the lysogens with phages originating from BR 
P. aeruginosa isolates. These data led to the assumption that the BR and CF 
phages are functioning via different mechanisms in order to provide their 
bacterial hosts with an elevated antimicrobial tolerance profile. These 
mechanistic differences may be representative of the fact that the phages have 
had altered lengths of time to colonise the chronic lung. Potentially the more 
naïve BR phages may not be conferring as great a selective advantage to their 
P. aeruginosa host compared to the evolved CF phages. Disease longevity is not 
an indication of P. aeruginosa colonisation time though.  
These results were generated via the use of one phage from each clinical 
aetiological subgroup, this means that care needs to be taken when analysing 
the data so that no presumptions are drawn relating to patient health and 
evolution/adaptation within the CF/BR lung.  
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Figure 4.7: Variation in antibiotic tolerance when comparing lysogenic bacteria to 
naïve non-lysogenic bacteria. Section 1 shows the alteration in the antibiotic sensitivity 
profiles for the lysogens when treated with Ceftazidime (0.08 µg/mL), Colistin (1.6 
µg/mL), Meropenem (0.08 µg/mL) or Piperacillin (0.8 µg/mL); n = 6. The changes are 
observed as an increase in absorbance (OD 600) over a 9 hour period. Non parametric t 
tests were utilised with two tailed p values shown in order to display the most discrete 
statistical significant data; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001. All the 
antibiotics were used at 1,000th of the MIC for each antibiotic and P. aeruginosa (BASC 
data – accessed 16.07.16).  
Panel A shows the change in absorbance (OD 600) for the lysogen compared to naïve 
PAO1 growth when treated with 0.08 µg/mL ceftazidime.  
Panel B shows the change in absorbance (OD 600) for the lysogen compared to naïve 
PAO1 growth when treated with 1.6 µg/mL colistin.  
Panel C shows the change in absorbance (OD 600) for the lysogen compared to naïve 
PAO1 growth when treated with 0.08 µg/mL meropenem.  
Panel D shows the change in absorbance (OD 600) for the lysogen compared to naïve 
PAO1 growth when treated with 0.8 µg/mL piperacillin.  
Section 2 details fold increase changes for each lysogen upon normalisation for lysogen 
growth. 
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Table 4.4: Cfu and Pfu calculations to show the results are due to lysogenic growth rather than an increase in cellular debris. The Pfu shows the 
free phage is present after 9 hours of growth and the cfu of the bacteria after 9 hours of growth was also determined. These values were calculated in order to 
show that the results seen are due to lysogenic conversion of the bacterial host rather than an increase in cell debris through lytic phage growth. Ceftazidime, 
Meropenem and Piperacillin targeted peptidoglycan synthesis whilst colistin targets the cytoplasmic membrane, the altered targets may affect the production 
of free phage. Colistin generated no detectable pfu counts post 9 hours of incubation so indicating that there may be no free phage present and that complete 
lysogenic conversion has occurred within these lysogenic bacteria. The different target of colistin may also be indicative as to why there is no discernible free 
phage present within the assays. Naïve PAO1 at the same time point had a Cfu value of 1.5 x1008 which is lower than the cfu values shown for the lysogens 
post antibiotic treatment. 
Antibiotic Lysogen Pfu  Cfu  
Ceftazidime 24 5.60 x 1010 3.25 x 1009 
 70 9.07 x 1010 5.00 x 1009 
 123 3.47 x 1011 8.50 x 1008 
 136 2.25 x1011 3.00 x1009 
Meropenem 24 5.26 x 1011 4.25 x 1009 
 70 7.55 x 1011 1.00 x 1009 
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 123 2.58 x 1010 4.50 x 1008 
 136 6.07 x 1011 3.00 x 1009 
Piperacillin 24 2.76 x 1011 8.58 x 1008 
 70 2.68 x 1011 3.00 x 1009 
 123 2.94 x 1011 4.25 x 1009 
 136 1.68 x 1011 1.00 x 1009 
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4.3.5. Mixed phage lysates impact on twitching motility of the clinical P. 
aeruginosa 
Twitching motility as previously described (section 4.1.3) is a biological function 
of P. aeruginosa which is utilised to move the bacterium along chemical 
gradients. Twitching of P. aeruginosa has previously been shown to lost with 
adaptation to the CF lung (Mahenthiralingam et al., 1994). Type IV pili have also 
been shown to be a preferential adsorption and chromosomal integration site for 
phages due to the presence of a tRNA gene (Ochman et al., 2000, Inouye et al., 
1991, McShan et al., 1997). Using the mixed phage communities induced from 
the individual P. aeruginosa isolates, it was possible to see if these phages 
altered the ability of the bacterium to twitch subsequent to infection. Raw data is 
described in appendix 6.  
Twitching motility assays were undertaken to ascertain the interaction and impact 
of phages, see methods section 2.4.4. Differences in twitching may correlate to 
the host range differences seen in the phage infectivity and bacterial sensitivity 
studies or may indicate whether a specific subtype is linked to this difference.  
The range and distribution of the twitching motility results and the median values 
are shown in table 4.5. In order to conclude whether the bacterial isolates were 
motile, LESB58 was used as a negative control as it is known not to twitch 
(Winstanley et al., 2009). Any isolate that exhibited a twitching profile that was 
greater than LESB58 was considered motile, shown in figure 4.8.  
These data generated show that the adult CF P. aeruginosa isolates did have 
reduced twitching in comparison to the BR isolates, so supporting previously 
drawn hypotheses about motility being lost during long term P. aeruginosa 
colonisation (Mahenthiralingam et al., 1994). These results also show that the 
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adult CF P. aeruginosa isolates had elevated motility when comparing them 
against the paediatric CF P. aeruginosa isolates.  
Twitching was seen to increase in some clinical P. aeruginosa isolates upon the 
addition of self-induced phage, indicating that the presence or induction of 
phages may have an evolutionary advantage for the host cell in reaching areas 
of high nutrient availability via chemotaxis. However, twitching was seen to 
decrease in most instances upon addition of self-induced phage, so showing the 
variability in bacterial-phage infections whilst also emphasising the complexity of 
interactions occurring within the CF/BR lung.  
3 paediatric CF P. aeruginosa isolates showed an elevation in twitching with the 
addition of exogenous phages and 5 adult CF P. aeruginosa isolates also 
showed this elevation. 4 < 10 BR P. aeruginosa isolates exhibited elevated 
twitching when exogenous self-induced phage was added into the twitching 
motility assay and 2 > 10 BR P. aeruginosa isolates also showed this elevation in 
motility. However, when comparing against the cut-off value for LESB58, none of 
the 3 paediatric CF isolates could be classed as motile but all 5 of the adult CF 
isolates could. Only 1 of the 3 < 10 BR P. aeruginosa isolates could be classed 
as motile but the 2 > 10 BR P. aeruginosa isolates could be classified as motile. 
In some instances, it was observed that the addition of exogenous phage caused 
a reduction in the twitching motility of the bacterium, indicating that these phages 
must be providing their hosts with a disadvantage compared to naïve, non-phage 
infected isolates.  
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Table 4.5: Range in the distribution seen in the twitching assays with and without 
the addition of self-induced phage. The median values are also included and they 
show the medians for twitching are higher in the BR P. aeruginosa isolates compared to 
the CF isolates with and without the addition of self-induced phage. This supports 
previous work that shows that the ability to twitch is lost in CF isolates.  
P. aeruginosa 
isolate 
Range of distribution with 
added phage (mm) 
Median value 
(mm) 
 
Paediatric CF 3 – 26 5 
W
ith add
ed ph
age
 
Adult CF 2 – 24 5 
< 10 BR 3 – 21 5 
> 10 BR 3 – 20 10 
Paediatric CF 3 – 27 6 W
itho
ut
 add
ed ph
age
 
Adult CF 3 – 32 6 
< 10 BR 3 – 21 7 
> 10 BR 5-26 11 
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Figure 4.8: Twitching motility of clinical P. aeruginosa from each aetiological group 
with addition of self-induced mixed phage lysates compared to no phage. PAO1 
was included as the positive control as it is known to contain type IV pili and so have the 
ability to twitch, LESB58 was included as a negative control. The line indicates strains 
that have elevated motility in respect to LESB58 and so in this context these strains are 
classed as motile; n = 3. Non parametric t tests were utilised in order to analyse this data 
and two tailed p values are shown on these data; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 and **** 
≤ 0.0001.  
Panel 1 is the paediatric CF P. aeruginosa strains with and without the addition of mixed 
phages.  
Panel 2 is the adult CF P. aeruginosa strains with and without the addition of mixed 
phages.  
Panel 3 is the < 10 BR P. aeruginosa strains with and without the addition of mixed 
phages.  
Panel 4 is the > 10 BR P. aeruginosa stains with and without the addition of mixed 
phages. 
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4.3.6. PCR characterisation of clinical P. aeruginosa isolates for the 
type IV twitching pili  
PCR of the pili was undertaken in order to determine which pilin subgroup was 
harboured by the P. aeruginosa isolates and to see if there some isolates which 
harboured no detectable pili via PCR. Type IV pili of P. aeruginosa may be 
detectable via PCR but this observation does not always indicate that P. 
aeruginosa isolates are motile (Kus et al., 2004). Type IV pili may be present on 
the P. aeruginosa isolate but are non–motile due to a defect in one of the pilus 
genes or potentially as a host immunity defence mechanism (Kus et al., 2004). 
Due to the similarity in band sizes for the different subgroups of the type IV pili, 
this work did not allow for observation of the discrete sub-groups. If it was 
possible to separate the PCR results into subgroups then according to Kus et al 
(2004); group II pili would generate a 1.4 kb product, group I or III would generate 
a 3 kb product, group I, III or V would generate a 2.5 kb product whilst a group IV 
pili would generate a 4 kb product.  
The PCR images for the various aetiologies are shown in figures 4.9 – 4.12. 
Identification of a PCR product allowed for the observation of the number of 
isolates from each of the clinical aetiologies which had no detectable pili: : 10 % 
of paediatric CF P. aeruginosa isolates, 24 % of adult CF P. aeruginosa isolates, 
23 % of < 10 BR P. aeruginosa isolates and 30 % of > 10 BR P. aeruginosa 
isolates. It is however, pertinent to remember differences in the cohort sizes 
when analysing these results. It was observed that some P. aeruginosa isolates 
generated more than one PCR product but this maybe a consequence of these 
P. aeruginosa isolates harbouring only a single flagellum but multiple pili (Skerker 
and Berg, 2001). Type IV pili have been seen to form bundles on the poles of 
cyanobacteria (Gram negative bacterium that has originated from an aquatic 
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environment), so it is possible to propose that this observation could also be 
apparent in P. aeruginosa isolates (Schuergers and Wilde, 2015).  
From the 10 % of paediatric P. aeruginosa isolates which have detectable pili 4 
can positively twitch and from the 24 % of adult P. aeruginosa isolates with 
detectable pili 12 isolates exhibit positive twitching. The data from without the 
addition of self-induced phage is used to generate these data as it is perceived to 
be more accurate and reproduce more accurate real-life results. 23 % of the < 10 
BR P. aeruginosa isolates have detectable type IV pili as determined by PCR 
and 7 of these strains exhibit positive twitching. 30 % of the > 10 BR P. 
aeruginosa isolates have detectable type IV pili and 11 could positively twitch. 
This would indicate that for some strains the type IV pili are non-functional as no 
positive twitching was recorded even though a product was generated via PCR. 
All the strains with detectable pili were sensitive to phage infection and so this 
may indicate that the phages in this thesis are utilising the pilus as a receptor to 
aid host infection. 
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Figure 4.9: Presence of type IV pili in paediatric CF isolates. 1 % agarose gel 
showing the PCR products for the paediatric CF P. aeruginosa isolates, the ladder sizes 
are shown on the gel. Lane 1 – Hyperladder 1 kb, lane 2 – Quick Load 100 bp ladder, 
lane 3 – Positive PAO1, lane 4 – Negative, lane 5 – CF47, lane 6 – CF53, lane 7 – CF69, 
lane 8 – CF70, lane 9 – CF124, lane 10 – CF165, lane 11 – CF187, lane 12 – CF208, 
lane 13 – CF213 and lane 14 – CF214 
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Figure 4.10: Presence of type IV pili in adult CF isolates. 1 % agarose gel showing 
the PCR products for the adult CF P. aeruginosa isolates, the ladder sizes are shown on 
the gel. Lane 1 – Hyperladder 1kb, lane 2 – Quick load 100 bp ladder, lane 3 – Positive 
PAO1, lane 4 – Negative, lane 5 – CF3, lane 6 – CF5, lane 7 – CF6, lane 8 – CF16, lane 
9 – CF23, lane 10 – CF24, lane 11 – CF28, lane 12 – CF30, lane 13 – CF34, lane 14 – 
CF42, lane 15 – CF44, lane 16 – CF52, lane 17 – CF54, lane 18 – CF55, lane 19 – 
CF57, lane 20 – CF60, lane 21 – CF63, lane 22 – CF65, lane 23 - CF67, lane 24 – CF72, 
lane 25 – CF74, lane 26 – CF77, lane 27 – CF78, lane 28 – CF79, lane 29 – CF81, lane 
30 – CF118, lane 31 – CF121, lane 32 – CF125, lane 33 – CF126, lane 34 – CF127, lane 
35 – CF136, lane 36 – CF140, lane 37 – CF142, lane 38 – CF145, lane 39 - CF177, lane 
40 – CF183 and lane 41 – CF211 
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Figure 4.11: Presence of type IV pili in < 10 BR isolates. 1 % agarose gel showing the 
PCR products for the < 10 BR P. aeruginosa isolates, the ladder sizes are shown on the 
gel. Lane 1 – Hyperladder 1 kb, lane 2 – Quick Load 100 bp ladder, lane 3 – Positive 
PAO1, lane 4 – Negative, lane 5 – BR59, lane 6 – BR123, lane 7 – BR133, lane 8 – 
BR150, lane 9 – BR152, lane 10 – BR193, lane 11 – BR206, lane 12 – BR227, lane 13 – 
BR233, lane 14 – BR293, lane 15 – BR298, lane 16 – BR299, lane 17 – BR319, lane 18 
– BR320, lane 19 – BR327, lane 20 – BR331 and lane 21 – BR332 
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Figure 4.12: Presence of type IV pili in > 10 BR isolates. 1 % agarose gel showing the 
PCR products for the > 10 BR P. aeruginosa isolates, the ladder sizes are shown on the 
gel. Lane 1 – Hyperladder 1 kb, lane 2 – Quick Load 100 bp ladder, lane 3 – Positive 
PAO1, lane 4 – Negative, lane 5 – BR52, lane 6 – BR53, lane 7 – BR58, lane 8 – BR136, 
lane 9 – BR141, lane 10 – BR143, lane 11 – BR144, lane 12 – BR146, lane 13 – BR153, 
lane 14 – BR161, lane 15 – BR177, lane 16 – BR178, lane 17 – BR181, lane 18 – 
BR195, lane 19 – BR197, lane 20 – BR199, lane 21 – BR200, lane 22 – BR201, lane  23 
– BR204, lane 24 – BR205, lane 25 – BR208, lane 26 – BR213, lane 27 – BR222, lane 
28 – BR228, lane 29 – BR243, lane 30 – BR244, lane 31 – BR285, lane 32 – BR313, 
lane 33 – BR322 and lane 34 – BR326 
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4.4. DISCUSSION 
Phages are increasingly being linked to adaptation and aiding the evolution of 
bacteria in environmental niches. Several studies have determined that phages 
carry a high number of small accessory genes with no known function which 
could potentially be driving this adaptation and evolution (Smith et al., 2007). 
These genes are however, conserved throughout their specific phage types and 
thus, must play a role in the phages survival. This statement can be supported by 
the observation of mosaic segments in the genomes of unrelated phages of E. 
coli and Salmonella. Phage Ȝ for example was isolated in 1λ51 as a prophage in 
an E. coli K12 isolated from a Californian patient (Lederberg, 1951, Sanger et al., 
1982, Juhala et al., 2000). The same mosaic genetic sequence was also 
detected in a phage of Salmonella typhimurium, P22, which was identified in 
1952 in either Sweden or Chile (Zinder and Lederberg, 1952, Lilleengen, 1984, 
Juhala et al., 2000). Finally, the same mosaic sequence was detected in HK97 
and HK022, phages of E. coli which were identified in 1975 in Hong Kong 
(Dhillon et al., 1980, Dhillon and Dhillon, 1976, Juhala et al., 2000). These 
findings show the conserved nature of certain genome regions between phages 
and led to the proposition that their importance for the phage is shown by their 
conserved nature.   
The majority of the work detailed in chapter 3 involved the use of mixed 
temperate bacteriophage communities in order to provide a general view of the 
relationship between phages and bacteria. The work detailed in this current 
chapter has described the possible evolutionary advantages for P. aeruginosa to 
harbour temperate phages. In order to allow for more detailed work to be 
undertaken, proposed well adapted phages were isolated from a subset of 
isolates via plaque purification. The bacteriophages were perceived to be well 
adapted due to their ability to re-infect their originating host bacterium, this is 
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considered advantageous as it means that the temperate bacteriophage always 
has a bacterium into which it can integrate and form a prophage. Restriction 
digestion showed that 3 out of the 4 induced phages had similar genetic profiles. 
This is not unexpected however, as the 4 P. aeruginosa isolates were originally 
selected due to their ability to re-infect their originating host.  
Another possible reason for this similarity could be because restriction enzymes 
which target conserved sites within the phage genome were selected. These 
enzymes may therefore, produce profiles that offer similar banding patterns. We 
can say though that due to the differences observed in the growth and 
antimicrobial tolerance profiles, these phages are genetically different in some 
way.  If this were to be repeated, the use of pulse field electrophoresis would be 
used to offer better definition of the phage restriction profiles. To overcome this, 
these phage and lysogen genomes are currently being sequenced and annotated 
for publication but due to time constraints these are not included in this thesis.  
The plaque purified phages were imaged through the use of electron microscopy 
and it was observed that all the phages had a Caudovirales morphology. This is 
not uncommon as in 2010 it was proposed that 97 % of all the known phages of 
P. aeruginosa harboured this morphology (Ceyssens and Lavigne, 2010). It is 
interesting to note that the tail fibre of the > 10 BR phage is different to the other 
3 purified phages, this adaptation may be due to an altered cell surface target for 
this phage for example. This phage also generated an alternative banding 
pattern upon restriction digestion potentially indicating that this phage has an 
alternative genomic backbone.  
Upon selection and plaque purification of the phages, lysogens were generated 
in order to determine how the incorporation of a phage altered the bacterial host 
cell’s phenotype. It was proposed that prophage incorporation would have an 
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effect on bacterial growth rates and antibiotic resistance due to the increased 
genetic size of the bacterium upon phage integration. Both Lyon and colleagues 
and Clowes and colleagues described the ability of plasmids to confer 
antimicrobial resistance to S. aureus through conjugation (Clowes, 1972, Lyon 
and Skurray, 1987). In 1975, Lacey described that the bacteriophages of S. 
aureus may be aiding antimicrobial resistance within the bacterial isolate (Lacey, 
1975). These studies support these data presented here. Bacteriophage 
encoded antimicrobial resistance has been recently reviewed by Davies et al. 
(2016).  
Bacterial growth rates were seen to be elevated in 75 % of the lysogens 
compared to the naïve PAO1. These data also support previous findings that E. 
coli strains harbouring a prophage region exhibit elevated growth rates in 
comparison to naïve E. coli strains (Edlin et al., 1977, Edlin et al., 1975, Lin et al., 
1977).  
The lysogen with the phage isolated from the < 10 BR patient displayed a slower 
growth rate over an 18 hour period whilst the other lysogens showed increased 
growth rates upon phage integration. These is proposed due to the idea that < 10 
BR P. aeruginosa isolates and their associated phages have had the shortest 
amount of time to co-evolve alongside their bacterial host and so are not as 
productive/infective as phages isolated from adult CF patients. However, disease 
time is not correlated to the length of time that the patient has been colonised 
with P. aeruginosa with but it is still possible to make hypothesis as long as this 
caveat is also considered.  
This trend compares to the original observations in chapter 3 that the phages 
from the most naïve environments, < 10 BR and paediatric CF, were the least 
infective in comparison to the phages isolated from > 10 BR and adult CF. These 
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data would indicate that the extra genetic burden on the host cell is not 
expensive for the bacterium.  
This elevation in growth would also lead to the assumption that phages are 
driving an increase in metabolism within their hosts which drives more rapid 
proliferation within a bacterial culture. These metabolites may then be released 
into the environment upon the host cell’s death providing a more nutrient rich 
environment for surrounding cells and thus, promoting an elevated growth rate in 
these surrounding cells. Prophage incorporation into these clinical P. aeruginosa 
isolates is therefore, showing a positive selective advantage in terms of 
increasing growth rates and possibly allowing P. aeruginosa to become the 
predominant bacterial species.    
Antibiotic tolerance is elevated in the lysogens indicating that the phages are 
subverting the bacterial cell and offering an evolutionary advantage. This 
potentially, is maintaining both the phage and the bacterial cell in an environment 
which is constantly under assault with anti-pseudomonal antibiotics. Even when 
treating the lysogens with clinically relevant antibiotics, it is determined that the 
phage increases the bacterial cell’s tolerance towards clinical anti-pseudomonal 
antibiotics. It is also possible to consider the effect that phage incorporation has 
on clinical treatments as sub-optimal treatment levels of antibiotic may actually 
induce phage induction (Wright et al., 2013). This phage induction would enable 
the phages to spread around a bacterial population and infect other host cells, so 
conferring this tolerance to other receptive bacterial cells.   
In order to be critical about the antibiotic tolerance profiles described previously, 
cell growth was normalised in relation to growth of the bacteria without the 
pressures of antibiotic treatment. The smallest change in growth in the presence 
of the drug was seen in the CF P. aeruginosa isolates and this may indicate that 
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these phages alone are driving the alterations seen in the tolerance profiles. It 
could be premised that the CF phages are capable of this due to their longevity 
within the chronic lung environment, which may have allowed the phage to 
accrue the functions required to increase their bacterial host cell’s resistance. 
The notion that the CF phages are the most evolved in the chronic lung supports 
data from chapter 3, which indicates that longevity and colonisation within the 
chronic lung alters as the patient ages. The largest change in growth in the 
presence of an antimicrobial was seen when studying the BR phages. BR 
phages may need to subvert their bacterial host cells rapidly as they are new 
colonisers to the chronic lung environment and so therefore, have not accrued 
the functions required to alter tolerance independently, like the CF phages.  
The results generated for the antibiotic tolerance profiles were based upon an 
increase in absorbance. In order to determine that the increases in the 
absorbance values were phage derived and due to cellular growth rather than a 
build-up of cellular debris, it was decided to undertake cell counts. It was also 
pertinent to look at the free phage titre to see if phages were propagating under 
the pressure of the antimicrobial. Colistin did not show any plaques when plaque 
assays were undertaken, potentially indicating that lysogenic events were 
occurring throughout the experiment resulting in no detectable free phage after 9 
hours of growth. Again this shows that prophage inclusion is conferring a positive 
selective advantage to the bacterial isolates in this investigation, as their ability to 
withstand antimicrobial pressures is elevated in comparison to non-lysogenic 
strains.  
This chapter also studied the interaction between phages and their host’s pili, as 
pili have previously been described as a key site for phage adsorption and 
infection (Ochman et al., 2000, Inouye et al., 1991, McShan et al., 1997). 
Mahenthiralingam et al (1994) proposed that adult CF isolates showed a 
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reduction in twitching compared to paediatric CF isolates, so initially twitching 
motility assays were undertaken to support these findings. These data indicated 
that the median levels of twitching motility were the same for the adult CF and 
paediatric CF isolates. However, the distribution of the motility showed that the 
paediatric CF isolates were less motile compared to the adult CF isolates, which 
is in contrast to previously published data (Mahenthiralingam et al., 1994, Kus et 
al., 2004). It is however, pertinent to mention that the paediatric CF cohort 
sample size was only n = 10. It is interesting to note that the BR P. aeruginosa 
isolates could twitch more than the CF P. aeruginosa isolates, supporting other 
published data which shows that the ability to twitch is lost during long term 
colonisation in CF (Mahenthiralingam et al., 1994).  
It was also demonstrate in this chapter that the addition of exogenous phage 
altered the motility of the bacterial isolates, as phage integration may provide 
both a positive and negative advantage for the bacterium. Twitching motility 
assays showed that the median values were greater for the P. aeruginosa 
isolates without the addition of exogenous self-induced phage. These data could 
indicate that in most instances phage may in fact be impeding the motility of a 
bacterial isolate. However, 14 P. aeruginosa isolates showed an elevation in 
twitching upon the addition of exogenous self-induced phage but only 8 of these 
isolates could be classed as motile when utilising the LESB58 cut-off value. P. 
aeruginosa strain type did not show any trends in these 14 isolates as they were 
all classed as unique upon VNTR typing. So these phages maybe conferring a 
positive advantage to their hosts as they are increasing the distance that the 
bacterium can move so therefore, increasing bacterial survival rates through the 
ability of the bacterium to reach more nutrients.  
Genes encoding for type IV pili were detectable via PCR in over 70 % of the P. 
aeruginosa isolates involved in this investigation, enforcing the essential role that 
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type IV pili may have in terms of motility. Multiple PCR products were detected 
for some P. aeruginosa isolates but this may be due to P. aeruginosa cells often 
harbouring multiple type IV pili but only one flagellum (Skerker and Berg, 2001). 
The increase in metabolism proposed when studying the growth profiles is also 
pertinent here, as the increase in freely available metabolites could also increase 
the amount of energy that the bacterial isolates have to utilise on motility. As 
previously stated, these metabolites may be released into the surrounding 
cellular environment upon host cell lysis thus, providing more metabolites for the 
bacteria to translocate towards.  
 All these studies have shown that prophage formation provides a selective 
advantage for the bacterial host in terms of growth, antimicrobial resistance and 
twitching.  
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5. METABOLITE AND METABOLISM CHARACTERISATION 
OF PSEUDOMONAS AERUGINOSA PELLICLE FORMATION 
AND THE IMPACT OF CONVERTING PHAGES 
 
5.1. INTRODUCTION 
Chapters 3 and 4 have shown that Pseudomonas aeruginosa (P. aeruginosa) 
phages from chronic respiratory diseases carry genes that can be additive in 
nature and subvert host cellular function. Chapter 3 focused on the mixed 
temperate phage communities induced from cystic fibrosis (CF) and 
bronchiectasis (BR) P. aeruginosa isolates. The chapter indicated that the adult 
CF phage communities were the most infective and this was proposed to be a 
result of their longevity within the chronic lung. In order to confer more specific 
functions to the temperate bacteriophages of P. aeruginosa, 4 phages (one from 
each clinical aetiological subgroup) were plaque-purified and stable lysogens 
were created in a PAO1 background. In chapter 4, these lysogens showed 
advantages compared to the non-lysogenic PAO1 in terms of antibiotic tolerance 
and increased growth rate. In order to determine the added functionality these 
phages encode, this chapter focuses on studying shifts in metabolism and 
metabolite production that may arise due to the infection of a temperate phage 
and their dissemination across a bacterial community.  
A key focus was to determine how these temperate phages subvert cellular 
function and how they aid bacterial growth, adaptation and evolution. This may 
be through the utilisation of new processes or differential expression of native 
biological pathways by the infecting phages. Pellicle cultures were generated for 
these studies as we propose that they may be more representative of the chronic 
lung. They form at the liquid-air interface which in the chronic lung would be 
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between the mucus layer and the air in the lower lung (Friedman and Kolter, 
2004b). The use of pellicle cultures may provide us with a more representative 
model of the relationships occurring between phages and their P. aeruginosa 
isolates in situ.  
Phages carry genetic material that when integrated into their bacterial host cell 
can influence virulence and/or the metabolic activity of their host (Nanda et al., 
2015, Brown et al., 2006, Fortier and Sekulovic, 2013). For this reason, the effect 
of prophages generated in this thesis wanted to be studied through various 
different methodologies to determine the impact of prophage formation on 
bacterial metabolism.  
5.1.1. Biofilms and their environmental importance 
The colonisation pattern and pathogenicity of P. aeruginosa in the CF lung is 
multifactorial and there are numerous methods that the bacterium and its 
associated phage can utilise in order to survive. P. aeruginosa can subvert host 
defences due to its ability to form biofilms; these are bacterial cell aggregates 
which form when an extracellular matrix (ECM) is generated and surrounds the 
bacterial cells. This matrix protects the internalised cells from external stimuli, 
such as antimicrobials and antibiotics (Drenkard and Ausubel, 2002a). There are 
some general principles that are required for biofilm formation and these are; a 
surface covered in nutrients for the initial colonisation, a metabolically active 
bacterium for surface attachment and adherence, an adequate nutrient supply to 
promote cellular replication and the associated cell growth along with ECM 
generation (Costerton et al., 1995, Costerton, 1995). It is believed that biofilm 
formation follows a strict and order pathway that is due to the up regulation and 
down regulation of certain genes within the bacterial genome.  
198 
 
A key gene that is often responsible for biofilm formation is rpoS which encodes 
for the protein RpoS, a subunit of RNA polymerase. RpoS is involved in the 
expression of many genes that may have roles in the stationary growth phase of 
P. aeruginosa, whilst in E. coli it is believed that this protein is one of the main 
regulators in the bacterium’s stress response system (Hengge-Aronis, 2002). 
Schembri et al (2003) described that 46 % of the genes differently up regulated in 
a DNA microarray of an E. coli biofilm were under the control of RpoS, so 
indicating the key role that this protein plays during biofilm formation in the 
stationary phase growth (Schembri et al., 2003). It is believed that the transition 
of a Gram negative bacteria from exponential growth into the stationary phase is 
under the control of RpoS (Latifi et al., 1996). It has been determined that the 
cellular level of E. coli RpoS increases dramatically during the late stages of 
logarithmic growth and as the bacterium enters into stationary phase (Hengge-
Aronis, 1993, Lange and Hengge-Aronis, 1994). A homologue of RpoS in P. 
aeruginosa follows the same pattern (Kan and Hideo, 1994). P. aeruginosa also 
harbours a multifactorial and hierarchical Quorum Sensing (QS) cascade which 
is involved in the activation of RpoS during stationary phase growth (Latifi et al., 
1996).  
The development of biofilms in the lower lung is perceived to be one of the many 
reasons which supports the establishment of P. aeruginosa as the dominant 
bacteria. It is believed that some bacterial communities commonly reside in 
biofilms in nature, even if in the laboratory they form planktonic communities 
(Costerton et al., 1995).  
Biofilm formation upon medical implants related to cardiac disease is a serious 
health problem worldwide; cardiac disease in 2006 was one of the major causes 
of morbidity in the USA (Padera, 2006). Treatment of biofilms on medical 
implants usually involves the removal of the contaminated item in order to try and 
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reduce the bacterial load present thus, containing the spread of biofilm forming 
bacterial species (Gjersing et al., 2007). Staphylococcal infections have been 
shown to have a fold increase in antibiotic resistance of between 10 – 1000 when 
the bacterium is growing within a biofilm and encased in the ECM (Campoccia et 
al., 2005, Nishimura et al., 2006, LaPlante and Woodmansee, 2009). 
 
5.1.2. Pellicle formation 
P. aeruginosa has been previously shown to form different biofilm structures 
depending on the environmental niche that the bacterium inhabits (Friedman and 
Kolter, 2004a). A pellicle is a biofilm that assembles at the air-liquid interface in 
liquid cultures (Friedman and Kolter, 2004b) and the pel locus is believed to be 
essential (amongst other genes) for the formation of biofilms and pellicles in 
PA14 (Friedman and Kolter, 2004a). Friedman and Kolter (2004a) when studying 
P. aeruginosa showed that the genes of the pel locus are responsible for the 
formation of a glucose-rich matrix and this matrix is essential for the stability and 
longevity of the biofilm. The pel locus is composed of an operon of 7 adjacent 
genes which span 12.2 kb of the PAO1 genome. This operon is also found in 
other P. aeruginosa isolates as there is a region with 98 % similarity in the PA14 
genome (Friedman and Kolter, 2004a).  
Homologues to this gene cluster are found in multiple other diverse bacteria, 
such as Ralstonia solanacearum (aerobic Gram negative plant pathogen), 
Ralstonia metallidurans (non-sporing Gram negative bacterium), Geobacter 
metallireducens (Gram negative metal reducing proteobacterium) and 
Burkholderia fungorum (proteobacterium) (Friedman and Kolter, 2004a). 
Elevated expression of pel in small colony variants (SCVs) of P. aeruginosa 
isolated from CF patients is proposed to aid P. aeruginosa colonisation and 
persistence within the lower lung (Starkey et al., 2009). These data may show 
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how essential this locus is for P. aeruginosa survival. Pel is required for PA14 
pellicle maturation but it is not essential for pellicle initiation, so it is believed that 
pel is involved in the later stages of pellicle generation (Friedman and Kolter, 
2004a). 
The psl locus is also involved in polysaccharide synthesis within the pellicle. Psl 
is known to aggregate P. aeruginosa to the airway epithelial cells through mucin 
interactions, so ensuring the maintenance of P. aeruginosa in the lower lung 
environment (Friedman and Kolter, 2004a, Friedman and Kolter, 2004b, Jackson 
et al., 2004, Vasseur et al., 2005, Ma et al., 2009). The 11 predicted protein 
products of psl are all homologues of carbohydrate processing proteins and it 
has been determined that the psl locus is involved in the generation of a 
mannose-rich matrix in P. aeruginosa (Friedman and Kolter, 2004b). The psl 
locus is conserved between PAO1 (Stover et al., 2000) and Pseudomonas 
syringae DC300 (Buell et al., 2003). In 2013, it was proposed that the gene 
products of the psl locus are of equal importance in biofilm formation as the gene 
products of the pel locus (Huse et al., 2013). Psl is involved alongside pel in 
pellicle stability but the gene products of psl alone are sufficient for pellicle 
maturation to occur (Friedman and Kolter, 2004b). This observation leads to the 
hypothesis that psl is involved throughout the pellicle production process.  
 
5.1.3. Quorum Sensing in P. aeruginosa 
P. aeruginosa has a hierarchical system of two QS systems; LasI/LasR 
(Passador et al., 1993) and RhlI/RhlR (Brint and Ohman, 1995). Both LasI and 
RhlI are the autoinducer synthases that catalyse the formation of the 
autoinducers; N-(3-oxododecanoyl)-L-homoserine lactone (Pearson et al., 1994) 
and N-(butyryl)-homoserine lactone, respectively (Pearson et al., 1995). When a 
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high cellular density of P. aeruginosa cells occurs, LasR binds to its autoinducer 
(lasI product) which leads to the activation of genes which are involved in 
virulence factor production (Davies et al., 1998, De Kievit and Iglewski, 2000, 
Jones et al., 1993, Passador et al., 1993, Miller and Bassler, 2001). The LasR-
autoinducer complex can also activate the second QS system of P. aeruginosa; 
RhlI/RhlR (Ochsner and Reiser, 1995). Upon expression of rhlR through the 
activation of the LasR-autoinducer complex, RhlR can bind to its autoinducer 
molecule (product of RhlI). The RhlR-autoinducer complex can then activate its 
own set of virulence genes which are involved in a range of processes within the 
P. aeruginosa host including alkaline proteases (Gambello et al., 1993, Latifi et 
al., 1996), rhamnolipid bio-surfactants (Ochsner et al., 1994, Latifi et al., 1996), 
exotoxin A (Blackwood et al., 1983, Brint and Ohman, 1995) and elastase 
(Blackwood et al., 1983, Brint and Ohman, 1995). Figure 5.1 shows the pathways 
that are involved in QS in P. aeruginosa (Dubern and Diggle, 2008). 
In order to control QS in P. aeruginosa, the LasR-dependent autoinducer 
prevents the RhlI autoinducer binding to its own receptor; RhlR (Pesci et al., 
1997). It is assumed that this second level of control of RhlI/RhlR by LasI/LasR is 
to ensure that the systems function in a sequential manner. Aside from these two 
aforementioned QS systems, there is an additional autoinducer; 2-heptyl-3-
hydroxy-4-quinolone (PQS) (Pesci et al., 1999). Expression of this autoinducer 
requires LasR and in turn, this molecule activates the expression of the 
autoinducer molecule of RhlI. It is believed that again this molecule adds another 
level of control to ensure that QS occurs sequentially and in an ordered fashion 
in P. aeruginosa.  
QS mutants have been described as a common phenotypic feature in chronic P. 
aeruginosa populations colonising the CF lung. These mutants induce host 
inflammatory responses in respiratory epithelial cells generating an elevation in 
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proinflammatory cytokines and neutrophil recruitment. The influx of these 
inflammatory metabolites increases tissue damage within the CF lung and this 
leads to a rapid decline in patient health (Winstanley and Fothergill, 2009, 
Heurlier et al., 2005, LaFayette et al., 2015, Mowat et al., 2011).  
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Figure 5.1: P. aeruginosa cell-to-cell signalling resulting in the formation of 
biofilms (Dubern and Diggle, 2008). The two QS systems are interlinked (RhlR/RhlI) by 
the LasR system. The various endpoints are shown on the figure including pyocyanin, 
elastase, 2-heptyl-3-hydroxy-4-quinolone and alkaline protease to name a few. The level 
of complexity is shown in this figure and it emphasises that the QS system is 
multifactorial.   
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5.1.4. Metabolomics 
Metabolomic studies using high-resolution liquid chromatography combined with 
mass spectrometry offer an approach to identify and quantify the metabolite 
profile of a particular biological sample or organism. These products are normally 
either the end point of cellular regulatory processes, intermediates of pathways, 
or other signalling molecules (Reo, 2002, Fiehn, 2002, Zhang and Powers, 
2012). Metabolomics links phenotypic and genotypic studies in order to generate 
a more comprehensive overview of the functionality of a particular biological 
community (Weckwerth, 2003, Weckwerth and Morgenthal, 2005, Fiehn, 2002). 
The technology is rapid and discrete enough to detect the steady state 
concentrations of the metabolites, and then determine any fluctuations that may 
occur upon the alteration of an external stimuli (Weckwerth and Morgenthal, 
2005). Metabolomic analysis doesn’t require the complete isolation and 
characterisation of individual metabolites within a biological sample instead it 
captures a snapshot or ‘fingerprint’ of the status of the metabolome (Fiehn, 2002, 
Ellis et al., 2007). Untargeted metabolomic systems offer semi-quantitative 
information about the possible metabolites present and their abundance in a 
biological system (Chokkathukalam et al., 2014). Mass spectroscopy (MS) and 
nuclear magnetic resonance (NMR) are the primary analytical tools used by 
researchers when undertaking metabolomic studies and these techniques are 
often preceded by a liquid chromatography (LC) stage (Zhang and Powers, 
2012).  
 
5.1.5. Liquid chromatography mass spectroscopy 
Liquid chromatography mass spectroscopy (LCMS) is one of the most commonly 
used analytical techniques (Snyder et al., 2011), and is often used for the 
quantification of unknown metabolites (Josephs and Sanders, 2004, Shockcor et 
205 
 
al., 2003, Yang et al., 2002, Weckwerth and Morgenthal, 2005). LCMS is 
composed of an LC stage which can separate samples according to molecular 
weight and an MS stage which ionises the compounds within a sample in order 
to generate the highest definition of metabolites.  
The principle of chromatography is based upon the physical separation of a 
sample with the addition of a solvent (Niessen, 2006, Covey et al., 1986, Arpino 
et al., 1974, Arpino et al., 1979). LC functions via two phases a mobile and a 
stationary phase; the mobile stage is the solvent and the stationary phase is the 
matrix of the column. The column is commonly around 10 – 30 cm in length and 
has an internal diameter of around 3 – 4.6 mm (Niessen, 2006). The column is 
tightly and uniformly packed with silica beads which have a diameter of around 3 
– 5 µM. These beads are usually porous in order to increase the surface area 
that is available for molecule binding. Two solvents are pumped across the 
column; one (solvent A), by convention is an aqueous solvent such as water with 
an addition of 0.1 % formic acid and the second, (solvent B) by convention is an 
organic solvent such as acetonitrile, methanol or propanol, again with the 
addition of 0.1 % formic acid. The addition of formic acid to both solvents 
improves chromatographic peaks along with providing a source of protons which 
are invaluable in the ionisation step of LCMS (Niessen, 2006).  
 
5.1.5.1. Mass spectroscopy 
MS is an analytical technique that can provide both quantative (molecular mass) 
and qualitative (structure) results for an individual sample upon its ionisation 
(Mann and Fenn, 1992, Mann et al., 1989). MS is the preferred platform for 
metabolite identification due to its high sensitivity and vast metabolite detection 
capabilities but it is also a destructive process due to the ionisation step 
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(Theodoridis et al., 2012, Chokkathukalam et al., 2014, Zhang and Powers, 
2012). MS is composed of 5 steps with the initial step being the introduction of 
the separated LC sample to the ionisation source. Electrospray ionisation is used 
to convert the liquid LC samples into ions for the MS stage. This process involves 
the bombardment of the samples with highly powered electrons followed by 
sample evaporation allowing for the generation of both positive and negative ions 
(Niessen, 2006, Ho et al., 2003, Mann and Fenn, 1992). The newly charged ions 
become gaseous due to electric field alterations. These gaseous ions are then 
accelerated through the system which allows for subsequent analysis to be 
undertaken (Ho et al., 2003). Further targeted MS studies are needed to confirm 
the true identify of an MS sample, usually using a fragmentation stage or 
comparison to standard compounds (Dunn et al., 2013, Chokkathukalam et al., 
2014) but untargeted studies such as this one allow for a representation of the 
metabolome of a sample to be elucidated. 
 
5.1.6. Metabolomics and biofilms  
Gjersing et al (2007) showed that the overall metabolism of P. aeruginosa was 
similar between planktonic and biofilm cells when comparing the extracellular 
metabolites present in spent media generated by continuous batch cultures via 
NMR. This indicates that the extracellular metabolites generated by P. 
aeruginosa cells are similar regardless of the growth stage whereas the 
intracellular metabolites were shown to vary when studying planktonic/biofilm 
cellular communities. Lower spectral peak intensities were determined for biofilm 
cells compared to planktonic cells when looking at intracellular metabolites 
potentially, indicating that different pathways are being utilised in the different 
growth stages (Gjersing et al., 2007). Sonkar et al (2012) investigated the effect 
that the filamentous phage, Pf1, had on the metabolites detected in P. 
207 
 
aeruginosa planktonic cultures. Prior to phage infection at mid exponential 
growth, the cultures had similar metabolite profiles but upon phage infection the 
metabolites varied dramatically with the phage infected culture showing a 
propensity for low molecular weight metabolites. Pf1 infected cultures had a high 
occurrence of branched chain amino acids, lactate, acetate, pyruvate, 
glyceraldehyde, indole, and ascorbate.  
The most actively expressed genes in P. aeruginosa biofilms are proposed to 
have a bacteriophage origin; Pf1 (Hill et al., 1991, Whiteley et al., 2001). Pf1 
transcripts have also been shown to be nearly 100 – 1000 fold greater in 
continuous biofilm reactor cultures compared to planktonic culture reactor 
communities (Whiteley et al., 2001). The observation of more energy metabolites 
in Pf1 infected cultures may indicate that these cultures are more active and so 
the phage is providing the bacterial culture with a metabolic advantage. The 
observation of acetate and lactate is consistent with previous findings (Schleheck 
et al., 2009). Pf1 infected cultures also exhibited elevated levels of agmatine; a 
polyamine utilised by P. aeruginosa to form biofilms (Sonkar et al., 2012).  
 
5.1.7. Metabolism studies and quantifying biofilms 
Metabolism studies targeting a marker of respiration are often used in 
conjugation with other methods such as metabolomics, in order to increase our 
knowledge of a particular biological system. Studies on bacterial biofilms using 
metabolism marker assays can confer putative information relating to the activity 
of the biofilm. Colorimetric assays can be used to determine cell/biofilm viability 
(Peeters et al., 2008). They discriminate between viable and dead cells in a 
biofilm community as a colourless substrate is utilised which can be modified to a 
coloured compound by an actively respiring cell (Mosmann, 1983). Two stains 
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are commonly used in these metabolic assays, these are 5-cyano-2,3-ditolyl 
tetrazolium chloride (CTC) and 2,3-bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) (Peeters et al., 2008, Gabrielson et al., 2002, 
McCluskey et al., 2005).  
 
5.1.7.1. XTT assays 
Finding assays which are linked to core energy metabolism offers a way to 
determine changes in cell respiration, especially when the bacterium is grown 
under different environmental conditions. There have however, been 
observations of poor correlation between XTT results and cell counts. It is 
believed that this alteration is due to microbial metabolic activity not always being 
solely affected by cell viability (Hatzinger et al., 2003, Honraet et al., 2005, 
Simões et al., 2007). It is also possible that other cellular factors might cause the 
reduction of the XTT dye thus, introducing potential bias and erroneous results 
when quantifying the number of viable cells within a biofilm (Bedwell et al., 2001, 
McCluskey et al., 2005, Al-Bakri and Afifi, 2007). Erroneous results can also be 
generated when comparing inter- and intra-species differences especially in the 
Candida albicans species and when investigating yeast at different stages of 
growth (Kuhn et al., 2003, Honraet et al., 2005, Al-Bakri and Afifi, 2007, Kuhn et 
al., 2002a, Kuhn et al., 2002b). However, the reasoning behind this alteration in 
XTT results between various bacterial species is currently not understood.  
XTT assays are based upon the reduction of the XTT tetrazolium salt to the 
water soluble dye, formazan, by metabolically active cells. This reduction is 
triggered by succinyl-dehydrogenase enzymes which are present in the electron 
transport system of the bacteria (McCluskey et al., 2005, Al-Bakri and Afifi, 
2007). Formazan can be detected in cell supernatants via spectrophotometry 
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because the colour changes from clear to orange. An increase in cellular 
respiration directly correlates to an increase in dye detection through the 
cleavage of XTT (Roehm et al., 1991, Peeters et al., 2008, Kuhn et al., 2002b). 
XTT assays have also been used to determine the minimum inhibitory 
concentration of phage required in phage therapy experiments (Vipra et al., 
2013). The XTT assay was used in this instance as a rapid alternative to 
traditional cell culture methods as it was possible to undertake the assay on both 
lytic and temperate phages (Vipra et al., 2013).  
Metabolomic and metabolism studies were utilised in this chapter to determine 
how the inclusion of a temperate phage into a pellicle culture alters the 
functionality of the pellicle and how the culture develops. As stated previously, 
our main focus was to determine how phages alter bacterial growth, adaptation 
and evolution and it was considered that these techniques may give us a good 
understanding of the underlying processes which may be manipulated upon 
phage incorporation into a pellicle.  
 
5.2. AIMS  
 
The aim of this investigation was to determine through metabolomics and 
metabolism studies, how phages influence the progression of pellicle 
development in P. aeruginosa. This was achieved by observing alterations in the 
metabolites produced and/or changes in metabolism during pellicle growth. In 
order to allow for more detailed analysis to be undertaken, these studies focused 
on a smaller cohort of P. aeruginosa hosts from each clinical aetiology (n = 4).  
The metabolism study using XTT involved P. aeruginosa hosts from each of the 
clinical aetiologies (n = 4) and a small scale cross infection involving the mixed 
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phage communities induced from each of the clinical P. aeruginosa isolates. This 
was undertaken to determine whether the host was most adapted to its own 
phage thus, showing an elevation in metabolism or whether the host metabolic 
rate was influenced solely by the incoming phage. 
The metabolomic study in this chapter utilised the lysogens created in chapter 4, 
which used PAO1 as the bacterial host cell. Bacteriophages can subvert their 
bacterial host cell therefore, we hypothesised that during pellicle formation the 
metabolite profile would alter and the metabolites detected via LCMS may be 
different between the naïve, uninfected cultures when compared to the phage 
infected cultures.  
 
5.3. RESULTS 
 
5.3.1. Pellicle formation  
 
The method shown in section 2.4.2 was the final method chosen for this process 
but preliminary work was undertaken in order to generate the most efficient 
process. The phages induced and utilised in chapter 4 were also used.  
Preliminary study: The mixed phage communities used in the preliminary study 
were CF47 (Paediatric CF), CF57 (Adult CF), BR152 (< 10 BR) and BR153 (> 10 
BR). This work also focused upon determining the best time for the addition of a 
phage into a growing pellicle culture. The times tested were 0, 24 hours post 
pellicle formation, 36 hours post pellicle formation and 48 hours post pellicle 
formation. The observations are all detailed in tables 5.1 – 5.4 and images of the 
pellicles during growth and after harvesting are shown in figure 5.2.  
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The results shown in these tables are based on visual observations taken every 
12 hours for a 108 hour period. The initial observation was taken 24 hours post 
culture set-up as it was perceived that this time point would allow for the pellicle 
to have started developing. Large variations were seen in the results but these 
variations were potentially generated due to the cultures drying out, this lead to 
the altered protocol used in the final method. With the exception of the pellicle 
products generated for the two most naïve P. aeruginosa isolates (CF47 and 
BR152), good growth was seen throughout and no major differences were seen 
between the different time points nor the different phage addition time points. The 
exceptions seen for the CF47 and the BR152 pellicles can be attributed towards 
the pellicle cultures drying out throughout the incubation process. The pellicle for 
CF47 did however, have the poorest pellicle growth when visual observations 
were undertaken but this is possibly due to the naivety of this P. aeruginosa 
isolate and therefore, the ability to form robust biofilms may not be as evolved in 
this isolate compared to the other P. aeruginosa isolates in this cohort. Naivety 
needs to be concluded with caution as just because the CF patient is only a 
paediatric, doesn’t mean that the patient has been only been colonised with P. 
aeruginosa for a short time period.  
For further study, it was decided to add the phage lysates directly to the culture (t 
= 0). This was because no differences were seen in the preliminary study 
between the various time points. It was also decided to grow the pellicles for 102 
hours but extract replicate samples after 36, 72 and 102 hours of growth in order 
to generate results which were the most representative of the pellicle formation 
process. This would show any potential metabolomic and respiration alterations 
that may be occurring throughout the process.  
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Table 5.1: Preliminary work into pellicle formation in paediatric CF isolates. Paediatric CF P. aeruginosa host and the addition of phages induced from 
the same P. aeruginosa host showing variations in the biofilm formation process. ++++ Good growth, +++ Thin growth, ++ Starting growth observed, + very 
small pellicle observed, - no observable pellicle or very little and – dried out.  These results were all achieved through visual observations of the cultures.  
Hours CF47 
MINUS ɸ 
CF47 
PLUS ɸ (straight 
away) 
CF47 
PLUS ɸ 
(24 hours) 
CF47 
PLUS ɸ 
(36 hours) 
CF47 
PLUS ɸ 
(48 hours) 
24 - ++ ++ ++ ++ 
36 +++ +++ +++ +++ +++ 
48 +++ +++ +++ +++ +++ 
60 - - + + + 
72 - - + + + 
84 - - + + + 
96 - - + + + 
108 - - + + + 
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Table 5.2: Preliminary work into pellicle formation in adult CF isolates. Adult CF P. aeruginosa host and the addition of phages induced from the same 
P. aeruginosa host showing variations in the biofilm formation process. ++++ Good growth, +++ Thin growth, ++ Starting growth observed, + very small 
pellicle observed, - no observable pellicle or very little and – dried out. These results were all achieved through visual observations of the cultures. 
Hours CF57 
MINUS ɸ 
CF57 
PLUS ɸ (straight 
away) 
CF57 
PLUS ɸ 
(24 hours) 
CF57 
PLUS ɸ 
(36 hours) 
CF57 
PLUS ɸ 
(48 hours) 
24 - ++ ++ ++ ++ 
36 + ++ ++ ++ ++ 
48 ++++ ++++ ++++ ++ ++ 
60 ++++ ++++ ++++ ++++ ++++ 
72 ++++ ++++ ++++ ++++ ++++ 
84 ++++ ++++ ++++ ++++ ++++ 
96 ++++ ++++ ++++ ++++ ++++ 
108 ++++ ++++ ++++ ++++ ++++ 
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Table 5.3: Preliminary work into pellicle formation in < 10 BR isolates. <10 BR P. aeruginosa host and the addition of phages induced from the same P. 
aeruginosa host showing variations in the biofilm formation process. ++++ Good growth, +++ Thin growth, ++ Starting growth observed, + very small pellicle 
observed, - no observable pellicle or very little and – dried out. These results were all achieved through visual observations of the cultures. 
Hours BR152 
MINUS ɸ 
BR152 
PLUS ɸ (straight 
away) 
BR152 
PLUS ɸ 
(24 hours) 
BR152 
PLUS ɸ 
(36 hours) 
BR152 
PLUS ɸ 
(48 hours) 
24 ++ + ++ ++ ++ 
36 ++++ ++++ ++ ++ ++ 
48 ++++ ++++ -- ++ ++ 
60 ++++ ++++ -- -- ++++ 
72 ++++ ++++ -- -- ++++ 
84 ++++ +++ -- -- ++++ 
96 -- ++++ -- -- ++++ 
108 -- ++++ -- -- ++++ 
215 
 
Table 5.4: Preliminary work into pellicle formation in > 10 BR isolates. >10 BR P. aeruginosa host and the addition of phages induced from the same P. 
aeruginosa host showing variations in the biofilm formation process. ++++ Good growth, +++ Thin growth, ++ Starting growth observed, + very small pellicle 
observed, - no observable pellicle or very little and – dried out. These results were all achieved through visual observations of the cultures. 
Hours BR153 
MINUS ɸ 
BR153 
PLUS ɸ (straight 
away) 
BR153 
PLUS ɸ 
(24 hours) 
BR153 
PLUS ɸ 
(36 hours) 
BR153 
PLUS ɸ 
(48 hours) 
24 ++ +++ ++ ++ ++ 
36 +++ +++ ++ ++ ++ 
48 +++ +++ ++ ++ ++ 
60 +++ +++ +++ ++++ ++++ 
72 +++ +++ ++++ ++++ ++++ 
84 +++ +++ ++++ ++++ ++++ 
96 +++ ++++ +++ ++++ ++++ 
108 ++++ ++++ ++++ ++++ ++++ 
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Figure 5.2: Images to show the pellicle formation process. Image A shows the 
harvested pellicle whilst image B shows the pellicle whilst still residing within the 6 well 
cell-culture plates. The darker area in the bottom 3 wells shows a pellicle product whilst 
the top 3 wells represent LB control cultures.  
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5.3.2. Respiration variations observed in pellicles with and without 
addition of purified phages 
As stated previously, (section 5.3.1.) the phages used for all the studies from this 
point forwards were the phages induced from the 4 P. aeruginosa strains which 
were selected for the generation of lysogens (chapter 4). The mixed temperate 
phage communities for these 4 P. aeruginosa isolates were utilised for the 
metabolism marker studies and the lysogens were used for the metabolomic 
investigation. The metabolism profiles of the phage infected cultures were 
compared to the pellicle products harvested at the same time points from naïve 
non-phage infected cultures. XTT raw data is shown in appendix 7.  
The mixed temperate phages were used for a small scale cross-infection study in 
order to determine whether the metabolism marker profiles were elevated due to 
the addition of a self-infecting phage lysate or whether the addition of phage from 
a different clinical origin would drive an elevation in the metabolism profiles. It 
has been proposed through previous work in chapter 3, that the adult CF phages 
are the most infective against the entire P. aeruginosa cohort, so it was 
hypothesised here that the adult CF phages would drive the largest alteration in 
the metabolic profiles. This assumption can be drawn as it is proposed that these 
adult CF bacteriophages have a large arsenal of genes which can generate the 
broad infection profile and so these genes may generate large metabolic 
changes within their new bacterial hosts.  
The metabolic potential of the pellicles was determined through the addition of 
2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide 
(XTT). Figure 5.3 illustrates the overall data from this study and therefore, the 
respiratory action of each pellicle. The negative phage control is represented by 
the first bar in each panel and this was the value used to determine whether 
there were any statistical differences between the pellicle communities.  
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With a few exceptions, the XTT assay results indicated that the addition of 
exogenous phage to a pellicle culture generated a more metabolically active 
pellicle. However, only a few significant observations were detected. Length of 
pellicle growth time did not appear to have any effect on the metabolic profiles. In 
general, the addition of exogenous phage 24 (adult CF) caused an elevation in 
the metabolic profiles of the various P. aeruginosa pellicle cultures however; 
these elevations were not always significant. Another finding that can be taken 
from these data is that the addition of exogenous phage 136 (> 10 BR) caused a 
decrease in the metabolic profiles of the various P. aeruginosa pellicle cultures 
but this trend was again not apparent in all the pellicle cultures involved and was 
specific when infecting certain P. aeruginosa backgrounds. Interestingly, the CF 
P. aeruginosa pellicles exhibited more metabolically active pellicles on average 
compared to the BR P. aeruginosa pellicles.  
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Figure 5.3: Absorbance readings at 490 nm, 120 minutes after the addition of the 
XTT to the pellicles. Non parametric t tests were utilised with two tailed p values shown 
in order to display the most discrete statistical significant data; * ≤ 0.05, ** ≤ 0.01, *** ≤ 
0.001 and **** ≤ 0.0001.  
The naïve pellicle is represented by the first bar in each panel allowing for observations 
to be drawn between all the pellicles with the addition of the various mixed temperate 
phage lysates.  
+ CF24 indicates the addition of purified phage from an adult CF P. aeruginosa isolate, + 
CF70 indicates the addition of purified phage from a paediatric CF P. aeruginosa isolate, 
+ BR123 indicates the addition of purified phage from a < 10 BR P. aeruginosa isolate 
and + BR136 indicates the addition of purified phage from a > 10 BR P. aeruginosa 
isolate. The various growth periods of the pellicle are also detailed on the graph – 36 
hours, 72 hours and 102 hours. 
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5.3.3. Orthologous PLS-DA and PLS-DA plots for 164 significant 
metabolites (p ≤ 0.05 and CV ≤ 5) when the plots are separated 
according to the duration of pellicle growth 
In order to maximise the variation in the data generated via LCMS, oPLS-DA and 
PLS-DA plots were generated using the discriminator of time and therefore, 
stage of growth, figures 5.4 and 5.5.  
PLS-DA plots maximise the variation in the metabolite profiles between pellicles 
formed with and without phage infection whilst using duration of growth as the 
discriminator. The R2Y value for the PLS-DA plot is 0.55 and the R2Y value for 
the oPLS-DA plot is 0.62; values > 0.5 are thought to be representative of a 
robust model. Biological duplicates were performed and the samples were run on 
the Q-Exactive LCMS as technical triplicates.  
The E. coli Metabolome Database (ECMDB) was used for metabolite comparison 
based on molecular weight. The ECMBD is based on metabolites identified in the 
E. coli strain K12, subspecies MG1655 and contains over 300 small molecule 
identifications with 1.4 x 102 associated enzymes and over 300 associated 
molecule transporters (Guo et al., 2013). 
After preliminary LCMS work it was decided to alter the timings utilised (data not 
shown for the preliminary data set). The new times were chosen in order to 
represent time points within the developmental process as it was proposed that 
the greatest alterations in the metabolite load would occur during the generation 
and formation of the pellicle cultures. The cultures at 36 hours post generation of 
the pellicle were assumed to represent biofilm cultures whereas, the previous 
time points could be considered more planktonic in nature. PAO1 was used as a 
non-lysogenic control in these data in order to allow for comparisons to be drawn 
between lysogenic and non-lysogenic cultures.  
222 
 
When looking at the individual subgroups on both the PLS-DA and oPLS-DA 
plots models of the 164 metabolites detected, it was seen that near identical 
profiles were seen for the PLS-DA and oPLS-DA plots. It is apparent from both 
figures 5.4 and 5.5, that the CF24 (adult CF) lysogen has the most distinct 
metabolite profile compared to the naïve PAO1 and this altered profile may be 
linked to phage infection and subversion. Most importantly, this profile is 
observed throughout growth. The lysogen which showed the second greatest 
difference compared to PAO1 was CF70 (paediatric CF). Again, this observation 
was found throughout the time points. In contrast, the BR123 (< 10 BR) lysogen 
was found to be most closely associated with the naïve PAO1 control at all the 
time points on both plots.  
The finding that CF24 (adult CF) lysogen showed the greatest difference to the 
naïve PAO1 was in concordance to the results shown previously in chapters 3 
and 4. In these chapters, the adult CF phages were either most infective against 
the entire P. aeruginosa cohort, showed the greatest antibiotic tolerance or 
showed the greatest elevation in growth compared to a non-lysogenic strain.  
The finding that the BR 123 (< 10 BR lysogen) shows the most similarity to the 
naïve PAO1 control also relates to previous findings in chapters 3 and 4, as the < 
10 BR phages have been shown to be the most naïve in terms of antibiotic 
tolerance, infection capabilities and growth profiles. 
In order to generate quantitative data to support both the oPLS-DA and PLS-DA 
plots described above, cell counts were undertaken for each lysogenic PAO1 
strain at the various extraction points, figure 5.6. It was seen that the average cell 
count increased throughout the developmental process, which shows that the 
metabolomic profiles generated are associated to a significant increase in cellular 
growth.  
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Figure 5.4: A PLS-DA plot describing proposed metabolite changes for 164 
significant metabolites (p ≤ 0.05) with a CV score of ≤ 5 during pellicle formation. 
Lysogens were grown for ~ 3 hours, average OD600 0.124 (early), ~ 5 hours, average 
OD600 0.494 (mid) and ~ 10 hours, average OD600 1.136 (late) and 36 hours to determine 
changes in the metabolite profile throughout the pellicle formation process.  
R2Y is 0.55 when the discriminating factor is time.  
Early growth is represented by the blue data points, mid growth by the pink data points, 
green points represent metabolites from late growth whilst burgundy points represent the 
36 hour growth profiles.  
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Figure 5.5: An oPLS-DA plot describing proposed metabolite changes for 164 
significant metabolites (p ≤ 0.05) with a CV score of ≤ 5 during pellicle formation. 
Lysogens were grown for ~ 3 hours, average OD600 0.124 (early), ~ 5 hours, average 
OD600 0.494 (mid) and ~ 10 hours, average OD600 1.136 (late) and 36 hours to determine 
changes in the metabolite profile throughout the pellicle formation process.  
R2Y is 0.62 when the discriminating factor is time. 
Early growth is represented by the blue data points, mid growth by the pink data points, 
green points represent metabolites from late growth whilst red points represent the 36 
hour growth profiles. 
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Figure 5.6: Cell count to validate the pellicle formation process. Average CFU/mL 
calculations for each bacterial lysogen and PAO1 at the various time points utilised for 
the metabolomic investigation; n = 15.  
Non parametric t tests were utilised with two tailed p values shown in order to display the 
most discrete statistical significant data; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 and **** ≤ 0.0001.   
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5.3.4. Variance of importance plot (VIP) of the PLS-DA to select for 
proposed metabolites of interest  
When characterising the metabolomic data, variance of importance plots (VIP) 
can be used to show which of the metabolites seen in the PLS-DA and oPLS-DA 
plots are significant and drive the differences observed on these models. The 
PLS-DA model was used for creating the VIP plot rather than the oPLS-DA. Both 
models have been shown to have equal predictive powers but the oPLS-DA plot 
has been previously shown in the literature to confer no beneficial advantage 
over the PLS-DA plot (Tapp and Kemsley, 2009, Ergon, 2005, Verron et al., 
2004, Svensson et al., 2002). This however, has been argued by other 
researchers therefore both models were included in these results (Mahadevan et 
al., 2008).  
VIP plots show the important variables involved in determining the variation seen 
in the PLS-DA plot, figure 5.7. VIP plots are scored in a high to low order with 
confidence levels in the data being at 95 % (Tremaroli et al., 2009). A VIP value 
greater than 1 indicates that the metabolite has been identified by PLS-DA to 
show a difference between the lysogenic and non-lysogenic hosts and this 
metabolite maybe important to function. A VIP value which is less than 0.5 
indicates that the proposed metabolites are unimportant and have no potential 
roles in driving the variation seen on the 2 models. The area of the plot which 
contains metabolites with VIP values between 1 and 0.5 can be included in the 
analysis if the data set is small. However, due to the size of the data set in this 
investigation, these metabolites were not included in further analysis.  
There were 41 metabolites that yielded a VIP score of greater than 1. These 
were subjected to further analysis and identification. Of these 41 possible 
metabolites, 85 % originated from positive electrospray ionisation (ESI) runs and 
15 % from negative ESI runs. Upon stratification of the positive ESI runs, the 
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majority of the metabolites originated from < 10 BR lysogens (46 %), followed by 
the adult CF lysogens, the naïve PAO1, paediatric CF lysogens and > 10 
lysogens (27 %, 10 %, 2 % and 0 %, respectively). When this stratification 
procedure was applied to the negative ESI run metabolites, it was observed that 
the adult CF lysogens, < 10 BR lysogens and naïve PAO1 all contributed equally. 
The paediatric CF and > 10 BR lysogens had no significant metabolites.   
As currently there is only a limited amount of metabolism data for P. aeruginosa, 
these 41 metabolites were compared using Progenesis QI 64 bit v 4.1 and the 
ECMDB but only limited similarity to known metabolites was seen. There were no 
metabolites with an identical match when the chosen criteria were imposed upon 
them; p value ≤ 0.05, CV score ≤ 5, mass error of +/- 1. A mass error of 1 was 
chosen as the cut-off value as it gives more strength to the data prediction. A 
value closer to 1 indicates that the metabolite identified may in fact be the correct 
metabolite instead of being an adduct with a similar m/z ratio. In order to identify 
potential metabolites, it was decided to repeat the analysis process but using the 
human metabolome database (HMDB).  
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Figure 5.7: VIP plot showing the importance of the different variables which all 
contribute towards the modelling of the PLS-DA plot. The x-variables or proposed 
metabolites that have a VIP value of above 1 are believed to be of particular interest and 
so further work was undertaken on these metabolites. The x-variables with a VIP value of 
below 0.5 are believed to have no impact on the plot and so no further work was 
undertaken on these samples. The x-variables with a VIP value of between 1 and 0.5 
were not included for further analysis. 
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5.3.5. Human metabolome database (HMDB) analysis of the 41 VIP 
derived metabolites  
 
As previously stated (section 5.3.4), the metabolite identification process yielded 
41 metabolites which showed a significant difference between infected and 
uninfected cells when time and therefore, growth stage was used as the 
discriminator. Information on those 41 metabolites was not available when 
comparing to the ECMDB.  
The HMDB was therefore, utilised to try and identify possible metabolites. The 
HMDB contains over 4.1 x 103 metabolite entries that are both water and lipid 
soluble. The database includes links to a range of metabolite identification 
programmes such as Encyclopaedia of Genes and Genomes (KEGG) and 
PubChem (Wishart et al., 2013, Wishart et al., 2009, Wishart et al., 2007), these 
pathways may therefore, be orthologous to those found in P. aeruginosa.  
The previous criteria used (p values ≤ 0.05, CV ≤ 5 and mass error +/- 1) were 
again applied to the samples with the only alteration being the metabolite 
identification database. Unfortunately, there were no metabolites detected using 
the HMDB when these stringent criteria were imposed. However, there were 5 
metabolites that could be included if the mass error was raised to +/- 2. Accurate 
identification via MS/MS was not included in this investigation. A metabolite that 
is a nitroaromatic, broad spectrum antibiotic, active against both Gram negative 
and Gram positive bacteria appeared to warrant further investigation (Ryan et al., 
2011, Tangallapally et al., 2007). 
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5.4. DISCUSSION  
Over the last 10 years, there have been rapid increases in the amount of data 
generated via “–omic” technologies, this data is now available to characterise 
differences between bacteria and determine how they alter during growth (Zhang 
et al., 2010). This study has shown subversion by phages during infection can be 
studied by changes in cellular metabolism and metabolite profiles. This study has 
also investigated the effect that time has on pellicle formation and has tried to 
elucidate the effect that P. aeruginosa phages may be exerting on their bacterial 
hosts at specific ‘snapshot’ points during pellicle formation. 
To recreate the establishment of a pellicle in the presence of phage, it was 
observed that the addition of phage immediately after setting up the pellicle, 
produced pellicles that could be effectively harvested for further analysis. 
Infection of the culture in this manner was preferred because the phages did not 
need to penetrate the ECM of the establishing pellicle which increased the 
chance of successful phage infection. Phages have however, been proven to 
penetrate the bacterial cell matrix post biofilm formation through their ability to 
encode for hydrolases or lyases which recognise and degrade bacterial polymers 
in the ECM (Labrie et al., 2010b, Sutherland, 1999, Sutherland et al., 2004). It is 
also possible that phages can infect bacterial biofilms through the water channels 
which make up the matrix structure, which therefore, allows the phages access to 
the inner biofilm (Sutherland et al., 2004). Whilst bacterial cells can protect 
themselves from phage infection through various mechanisms (section 1.6.5.), 
and phages have co-evolved in order to penetrate the ECM, the decision to add 
the mixed temperate phage lysate initially to the P. aeruginosa culture was to 
reduce any barriers which the phage may encounter whilst crossing the ECM.  
The metabolism marker study shows that the addition of phage to a growing 
pellicle culture can increase the metabolic activity of the bacterial host, as 
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previously proposed by Sonkar et al (2012). This was determined using an XTT 
assay which directly linked cellular respiration and colorimetric changes, these 
changes were detected by spectrophotometry. Not all the alterations in the 
metabolism profiles were significant. This indicated that the addition of a phage 
doesn’t provide the bacterial host cell with this evolutionary advantage under all 
circumstances. There seemed to be no increase in metabolism when self-phage 
was used in the cross infection study as the greatest differences were observed 
when phages originating from other P. aeruginosa isolates were utilised. This 
potentially indicates that the phages, regardless of their clinical origin are 
subverting their bacterial host cells and the process is not due to the phages 
being ‘known’ by the host cells.  
This is one of the first studies which utilises XTT assays to determine how 
phages affect cellular metabolism within a pellicle community. XTT assays have 
previously been used to study bacterial metabolism (Cerca et al., 2005) but the 
inclusion of bacteriophage is a novel aspect. Studying alterations in the 
metabolism of bacterial biofilms/pellicle has also previously been shown (Peeters 
et al., 2008, Palomino et al., 2002, Adam et al., 2002), but studying metabolism 
alterations when a pellicle community harbours a mixed temperate phage lysate 
is again a novel concept.  
In general for the XTT assays, it was observed that the addition of phage 24 
(adult CF) led to an increase in the metabolism profiles across the bacterial hosts 
tested. It was also interesting to note that during the analysis of the LCMS data, 
the adult CF was the most disparate as a lysogen throughout growth, as shown 
on both the PLS-DA and oPLS-DA plots. These two findings were not 
unexpected as the adult CF phages in the previous chapters have been shown to 
be the “most evolved” and generate the most extreme profiles in terms of 
bacterial growth, antibiotic tolerance and infectivity profiles. This evolution is 
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proposed to be related to P. aeruginosa colonisation time but care is needed 
when inferring results in this manner, as there is no clinical data available for 
these samples to determine when the patient was initially colonised with P. 
aeruginosa.  
The CF pellicles in general were more metabolically active compared to the BR 
pellicles and this is perceived to be a consequence of the CF phages being more 
infective compared to the BR phages, again this perception is based upon P. 
aeruginosa colonisation time and so the aforementioned caveat needs to be 
considered. This perception is enforced by work shown in the previous chapters, 
where the BR phages are seen to drive less extreme responses compared to the 
CF phages, especially when studying the growth profiles in chapter 4. Potentially, 
the CF phages increase the metabolism of their host cells and this allows for the 
maintenance of the phage within the bacterial cell. These active host cells would 
have replication machinery constantly driving cellular proliferation thus, allowing 
for the replication of the phage residing within a prophage region. The 
observation of an elevation in metabolism may also be due to the pellicles being 
thin therefore, only the active cells at the cell-surface interface may have been 
harvested and selected for the XTT analysis (Davies, 2003, Gjersing et al., 
2007). It is possible to premise that the increase in metabolism links to an 
increase in the amount of viable cells present in a community, so indicating that 
the pellicles prior to XTT addition were actively growing. The low MOI (0.1) used 
for the generation of the pellicles supports the constant replication of lysogenic 
bacterial cells and increasing bacterial numbers, which may also have led to an 
elevation in absorbance levels.  
It was also interesting to note that the addition of the > 10 BR phage led to a 
decrease in the metabolism of the bacterial cultures in some pellicles. It is 
possible to propose that this is because the BR phages are less evolved to the 
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specific environment and therefore, are not providing their bacterial hosts with a 
selective advantage in order to increase their metabolic activity. It is possible that 
the addition of the phage DNA in this instance confers a burden onto the cell and 
so lowers its ability to respire. This may be a result of the phage integrating into 
an area of the bacterial chromosome which lowers respiration or blocks a key 
cellular process. In support of this reduction in metabolism upon the addition of a 
BR phage, it was seen that the lysogen which aligned closest to the PAO1 
control upon LCMS analysis also contained a BR phage but in this instance it 
originated from the < 10 BR P. aeruginosa isolate. This would potentially indicate 
that the BR phages are not exerting large differences on their PAO1 bacterial 
host cells but these findings are not unexpected. This is because our previous 
findings have shown that the BR phages are the least evolved and the most 
naïve due to their new colonisation state.  
oPLS-DA plots were chosen to represent the metabolomic data alongside PLS-
DA plots, as these plots maximise the separation between classes based on the 
inputted data whilst also minimising within class variation (Zhang and Powers, 
2012, Beale et al., 2013). When comparing the time points on both models, it 
was seen that the metabolites generated during mid and late growth aligned 
together with minimum separation along the x-axis. This potentially demonstrates 
that the metabolites used to stratify the data in these models didn’t change 
dramatically during these growth phases. The metabolites generated after 36 
hours of growth align in a separate group, this group shows variation from the 
mid and late growth profiles due its location along the x-axis. The metabolites 
generated during early growth show the most variation which suggests that these 
metabolites are the most unique and are possibly related to a planktonic mode of 
bacterial growth. These LCMS findings agree with the findings of Gjersing et al 
(2007) as that study showed that metabolic profiles differ due to variations in 
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infection, adaptation and evolution. Gjersing et al (2007) showed a marked 
difference in NMR profiles when comparing the intracellular metabolites 
generated by biofilm and planktonic cells and these results could be indicative of 
differences in bacterial infection, evolution and adaptation. This difference is also 
shown in these data due to the alignment of the early (planktonic) and 36 hour 
(biofilm) metabolites on both the PLS-DA and oPLS-DA plots.  
The data proposed by the PLS-DA and oPLS-DA plots was transposed into a VIP 
plot. This plot offered 41 discrete metabolites with VIP values greater than 1. 
These were the metabolites which drove the variation in the data and thus, the 
differences observed between the metabolic profiles for the naïve and lysogenic 
cultures. Even though these metabolites were determined to be important due to 
their CV scores, they were not detailed enough in order to be significant upon 
further progenesis analysis utilising the ECMDB. The main reason for this was 
that upon comparison of these data to the ECMDB, the mass error rates were not 
specific enough. The mass error should be +/- 1 but in some instances the mass 
error was 300. This made it difficult to specifically identify these metabolites and 
confer a putative function. The lack of a P. aeruginosa specific metabolome 
database hindered the identification process of specific P. aeruginosa 
metabolites.  
In order to try and identify metabolites which were significant and also had good 
mass error values, it was decided to raise the mass error to +/- 2. These less 
stringent criteria were applied when undertaking a second round of analysis with 
the HMDB. When these conditions were applied, 5 metabolites were identified 
but the most interesting metabolite was Nitrofurazone (NTZ). NTZ has been 
observed to be active against some Enterobacteriaceae and Gram positive 
bacteria but it is in fact ineffective against P. aeruginosa and Candida albicans 
(Stefanides et al., 1976, Cunha et al., 2011, Brumfitt and Hamilton-Miller, 1998). 
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NTZ has previously been used to treat burn infections and this was of interest 
due to the knowledge that P. aeruginosa infections can cause serious 
complications in the treatment of burns patients (Japoni et al., 2009, Church et 
al., 2006, Altoparlak et al., 2004). NTZ is also used to topically treat skin and 
mucosal membrane wounds, burns, infections and ulcers (Kouchak et al., 2014, 
M Balcao et al., 2013). No link towards P. aeruginosa naturally produced 
antibiotics could be drawn from the literature but NTZ intermediates and 
derivatives also have no activity against P. aeruginosa. Nitrofurantoin is an 
example of an NTZ derivative, this is an often under-used antibiotic which 
functions via interrupting growth at γ sites within the bacterial Krebb’s cycle 
(Cunha et al., 2011, Cunha, 2006, McOsker and Fitzpatrick, 1994, Brumfitt and 
Hamilton-Miller, 1998). P. aeruginosa is naturally resistant towards this antibiotic 
(Brumfitt and Hamilton-Miller, 1998, Cunha et al., 2011). It is interesting to 
consider why a phage from a clinical P. aeruginosa isolate derived from a < 10 
BR patient (mass error + 1.57) potentially encodes for this antibiotic – could the 
acquisition of this antibiotic be a potential survival technique for the P. 
aeruginosa species thus, allowing P. aeruginosa to become predominant within 
the lung?  
This study has emphasised the complexity of the bacterial communities and their 
metabolism in the lower lung. Even though no MS/MS analysis was undertaken, 
these data showed global differences in P. aeruginosa metabolite profiles when 
infected with phages. A confounding problem was the lack of available databases 
which would have allowed for more comparisons to be undertaken and could 
feed into KEGG pathway analysis. This would have allowed us to characterise 
which systems the phages subverted over time and how this linked to growth, 
adaptation and evolution of the bacterial host within the chronic lung. This study 
has shown that it is possible to undertake metabolomics on pellicle cultures of P. 
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aeruginosa and potentially identify metabolites of interest. Furthermore, this 
study has proposed that phages subvert their bacterial host cell via the utilisation 
of new processes or biological pathways.  
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6. METAGENOMIC ANALYSIS OF MIXED TEMPERATE 
PHAGE LYSATES INDUCED FROM SINGLE 
PSEUDOMONAS AERUGINOSA ISOLATES 
 
6.1. INTRODUCTION 
So far this study has focused on a culture collection of 94 Pseudomonas 
aeruginosa (P. aeruginosa) isolates from cystic fibrosis (CF) and bronchiectasis 
(BR). Polylysogeny has been determined to in part be associated with a broader 
host range potential (chapter 3). The ability of phages to re-infect their originating 
host cell also increases as lung infections progress (chapter 3). During disease 
progression, the bacteria adapt certain traits which correlate to fitness increases 
in the chronic lung and therefore, we can hypothesise that phages may mirror 
this evolutionary pattern of continual interaction and evolution. 
The introduction of next generation sequencing and in this instance the 
sequencing-by-synthesis method; offers an affordable method to look at the 
phage-ome of the mixed induced phage lysates isolated from each of the 94 
clinical P. aeruginosa isolates. This chapter characterises the metagenomic 
profiles of the phage lysates from each clinical aetiological subgroup. It is 
proposed that the adult CF phages will have the most complex metagenomic 
profiles, which may be linked to their longevity within the chronic lung 
environment. A caveat relating to P. aeruginosa colonisation times is pertinent to 
mention here, the age of the patient doesn’t always correlate with the length of 
time that a patient may have been colonised with P. aeruginosa for and so care 
needs to be taken here.  
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6.1.1. Culture dependent techniques 
Culture dependent isolation of bacterial or viral species relies on the ability to 
cultivate these biological entities or having a sensitive host for the virus to infect 
and proliferate on within a laboratory setting. Over 70 % of bacterial species 
inhabiting mucosal surfaces have yet to be cultured (Barer and Harwood, 1999). 
The remaining 30 % whilst able to be grown in laboratory settings can be difficult 
to propagate (Suau et al., 1999, Hayashi et al., 2002, Sibley et al., 2011, Han et 
al., 2012).  
CF sputum samples in hospital environments are routinely assayed for a limited 
but known set of bacterial species including P. aeruginosa, Staphylococcus 
aureus (S. aureus), Haemophilus influenzae and Burkholderia cepacia complex 
C. These culture dependent methods however, are open to detection bias 
(Rogers et al., 2004). The selective media utilised for culturing the ‘traditional’ CF 
microbes do not support the isolation of fastidious bacteria or fungi and 
anaerobic species colonising the lungs (Bittar et al., 2008, Belkum et al., 2000). 
This media can also become contaminated due to the overgrowth of a ‘traditional’ 
CF bacterium such as P. aeruginosa (Bittar et al., 2008, Belkum et al., 2000). 
Even if bacterial species are isolated via culture dependant mechanisms, then 
there are often other problems involved in the identification process. For 
example, bacteria isolated from the chronic lung often exhibit multiple 
phenotypes which could potentially have an impact on the identification process 
(Wellinghausen et al., 2005, Vaudaux et al., 2006, McMenamin et al., 2000, Bittar 
et al., 2008). Culture dependent studies were not utilised in this thesis due to the 
potential issues that may have arisen through cultivation of P. aeruginosa phages 
and the possible lack of a receptive host. Lack of a sensitive host cell may allow 
some of the phage isolates to go undetected so to misrepresent the true and 
entire viral load of the P. aeruginosa isolates. Due to the large scale nature of the 
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investigation, time pressures of phage purification were also a key consideration 
that needed to be taken into account when conducting the experimental design. 
 
6.1.2. Metagenomics 
Metagenomics is based upon sequencing DNA directly from the environment 
without the need for prior cloning steps or PCR amplification, this technique was 
initially proposed by Pace and colleagues in 1985 (Pace et al., 1985). The first 
metagenomics investigation focused on seawater, with the study aiming to link 
functionality to unknown microorganisms within the community (Schmidt et al., 
1991, Stein et al., 1996, Riesenfeld et al., 2004). Many environmental 
metagenomes have been studied including the soil (Delmont et al., 2011, 
Rondon et al., 2000), the oral cavity (Lazarevic et al., 2009, Belda-Ferre et al., 
2012), faeces (Breitbart et al., 2003, Manichanh et al., 2006, Victoria et al., 2009) 
and aquatic environments (Suttle, 2005, Suttle, 2007, Rodriguez-Brito et al., 
2010). Rodriquez-Brito et al (2010) utilised metagenomics in order to determine 
whether bacterial and viral taxa in aquatic environments follow the same growth 
patterns as seen in macro organisms. This question had been proposed 
previously but without the use of metagenomics and therefore, was limited by the 
non-cultivability of certain viruses and microbes. Their results showed that 
bacterial and viral populations fluctuate over time which is something that may  
not have been detected using culture based techniques (Rodriguez-Brito et al., 
2010). This population fluctuation supports the red queen hypothesis that has 
been previously described between bacteriophages and their bacterial hosts and 
supports the theory of co-evolution (section 3.3.1).  
Current next generation sequencing techniques involving sequencing-by-
synthesis have allowed metagenomics to become economical and have added 
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power through increased DNA sequencing depths. This approach generates a 
large amount of data relating to the genomic DNA content of an environment 
(Huson et al., 2007). These shotgun sequencing methods allow researchers to 
take a ‘snapshot’ of a particular environment at a specific time point and due to 
the direct sequencing approach the entire microbiota can be investigated at 
once.  
 As this study is targeting multiple temperate phages in one P. aeruginosa 
isolate, a metagenomic approach is beneficial as it allows for the detection of all 
the individual phages without the need for purifying them. Now deep sequencing 
is possible both for phages with low titres and those that are non-infective due to 
lack of a known host range can be characterised. Metagenomics also allows for a 
function to be assigned to a metagenome. This has particular interest in this 
thesis which is based upon linking bacteriophages to adaptation, evolution of 
function within the lung and how these underlying variations in host cell 
functionality occur over time.   
 
6.1.2.1. Metagenomic studies within the lungs 
The human respiratory tract is a unique environment due to the constant 
bombardment from airborne particles including viruses, bacteria and allergens as 
well as antibiotic/antimicrobial treatments (Heyder, 2004). A study undertaken by 
Willner et al (2009) focused on the comparison of viruses isolated from both CF 
patients and non-CF individuals. In the majority of the sequences, over 90 % 
were unknown which is a comparable finding to other environmental viromes 
(Angly et al., 2006, Desnues et al., 2008, Dinsdale et al., 2008, Willner et al., 
2009). Willner et al (2009) through metagenomics proposed that there were ~ 
170 unique DNA viruses in the respiratory virome regardless of clinical aetiology. 
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Other viromes have been shown to have a much greater species richness for 
example, the ocean was found to harbour around 1.2 x 103 viruses and hot 
springs 1.4 x 102 viruses (Angly et al., 2006, Schoenfeld et al., 2008). The low 
species diversity in the lungs is hypothesised to be a result of both the physical 
and biological barriers present whilst antibiotic treatment may also further deplete 
the species present (Knowles and Boucher, 2002, See and Wark, 2008, Palmer 
et al., 2005, Palmer et al., 2007).  
 
6.1.2.2. Bacteriophage metagenomics 
Metagenomic studies have been undertaken on phage communities either to 
identify novel species or to identify specific binding regions that may influence 
phage longevity within a specific microenvironment (Barr et al., 2013, Tariq et al., 
2015). Viral metagenomes have been shown to be mostly comprised of novel 
sequences with no known homologues (Pedulla et al., 2003a, Rohwer et al., 
2000, Chen and Lu, 2002). Breitbart et al (2003) using a metagenomic approach 
studied the faeces from one healthy adult male. The most abundant sequences 
were related to bacterial species with the second most abundant being related to 
bacteriophages in particular; A118 of Listeria monocytogenes, E125 of 
Burkholderia thailandensis and bIL285 of Lactobacillus lactis. This study 
emphasised the ability to identify previously unknown bacteriophages and so it 
has proposed that metagenomics is an ideal tool that phage researchers should 
utilise in order to identify and classify novel bacteriophage genomes.  
The majority of known marine viruses are phages that can influence global 
biogeochemical cycles (Fuhrman, 1999), genetic exchange (Paul, 1999, Breitbart 
et al., 2002) and microbial diversity (Wommack and Colwell, 2000, Bratbak et al., 
1996). The viral biodiversity of these marine viruses however, is poorly 
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understood and the evolutionary relationship between these marine and non-
marine phages is also unknown. Thus, metagenomic studies have tried to 
elucidate evolutionary relationships and functional similarities between these 
viruses (Fuller et al., 1998, Hambly et al., 2001, Breitbart et al., 2002). Of the 
metagenome sequences identified in one study, the majority showed no 
significant similarity to previously reported sequences in GenBank (Breitbart et 
al., 2002). This enforces the idea that metagenomics is a technique that can be 
utilised to identify free phage, which would otherwise remain undetected using 
traditional culturing based methods due to the possible inability to find a sensitive 
bacterial host range to propagate the virus on.   
The field of DNA sequencing and its chemistry is constantly evolving in order to 
elucidate the entire bacterial and viral load in a population and metagenomics is 
becoming an increasingly common tool in unknown community studies. Novel 
bacterial and viral species are being identified and uploaded to GenBank on a 
frequent basis and this is proposed to be due to the development of low cost 
sequencing platforms. The development of Sanger sequencing in the 1λ70’s led 
to an explosion in commercial sequencing platforms and available sequencing 
chemistries (Sanger, 1975, Sanger and Coulson, 1975, Gilbert and Maxam, 
1973) These platforms are still being developed in order to generate platforms 
with the most high throughput data outputs and the lowest error rates.  
In order to perform metagenomic analysis in this chapter, the Illumina MiSeq 
platform was utilised (Illumina, CA, USA). Illumina employs a unique indexing 
system which places an individual barcode for the sample within one of the 
sequencing adaptors. This is unique as other platforms add the barcode directly 
to the terminal end of the fragments (Craig et al., 2008, Meyer et al., 2008, Meyer 
and Kircher, 2010). This set up allows for a high degree of flexibility in 
experimental design, which is often of interest during sequencing investigations 
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(Meyer and Kircher, 2010). The sequencing chemistry that this machine uses is 
sequencing-by-synthesis and this chemistry is described in more depth in section 
2.8.1. 
 
6.2. AIMS  
 
In chapter 3, the host range and evolution between the P. aeruginosa phages 
isolated from clinical CF and BR related isolates was linked to polylysogeny. It is 
also thought that genome assembly of mixed phage samples is difficult as Smith 
et al (2012) describes high levels of similarity between gene regions which would 
offer problems when constructing single phage genomes.  
The key aim in this chapter was to compare the aetiology of infection and the 
clinical groupings in order to assess functionality changes in the phage 
metagenomes. The question of interest was ‘do genes linking to survival, 
adaptation and evolution in the chronic lung become more prevalent as disease 
progresses?’. The previously mentioned caveat needs to be considered also in 
this instance.  
Before this was attempted, a rigorous experimental design was needed to create 
an effective protocol for clearing contaminating bacterial chromosomal DNA from 
the phage viral preparations. The removal of bacterial DNA was required in order 
to aid downstream analysis, removing the bacterial DNA improves confidence 
that the regions of similarity observed are due to phages and not bacterial 
chromosomal DNA. In order to generate the metagenomic profiles for the phage 
lysates in this investigation, the samples were sequenced on the Illumina MiSeq 
using a 250 bp paired end library preparation. Metagenomics Rapid Annotations 
based on Subsystem Technology (MG-RAST) and the generation of Kyoto 
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Encyclopaedia of Genes and Genomes (KEGG) pathway maps were used to 
assign gene functions. These maps show the ‘incidence’ of relatedness of the 
DNA profiles of the phage lysates. 
  
6.3. METHOD DEVELOPMENTS 
 
There are a wide number of manufacturer kits and methods available to isolate 
total viral DNA, although for analysis of the virome via metagenomics DNA needs 
to be free from bacterial contamination. Prior to the various DNA purification 
methods being used, the phages were induced from the bacterial chromosome 
using fluroquinolone antibiotic, Norfloxacin (section 2.3.3.).  
 
6.4. RESULTS 
 
6.4.1. PEG8000 purification of 94 mixed temperate phage lysates 
originating from clinical P. aeruginosa isolates 
PEG8000 was used to precipitate the virus DNA using the method proposed by 
Sambrook et al (1989). Preliminary work involved the use of E. coli ɸ 24B to 
determine how effective the process was for clearing contaminating bacterial 
chromosomal DNA away from the lysate. PCR amplification of the Q gene (late 
gene antiterminator), was undertaken on the phage samples post PEG8000 
purification in order to determine whether a phage was present or absent (435 
bp) (Smith et al., 2007). PCR amplification did show the presence of the phage Q 
gene after PEG8000 purification, showing that this process was indeed 
successful for purifying phages.  
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When the same method was applied to the P. aeruginosa phage lysates 
however, it was decided to utilise PCR amplification of the V3 region of the 16S 
rRNA gene to ascertain the level of bacterial chromosomal contaminaton 
(Muyzer et al., 1993, Chakravorty et al., 2007). The V3 region post PCR 
amplification generates a product on an agarose gel of 195 bp (Chakravorty et 
al., 2007), figure 6.1. A low intensity band was detected on a 1 % agarose gel 
after PCR amplification and this lead to the QUBIT 2.0 (Life technologies Ltd), 
being utilised in order to determine the exact amount of DNA present in the 
samples. The QUBIT 2.0 showed that the DNA concentration was too low for 
further downstream applications.  
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Figure 6.1: A 1 % agarose gel showing amplification of the 16S rRNA gene 
following PEG8000 purification Lane 1 is Hyperladder 1, lanes 2 – 5 are various phage 
lysates subjected to PCR amplification post PEG8000 analysis. The low intensity band is 
apparent in this gel image.  
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6.4.2. QIAGEN QIAmp MinElute Viral Spin Kits use in the purification 
of 94 mixed temperate phage lysates originating from clinical P. 
aeruginosa isolates 
The QIAGEN QIAmp MinElute Viral Spin Kit was next selected to isolate the 
phage DNA isolation in this investigation, as the manufacturer has previously 
shown the effectiveness of this kit in purifying viral DNA.  
In order to clear the contaminating bacterial chromosomal DNA from the phage 
lysate, varying amounts of TURBRO DNAse and RNAse cocktail were used (Life 
technologies) and different incubation periods prior to running the phage lysate 
through the QIAGEN kit. It was proposed that varying the levels of DNAse and 
RNAse would clear the contaminating bacterial DNA from the lysate whilst 
leaving the phage DNA intact due to protection by the phage capsid.  
DNase has been used in the molecular biology field to clear genomic DNA 
contamination and it works by digesting the DNA from dead bacterial cells. The 
bacterial cells in this investigation are presumed to be dead as they have just 
been subjected to processing by the QIAGEN QIAmp MinElute Viral Spin Kit 
(Villarreal et al., 2013, Wang et al., 2002). However, DNAse is not effective at 
clearing genomic DNA from intact bacterial cells and so this is why downstream 
removal of the DNA was required (Villarreal et al., 2013). The increasing volumes 
of DNAse and RNAse were added into 1 mL of induced phage lysate in 
increasing amounts and incubation at 37 °C was performed with the time being 
altered from between 30 minutes to 4 hours. A 1 % agarose gel image showing 
the presence of a 16S rRNA gene post DNAse/RNAse and the QIAGEN kit 
treatment is shown in figure 6.2. 
2 U/L of DNase and and 500 U/L of RNase A and 20,000 U/L of RNase T1 was 
selected for future work and an incubation time period of 30 minutes at 37 °C. 
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This time point was chosen as there were no discernible differences between the 
results generated when using larger volumes of DNAse and RNAse with longer 
incubation times. Due to the high level of contaminating bacterial chromosomal 
DNA, detected by PCR after the use of the QIAGEN kit even after the varying 
amounts of DNase and RNase, it was decided that another method was needed 
in order to generate the purest phage DNA. 
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Figure 6.2: 1 % agarose gel image showing 16S rRNA gene PCR following varying 
treatments with DNAse and RNAse. Lane 1 treatment with: 10 µL of DNAse and 
RNAse for 1 hour, lane 2 treatment with: 9 µL of DNAse and RNAse for 1 hour, lane 3 
treatment with: 7 µL of DNAse and RNAse for 1 hour, lane 4 treated with: 5 µL of DNAse 
and RNAse for 1 hour, lane 5 treated with 3 µL of DNAse and RNAse for 1 hour, lane 6 
treated with: 1 µL of DNAse and RNAse for 1 hour. Lane 7 treated with:10 µL of DNAse 
and RNAse for 30 minutes, lane 8 treated with: 9 µL of DNAse and RNAse for 30 
minutes, lane 9 treated with: 7 µL of DNAse and RNAse for 30 minutes, lane 10 treated 
with: 5 µL of DNAse and RNAse for 30 minutes, lane 11 treated with: 3 µL of DNAse and 
RNAse for 30 minutes, lane 12 treated with: 1 µL of DNAse and RNAse for 30 minutes. 
Lane 13 is the negative control, lane 14 is the positive control (PAO1) and lane 15 is 
Hyperladder 1. 
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6.4.3. NORGEN Phage DNA Isolation Kit use for the purification of 94 
mixed temperate phage lysates originating from clinical P. 
aeruginosa isolates 
Due to the problems encountered previously with both the PEG8000 purification 
and the QIAGEN kit, the NORGEN Phage DNA Isolation Kit (Geneflow Limited, 
Lichfield, UK), was selected in an attempt to clear the contaminating P. 
aeruginosa chromosomal DNA from the phage lysate. PCR amplification of the 
V3 region of the 16S rRNA gene was again undertaken in order to determine the 
effectiveness of this DNA isolation kit (Muyzer et al., 1993). A PCR product was 
still present at 195 bp (Chakravorty et al., 2007). Upon visualisation of the 1 % 
agarose gel, a band which showed a lower intensity in brightness was detected 
so indicating through a semi-quantitative observation, that this kit was the most 
efficient at clearing the P. aeruginosa chromosomal DNA compared to the two 
previously described methods.  
Two elutions were undertaken using the NORGEN kit in order to increase the 
DNA yield present. The QUBIT 2.0 was again utilised in order to determine the 
DNA level present within a sample; one sample post NORGEN processing and 
two elutions possessed a DNA level of 0.495 ng/µL. This was suitable for 
downstream DNA analysis. It was decided to use this kit for the purification of the 
94 clinical P. aeruginosa phage lysates and to discount any remaining bacterial 
DNA contamination via bioinformatics. The QUBIT 2.0 values for the mixed 
temperate phage lysates are detailed in appendices 8 and 9. PCR amplification 
of the 16S rRNA gene is shown in figure 6.3 and it shows the lack of detectable 
bands in the NORGEN treated phage lysates thus, indicating that the 
contaminating bacterial chromosomal DNA had been cleared from the sample.  
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Figure 6.3: 1 % agarose gel showing amplification for the 16S rRNA gene (195 bp) 
after using the NORGEN phage DNA isolation kit. Lane 1 – Quick load ladder, lane 2 
– Hyperladder 1, lane 3 – positive PAO1 control, lane 4 – negative control, lanes 5 and 
6– paediatric CF phage DNA post use of the NORGEN phage DNA isolation kit.  
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6.4.4. Metagenomics Rapid Annotations based on Subsystem 
Technology (MG-RAST) analysis of 92 mixed temperate phage 
lysates originating from clinical P. aeruginosa isolates 
Metagenomic analysis was undertaken on the 92 mixed temperate phage lysates 
generated from the clinical P. aeruginosa isolates post sequencing on the 
Illumina MiSeq platform; the number of reads generated for each sample are 
detailed in appendix 10. 2 samples were removed from downstream applications 
due to poor sequencing data (1 < 10 BR and 1 > 10 BR). In order to remove any 
remaining bacterial chromosomal DNA that persisted following NORGEN kit 
application, the Khmer bioinformatics toolkit was used (Brown et al., 2012). As 
the bacterial chromosomal DNA is sheared in part through DNAse, any 
remaining chromosome looked like an error Khmer which generated an individual 
error peak that could be removed via bioinformatics analysis from the sample 
(method in preparation for journal submission). 
The reads generated by the Illumina MiSeq were uploaded onto the 
Metagenomics Rapid Annotations based on Subsystem Technology (MG-RAST) 
website to allow for metagenomic analysis. 82 of 92 total samples were 
processed on MG-RAST, 10 samples fell below the required cut off values 
stipulated by MG-RAST (5 > 10 BR and 5 < 10 BR).  
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways were generated 
and the samples were split into aetiological subgroups according to their 
associated clinical data (paediatric CF, adult CF, < 10 BR and > 10 BR). This 
was done in order to allow for more pertinent observations to be drawn. The 
KEGG pathways are shown in figure 6.4. These pathways allowed identification 
of the ‘incidence’ of DNA sequences which shared similarity to a known 
metabolic pathway, for each of the clinical aetiological groups. Figure 6.4 
describes the KEGG atlas maps for the stratified phage metagenomes. Similar 
256 
 
regions are illuminated in all the maps so potentially indicating that these relate to 
essential cellular functions. It was also apparent when studying these maps that 
the < 10 BR map showed the lowest number of gene targets for putative 
functionality, this could be related to the naivety of these phages however, the 
previously mentioned caveat needs considering alongside this data. This naivety 
has been shown in the previous chapters so this result is not unexpected. All the 
associated raw KEGG derived values are shown in appendix 11. Tariq and 
Everest et al (2015) have previously published the figures for both the KEGG 
pathways and the images conferring a putative function for each of the clinical 
metagenomes.  
Figure 6.5 details the increase in putative functionality; these related hits were 
seen to increase with patient age/disease severity. The highest numbers of 
putative identifications were seen in the phage metagenomes from the adult CF 
and > 10 BR patients. The < 10 BR phage metagenomes display the lowest 
number of putative functionality hits which may correlate to the naivety of this 
particular phage and P. aeruginosa cohort.  
Figure 6.6 stratifies the metagenomic dataset according to defining areas of 
physiology on the KEGG atlas whilst also stratifying the data according to the 
specific clinical aetiologies. KEGG pathway analysis allows for identification of 
specific gene regions and these identifications can be linked to functional 
pathways related to both metabolism and signalling. Metagenomic analysis has 
shown that functionality increases in complexity in accordance with disease 
progression. This supports previous findings in this thesis which have shown that 
the adult CF phages are the most infective and that this infectivity may be due to 
an additive effect of multiple phages residing within a P. aeruginosa genome. 
However, as there is no clinical data regarding the initial colonisation time of 
each patient with P. aeruginosa then care needs to be taken when drawing 
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conclusions such as these. Previous work has also shown that the > 10 BR 
phages are the most infective in the BR cohort. Again, this is perceived to be a 
result of elevated complexity due to disease progression and longevity. The 
previously mentioned caveat should also be applied in this instance prior to 
conclusions being drawn.  
Due to the nature of the KEGG atlas maps being utilised for this analysis, it is not 
possible to determine the amount of hits relating to a particular pathway though. 
The analysis just indicates that the phage metagenomes under investigation 
share some similarity with specific pathways and genes located on the KEGG 
atlas. The results are just an indication of the possible pathways present/absent 
in the various phage metagenomes. The metagenomes are stratified according 
to the clinical aetiological data in order for trends and patterns to be observed 
which may be indicative of the phages residing in the P. aeruginosa populations 
isolated from the different patient subgroups.  
Glycan biosynthesis and metabolism is elevated in the most evolved phage 
metagenomes, showing that these phages may have had to evolve in order to 
offer the bacteria the ability to metabolise glycans to allow for persistence within 
the chronic lung. This finding has been previously shown by Simpson et al (2015) 
this study showed that phage harboured a large reserve of glycan binding 
proteins and hydrolysing proteins which may provide the host with an 
evolutionary advantage and aid persistence within the lung (Simpson et al., 
2015). 
Another putative KEGG functionality hit that follows this pattern is mechanism of 
cofactors and vitamins. Again, this suggests that complex phages may have 
evolved in order to metabolise additional metabolites, which may aid the long 
term colonisation and persistence of phages within the chronic lung.  
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The BR phage metagenomes showed higher incidence for sequences relating to 
energy metabolism compared to the CF metagenomes. Upon analysis of the 
KEGG pathway map, (figure 6.4) the pathways that are involved in energy 
metabolism were seen to be different between the BR and CF phage 
metagenomes. So this would indicate that the phages from the two clinical 
aetiologies are utilising different energy metabolism pathways. This finding is in 
contrast to the reduced growth profiles seen for the BR lysogens in chapter 4, 
although this may relate to the environment that the bacteria and phage are co-
evolving in.   
Another putative functionality pathway that is enriched in BR phage 
metagenomes is the biosynthesis of other secondary metabolites. It is possible 
that these metabolites are involved in the changes in antibiotic tolerance seen in 
chapter 4. Therefore, these metabolites may potentially aid the phage’s 
conversion and long term survival of their bacterial host. As seen in chapter 5, a 
broad spectrum antibiotic, NTZ was isolated from a BR patient and this may be 
an example of secondary metabolite which aids P. aeruginosa survival and 
colonisation within the BR lung.  
Sequences identified which are related to xenobiotic degradation were seen at 
the highest levels in the adult CF phage metagenomes, possibly showing that the 
phages have evolved functions to degrade xenobiotic’s as a consequence of the 
constant bombardment of the CF lower lung with antimicrobials and antibiotics. 
Xenobiotic degradation is the breakdown of xenobiotics which include antibiotics 
and antimicrobials. It may be advantageous for the phages to harbour functions 
relating to this degradation as it will aid their persistence within the CF lung whilst 
also aiding P. aeruginosa persistence within the CF lung.  
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Figure 6.6 also shows equal levels of sequences relating to lipid metabolism in all 
the phage metagenomes with the exception of the < 10 BR phage. This may be 
explained by the naïve nature of the < 10 BR phages. This pattern is also seen in 
carbohydrate metabolism. Interestingly, the proposed less adapted < 10 BR 
phage metagenomes identified no sequences homologous to amino acid 
metabolism. 
Metabolism of Terpenoids and Polyketides is low in all the phage metagenomes, 
so potentially showing that these secondary metabolites may not be utilised by 
phages and bacteria when surviving and evolving in the chronic lung. 
Sequences relating to nucleotide metabolism were lowest in the > 10 BR phage 
metagenomes. This is considered unusual, as we would expect an elevated 
complexity in this later stage disease. These phages may however, utilise 
different pathways or these phages are totally dependent upon host cell 
machinery for their replication. 
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Figure 6.4: KEGG pathway maps for the 82 phage metagenomes stratified 
according to clinical aetiologies. The pathways are generated via the KEGG function 
on MG-RAST. All the pathways indicated show regions of DNA similarity between the 
phage metagenomes and known functional pathways on the KEGG atlas.  
The blue lines indicate when a region of similarity has been observed between the phage 
metagenomes and the KEGG pathway. The circled area’s indicate where large 
differences are observed between the phage metagenomes when studying paediatric CF 
v’s adult CF and < 10 BR v’s > 10 BR.  
Panel 1 describes the metagenomes for the paediatric CF phages, panel 2 describes the 
metagenomes for the adult CF phages, panel 3 describes the metagenomes for the <10 
BR phages, and panel 4 describes the metagenomes for the >10 BR phages.  
The adult CF phage metagenomes have an increase in pathway similarities for amino 
acid metabolism and energy metabolism particularly oxidative phosphorylation, these 
regions are not apparent in the paediatric phage metagenomes so indicating a possible 
evolutionary event has occurred. The > 10 BR phage metagenome is more enriched in 
pathways with similarities to amino acid metabolism and carbohydrate metabolism as 
described by the highlighted areas on the KEGG pathway map.  
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Figure 6.5: Total KEGG putative function identifications derived for the phage 
metagenomes when stratified according to clinical aetiology. Each putative 
functional pathway is represented as a single identification regardless of the amount of 
times that the putative function may have been conferred in each of the clinical 
subgroups (Tariq et al., 2015). Number in this figure refers to the number of 
identifications observed for each clinical subgroup, exact numbers are not possible to 
elucidate however.   
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Figure 6.6: Incidence of amino acid similarity to KEGG functional pathways 
generated through MG-RAST. The functional pathways are characterised according to 
their location on the KEGG atlas and the data is also further subdivided according to the 
clinical aetiologies of the phage metagenomes. Each putative functional pathway is 
represented as a single identification regardless of the amount of times that the putative 
function may have been conferred in each of the clinical subgroups. The functional 
information inferred from these KEGG pathways can be used to confer possible 
functionality differences between the phage metagenomes and relate these back to 
information relating to the various clinical aetiologies (Tariq et al., 2015). Number in this 
figure refers to the number of identifications observed for each clinical subgroup for each 
section of the atlas map, definitive numbers of identifications can’t be concluded from this 
data though. 
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6.5. DISCUSSION 
Various DNA purification techniques were undertaken in order to generate the 
purest and highest quantity DNA yield possible for the phage lysates involved in 
this investigation. The NORGEN phage DNA isolation kit was eventually chosen 
after assessing two other DNA extraction protocols for their ability to remove 
contaminating P. aeruginosa chromosomal DNA. This contamination was 
determined via PCR amplification of the V3 region of the 16S rRNA gene of P. 
aeruginosa (Muyzer et al., 1993, Chakravorty et al., 2007).  
The original PEG8000 method of purification has been previously used to purify 
phage DNA. Rooks et al (2010) showed that the Q gene could be amplified after 
serial dilutions of purified ϕ 24B phage lysates post PEG8000 purification. The 
amplification of this gene following multiple serial dilutions showed that the PCR 
process was as sensitive as a traditional plaque assay for identifying individual 
24B phage particles. This finding by Rooks et al (2010) supports the QUBIT 2.0 
read out value of 0.000 ng/µL as it shows that the phage can be amplified even 
when the amount of the phage DNA present is negligible. These two 
observations would lead to two hypotheses being drawn. Firstly, that PEG8000 
can purify phage DNA but at incredibly low levels and secondly, that the PCR 
amplification of the Q gene was dependant on the sensitivity of the PCR assay 
rather than large amounts of phage DNA being present post PEG8000 
processing (Rooks et al., 2010). 
The PEG8000 method initially was developed for use with high titre phage stocks 
whereas, this investigation was based upon phage induction rates which may 
produce suboptimal phage titres (Sambrook et al., 1989). Plaque purification and 
amplification could not be utilised in this investigation as the mixed phage 
community was under investigation and plaque purification focuses upon single 
phage purifications. These assays also require a sensitive bacterial host to 
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propagate on. Any remaining bacterial chromosomal DNA was negated from the 
culture post sequencing via the use of the Khmer toolkit (Brown et al., 2012, 
Tariq et al., 2015). This toolkit removes error khmers which appear as low level 
sheared DNA and thus, can be removed from the sample. 
After DNA isolation and sequencing on the Illumina MiSeq (NU-Omics, 
Northumbria University at Newcastle, UK), the DNA was subjected to 
metagenomic analysis. No single gene is common to all viral species as 
previously mentioned - so metagenomics was utilised in order to potentially 
identify and confer functionality to all the phage particles present in the lung 
microbiome (Edwards and Rohwer, 2005). Tariq and Everest et al (2015) 
reported the first use of metagenomics to identify inducible mixed temperate 
phage communities induced from P. aeruginosa isolates which colonised the 
lungs of CF and BR patients; some of the data is presented here. MG-RAST was 
used to undertake the analysis on the metagenomes of these mixed temperate 
phage lysates. Upon the generation of KEGG atlas maps, there was a clear 
observation that the complexity of the metagenomes related to an increase in 
patient age (CF) or length of time since diagnosis (BR).  
The finding that the adult CF phage metagenomes had the highest number of 
putative KEGG pathway incidences supports previously described work in this 
thesis, which has shown that the CF phages are the most infective and capable 
of causing infection in a broad P. aeruginosa host range (chapter 3). It is possible 
to premise that this previously described elevation in host range and infectivity 
may be linked to the phage metagenome. KEGG pathways can also be used to 
confer possible functionality to DNA sequences which exhibit similarity to known 
metabolites and metabolic pathways (Tariq et al., 2015).  
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KEGG pathways in this instance were used to identify specific functional traits 
that may link the metagenomic profiles of the phages to disease severity and 
progression. As disease progresses in both CF and BR patients, an increase in 
DNA incidences relating to the KEGG atlas section; glycan biosynthesis and 
metabolism, was seen in the mixed phage metagenomes. Due to mucociliary 
defects and CFTR mutations (Knowles and Boucher, 2002, Matsui et al., 1998, 
Pilewski and Frizzell, 1999, Holmén et al., 2004), the CF lung contains a large 
amount of human produced mucins which are covered in glycans. Mucins are 
massive glycoconjugates that in CF patients are composed of ~ 80 % 
carbohydrate and these mucins form O-linked glycans. Mucus and the 
associated mucins in healthy people are much less complicated and contain 
fewer cellular components (Moniaux et al., 2001, Holmén et al., 2004, Rubin et 
al., 1990, Voynow et al., 2006).  
P. aeruginosa binds to mucin glycans via lectins specifically PA-IL and PA-IIL 
which bind to galactose and fucose/mannose glycoproteins, respectively. PA-IL 
is a 51 kDa protein (Gilboa-Garber et al., 1972, Winzer et al., 2000) and PA-IIL is 
a 47 kDa protein (Gilboa-Garber, 1986, Gilboa-Garber et al., 2000, Winzer et al., 
2000). These lectins regulated by the quorum sensing system in P. aeruginosa 
and they are co-expressed with other virulence factors. Lectins can therefore, be 
proposed to be virulence factors due to their ability to bind to carbohydrates and 
so retain P. aeruginosa within an environment (Gilboa-Garber, 1983, Jørgensen 
et al., 1999, Gilboa-Garber, 1997, Winzer et al., 2000).  
It is possible to propose that phage metagenomes have evolved functions 
relating to glycan biosynthesis in order to elevate the potential binding sites 
available for P. aeruginosa lectins therefore, promoting bacterial longevity in the 
lower lung along with the associated phage longevity and survival. Winzer et al 
(2000) stated that cell density and the age of the bacterial culture altered glycan 
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synthesis, so it is pertinent to mention that the phage metagenomes which were 
the most enriched for putative functionality hits relating to glycan biosynthesis 
were observed in the phages originating from adult CF and > 10 BR patients. 
The observation of putative functions in the phage metagenomes relating to 
glycan biosynthesis may show that phages are involved in driving the generation 
of glycans in the lower lung thus, providing the bacterial-phage communities with 
a selective advantage in order for them to persist within the lung microbiota 
(Tariq et al., 2015).  
In contrast to the BR phage metagenomes, the CF phage metagenomes were 
completely devoid of incidences relating to ‘metabolism of other secondary 
metabolites’. This may indicate that the phages colonising the CF lung are 
incredibly well adapted to survive within this environment and do not require 
other metabolites aside from those which are found within this community.  
Through utilising KEGG pathways and by conferring putative functions to the 
metagenomes, it was observed that there was an elevation in the xenobiotic 
degradation atlas class which again related to an increase in disease severity in 
CF and BR patients. Winstanley et al (2009) showed that P. aeruginosa isolates 
originating from the CF lung had a fluctuating antibiotic resistance profile and this 
is supported by these data presented in this thesis. Variation in P. aeruginosa 
antimicrobial resistance has been shown in numerous studies and they have also 
shown how sub-optimal antibiotic treatment can also change the antimicrobial 
resistance profiles of P. aeruginosa (Mowat et al., 2011, Ashish et al., 2013, 
Wright et al., 2013). These data showed that the adult CF phage metagenomes 
exhibited the highest putative functionality hits relating to xenobiotic degradation. 
It is possible to premise that due to the constant bombardment of antibiotics, 
phage metagenomes have evolved to encode for resistance to antibiotics thus, 
enhancing their survival potential in this adverse niche. This finding also relates 
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to data presented in chapter 4 where it was seen that the CF lysogens exhibited 
greater antibiotic tolerance results in respect to the naïve PAO1 host thus, 
proposing that the phage metagenome alone may be influencing this alteration in 
tolerance.  
This elevation in complexity in the phage metagenomes could elucidate that 
extensive interplay is occurring between phage and bacterial communities within 
the chronic lung. The increase in complexity relating to disease progression 
could potentially indicate that adaptation is occurring in ‘real time’ within the lung. 
The phage metagenomes may have therefore, evolved in order to only harbour 
beneficial selective advantages and have lost the more costly genomic functions. 
The work described by Tariq and Everest et al (2015) and presented here shows 
that adaptation is occurring in phage metagenomes alongside their P. aeruginosa 
hosts. 
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7. DISCUSSION 
Microbial disease is multi-factorial and therefore, multiple approaches need to be 
utilised to try to understand the biology of disease and how it progresses. 
Through environmental changes in the lung from both a congenital and acquired 
chronic lung disease, there are progressive rounds of inflammation and the 
continuous generation of scar tissue which inhibits normal mucocilliary action. 
These changes and a constantly evolving mucus-rich environment means that 
bacteria need to adapt to in order to stay in this niche. Opportunistic bacteria like 
Pseudomonas aeruginosa (P. aeruginosa), readily colonise the Bronchiectasis 
(BR)/ Cystic Fibrosis (CF) lung as mentioned in section 1.4.  
The continuing interaction between bacteriophages and their bacterial hosts 
provides variation within this environmental niche either due to temperate phage 
infection and their integration into the bacterial chromosome or through phage’s 
ability to drive recombination events in the lung microbiota via single stranded 
DNA recombinases which are readily carried by lambdoid-like phages 
(Brockhurst et al., 2005). This interaction is thought to be antagonistic but it is in 
some way also symbiotic, as each biological entity evolves and adapts within the 
chronic lung, this is an example of the red queen hypothesis occurring within the 
lung microbiota (Stern and Sorek, 2011, Van Valen, 1973, Lenski and Levin, 
1985, Schaffer and Rosenzweig, 1978, Dawkins and Krebs, 1979).  The bacterial 
hosts evolve in order to overcome the threat of phage infection through the 
generation of alternative phage adsorption sites (section 1.6.1.1.) or through 
adaptation to overcome host defence systems (section 1.6.5.). The phages can 
also develop new strategies to increase the likelihood of subsequent phage 
infections through the subversion of bacterial host defence systems. This 
increase in environmental fitness of the bacterium offers negative clinical 
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outcomes for the patient as the P. aeruginosa infections become increasingly 
difficult to treat (Hart and Winstanley, 2002). 
The aim of this research was to characterise the role that temperate 
bacteriophages play in the progression of CF and BR. The temperate 
bacteriophages involved in this investigation were induced from 94 clinical P. 
aeruginosa isolates [paediatric CF patients (n = 10), adult CF patients (n = 37), < 
10 BR patients (n = 17) and > 10 BR patients (n = 30).] This thesis focused on 4 
separate areas of biology in order to look at the interactions of phages and their 
P. aeruginosa hosts, for ease the data has been split into 4 subgroups according 
to patient data.  
Chapter 3, focused upon the interaction between mixed P. aeruginosa phage 
lysates induced from single bacterial isolates and how they interacted with the 
complete panel of P. aeruginosa clinical isolates. This was completed through 
the use of a large scale cross-infection study, which is the largest of its kind 
mentioned in the literature for P. aeruginosa. A key driver of this chapter was to 
determine how the infectivity profiles of the phages and the sensitivity of P. 
aeruginosa isolates towards phage infection altered alongside disease 
progression. However, disease progression doesn’t always link with an increase 
in P. aeruginosa colonisation time.  
This work is novel for two reasons, firstly due to the large scale nature of the 
investigation and secondly, because it utilised mixed temperate phage 
communities. These mixed phage communities are a cell’s entire repository of 
viruses that can be induced and infect other bacterial isolates. Using the mixed 
temperate bacteriophage load may produce results which are more indicative 
and representative of the chronic lung and so therefore, more weight can be 
given to the findings presented in chapter 3.  
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It was determined that the phages isolated from the older patients (adult CF and 
> 10 BR) had greater infectivity profiles compared to the more naïve P. 
aeruginosa isolates. When investigating bacterial sensitivity to phage infection, it 
was observed that similar sensitivity profiles were seen for the P. aeruginosa 
isolates regardless of the clinical origin of the phage lysate. This may indicate 
that a complex co-evolution is occurring which could indicate that the bacterium 
and phage are both equally infective and susceptible thus, ensuring the survival 
of both entities within the chronic lung environment. Buckling and Rainey (2002) 
showed antagonistic co-evolution occurring between bacteria and phage, this 
study is supported by these data presented in chapter 3.  
Chapter 3 also presented some of the data published in Tariq and Everest et al 
(2015). It was shown that the phages isolated from P. aeruginosa isolates 
originating from the later disease stages had the greatest capabilities to re-infect 
their originating bacterial hosts and this finding was contrasted in the more naïve 
P. aeruginosa derived phages (Tariq et al., 2015). The ability of a large subset of 
these phages to re-infect their originating host does not conform to the typical 
lambda model of phage infection. Fogg et al (2010) reviewed the lambda phage 
model, this model states that upon phage infection the infected bacterium is 
immune to further phage infection events including re-infection by the same 
phage. The re-infection model of phage infection shown in this chapter has also 
been shown by Allison et al (2003) when studying the Escherichia coli (E. coli) 
phage 24B.  
In order to determine whether these phage infectivity and bacterial sensitivity 
profiles were due to the additive effect of multiple phage incorporation into the 
bacterial chromosome or due to a single predominant phage, we decided to 
generate plaque purified phages of the predominant phage species from 20 P. 
aeruginosa isolates. Polylysogeny has previously been seen in other P. 
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aeruginosa isolates such as LES which allowed the assumption that the P. 
aeruginosa isolates in this study were also polylysogens (Winstanley et al., 
2009). 5 P. aeruginosa isolates originating from each clinical aetiological 
subgroup were utilised in order to generate lysogens within a PAO1 backbone. 
These lysogens were compared against the non-lysogenic strains and 
differences in the infectivity profiles were observed.  
The mixed phage P. aeruginosa isolates showed greater infectivity profiles 
compared to the plaque purified phages thus, enforcing the importance of 
polylysogeny in these clinical P. aeruginosa isolates. Polylysogeny is often 
overlooked within the chronic lung setting where only recent investigations are 
beginning to show its importance. However, James et al (2015) showed that 
there was a high prevalence of free temperate bacteriophages in CF sputum and 
so these phages may also influence interactions seen in the CF lung. These 
observations therefore, are novel but they also provide further indications of the 
future challenges which will need to be faced when treating phage infected P. 
aeruginosa isolates (James et al., 2015).  
Chapter 4 focused on a subset of the PAO1 lysogens generated in chapter 3 to 
allow for more detailed analysis to be undertaken to elucidate changes that occur 
in the bacterium’s phenotype upon prophage inclusion. It has previously been 
shown that lysogenic strains of E. coli have an elevated growth rate in the lab, 
but this is one of the first instances where an elevation in growth rate has been 
shown in clinical P. aeruginosa lysogens (Edlin et al., 1977, Edlin et al., 1975, Lin 
et al., 1977).  
The lysogen which exhibited a reduction in bacterial growth was elucidated to 
harbour a prophage region originating from a < 10 BR phage. In chapter 3, it was 
identified that the P. aeruginosa isolates isolated from the < 10 BR patient cohort 
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had lower infection profiles and reduced bacterial sensitivity. It is possible to 
assume that this phage upon prophage formation may be integrating into a site 
on the chromosome that is deleterious to cell physiology and function. Another 
reason which may explain this deviation away from the trend may be that this 
phage has evolved in an environment where an elevation in the growth rate of 
the bacterial host is not essential thus, this phage has an alternative evolutionary 
strategy. When excluding this lysogen, it is possible to propose that the other 
phages maybe providing their bacterial hosts with a selective advantage. As an 
elevated growth rate may allow for the rapid establishment of a P. aeruginosa 
community within the lower lung. So it is possible to premise that this selective 
advantage enables P. aeruginosa to become the predominant bacterium in the 
CF/BR lung.  
Research undertaken in chapter 6 describes that P. aeruginosa phages increase 
the metabolism of their host cells, so it is possible to hypothesis that this in turn 
drives the enhanced growth of the lysogenic strains. With increased rates of 
growth, there would be increased rates of host cell lysis. Metabolites released 
from these lysing cells into the surrounding environment could also potentially 
enhance the growth of the other cells residing in the community through alternate 
carbon turnover. These increased metabolites will also create an environment 
which is nutrient rich and so therefore, twitching motility may be elevated. 
Twitching may be elevated in a nutrient rich environment due to the large amount 
of metabolites available for the bacterium, the data presented here utilised LB 
media and this is a nutrient rich environment. So the data presented here is 
indicative of a nutrient rich environment.  
Another advantage that the lysogens exhibited over the naïve PAO1 control was 
an elevation in tolerance to clinically relevant anti-pseudomonal antibiotics, again 
shown in chapter 4. Even though the antibiotics administered in this investigation 
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were at levels which are lower than the therapeutic dose of the drug, the 
pharmacokinetic profile of the CF/BR lung is poor and this provides clinicians 
with serious treatment problems. The thick mucus layer alongside damaged 
tissue could allow for resistance to build up in a small subset of the bacterial 
population because certain areas wouldn’t be encountering antibiotics at optimal 
levels (Wright et al., 2013).  
This resistance would therefore, increase the number of sensitive hosts for the 
phages thus, supporting their survival within the chronic lung. As antibiotic 
resistance is often chromosomally linked, resistance profiles within the bacterial 
community will change through selection. The increase in tolerance may have 
serious downstream consequences, as it could potentially indicate that 
suboptimal treatment of a bacterial infection will enhance the spread of phages 
around a particular niche due to the increased number of sensitive hosts which 
have not been eradicated through effective antibiotic treatment. The observation 
of polylysogeny occurring within these P. aeruginosa isolates is pertinent to 
mention here. To support this statement, this study has shown that a subset of P. 
aeruginosa isolates harboured multiple phages and these multiply infected 
isolates could potentially increase the spread of phage encoded resistance within 
a bacterial community. This has previously been seen and this led to the 
development of a P. aeruginosa strain (Liverpool Epidemic Strain/LES) which is 
resistant to entire classes of antibiotics (Ashish et al., 2012). It has also been 
shown that lysogenic strains have elevated growth rates therefore, these 
resistant bacterial cells would be able to successfully colonise a new niche thus, 
spreading antibiotic resistance.   
The ability of CF lysogens to generate a small change upon normalisation for 
growth allows assumptions to be drawn that the CF phages can manipulate their 
host cells in such an effective way that the phages are in essence driving the 
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increase in antibiotic tolerance observed in chapter 4. In chapter 6, it was seen 
that the phage metagenomes for the adult CF phages had the highest incidence 
rate for metagenomes relating to ‘xenobiotic degradation’. The metagenomic 
data supports the MIC profiles as they indicate that the CF phages can effectively 
clear antibiotics from an environment and so this would warrant the small change 
upon normalisation for growth. The BR phages generate a large change in 
tolerance upon normalisation for growth and it is proposed that this is because 
these phages can’t manipulate their host cells as effectively as the CF phages.   
Chapter 3 as mentioned previously showed that there were differences in the 
phage infectivity and bacterial sensitivity profiles. In order to determine whether 
there were any phenotypic differences in the P. aeruginosa isolates which 
potentially may drive these infectivity and sensitivity differences, chapter 4 looked 
to study the type IV pili. These appendages were studied as it has been 
described in previous studies that P. aeruginosa phages target the pili for 
adsorption and infection (Feary et al., 1964, Bradley and Pitt, 1974, Bradley, 
1973c, Olszak et al., 2015, Mattick, 2002). Chapter 4 looked at molecular 
characterisation of these regions and the presence/absence of the type IV pili on 
the P. aeruginosa hosts was determined via polymerase chain reaction (PCR) 
amplification.  
It was hypothesised that in accordance with previously published studies the BR 
isolates would be the most motile and the CF isolates would be the least motile, 
as motility has been perceived as an unnecessary and costly process for these 
bacterial isolates to retain (Mahenthiralingam et al., 1994, Burke et al., 1991). 
These data presented in chapter 4 supported the proposed hypothesis that the 
BR P. aeruginosa isolates would exhibit greater motility compared to the CF P. 
aeruginosa isolates (Mahenthiralingam et al., 1994).  
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The paediatric CF phages were in fact less motile than the adult CF isolates 
when the distribution of motility was studied and this finding is in contrast to work 
shown by Kus et al (2004). It is pertinent to mention however, that the paediatric 
CF cohort used in this thesis has a low sample number (n = 10) and so the small 
cohort size may influence the results generated.  
70 % of the P. aeruginosa isolates had type IV pili genes which were detectable 
via PCR amplification thus, potentially indicating the importance of these 
appendages for bacterial survival within the lung. However, these appendages 
may be detectable by PCR but the bacterium may not be motile due to other 
genetic alterations. When self-induced phage was added to the assays, there 
was not a consistent increase in motility or a consistent decrease. Phages are 
known to utilise the tRNA site (Ochman et al., 2000, Ritter et al., 1995, Inouye et 
al., 1991) as a receptor site, this lead to the proposal that in some instances 
phage incorporation can be beneficial for the bacterial isolates. However, in 
some instances it was observed that the addition of a phage decreased twitching. 
This would lead to the assumption that the phages may have incorporated into 
an essential motility gene thus, preventing bacterial movement. It is also possible 
that phage incorporation has increased the genetic size of the bacterium which 
has had a detrimental effect on the bacterium.  
In order to confer as much depth to our knowledge about these clinical P. 
aeruginosa isolates, it was decided to focus a chapter of this thesis (chapter 5) 
on metabolomics. The aim was to determine whether there were specific 
metabolites which could perceivably drive the biological phenotypes observed in 
the previous chapters. A key point was to determine whether these phages 
brought any new metabolites to the system which would influence the phage 
biology results seen in the previous chapters.  
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Alongside metabolomics, it was possible to utilise metabolism studies to 
determine the impact on respiration which may be caused by phage infection and 
to see how this respiration is altered during pellicle formation. XTT results 
showed that phage addition to a pellicle culture could increase the respiration of 
the bacterial community residing within the pellicle. However, this observed 
increase was not always statistically significant. It was proposed that the time 
points used in these assays may have influenced the results seen as the initial 
harvesting step was post 24 hours of pellicle formation. The selection of this time 
point may have been too late in the developmental process in order to allow for 
the observations of significant metabolism alterations. In conclusion, we 
hypothesised that the mixed phage communities alter the metabolism of their P. 
aeruginosa host bacterium but the amount depends upon the bacterial isolate.  
The pellicle cultures derived from CF P. aeruginosa isolates were more 
metabolically active on average compared to the pellicle cultures from the BR P. 
aeruginosa isolates. These findings are in accordance with the results shown in 
the previous chapters which indicate that the CF phages are the most adapted to 
co-evolve alongside P. aeruginosa. When observing the effect that phage 
addition had on pellicle formation, the addition of exogenous adult CF phage (24) 
was seen to cause the most significant elevation in respiratory metabolism. It 
may be assumed that this increase in respiration maintains both the phage and 
the bacteria within an environment that mostly consists of biofilm communities.  
The metabolomic part of chapter 5 was focused upon the pellicle formation 
process utilising the lysogens generated and studied in chapter 4. Cell counts 
generated quantitative data to support the findings seen in the metabolomics 
study. An increase in cell number was determined through these counts, and this 
indicated that any differences observed in the metabolomic profiles were due to 
viable cells. As larger cell counts were detected as the pellicle formation process 
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continued, equal loading of the samples by dry weight excluded any bias in the 
analysis process.  
Both PLS-DA and oPLS-DA plots were utilised to show the maximum variation 
present in the metabolomic data in this thesis. Both models showed that when 
using the E. coli metabolome database (ECMDB), the lysogens formed discrete 
groups irrespective of their clinical origin. This led to us concluding that the 
lysogens had different metabolite profiles which were linked to the developmental 
stage of the pellicle and that the individual phages were not driving the diverse 
profiles observed. However, when studying the individual time points in more 
depth, it was observed that the adult CF lysogen had a metabolite profile which 
showed the maximum variation compared to the naïve PAO1 profile. This 
observation was apparent in all the data sets shown on the models and this 
finding supports work that has been previously shown in this thesis relating to the 
complexity of the adult CF phages.  
The previously described data has shown that the adult CF phages are the most 
adapted to co-evolve alongside P. aeruginosa and generate the greatest 
differences in phenotypic profiles compared to naïve controls. These metabolite 
profiles support these previous findings as they show that the metabolites 
generated by the adult CF lysogen are the most discrete compared to the control 
samples. The variation between the metabolite profiles was determined by the 
data point’s location upon the x-axis of both plots.  
The paediatric CF lysogen metabolite profile was also discrete compared to the 
control profile but the variation was reduced in relation to the adult CF lysogen. 
The metabolite profile which showed the least amount of variation was the < 10 
BR lysogen. Again this finding is in support of previous data presented in this 
thesis.  
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In order to confer putative functionality to the metabolites generated, a VIP plot 
was generated from the PLS-DA plot and it showed 41 possible metabolites of 
interest. When the data was analysed using the ECMDB, no metabolites were 
detected which were significant, had a CV of ≤ 5 and a mass error of +/- 1. The 
lack of detection of a putative metabolite is perceived to be a result of there being 
no specific database for P. aeruginosa metabolomic analysis. The mass error 
value of 1 was selected for this analysis as it gave added support and strength to 
any metabolite identifications.  
In order, to try and identify putative metabolites from the data presented in this 
chapter, the human metabolome database (HMDB) was utilised. However, no 
putative metabolites were detected using the previously described criteria but 
when the mass error was raised to +/- 2, there were 5 potential metabolites 
identified. Out of these metabolites identified, one appeared to warrant further 
investigation; Nitrofurazone (NTZ). However, in order to definitely confirm the 
presence of this metabolite MS/MS analysis would need to be undertaken 
because MS is not descriptive enough to allow for accurate metabolite 
identifications but MS/MS analysis was outside the remit of this thesis.  
This thesis has thus far described differences in phage infectivity profiles, 
bacterial sensitivity, re-infection capabilities of phages, polylysogeny, lysogenic 
growth alterations, phage-derived antibiotic tolerance, motility, metabolism and 
metabolomics. The final chapter of this thesis focused on the metagenomic 
profiles of the phages in order to generate genetic data to describe the results 
previously observed. The adult CF phages throughout the previous chapters 
have been shown to be the most adapted to a particular environment and drive 
the greatest differences in phenotypic outcomes. The < 10 BR phages by 
contrast have been shown to the least adapted. In this final chapter, a 
metagenomic approach was used to link the phages genetic profile to a particular 
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patient subgroup. Changes in genes with annotated functions were specifically 
targeted as these genes may provide some clues into what phages encode and 
how these genes may aid bacterial survival within the chronic lung.  
The metagenomics rapid annotations based on subsystem technology (MG-
RAST) online portal was utilised in order to try and confer putative functionality to 
the shotgun sequenced phage lysates. The data presented in chapter 6 was also 
presented by Tariq and Everest et al (2015). This chapter along with the 
publication showed that bacterial chromosomal DNA can be hard to negate 
completely from a viral DNA preparation and these data have shown the 
importance of bioinformatic analysis to clear contaminating DNA prior to phage 
metagenomic analysis being undertaken (Tariq et al., 2015).  
These data presented in chapter 6 described that the adult CF metagenomes 
harboured the highest number of genes with putative functionalities when 
comparing the sequence data to kyoto encyclopaedia of genes and genomes 
(KEGG) pathway maps generated by MG-RAST. This finding therefore, provides 
genetic data to support the previous phage biology data and the previously 
proposed hypotheses, that the phages become more complex in their infection 
capabilities and generate a broader host range as CF progresses. This finding 
has a key clinical interest as it may be possible through future work to alter 
certain areas of the phages metagenome in order to control their spread and 
infectivity within a P. aeruginosa population.  
When KEGG metagenomic profiles of CF and BR phages were analysed further, 
it was observed that the profiles altered according to the patient subgroup. The 
paediatric CF phage metagenomes showed reduced numbers of proposed 
identifications compared to the adult CF phage metagenomes thus, suggesting 
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that time may influences the genetic backbone of the phages which in turn drives 
the alterations previously observed in this thesis (Tariq et al., 2015).  
This alteration in the phage metagenomes was notable when studying the KEGG 
atlas section; glycan biosynthesis and metabolism (Tariq et al., 2015). In this 
atlas map, the CF phages in particular the adult CF phages were seen to be the 
most enriched for these functions. Notably, the CF lung contains a large amount 
of mucins which are covered in glycans to which P. aeruginosa can adhere. 
Therefore, the CF phages may have evolved to aid glycan metabolism which 
would promote long term bacterial survival and the associated phage survival. 
This relationship is another example of the antagonistic co-evolution as proposed 
by Buckling and Rainey (2002). 
This metagenomic chapter has potentially shown a ‘snapshot’ of phage evolution 
occurring within the lung. This evolutionary snapshot can be proposed because 
the metagenomes from the phages isolated from each clinical subgroup can be 
aligned next to each other and conclusions be drawn relating to their functionality 
profiles and the changes observed.  
This research thesis has shown that temperate bacteriophages have a role in 
bacterial disease and the progression and severity of chronic respiratory 
diseases. This investigation has tried to answer the following research question 
“are phages the new clinical challenge in the treatment of chronic respiratory 
diseases?” I believe that through all the work undertaken that it is possible to 
answer the question. The answer would be yes, temperate bacteriophages do 
provide the bacteria with an added level of complexity which may have an effect 
on clinical treatments both now and in the future.  
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Future Work: 
In order to further elucidate the relationships between bacteriophages and their 
bacterial host cells then a longitudinal study would be the ideal investigation to 
undertake and support the data presented in this thesis. A longitudinal study 
would allow the researcher to determine how the bacterial isolates evolve in 
order to prevent further phage infection whilst it would also allow a researcher to 
determine how phages have co-evolved to overcome these restrictions. It would 
be interesting to determine how the host range of the phages evolve and change 
throughout the course of the investigation whilst also observing ‘real time’ 
changes in the phages infectivity profiles.  
A large majority of this work has been based upon the formation of prophages so 
further work elucidating the integration sites for these phage particles may also 
be of importance. The integrases involved in the formation of the prophage could 
be determined and this would give us some genetic information relating to the 
replication capabilities of these phages. It would also allow us to determine how 
the phages integrate into the bacterial chromosome and the effect that 
integration may impose on the bacterium’s genetic profile as well as the 
phenotypic outcome. The P. aeruginosa isolates in this investigation have not 
been sequenced and this would be essential if this work was to progress further.  
This thesis has shown how the field of phage evolution is constantly evolving and 
how there are numerous new studies which can be undertaken in order to 
elucidate the effects that phages impose upon their bacterial host cells.  
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Appendix 1: Clinical data relating to the samples involved in this investigation 
CF sample ID Strain Information Adult / Paediatric Date of isolation Patient age upon 
isolation (years) 
Phenotype 
3 Same as 3 Adult 08.11.2010 32 Non mucoid 
5 Manchester Epidemic 
Strain 
Adult 09.11.2010 28 Non mucoid 
6 Liverpool Epidemic 
Strain 
Adult 09.11.2010 27 Non mucoid 
16 Leeds Epidemic Strain Adult 10.11.2010 25 Mucoid 
23 Same as CF63 Adult 15.11.2010 18 Non mucoid 
24 Same as CF183 Adult 15.11.2010 39 Non mucoid 
28 Liverpool Epidemic 
Strain 
Adult 18.11.2010 28 Non mucoid 
30 Same as CF30 Adult 17.11.2010 23 Non mucoid 
34 Liverpool Epidemic 
Strain 
Adult 18.11.2010 38 Non mucoid 
42 Same as CF121 Adult 22.11.2010 27 Non mucoid 
44 Cluster E Adult 24.11.2010 41 Non mucoid 
52 Unique Adult 26.11.2010 25 Mucoid 
54 Unique Adult 25.11.2010 17 Mucoid 
55 Unique Adult 25.11.2010 25 Non mucoid 
xix 
 
57 Unique Adult 25.11.2010 28 Non mucoid 
60 Unique Adult 26.11.2010 28 Non mucoid 
63 Same as CF23 Adult 27.11.2010 29 Non mucoid 
65 Clone C Adult 27.11.2010 27 Non mucoid 
67 Liverpool Epidemic 
Strain 
Adult 29.11.2010 24 Non mucoid 
72 Unique Adult 30.11.2010 27 Non mucoid 
74 Unique Adult 01.12.2010 33 Mucoid 
77 Same as nCFBR206 Adult 06.12.2010 33 Non mucoid 
78 Clone C Adult 06.12.2010 23 Mucoid 
79 Unique Adult 06.12.2010 33 Non mucoid 
81 Manchester Epidemic 
Strain 
Adult 08.12.2010 49 Mucoid 
118 Non defined cluster 2 Adult 25.02.2011 31 Non mucoid 
121 Same as CF42 Adult 25.02.2011 19 Non mucoid 
125 Unique Adult 16.02.2011 59 Non mucoid 
126 Matches another local 
CF 
Adult 16.02.2011 29 Non mucoid 
127 Unique Adult 18.02.2011 29 Non mucoid 
136 Manchester Epidemic 
Strain 
Adult 02.03.2011 24 Non mucoid 
140 Same as CF208, Adult 02.03.2011 36 Non mucoid 
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CF214 and nCFBR53 
142 Manchester Epidemic 
Strain 
Adult 02.03.2011 30 Non mucoid 
145 Leeds Epidemic Strain Adult 04.03.2011 44 Non mucoid 
177 Midlands – 1 Epidemic 
Strain 
Adult 26.04.2011 38 Non mucoid 
183 Same as CF24 Adult 10.05.2011 39 Mucoid 
211 Matches another local 
CF 
Adult 23.09.2011 29 Non mucoid 
47 Same as CF70 Paediatric 24.11.2010 16 Non mucoid 
53 Unique Paediatric 25.11.2010 4 Mucoid 
69 Unique Paediatric 30.11.2010 10 Non mucoid 
70 Same as CF47 Paediatric 30.11.2010 17 Mucoid 
124 Unique Paediatric 22.02.2011 10 Non mucoid 
165 Same as CF187 Paediatric 24.03.2011 1.8 Mucoid 
187 Same as CF165 Paediatric 20.05.2011 2 Mucoid 
208 Same as CF140, 
CF214 and nCFBR53 
Paediatric 08.07.2011 15 Mucoid 
213 Matches another local 
CF 
Paediatric 16.09.2011 14 Non mucoid 
214 Typing currently Paediatric 11.11.2011 4 Non mucoid 
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BR sample ID Strain Information > 10 / < 10 BR Date of isolation Patient age upon 
isolation (years) 
Phenotype 
52 Unique > 10 06.08.2008 56 Mucoid 
53 Same as CF140, 
CF208 and CF214 
> 10 06.08.2008 88 Mucoid 
58 Unique > 10 12.08.2008 44 Mucoid 
136 Unique > 10 13.10.2010 64 Mucoid 
141 Unique > 10 12.01.2011 71 Mucoid 
143 Same as nCFBR123 > 10 12.01.2011 68 Non mucoid 
144 Unique > 10 02.02.2011 61 Mucoid 
146 Unique > 10 02.02.2011 72 Mucoid 
153 Unique > 10 15.03.2011 62 Mucoid 
161 Unique > 10 13.06.2011 65 Mucoid 
177 Unique > 10 14.07.2011 61 Non mucoid 
178 Clone C > 10 12.07.2011 56 Mucoid 
181 Unique > 10 13.07.2011 64 Non mucoid 
195 Unique > 10 14.07.2011 75 Non mucoid 
197 Unique > 10 20.07.2011 74 Non mucoid 
199 Unique > 10 20.07.2011 27 Non mucoid 
200 Same as another 
nCFBR 
> 10 21.07.2011 78 Non mucoid 
201 Unique > 10 20.07.2011 78 Mucoid 
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204 Cluster A > 10 20.07.2011 70 Non mucoid 
205 Same as another local 
CF 
> 10 27.07.2011 61 Non mucoid Non 
mucoid 
208 Unique > 10 26.07.2011 61  
213 Unique > 10 25.07.2011 64 Non mucoid 
222 Same as another local 
CF 
> 10 28.07.2011 33 Non mucoid 
228 Unique > 10 27.11.2011 60 Non mucoid 
243 Clone C > 10 30.08.2011 60 Non mucoid 
244 Clone C > 10 31.08.2011 76 Non mucoid 
285 Not typed > 10 23.09.2011 68 Mucoid 
313 Not typed > 10 17.20.2011 38 Mucoid 
322 Not typed > 10 27.10.2011 74 Non mucoid 
326 Not typed > 10 02.11.2011 73 Mucoid 
59 Unique < 10 12.08.2008 83 Mucoid 
123 Same as nCFBR143 < 10 20.05.2010 74 Non mucoid 
133 Unique < 10 11.08.2010 82 Mucoid 
150 Unique < 10 04.03.2011 56 Mucoid 
152 Unique < 10 15.03.2011 85 Mucoid 
193 Unique < 10 21.07.2011 87 Mucoid 
206 Same as CF77 < 10 27.07.2011 59 Mucoid 
227 Unique < 10 02.08.2011 81 Non mucoid 
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233 Not typed < 10 04.08.2011 87 Mucoid 
293 Not typed < 10 27.09.2011 72 Non mucoid 
299 Not typed < 10 11.10.2011 80 Non mucoid 
298 Not typed < 10 12.10.2011 87 Non mucoid 
319 Not typed < 10 04.11.2011 60 Non mucoid 
320 Not typed < 10 02.11.2011 63 Non mucoid 
327 Not typed < 10 04.11.2011 81 Mucoid 
331 Not typed < 10 11.11.2011 78 Mucoid 
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Appendix 2: Clinical history of the BR patients 
 
Strain ID > 10 / < 10 BR Clinical history 
52 > 10 Ulcerative colitis 
53 > 10 Idiopathic 
58 > 10 Idiopathic 
136 > 10 Rheumatoid arthritis 
associated 
141 > 10 Idiopathic 
143 > 10 Measles 
144 > 10 Idiopathic 
146 > 10 Rheumatoid arthritis 
associated 
153 > 10 Post infectious 
161 > 10 Pink’s disease 
177 > 10 Wegener’s 
178 > 10 Idiopathic 
181 > 10 Specific antibody deficiency 
195 > 10 Post infectious 
197 > 10 Asthma 
199 > 10 Primary ciliary dyskinesia 
200 > 10 Idiopathic 
201 > 10 Idiopathic 
204 > 10 Colitis 
205 > 10 Idiopathic 
208 > 10 Idiopathic 
213 > 10 Pinks 
222 > 10 Idiopathic 
228 > 10 Idiopathic 
243 > 10 Post infectious (childhood 
pneumonia) 
244 > 10 Post infectious (childhood 
pneumonia) 
285 > 10 Idiopathic 
313 > 10 Idiopathic 
322 > 10 Idiopathic 
326 > 10 Post infectious 
59 < 10 Idiopathic 
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123 < 10 Asthma 
133 < 10 Idiopathic 
150 < 10 Post infectious 
152 < 10 Idiopathic 
193 < 10 Idiopathic 
206 < 10 Idiopathic 
227 < 10 COPD 
233 < 10 Asthma 
293 < 10 COPD 
298 < 10 Idiopathic 
299 < 10 Asthma 
319 < 10 Sjögren's 
320 < 10 Idiopathic 
327 < 10 COPD 
331 < 10 Idiopathic 
332 < 10 Idiopathic 
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Appendix 3: Equipment utilised during this thesis including company information. 
Equipment Company Company address 
Plastic consumables Greiner Bio Stonehouse, UK 
Static incubator BINDER GmbH Tuttlingen, Germany 
Orbital incubator, Innova 44 Eppendorf Stevenage, UK 
Pipetes, BioPette PLUS Labnet Edison, NJ, USA 
Spectrophotometer, Helicos Spectronic Camspec Ltd Leeds UK 
Centrifuge, Sigma 3 – 18 KS, 
rotor 11133 and 13104 
Sigma Aldrich Gillingham, UK 
Plate Reader, Synergy HT BioTek Potton, UK 
96 well cell culture plates Sarstedt Nümbrecht, Germany 
Plate Reader software, Gen5 
1.06 
BioTek Potton, UK 
Desktop centrifuge, Sigma 1 
-5 
Paul Harris Scientific Hyde, UK 
Desktop centrifuge, 
MicroCentaur 
DJB Labcare Limited Newport Pagnell, UK 
Vortex, Vortex Genie 2 Mo Bio Cambridge, UK 
NanoDrop, NanoDrop 1000 
Spectrophotometer V3.7 
Thermo Fisher Scientific 
Ltd 
Cramlington, UK 
PCR machine, C1000 
Thermal Cycler 
BioRad Hemel Hempstead, UK 
Power Pack, PowerPac 
Basic 
BioRad Hemel Hempstead, UK 
Syngene, GeneSys software Syngene Limited Cambridge, UK 
Freeze drier, Alpha 1 - 2 Scientific Laboratory 
Supplies 
Hessle, UK 
Balance, Acculab Scientific Laboratory 
Supplies 
Hessle, UK 
Bandelin Sonorex, Sonicator Bandelin Electronic Berlin, Germany 
Ultimate 3000 LC System Thermo Fisher Scientific 
Ltd 
Cramlington, UK 
Q Exactive Thermo Fisher Scientific 
Ltd 
Cramlington, UK 
Illumina MiSeq platform Illumina Saffron Walden, UK 
Sorval centrifuge, Sorval RC 
5 B Plus 
Thermo Fisher Scientific 
Ltd 
Cramlington, UK 
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Appendix 4: Lysogen growth rate raw data 
Time (hrs) PAO1 PAO1 PAO1 PAO1 CF24 CF24 CF24 CF24 
0.00 0.109 0.112 0.11 0.112 0.145 0.156 0.148 0.155 
0.30 0.215 0.227 0.144 0.135 0.239 0.25 0.263 0.289 
1.00 0.128 0.113 0.135 0.135 0.161 0.165 0.169 0.172 
1.30 0.231 0.347 0.108 0.1 0.225 0.251 0.242 0.235 
2.00 0.21 0.268 0.116 0.116 0.215 0.265 0.245 0.243 
2.30 0.213 0.246 0.136 0.148 0.246 0.272 0.245 0.251 
3.00 0.179 0.259 0.179 0.179 0.273 0.287 0.284 0.312 
3.30 0.192 0.266 0.192 0.198 0.349 0.37 0.368 0.405 
4.30 0.278 0.344 0.29 0.308 0.471 0.518 0.454 0.603 
5.30 0.375 0.439 0.381 0.423 0.521 0.57 0.575 0.628 
6.30 0.468 0.728 0.453 0.542 0.646 0.731 0.738 0.813 
7.30 0.606 0.728 0.621 0.65 0.813 0.825 0.817 0.932 
8.30 0.714 0.783 0.73 0.772 0.855 0.906 0.888 1.063 
9.30 0.838 0.86 0.767 0.887 0.957 0.974 0.959 1.122 
18.00 1.136 1.39 1.076 1.025 1.344 1.462 1.414 1.609 
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Time (hrs) PAO1 PAO1 PAO1 PAO1 CF70 CF70 CF70 CF70 
0.00 0.109 0.112 0.11 0.112 0.147 0.143 0.151 0.148 
0.30 0.215 0.227 0.144 0.135 0.264 0.242 0.236 0.24 
1.00 0.128 0.113 0.135 0.135 0.174 0.167 0.165 0.165 
1.30 0.231 0.347 0.108 0.1 0.242 0.219 0.207 0.227 
2.00 0.21 0.268 0.116 0.116 0.224 0.202 0.191 0.225 
2.30 0.213 0.246 0.136 0.148 0.269 0.232 0.191 0.235 
3.00 0.179 0.259 0.179 0.179 0.326 0.284 0.227 0.212 
3.30 0.192 0.266 0.192 0.198 0.419 0.357 0.272 0.257 
4.30 0.278 0.344 0.29 0.308 0.583 0.48 0.369 0.255 
5.30 0.375 0.439 0.381 0.423 0.622 0.505 0.427 0.229 
6.30 0.468 0.728 0.453 0.542 0.733 0.621 0.57 0.218 
7.30 0.606 0.728 0.621 0.65 0.873 0.797 0.717 0.285 
8.30 0.714 0.783 0.73 0.772 0.857 0.842 0.882 0.39 
9.30 0.838 0.86 0.767 0.887 0.842 0.865 1.02 0.496 
18.00 1.136 1.39 1.076 1.025 0.785 0.916 1.651 1.317 
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Time (hrs) PAO1 PAO1 PAO1 PAO1 BR123 BR123 BR123 BR123 
0.00 0.109 0.112 0.11 0.112 0.117 0.134 0.119 0.123 
0.30 0.215 0.227 0.144 0.135 0.17 0.192 0.185 0.187 
1.00 0.128 0.113 0.135 0.135 0.157 0.171 0.178 0.184 
1.30 0.231 0.347 0.108 0.1 0.085 0.093 0.096 0.119 
2.00 0.21 0.268 0.116 0.116 0.087 0.099 0.095 0.136 
2.30 0.213 0.246 0.136 0.148 0.089 0.104 0.101 0.154 
3.00 0.179 0.259 0.179 0.179 0.091 0.108 0.103 0.189 
3.30 0.192 0.266 0.192 0.198 0.095 0.115 0.102 0.207 
4.30 0.278 0.344 0.29 0.308 0.112 0.163 0.107 0.306 
5.30 0.375 0.439 0.381 0.423 0.126 0.258 0.119 0.381 
6.30 0.468 0.728 0.453 0.542 0.148 0.384 0.148 0.423 
7.30 0.606 0.728 0.621 0.65 0.194 0.644 0.203 0.484 
8.30 0.714 0.783 0.73 0.772 0.233 0.719 0.274 0.56 
9.30 0.838 0.86 0.767 0.887 0.303 0.746 0.39 0.591 
18.00 1.136 1.39 1.076 1.025 0.574 1.255 0.428 0.612 
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Time (hrs) PAO1 PAO1 PAO1 PAO1 BR136 BR136 BR136 BR136 
0.00 0.109 0.112 0.11 0.112 0.125 0.125 0.131 0.137 
0.30 0.215 0.227 0.144 0.135 0.181 0.181 0.191 0.183 
1.00 0.128 0.113 0.135 0.135 0.174 0.179 0.213 0.214 
1.30 0.231 0.347 0.108 0.1 0.151 0.193 0.214 0.22 
2.00 0.21 0.268 0.116 0.116 0.15 0.166 0.192 0.251 
2.30 0.213 0.246 0.136 0.148 0.214 0.243 0.231 0.26 
3.00 0.179 0.259 0.179 0.179 0.228 0.252 0.269 0.293 
3.30 0.192 0.266 0.192 0.198 0.25 0.253 0.267 0.323 
4.30 0.278 0.344 0.29 0.308 0.475 0.388 0.427 0.654 
5.30 0.375 0.439 0.381 0.423 0.586 0.593 0.554 0.915 
6.30 0.468 0.728 0.453 0.542 0.711 0.642 0.615 1.039 
7.30 0.606 0.728 0.621 0.65 0.854 0.788 0.716 1.169 
8.30 0.714 0.783 0.73 0.772 0.916 0.786 0.768 1.306 
9.30 0.838 0.86 0.767 0.887 0.972 0.78 0.746 1.314 
18.00 1.136 1.39 1.076 1.025 1.213 0.769 0.689 1.614 
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Appendix 5: MIC raw data  
Lysogen + Ceft + Ceft + Ceft PAO1 + 
Ceft 
PAO1 + 
Ceft 
PAO1 + 
Ceft 
Lysogen 
Growth 
Lysogen 
Growth 
Lysogen 
Growth 
PAO1 PAO1 PAO1 
CF24 
(9 hrs) 
0.524 0.581 0.759 0.193 0.239 0.265 1.184 1.379 1.300 0.786 0.888 0.988 
CF24  
(18 hrs) 
0.336 0.582 0.529 0153 0.160 0.160 0.988 1.022 1.211 1.221 1.336 1.266 
CF70 
(9 hrs) 
0.835 0.865 0.896 0.544 0.608 0.470 0.839 0.978 1.117 0.910 0.913 0.927 
CF70  
(18 hrs) 
0.279 0.168 0.385 0.401 0.669 0.340 1.502 1.473 1.503 1.248 1.227 1.226 
BR123  
(9 hrs) 
0.740 0.762 0.747 0.754 0.781 0.708 1.421 1.442 1.315 0.959 1.032 1.165 
BR123 (18 
hrs) 
0.874 0.912 1.024 0.747 0.650 0.755 0.794 0.435 0.389 1.120 1.182 1.048 
BR136  
(9 hrs) 
1.014 1.071 1.007 0.754 0.781 0.708 1.723 1.725 1.672 0.959 1.032 1.165 
BR136 (18 
hrs) 
0.940 0.748 0.663 0.747 0.650 0.755 1.456 1.156 1.484 1.120 1.182 1.048 
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Lysogen + Colo + Colo + Colo PAO1 + 
Colo 
PAO1 + 
Colo 
PAO1 + 
Colo 
Lysogen 
Growth 
Lysogen 
Growth 
Lysogen 
Growth 
PAO1 PAO1 PAO1 
CF24 
(9 hrs) 
0.616 1.528 1.472 0.449 0.550 0.431 1.184 1.379 1.300 0.786 0.888 0.988 
CF24  
(18 hrs) 
1.860 1.846 1.888 1.483 1.506 1.404 0.988 1.022 1.211 1.221 1.336 1.226 
CF70 
(9 hrs) 
0.630 0.628 0.608 0.449 0.550 0.431 0.890 0.814 0.832 0.786 0.888 0.988 
CF70  
(18 hrs) 
1.328 1.387 1.422 1.483 1.506 1.404 1.769 1.805 1.805 1.221 1.336 1.266 
BR123  
(9 hrs) 
0.844 0.893 0.864 0.449 0.550 0.431 1.496 1.516 1.450 0.786 0.888 0.988 
BR123 (18 
hrs) 
1.084 1.034 1.054 1.483 
 
1.506 1.404 1.398 1.385 1.379 1.221 1.336 1.266 
BR136  
(9 hrs) 
0.532 0.586 0.604 0.449 0.550 0.431 1.355 1.400 1.368 0.786 0.888 0.988 
BR136 (18 
hrs) 
0.839 0.943 0.625 1.483 1.506 1.404 1.219 1.043 1.250 1.221 1.336 1.266 
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Lysogen + Mero + Mero + Mero PAO1 + 
Mero 
PAO1 + 
Mero 
PAO1 + 
Mero 
Lysogen 
Growth 
Lysogen 
Growth 
Lysogen 
Growth 
PAO1 PAO1 PAO1 
CF24 
(9 hrs) 
0.383 0.781 0.986 0.163 0.244 0.131 1.453 1.523 1.305 0.910 0.913 0.927 
CF24  
(18 hrs) 
0.974 1.210 1.124 0.225 0.260 0.214 0.983 1.031 1.000 1.248 1.227 1.226 
CF70 
(9 hrs) 
1.164 1.238 1.293 0.266 0.261 0.133 1.222 1.299 1.209 0.959 1.032 1.165 
CF70  
(18 hrs) 
0.974 0.845 0.812 0.816 0.858 0.751 0.956 0.964 0.987 1.120 1.182 1.048 
BR123  
(9 hrs) 
0.410 0.455 0.564 0.364 0.440 0.348 1.125 1.325 1.337 1.150 1.174 1.166 
BR123 (18 
hrs) 
0.855 1.078 0.527 0.601 0.535 0.502 0.937 0.967 1.023 1.045 1.347 1.138 
BR136  
(9 hrs) 
0.678 0.561 0.684 0.266 0.261 0.133 1.723 1.725 1.672 0.959 1.032 1.165 
BR136 (18 
hrs) 
0.444 0.271 0.531 0.816 0.858 0.751 1.456 1.156 1.484 1.120 1.182 1.048 
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Lysogen + Pipp + Pipp + Pipp PAO1 + 
Pipp 
PAO1 + 
Pipp 
PAO1 + 
Pipp 
Lysogen 
Growth 
Lysogen 
Growth 
Lysogen 
Growth 
PAO1 PAO1 PAO1 
CF24 
(9 hrs) 
0.984 0.893 1.055 0.118 0.198 0.064 1.453 1.523 1.305 0.910 0.913 0.927 
CF24  
(18 hrs) 
1.129 1.071 1.111 0.319 0.326 0.309 0.983 1.031 1.000 1.248 1.227 1.226 
CF70 
(9 hrs) 
0.980 1.221 1.249 0.312 0.322 0.166 1.222 1.299 1.209 0.959 1.032 1.165 
CF70  
(18 hrs) 
0.837 0.612 1.123 0.769 0.827 0.784 0.956 0.964 0.987 1.120 1.182 1.048 
BR123  
(9 hrs) 
0.561 0.628 0.530 0.312 0.322 0.166 1.421 1.442 1.315 0.959 1.032 1.165 
BR123 (18 
hrs) 
1.140 1.104 0.957 0.769 0.827 0.784 0.794 0.435 0.389 1.120 1.182 1.048 
BR136  
(9 hrs) 
0.833 0.842 0.836 0.312 0.322 0.166 1.723 1.725 1.672 0.959 1.032 1.165 
BR136 (18 
hrs) 
0.681 0.745 0.551 0.769 0.827 0.784 1.456 1.156 1.484 1.120 1.182 1.048 
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Appendix 6: Raw data for the twitching motility assays 
 
+ ɸ 
(mm) 
+ ɸ 
(mm) 
+ ɸ 
(mm) 
Average 
(mm) 
-ɸ 
(mm) 
-ɸ 
(mm) 
-ɸ 
(mm) 
Average 
(mm) 
PAO1 11 10 6 9 8 9 9 9 
LESB58 7 9 6 7 4 9 8 7 
CF3 5 9 6 7 7 7 5 6 
CF5 6 0 6 4 6 7 8 7 
CF6 12 19 13 15 18 21 20 20 
CF16 6 7 5 6 6 5 6 6 
CF23 24 16 19 20 23 19 20 21 
CF24 5 6 6 6 4 5 8 6 
CF28 5 3 6 5 6 4 7 6 
CF30 5 0 5 3 4 6 0 3 
CF34 11 14 13 13 17 18 19 18 
CF42 8 10 11 10 23 11 20 18 
CF44 4 4 4 4 8 6 8 7 
CF47 13 12 14 13 22 17 15 18 
CF52 4 2 0 2 4 5 4 4 
CF53 4 7 5 5 5 3 3 4 
CF54 4 4 6 5 2 5 5 4 
CF55 17 18 23 19 14 19 14 16 
CF57 16 14 15 15 17 16 19 17 
CF60 21 22 11 18 10 19 18 16 
CF63 16 14 12 14 22 19 24 22 
CF65 9 16 13 13 21 24 20 22 
CF67 17 20 12 16 24 21 24 23 
CF69 9 15 18 14 18 24 16 19 
CF70 5 4 2 4 4 4 5 4 
CF72  4 5 5 7 6 7 7 
CF74 15 15 13 14 15 13 12 13 
CF77 28 21 22 24 39 36 22 32 
CF78 13 10 12 12 23 17 22 21 
CF79 12 10 16 13 12 13 13 13 
CF81 5 6 4 5 6 5 4 5 
CF118 4 5 5 5 6 5 9 7 
CF121 11 15 11 12 15 18 16 16 
CF124 20 29 28 24 25 28 28 27 
CF125 5 4 3 4 5 7 8 7 
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CF126 3 4 4 4 0 7 9 5 
CF127 4 4 0 3 4 7 4 5 
CF136 2 4 0 2 3 6 4 4 
CF140 3 5 3 4 5 3 5 4 
CF142 4 4 4 4 3 3 5 4 
CF145 3 6 4 4 6 6 6 6 
CF165 1 2 6 3 3 5 4 4 
CF177 1 4 4 3 4 3 3 3 
CF183 6 5 0 4 9 6 9 8 
CF187 3 5 4 4 3 2 3 3 
CF208 5 5 5 5 6 0 7 4 
CF211 0 4 5 3 5 4 2 4 
CF213 0 5 4 3 6 6 7 6 
CF214 6 4 6 5 5 8 8 7 
BR52 4 0 4 3 5 7 0 4 
BR53 12 13 12 12 20 16 16 17 
BR58 15 10 14 13 11 17 21 16 
BR59 15 11 18 15 17 20 23 20 
BR123 10 8 0 6 0 6 6 4 
BR133 9 10 8 9 2 6 0 3 
BR136 7 6 7 7 13 9 7 10 
BR141 10 7 16 11 13 12 19 15 
BR143 12 10 12 11 25 20 21 22 
BR144 11 8 10 10 12 7 0 6 
BR146 5 3 5 4 5 6 4 5 
BR150 22 22 12 19 23 26 25 25 
BR152 20 20 23 21 35 38 30 34 
BR153 17 17 16 17 23 30 25 26 
BR161 11 18 14 14 23 24 22 23 
BR177 12 13 13 13 16 16 12 15 
BR178 9 14 13 12 15 9 13 12 
BR181 9 15 10 11 20 22 17 20 
BR193 16 24 19 20 16 22 15 18 
BR195 19 19 20 19 13 20 23 19 
BR197 17 14 25 19 15 32 22 23 
BR199 11 11 11 11 20 16 19 18 
BR200 22 14 12 16 23 21 19 21 
BR201 14 19 13 15 20 15 9 15 
BR204 20 20 20 20 17 17 16 17 
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BR204 7 6 0 4 9 5 0 5 
BR205 5 6 5 5 5 5 4 5 
BR208 5 8 0 4 8 8 7 8 
BR213 9 7 8 8 9 8 10 9 
BR222 4 7 0 4 14 11 9 11 
BR227 0 8 7 5 5 0 6 4 
BR228 9 7 7 8 11 11 11 11 
BR233 5 10 6 7 9 7 6 7 
BR243 6 10 6 7 4 9 12 8 
BR244 8 8 7 8 12 7 10 10 
BR285 7 7 7 7 10 9 10 10 
BR293 6 6 6 6 6 9 9 8 
BR298 0 8 9 6 8 12 0 7 
BR299 4 5 2 4 8 10 0 6 
BR313 7 6 7 7 10 6 8 8 
BR319 4 8 0 4 10 11 0 7 
BR320 7 4 3 5 10 0 10 7 
BR322 6 3 6 5 7 8 8 8 
BR326 5 0 7 4 6 8 4 6 
BR327 5 4 3 4 4 4 6 5 
BR331 2 3 6 4 8 8 7 8 
BR332 0 5 4 3 5 4 7 5 
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Appendix 7: Raw data for the XTT Metabolism study 
Strain  n = 1 n = 2 n = 3 
CF24 (36 hrs) 0.200 0.239 0.156 
+ CF24 0.500 0.409 0.372 
+ CF70 0.397 0.349 0.348 
+ BR123 0.469 0.495 0.416 
+ BR136 0.367 0.485 0.235 
    
CF24 (72 hrs) 0.221 0.229 0.271 
+ CF24 0.377 0.359 0.374 
+ CF70 0.304 0.270 0.185 
+ BR123 0.456 0.520 0.095 
+ BR136 0.260 0.219 0.244 
    
CF24 (102 hrs) 0.113 0.380 0.476 
+ CF24 0.601 0.245  
+ CF70 0.119 0.202 0.168 
+ BR123 0.597 0.402 0.478 
+ BR136 0.509 0.144 0.356 
    
CF70 (36 hrs) 0.248 0.187 0.254 
+ CF24 0.240 0.467 0.236 
+ CF70 0.239 0.189 0.247 
+ BR123 0.246 0.234 0.261 
+ BR136 0.224 0.235 0.237 
    
CF70 (72 hrs) 0.262 0.254 0.181 
+ CF24 0.257 0.217 0.178 
+ CF70 0.512 0.199 0.301 
+ BR123 0.131 0.229 0.254 
+ BR136 0.217 0.165 0.173 
    
CF70 (102 hrs) 0.409 0.345 0.319 
+ CF24 0.441 0.183 0.384 
+ CF70 0.818 0.272 1.899 
+ BR123 0.288 0.294 0.396 
+ BR136 0.306 0.246 0.295 
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BR123 (36 hrs) 0.209 0.111 0.255 
+ CF24 0.280 0.305 0.294 
+ CF70 0.255 0.271 0.311 
+ BR123 0.260 0.214 0.217 
+ BR136 0.257 0.229 0.265 
    
BR123 (72 hrs) 0.191 0.184 0.190 
+ CF24 0.383 0.645 0.421 
+ CF70 0.395 0.204 0.260 
+ BR123 0.199 0.169 0.183 
+ BR136 0.174 0.187 0.164 
    
BR123 (102 hrs) 0.240 0.179 0.221 
+ CF24 0.347 0.435 0.310 
+ CF70 0.258 0.198 0.247 
+ BR123 0.266 0.202 0.264 
+ BR136 0.281 0.197 0.223 
    
BR136 (36 hrs) 0.425 0.386 0.385 
+ CF24 0.380 0.375 0.357 
+ CF70 0.283 0.291 0.424 
+ BR123 0.291 0.437 0.394 
+ BR136 0.264 0.262 0.374 
    
BR136 (72 hrs) 0.273 0.276 0.326 
+ CF24 0.195 0.182 0.204 
+ CF70 0.265 0.094  
+ BR123 0.445 0.278 0.495 
+ BR136 0.454 0.562 0.480 
    
BR136 (102 hrs) 0.752 0.308 0.615 
+ CF24 0.347 0.435 0.310 
+ CF70 0.234 0.373 0.527 
+ BR123 0.280 0.524 0.461 
+ BR136 0.481 0.377 0.371 
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Appendix 8: QUBIT 2.0 values for the mixed temperate phage lysates induced from 
clinical CF P. aeruginosa isolates.  
CF sample ID QUBIT 2.0 value (ng/µL) Dilution required (Y/N) 
3 0.800 Y 
5 0.700 Y 
6 0.400 N 
16 0.264 N 
23 0.886 Y 
24 0.254 N 
28 0.426 N 
30 0.332 N 
34 0.302 N 
42 0.272 N 
44 0.346 N 
47 0.170 N 
52 0.452 N 
53 0.988 Y 
54 0.710 Y 
55 1.150 Y 
57 0.370 N 
60 0.226 N 
63 1.170 Y 
65 1.180 Y 
67 0.266 N 
69 0.330 N 
70 0.856 Y 
72 0.198 N 
74 0.270 N 
77 0.568 Y 
78 1.490 Y 
79 1.330 Y 
81 1.120 Y 
118 0.200 N 
121 0.290 N 
124 0.262 N 
125 0.282 N 
126 0.492 N 
127 0.212 N 
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136 0.460 N 
140 0.386 N 
142 2.400 Y 
145 0.314 N 
165 3.100 Y 
177 1.030 Y 
183 1.920 Y 
187 0.130 N 
208 0.820 Y 
211 N/A N 
213 0.378 N 
214 0.306 N 
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Appendix 9: QUBIT 2.0 values for the mixed temperate phage lysates induced from 
clinical BR P. aeruginosa isolates.  
BR sample ID QUBIT 2.0 value (ng/µL) Dilution required (Y/N) 
52 0.864 Y 
53 0.238 N 
58 0.146 N 
59 0.426 N 
123 0.800 Y 
133 N/A N 
136 N/A N 
141 N/A N 
143 0.198 N 
144 0.132 N 
146 N/A N 
150 0.134 N 
152 0.588 Y 
153 0.968 Y 
161 0.164 N 
177 0.284 N 
178 0.344 N 
181 N/A N 
193 0.418 N 
195 0.170 N 
197 0.160 N 
199 0.234 N 
200 0.104 N 
201 0.128 N 
204 1.680 Y 
205 0.662 Y 
206 N/A N 
208 0.178 N 
213 1.320 Y 
222 1.190 Y 
227 0.296 N 
228 0.130 N 
233 0.228 N 
243 0.186 N 
244 0.116 N 
xl 
 
285 0.824 Y 
293 0.906 Y 
298 1.020 Y 
299 0.944 Y 
313 1.140 Y 
319 0.612 Y 
320 1.090 Y 
322 1.070 Y 
326 0.960 Y 
327 0.936 Y 
331 0.934 Y 
332 0.992 Y 
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Appendix 10: The raw data from MG RAST generated for all the samples which 
passed its internal quality control, 11/17 < 10 BR, 25/28 > 10 BR, 10/10 Pediatric CF 
and 36/37 Adult CF. 
 
Clinical group Sample ID Number of Reads uploaded 
to MG-RAST 
< 10 year BR Phage50 135,229 
Phage52 479,192 
Phage68 698,674 
Phage72 496,093 
Phage73 618,612 
Phage74 439,489 
Phage76 23,898 
Phage77 278,743 
Phage80 862,415 
Phage86 404,422 
Phage91 383,572 
> 10 year BR Phage46 25,262 
Phage47 397,339 
Phage48 546,201 
Phage51 248,902 
Phage53 313,599 
Phage54 372,256 
Phage55 904,450 
Phage56 258,012 
Phage59 368,431 
Phage60 39,831 
Phage61 382,264 
Phage62 274,339 
Phage63 362,896 
Phage64 326,612 
Phage65 1,018,124 
Phage69 415,920 
Phage75 97,351 
Phage78 708,098 
Phage79 442,845 
Phage85 236,330 
Phage87 17,953 
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Phage88 540,788 
Phage89 1,115,698 
Phage92 594,975 
Phage93 62,894 
Paediatric CF Phage13 606,526 
Phage14 232,852 
Phage22 26,409 
Phage23 17,862 
Phage32 308,499 
Phage40 710,926 
Phage43 1,020,308 
Phage44 337,907 
Phage45 24,446 
Phage83 15,484 
Adult CF Phage1 336,053 
Phage2 10,860 
Phage3 1,112,907 
Phage4 46,152 
Phage5 335,623 
Phage6 453,949 
Phage7 307,972 
Phage8 649,773 
Phage9 809,956 
Phage10 25,305 
Phage12 57,446 
Phage15 371,506 
Phage16 806,898 
Phage17 343,106 
Phage18 983,127 
Phage19 1,035,849 
Phage20 238,769 
Phage21 1,092,624 
Phage24 19,468 
Phage25 129,064 
Phage26 93,154 
Phage27 90,725 
Phage28 978,403 
Phage29 256,542 
Phage30 56, 252 
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Phage31 397,022 
Phage33 434,882 
Phage34 186,544 
Phage35 493,891 
Phage36 355,818 
Phage37 252,476 
Phage38 16,271 
Phage39 653,032 
Phage41 442,560 
Phage42 685,801 
Phage84 44,228 
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Appendix 11: KEGG putative functionality kits 
GLYCAN BIOSYNTHESIS 
AND METABOLISM 
KEGG Identification Putative function 
Paediatric CF Lipopolysaccharide 
biosynthesis 
Cell wall function 
< 10 BR Glycosphingolipid 
biosynthesis 
Involved in inflammation in 
chronic lung diseases 
Adult CF Other types of O-
glycan biosynthesis 
Mucin binding domain – 
phage may encode to aid its 
attachment 
(serine/threonine base) 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation in 
CF 
Lipopolysaccharide 
biosynthesis 
Synthesis of 
lipopolysaccharides 
> 10 BR 
  
Sphingolipid 
metabolism 
Involved in inflammation in 
chronic respiratory diseases 
Glycosphingolipid 
biosynthesis - lacto and 
neolacto series 
Involved in inflammation in 
chronic respiratory diseases 
Other types of O-
glycan biosynthesis 
Mucin binding domain – 
phage may encode to aid its 
attachment 
(serine/threonine base) 
Various types of N-
glycan biosynthesis 
Involved in correct protein 
folding (aspartate base) 
Galactose metabolism Energy – sugar 
Other glycan 
degradation 
Degradation of linked 
monosaccharides 
Glycosaminoglycan 
degradation 
Long unbranched 
polysaccharides made of 
repeating disaccharide units 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation in 
chronic respiratory diseases 
Lysosome Break down of biomolecules 
including proteins, amino 
xlv 
 
acid, lipids and CHO – 
found in animal cells 
LIPID METABOLISM KEGG Identification Putative function 
Paediatric CF Sphingolipid 
metabolism 
Involved in inflammation in 
CF – possible drug target 
Other types of O-
glycan biosynthesis 
Mucin binding domain – 
phage may encode to aid its 
attachment 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation in  
CF 
Fatty acid degradation Degradation of fatty acids 
alpha-Linolenic acid 
metabolism 
Alter the Fatty Acids in CF – 
have an effect on potential 
CF diet management 
Fatty acid metabolism Fatty Acid metabolism 
Valine, leucine and 
isoleucine degradation 
These are previously seen 
to be elevated in the CF 
lung  
Geraniol degradation Geraniol (bacterial nutrient 
source)  
Benzoate degradation Utilize alternative Carbon 
sources – longevity 
Ethylbenzene 
degradation 
Plant originating metabolite 
Glycerolipid 
metabolism 
Involved in inflammation in  
CF 
Glycerophospholipid 
metabolism 
Involved in inflammation in 
CF 
Ether lipid metabolism One or more Carbons on 
glycerol is bound to an alkyl 
chain via an ether linkage 
rather than the usual ester 
linkage 
Fc gamma R-mediated 
phagocytosis 
Phagocytosis/Engulfment of 
cells mediated by the Fc 
domain on certain cellular 
proteins 
Fat digestion and Degradation and absorption 
xlvi 
 
absorption of fats 
Fatty acid biosynthesis Fatty acid biosynthesis 
AMPK signaling 
pathway 
Cellular homeostasis – 
phage utilizes to enhance its 
survival 
Insulin signaling 
pathway 
Insulin 
Lysine degradation Lysine degrades DNA  
Phenylalanine 
metabolism 
Amino acid metabolism 
Tryptophan metabolism Amino acid metabolism 
beta - Alanine 
metabolism 
Amino acid metabolism 
Aminobenzoate 
degradation 
Aminobenzonate has been 
trialed as a drug previously 
Proponate metabolism Precursor to propanoic acid 
Butanoate metabolism Precursor to butanoic acid 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs – 
phage aid breakdown? 
alpha-Linolenic acid 
metabolism 
Essential Fatty Acid 
Biosynthesis of 
unsaturated fatty acids 
Unsaturated Fatty Acid 
synthesis 
PPAR signaling 
pathway 
Link to obesity/insulin etc. 
cAMP signaling 
pathway 
Energy generation 
Peroxisome Link to obesity/insulin etc. 
Steroid biosynthesis Steroid generation 
 
< 10 BR Ether lipid metabolism One or more carbons on 
glycerol is bound to an alkyl 
chain via an ether linkage 
rather than the usual ester 
linkage 
Fatty acid biosynthesis Biosynthesis of fatty acids 
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Glycerophospholipid 
metabolism 
Involved in inflammation in 
chronic lung diseases 
Fatty acid biosynthesis, 
initiation 
Initiation of fatty acid 
biosynthesis 
Fatty acid biosynthesis, 
elongation 
Elongation stage of fatty 
acid biosynthesis 
Fatty acid degradation Degradation of fatty acids 
Adult CF Sphingolipid 
metabolism 
Involved in inflammation in 
CF 
Taurine and 
hypotaurine 
metabolism 
Taurine is found in a large 
proportion of animal tissues, 
hypotaurine is an 
intermediate in this process 
Cyanoamino acid 
metabolism 
Amino acid metabolism – 
addition of a nitrile group to 
the front of the amino acid 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
Arachidonic acid 
metabolism 
Unsaturated fatty acid 
Fatty acid degradation Degradation of fatty acids 
alpha-Linolenic acid 
metabolism 
Alter the fatty acid in CF – 
have an effect on potential 
CF diet management 
Fatty acid metabolism Self-explanatory 
Glycerolipid 
metabolism 
Lipid metabolism 
Glycerophospholipid 
metabolism 
Involved in inflammation in 
CF 
Fatty acid biosynthesis Biosynthesis of fatty acids 
AMPK signaling 
pathway 
Cellular homeostasis – 
phage utilizes to enhance its 
survival 
Insulin signaling 
pathway 
Insulin 
Steroid hormone 
biosynthesis 
Synthesis of steroid 
hormone’s 
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Metabolism of 
xenobiotics by 
cytochrome P450 
Cytochrome P450’s are key 
in xenobiotic degradation 
Chemical 
carcinogenesis 
Chemicals that are capable 
of causing cancer 
Valine, leucine and 
isoleucine degradation 
These are previously seen 
to be elevated in the CF 
lung  
Geraniol degradation Geraniol (bacterial nutrient 
source) – phage utilize for 
energy 
Lysine degradation Lysine degrades DNA 
Phenylalanine 
metabolism 
Amino acid metabolism 
Benzoate degradation Utilize alternative Carbon 
sources – longevity 
Tryptophan metabolism Amino acid metabolism 
beta-Alanine 
metabolism 
Amino acid metabolism 
Aminobenzoate 
degradation 
Aminobenzonate has been 
trialed as a drug previously 
Propanoate 
metabolism 
Precursor to propanoic acid 
Butanoate metabolism Precursor to butanoic acid 
Limonene and pinene 
degradation 
Drug degradation – 
bronchitis drug 
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs 
Synthesis and 
degradation of ketone 
bodies 
Water soluble molecules 
produced in times of 
starvation, produced from 
Acetyl CoA 
Carbon fixation 
pathways in 
Prokaryotes 
Fixation of carbon in 
Prokaryotes 
Terpenoid backbone 
biosynthesis 
Secondary metabolite 
biosynthesis 
Ethylbenzene 
degradation 
Utilize alternative Carbon 
sources – longevity 
xlix 
 
Ether lipid metabolism One or more Carbons on 
glycerol is bound to an alkyl 
chain via an ether linkage 
rather than the usual ester 
linkage 
 
> 10 BR Fatty acid degradation Degradation of fatty acids 
  
  
alpha-Linolenic acid 
metabolism 
Alter the fatty acids in CF – 
have an effect on potential 
CF diet management 
Glycerophospholipid 
metabolism 
Involved in inflammation in 
chronic lung diseases 
Ether lipid metabolism One or more Carbons on 
glycerol is bound to an alkyl 
chain via an ether linkage 
rather than the usual ester 
linkage 
Ras signaling pathway Control of cellular signaling, 
normally involved in 
pathways that are involved 
in cell growth, differentiation 
and survival 
cAMP signaling 
pathway 
Energy generation 
Endocytosis Process where the cell 
engulfs products such as 
proteins, uses energy 
Fc gamma R-mediated 
phagocytosis 
Phagocytosis/Engulfment of 
cells mediated by the Fc 
domain on certain cellular 
proteins 
Glutamatergic synapse Post synaptic synapse – 
NMDA type 
GnRH signaling 
pathway 
Gonadotropin-releasing 
hormone generated 
(benzene ring product) 
Sphingolipid 
metabolism 
Involved in inflammation in 
chronic respiratory diseases 
Phosphonate and 
phosphinate 
Degradable organic Carbon 
products which can be used 
l 
 
metabolism for pest control – benzene 
ring containing 
Fatty acid biosynthesis Biosynthesis of fatty acid’s 
Fatty acid metabolism Metabolism of fatty acid’s 
AMPK signaling 
pathway 
Cellular homeostasis – 
phage utilizes in order to 
enhance its survival 
Insulin signaling 
pathway 
Insulin productio 
Valine, leucine and 
isoleucine degradation 
These are seen to be 
elevated in the CF lung  
Geraniol degradation Geraniol (bacterial nutrient 
source)  
Lysine degradation Lysine degrades DNA  
Phenylalanine 
metabolism 
Amino acid metabolism 
Benzoate degradation Utilize alternative Carbon 
sources – longevity Phage 
encoded 
Tryptophan metabolism Amino acid metabolism 
beta-Alanine 
metabolism 
Amino acid metabolism 
Aminobenzoate 
degradation 
Aminobenzoate has been 
trialed as a drug previously 
Propanoate 
metabolism 
Precursor to propanoic acid 
Butanoate metabolism Precursor to butanoic acid 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs – 
phage aid breakdown 
Lipopolysaccharide 
biosynthesis 
Cell wall 
Steroid hormone 
biosynthesis 
Synthesis of steroid 
hormone’s 
Metabolism of 
xenobiotics by 
cytochrome P45 
Using cytochrome P45 to 
generate xenobiotics 
li 
 
Chemical 
carcinogenesis 
Chemicals that are capable 
of causing cancer 
Metabolism of Terpenoids 
and Polyketides (secondary 
metabolites naturally 
produced) 
KEGG Identification Putative function 
Paediatric CF 
  
Bisphenol degradation Common chemical exposed 
to in daily life 
Polycyclic aromatic 
hydrocarbon 
degradation 
Break down of compounds 
containing these rings 
Aminobenzoate 
degradation 
Drug degradation 
Limonene and pinene 
degradation 
Drug degradation – 
bronchitis drug 
Stilbenoid, 
diarylheptanoid and 
gingerol biosynthesis 
Plant related drug 
< 10 BR 
  
Zeatin biosynthesis Benzene ring plant hormone 
Diterpenoid 
biosynthesis 
Benzene ring plant hormone 
Biosynthesis of 
secondary metabolites 
Generation of secondary 
metabolites 
Adult CF 
  
Brassinosteroid 
biosynthesis 
Plant hormone with a 
potential role in agricultural 
processes 
Terpenoid backbone 
biosynthesis 
Secondary metabolite 
biosynthesis 
> 10 BR Diterpenoid 
biosynthesis 
Potential use for 
antibacterial functions, plant 
based metabolite 
Brassinosteroid 
biosynthesis 
Plant hormone with a 
potential role in agricultural 
processes 
 
CARBOHYDRATE 
METABOLISM 
KEGG Identification Putative function 
Paediatric CF 
  
Galactose metabolism Energy - sugar 
Other glycan Chemicals that are capable 
lii 
 
degradation of causing cancer 
Glycosaminoglycan 
degradation 
Long unbranched 
polysaccharides made of 
repeating disaccharide units 
Sphingolipid 
metabolism 
Involved in inflammation in 
CF 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation in  
CF 
Lysosome Break down of biomolecules 
including proteins, amino 
acid, lipids and CHO – 
found in animal cells 
Phosphotransferase 
system (PTS) 
Sugar transport system 
Pentose and 
glucuronate 
interconversions 
Transferring sugar groups 
Fructose and mannose 
metabolism 
Amino acid metabolism 
Glycerolipid 
metabolism 
Plant originating metabolite 
Bisphenol degradation Common chemical exposed 
to in daily life 
Linoleic acid 
metabolism 
Unsaturated fatty acid 
Chloroalkane and 
chloroalkene 
degradation 
Degrading chloro derivative 
alkene’s and alkane’s 
Butanoate metabolism Precursor to butanoic acid 
Steroid hormone 
biosynthesis 
Biosynthesis of steroid 
hormone’s 
Metabolism of 
xenobiotics by 
cytochrome P450 
Cytochrome P450’s are key 
in xenobiotic degradation 
Chemical 
carcinogenesis 
Chemicals that are capable 
of causing cancer 
Methane metabolism Metabolism of methane 
Carbon metabolism Metabolism of carbon 
liii 
 
Carbon fixation in 
photosynthetic 
organisms 
Transfer of inorganic 
Carbon to organic Carbon 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
Glycine, serine and 
threonine metabolism 
Amino acid metabolism 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Peroxisome Break down of long chain 
fatty acids by beta oxidation 
Citrate cycle (TCA 
cycle) 
Energy generation via the 
oxidization of acetate 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
2-Oxocarboxylic acid 
metabolism 
The most elementary set of 
metabolites -pyruvate (2-
oxopropanoate), 2-
oxobutanoate, oxaloacetate 
(2-oxosuccinate) and 2-
oxoglutarate 
Biosynthesis of amino 
acids 
Amino acid biosynthesis 
Glycolysis / 
Gluconeogenesis 
Converts glucose to 
pyruvate/Generation of 
glucose from non-Carbon 
sources 
Fatty acid degradation Degradation of fatty acid’s 
Valine, leucine and 
isoleucine degradation 
These are previously seen 
to be elevated in the CF 
lung  
Lysine degradation Lysine degrades DNA  
Arginine and proline 
metabolism 
Amino acid metabolism 
Histidine metabolism Amino acid metabolism 
Tryptophan metabolism Amino acid metabolism 
liv 
 
beta-Alanine 
metabolism 
Amino acid metabolism 
Pyruvate metabolism Glycolysis end product 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
Propanoate 
metabolism 
Precursor to propanoic acid 
GABAergic synapse Neurotransmitter in CNS 
(Central Nervous System) 
Pentose phosphate 
pathway 
Parallel to glycolysis and 
generates NAPDH and 
pentose 
Ascorbate and aldarate 
metabolism 
Ascorbate – Vitamin C by-
product 
Aldarate – acid generated 
from oxidation of the 
terminal groups on aldose 
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs  
Cyanoamino acid 
metabolism 
Amino acid metabolism – 
addition of a nitrile group to 
the front of the amino acid 
Tryptophan metabolism Amino acid metabolism 
Sulphur metabolism Metabolism of sulphur 
Cysteine and 
methionine metabolism 
Metabolism of cysteine and 
methionine 
Taurine and 
hypotaurine 
metabolism 
Taurine is found in a large 
proportion of animal tissues, 
hypotaurine is an 
intermediate in this process 
< 10 BR 
  
Fructose and mannose 
metabolism 
Amino acid metabolism 
Glycolysis Converts glucose to 
pyruvate 
Nucleotide sugar 
biosynthesis 
Biosynthesis of nucleotide 
sugars 
Streptomycin 
biosynthesis 
Antimicrobial – protein 
synthesis inhibitor - 
Aminoglycoside 
lv 
 
Polyketide sugar unit 
biosynthesis 
Secondary metabolites 
produced by most living 
organisms – contain a 
benzene ring 
Lipopolysaccharide 
biosynthesis 
Cell wall 
Gluconeogenesis Generation of glucose from 
non-Carbon sources 
Pentose phosphate 
pathway 
Parallel to glycolysis and 
generates NAPDH and 
pentose 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
 
Adult CF 
  
Galactose metabolism Energy – sugar 
Other glycan 
degradation 
Degradation of glycan’s 
Glycosaminoglycan 
degradation 
Long unbranched 
polysaccharides made of 
repeating disaccharide units 
Sphingolipid 
metabolism 
Involved in inflammation CF 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation CF 
Lysosome Break down of biomolecules 
including proteins, amino 
acid, lipids and CHO – 
found in animal cells 
Starch and sucrose 
metabolism 
Energy generation 
Fructose and mannose 
metabolism 
Amino acid metabolism 
Glycolysis / 
Gluconeogenesis 
Converts glucose to 
pyruvate/Generation of 
glucose from non-Carbon 
sources 
Amino sugar and 
nucleotide sugar 
Generation of components 
of nucleic acids 
lvi 
 
metabolism 
Streptomycin 
biosynthesis 
Antimicrobial – protein 
synthesis inhibitor - 
Aminoglycoside 
Butirosin and neomycin 
biosynthesis 
Aminoglycosides – drugs 
that originate from bacterial 
species 
Carbon metabolism Metabolism of carbon 
HIF-1 signaling 
pathway 
Cellular signaling - 
participate in angiogenesis, 
iron metabolism, glucose 
metabolism, and cell 
proliferation/survival 
Carbohydrate digestion 
and absorption 
Digestion and absorption of 
carbohydrate’s 
Pyruvate metabolism End product of glycolysis 
Methane metabolism Methane metabolism 
Carbon fixation in 
photosynthetic 
organisms 
Fixing carbon in 
photosynthetic organisms 
Carbon fixation 
pathways in 
Prokaryotes 
Fixation of carbon in 
Prokaryotes 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
Pentose phosphate 
pathway 
Parallel to glycolysis and 
generates NAPDH and 
pentose 
Biosynthesis of 
ansamycins 
Secondary metabolite – 
benzene ring product 
Antimicrobial activity 
Biosynthesis of amino 
acids 
Synthesis of amino acids 
Glycine, serine and 
threonine metabolism 
Amino acid metabolism 
Glycerolipid 
metabolism 
Lipid metabolism 
Bisphenol degradation Common chemical exposed 
lvii 
 
to in daily life 
Linoleic acid 
metabolism 
Unsaturated fatty acid 
Chloroalkane and 
chloroalkene 
degradation 
Degrading chloro derivative 
alkene’s and alkane’s 
Butanoate metabolism Precursor to butanoic acid 
Pentose and 
glucuronate 
interconversions 
Transferring sugar groups 
Ascorbate and aldarate 
metabolism 
Ascorbate – Vitamin C by-
product 
Aldarate – acid generated 
from oxidation of terminal 
groups on aldose 
Fatty acid degradation Degradation of fatty acid’s 
Valine, leucine and 
isoleucine degradation 
These are seen to be 
elevated in the CF lung  
Lysine degradation Lysine degrades DNA  
Arginine and proline 
metabolism 
Amino acid metabolism 
Histidine metabolism Amino acid metabolism 
Tryptophan metabolism Amino acid metabolism 
beta-Alanine 
metabolism 
Amino acid metabolism 
Glycerolipid 
metabolism 
Lipid metabolism 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
Citrate cycle (TCA 
cycle) 
Energy generation via the 
oxidation of acetate 
Benzoate degradation Utilize alternative Carbon 
sources – longevity  
Bisphenol degradation Common chemical exposed 
to in daily life 
Naphthalene 
degradation 
Double benzene ring 
product – used in mothballs 
Butanoate metabolism Precursor to butanoic acid 
2-Oxocarboxylic acid The most elementary set of 
lviii 
 
metabolism metabolites – pyruvate, 
oxaloacetate and 2 – 
oxoglutarate 
C5-Branched dibasic 
acid metabolism 
Involved in acid/base 
reactions 
> 10 BR 
  
Mannosyl phosphate 
transferase 
Important in human 
metabolism – energy 
Galactose metabolism Energy metabolism 
Other glycan 
degradation 
Glycan degradation 
Glycosaminoglycan 
degradation 
Long unbranched 
polysaccharides made of 
repeating disaccharide units 
Sphingolipid 
metabolism 
Involved in inflammation in 
chronic respiratory diseases 
Glycosphingolipid 
biosynthesis - ganglio 
series 
Involved in inflammation in 
chronic respiratory diseases 
Lysosome Break down of biomolecules 
including proteins, amino 
acid, lipids and 
carbohydrates – found in 
animal cells 
Pentose phosphate 
pathway 
Parallel to glycolysis and 
generates NEPDH and 
pentose 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
Carbon metabolism Carbon metabolism 
Central Carbon 
metabolism in cancer 
Carbon metabolism in 
cancer 
Pentose and 
glucuronate 
interconversions 
Transferring sugar groups 
Ascorbate and aldarate 
metabolism 
Ascorbate – Vitamin C by-
product 
Aldarate – acid generated 
lix 
 
from oxidation of terminal 
groups on aldose 
Starch and sucrose 
metabolism 
Sugar metabolism 
Amino sugar and 
nucleotide sugar 
metabolism 
Generation of components 
of nucleic acids 
Glycolysis / 
Gluconeogenesis 
Converts glucose to 
pyruvate/Generation of 
glucose from non-Carbon 
sources 
Fructose and mannose 
metabolism 
Amino acid metabolism 
Galactose metabolism Energy – sugar 
Streptomycin 
biosynthesis 
Antimicrobial – protein 
synthesis inhibitor - 
Aminoglycoside 
Butirosin and neomycin 
biosynthesis 
Aminoglycosides – drugs 
that originate from bacterial 
species 
HIF-1 signaling 
pathway 
Cellular signaling - 
participate in angiogenesis, 
iron metabolism, glucose 
metabolism, and cell 
proliferation/survival 
Insulin signaling 
pathway 
Insulin production 
Type II diabetes 
mellitus 
Related to insulin 
Carbohydrate digestion 
and absorption 
Digestion and absorption of 
carbohydrates 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Cysteine and 
methionine metabolism 
Amino acid metabolism 
Sulphur metabolism Metabolism of sulphur 
Carbon metabolism Metabolism of carbon 
Biosynthesis of amino 
acids 
Biosynthesis of amino acids 
lx 
 
Histidine metabolism Amino acid metabolism 
Fatty acid degradation Degradation of fatty acids 
Valine, leucine and 
isoleucine degradation 
These are seen to be 
elevated in the CF lung  
Lysine degradation Lysine degrades DNA  
Arginine and proline 
metabolism 
Amino acid metabolism 
Histidine metabolism Amino acid metabolism 
Tryptophan metabolism Amino acid metabolism 
beta-Alanine 
metabolism 
Amino acid metabolism 
Glycerolipid 
metabolism 
Lipid metabolism 
Pyruvate metabolism End product of glycolysis 
Chloroalkane and 
chloroalkene 
degradation 
Degrading chloro derivative 
alkene’s and alkane’s 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
aldehyde 
dehydrogenase 
Oxidise aldehyde’s 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
Citrate cycle (TCA 
cycle) 
Energy generation via the 
oxidation of acetate 
Carbon fixation in 
photosynthetic 
organisms 
Fixation of carbon in 
photosynthetic organisms 
Methane metabolism Metabolism of methane 
Carbon fixation 
pathways in 
prokaryotes 
Fixation of carbon in 
Prokaryotes 
Benzoate degradation Utilize alternative Carbon 
sources – longevity 
Bisphenol degradation Common chemical exposed 
to in daily life 
Naphthalene 
degradation 
Double benzene ring 
product – used in mothballs 
lxi 
 
Butanoate metabolism Precursor to butanoic acid 
 
NUCLEOTIDE METABOLISM KEGG Identification Putative function 
Paediatric CF 
  
Pyrimidine metabolism Nucleotide protein – 
Cytosine/Thymine/Uracil 
beta-Alanine 
metabolism 
Amino acid metabolism 
Pantothenate and CoA 
biosynthesis 
Pantothenate is needed in 
animals to combine with 
CoA 
CoA is involved in fatty acid 
metabolism and the TCA 
cycle 
Drug metabolism - 
other enzymes 
Drug metabolism 
Purine metabolism Nucleotide protein – 
Adenine/Guanine 
DNA replication Replication of DNA 
Base excision repair Involved in Nucleotide 
Excision Repair 
Nucleotide excision 
repair 
Removal of large damaged 
amino acids before 
mutations form 
Homologous 
recombination 
Repairs DSB (Double 
Strand Breaks) 
Riboflavin metabolism Vitamin B2, important 
cofactor in FAD which are 
essential in pathways such 
as - fatty acid metabolism, 
citrate cycle and electron 
transport chain 
Nicotinate and 
nicotinamide 
metabolism 
Nicotinamide (B vitamin) is 
the amide of nicotinic acid 
which is an essential human 
nutrient 
Tyrosine metabolism Amino acid metabolism 
Biotin metabolism B vitamin, involved in 
Gluconeogenesis 
< 10 BR Pyrimidine degradation Degrading nucleotide 
lxii 
 
  proteins – 
Cytosine/Thymine/Uracil 
Purine metabolism Nucleotide protein 
metabolism – 
Adenine/Guanine 
Pyrimidine metabolism Metabolizing nucleotide 
proteins – 
Cytosine/Thymine/Uracil 
DNA replication Replication of DNA 
Base excision repair Involved in Nucleotide 
Excision Repair 
Nucleotide excision 
repair 
Removal of large damaged 
amino acids before 
mutations form 
Homologous 
recombination 
Repairs DSB (Double 
Strand Breaks) 
Tyrosine metabolism Amino acid metabolism 
Tryptophan 
biosynthesis 
Amino acid metabolism 
Tyrosine degradation Amino acid degradation 
Phenylalanine 
metabolism 
Amino acid metabolism 
Glycine, serine and 
threonine metabolism 
Amino acid metabolism 
Cysteine and 
methionine metabolism 
Amino acid metabolism 
Arginine and proline 
metabolism 
Amino acid metabolism 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Nitrogen metabolism Part of the nitrogen cycle – 
energy for the cell 
 
Adult CF 
  
Tyrosine metabolism Amino acid metabolism 
Styrene degradation Benzene ring structure 
lxiii 
 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Arginine and proline 
metabolism 
Amino acid metabolism 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
Nitrogen metabolism Nitrogen metabolism 
Biosynthesis of amino 
acids 
Amino acid biosynthesis 
Two-component 
system 
Response to the 
environment, allows 
adaptation to changing 
environments 
Glutamatergic synapse Post synaptic synapse – 
NMDA type 
GABAergic synapse Neurotransmitter in CNS 
(Central Nervous System) 
Pyrimidine metabolism Amino acid metabolism 
beta-Alanine 
metabolism 
Amino acid metabolism 
Pantothenate and CoA 
biosynthesis 
Pantothenate is needed in 
animals to combine with 
CoA 
CoA is involved in fatty acid 
metabolism and the TCA 
cycle 
Drug metabolism - 
other enzymes 
Drug metabolism 
Biotin metabolism B vitamin, involved in 
Gluconeogenesis 
Carbapenem 
biosynthesis 
Beta lactam antibiotic 
2-Oxocarboxylic acid 
metabolism 
The most elementary set of 
metabolites – pyruvate, 
oxaloacetate and 2 – 
oxoglutarate 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
lxiv 
 
caused by ROS (Reactive 
Oxygen Species) 
Cysteine and 
methionine metabolism 
Amino acid metabolism 
Valine, leucine and 
isoleucine degradation 
These are seen to be 
elevated in the CF lung – 
possible phage degradation 
to increase survival 
Histidine metabolism Amino acid metabolism 
Phenylalanine, tyrosine 
and tryptophan 
biosynthesis 
Amino acid metabolism 
Pyrimidine metabolism Metabolizing nucleotide 
proteins – 
Cytosine/Thymine/Uracil 
Selenocompound 
metabolism 
Common metabolite found 
in a range of organisms 
Phenylalanine 
metabolism 
Amino acid metabolism 
Purine metabolism Nucleotide protein – 
Adenine/Guanine 
 
> 10 BR 
  
Purine metabolism Nucleotide protein – 
Adenine/Guanine 
Pyrimidine metabolism Nucleotide protein – 
Cytosine/Thymine/Uracil 
DNA replication Replication of DNA 
Base excision repair Involved in Nucleotide 
Excision Repair 
Nucleotide excision 
repair 
Removal of large damaged 
amino acids before 
mutations form 
Homologous 
recombination 
Repairs DSB (Double 
Strand Breaks) 
beta-Alanine 
metabolism 
Amino acid metabolism 
Pantothenate and CoA 
biosynthesis 
Pantothenate is needed in 
animals to combine with 
CoA 
lxv 
 
CoA is involved in fatty acid 
metabolism and the TCA 
cycle 
Drug metabolism - 
other enzymes 
Drug metabolism 
 
 
ENERGY METABOLISM KEGG Identification Putative function 
Paediatric CF 
  
Oxidative 
phosphorylation 
Release of energy from the 
mitochondria 
Porphyrin and 
chlorophyll metabolism 
Porphyrin (Heme) and 
Chlorophyll are energy 
supplies 
 
< 10 BR 
  
Oxidative 
phosphorylation 
Release of energy from the 
mitochondria 
Porphyrin and 
chlorophyll metabolism 
Porphyrin (Heme) and 
Chlorophyll are energy 
supplies 
Cytochrome bc1 
complex respiratory 
unit 
Component in the 
respiratory chain complex – 
contains two heme groups 
and works in electron 
donating 
Pyruvate metabolism Glycolysis end product 
Carbon fixation in 
photosynthetic 
organisms 
Transfer of inorganic 
Carbon to organic Carbon 
Carbon metabolism Metabolism of Carbon 
Glyoxylate and 
dicarboxylate 
metabolism 
Reactions involving 
glyoxylate and dicarboxylate 
Methane metabolism Methane metabolism 
Carbon metabolism Methane metabolism 
Adult CF Oxidative 
phosphorylation 
Release of energy from the 
mitochondria 
> 10 BR 
  
Galactose metabolism Energy – sugar 
Other glycan 
degradation 
Glycan degradation 
Sphingolipid Involved in inflammation in 
lxvi 
 
metabolism chronic lung diseases 
Starch and sucrose 
metabolism 
Sugar metabolism 
F-type ATPase Energy generation – ATP 
Oxidative 
phosphorylation 
Release of energy from the 
mitochondria 
Photosynthesis Energy supply generated by 
the mitochondria 
 
XENOBIOTIC DEGRADATION KEGG Identification Putative function 
Paediatric CF 
  
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs  
Dioxin degradation Heterocyclic 6 membered 
ring where two Carbons are 
replaced by oxygen 
Degradation of 
aromatic compounds 
Degradation of amino acids 
Benzene degradation Benzene ring degradation 
Chlorocyclohexane and 
chlorobenzene 
degradation 
Chlorobenzene – common 
chemical, initially DTT 
(pesticide) 
Fluorobenzoate 
degradation 
Utilize alternative Carbon 
sources – longevity 
Toluene degradation Benzene ring derivative – 
drug related 
Degradation of 
aromatic compounds 
Degradation of aromatic 
compounds 
Polycyclic aromatic 
hydrocarbon 
degradation 
Degradation of polycyclic 
hydrocarbons 
 
< 10 BR 
  
Benzoate degradation Utilize alternative Carbon 
sources – longevity 
Dioxin degradation Heterocyclic 6 membered 
ring where two Carbons are 
replaced by oxygen 
Toluene degradation Benzene ring derivative - 
drug related 
Degradation of 
aromatic compounds 
Degradation of aromatic 
compounds 
lxvii 
 
Adult CF 
  
Toluene degradation Benzene ring derivative - 
drug related 
Degradation of 
aromatic compounds 
Degradation of aromatic 
compounds 
Polycyclic aromatic 
hydrocarbon 
degradation 
Degradation of polycyclic 
hydrocarbons 
Benzoate degradation Utilize alternative Carbon 
sources – longevity 
Chlorocyclohexane and 
chlorobenzene 
degradation 
Chlorobenzene – common 
chemical, initially DTT 
(pesticide) 
Bisphenol degradation Common chemical exposed 
to in daily life 
Naphthalene 
degradation 
Double benzene ring 
product – used in mothballs 
Aminobenzoate 
degradation 
Aminobenzoate has been 
trialled as a drug previously 
Limonene and pinene 
degradation 
Bronchitis drug – phage can 
breakdown 
Caprolactam 
degradation 
Natural product that is the 
basis of some drugs  
Drug metabolism - 
other enzymes 
Drug metabolism 
> 10 BR 
  
Chlorocyclohexane and 
chlorobenzene 
degradation 
Benzene ring degradation 
Chloroalkane and 
chloroalkene 
degradation 
Chlorobenzene – common 
chemical, initially DTT 
(pesticide) 
Atrazine degradation Degrading chloro derivative 
alkene’s and alkane’s 
Caprolactam 
degradation 
Herbicide – benzene ring 
product 
Toluene degradation Benzene ring derivative - 
drug related 
Degradation of 
aromatic compounds 
Degradation of aromatic 
compounds 
  
lxviii 
 
MECHANISM OF 
COFACTORS AND VITAMINS 
KEGG Identification Putative function 
Paediatric CF N/A 
< 10 BR 
 
N/A 
Adult CF 
  
Ubiquinone and other 
terpenoid-quinone 
biosynthesis 
Involvement in QS (Quorum 
Sensing) 
Thiamine metabolism B vitamin – Benzene ring 
product 
Sulphur relay system Generation of sulphur – 
ubiquinated products aid its 
movement 
Riboflavin metabolism Vitamin B2, important 
cofactor in FAD which are 
essential in pathways such 
as - fatty acid metabolism, 
citrate cycle and electron 
transport chain 
Porphyrin and 
chlorophyll metabolism 
Porphyrin (Heme) and 
Chlorophyll are energy 
supplies 
 
> 10 BR 
  
Thiamine metabolism B vitamin – Benzene ring 
product 
Sulphur relay system Generation of sulphur – 
ubiquinated products aid its 
movement 
METABOLISM OF OTHER 
AMINO ACIDS 
KEGG Identification Putative function 
Paediatric CF Arginine and proline 
metabolism 
Amino acid metabolism 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
Lysine biosynthesis DNA degradation enzyme 
Lysine degradation Lysine degrades DNA 
Biosynthesis of amino Biosynthesis of amino acids 
lxix 
 
acids 
Valine, leucine and 
isoleucine degradation 
These are previously seen 
to be elevated in the CF 
lung  
Glycine, serine and 
threonine metabolism 
Amino acid metabolism 
Cysteine and 
methionine metabolism 
Amino acid metabolism 
2-Oxocarboxylic acid 
metabolism 
The most elementary set of 
metabolites -pyruvate (2-
oxopropanoate), 2-
oxobutanoate, oxaloacetate 
(2-oxosuccinate) and 2-
oxoglutarate 
Pantothenate and CoA 
biosynthesis 
Pantothenate is needed in 
animals to combine with 
CoA 
CoA is involved in fatty acid 
metabolism and the TCA 
cycle 
Valine, leucine and 
isoleucine biosynthesis 
Amino acid metabolism – 
seen in elevated levels in 
CF lungs 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Two-component 
system 
Response to the 
environment, allows 
adaptation to changing 
environments 
Glutamatergic synapse Post synaptic synapse – 
NMDA type 
GABAergic synapse Neurotransmitter in CNS 
(Central Nervous System) 
 
< 10 BR N/A 
Adult CF 
  
Lysine biosynthesis DNA degradation enzyme 
Peptidoglycan 
biosynthesis 
Sugar metabolism in the 
cytosol – various enzymes 
needed 
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Histidine metabolism Amino acid metabolism 
Phenylalanine 
metabolism 
Amino acid metabolism 
Arginine and proline 
metabolism 
Amino acid metabolism 
Taurine and 
hypotaurine 
metabolism 
Taurine is found in a large 
proportion of animal tissues, 
hypotaurine is an 
intermediate in this process 
Cyanoamino acid 
metabolism 
Amino acid metabolism – 
addition of a nitrile group to 
the front of the amino acid 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
Aminoacyl-tRNA 
biosynthesis 
Combines with amino acid 
whilst they are being 
synthesized 
Alanine, aspartate and 
glutamate metabolism 
Amino acid metabolism 
Biosynthesis of amino 
acids 
Biosynthesis of amino acids 
Phenylalanine, tyrosine 
and tryptophan 
biosynthesis 
Amino acid metabolism 
Cysteine and 
methionine metabolism 
Amino acid metabolism 
> 10 BR 
  
Lysine biosynthesis DNA degradation enzyme 
2-Oxocarboxylic acid 
metabolism 
The most elementary set of 
metabolites – pyruvate, 
oxaloacetate and 2 – 
oxoglutarate 
Biosynthesis of amino 
acids 
Biosynthesis of amino acids 
Valine, leucine and 
isoleucine biosynthesis 
These are seen to be 
elevated in the CF lung – 
possible phage degradation 
to increase survival 
lxxi 
 
Pyruvate metabolism End product of glycolysis 
Arginine and proline 
metabolism 
Amino acid metabolism 
Tryptophan metabolism Amino acid metabolism 
Glutathione 
metabolism 
Antioxidant that protects 
cells from the damage 
caused by ROS (Reactive 
Oxygen Species) 
BIOSYNTHESIS OF OTHER 
SECONDARY METABOLITES 
KEGG Identification Putative function 
Paediatric CF N/A 
< 10 BR 
  
Ubiquinone and other 
terpenoid-quinone 
biosynthesis 
Involvement in QS (Quorum 
Sensing) 
Porphyrin and 
chlorophyll metabolism 
Porphyrin (Heme) and 
Chlorophyll are energy 
supplies 
Drug metabolism - 
other enzymes 
Drug metabolism 
Lysine degradation Lysine degrades DNA – 
possible survival tactic 
Biotin metabolism B vitamin, involved in 
Gluconeogenesis 
Adult CF N/A 
> 10 BR 
  
Heme biosynthesis Energy supply 
Porphyrin and 
chlorophyll metabolism 
Porphyrin (Heme) and 
Chlorophyll are energy 
supplies 
Ubiquinone 
biosynthesis 
Coenzyme Q10, benzene 
ring product 
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